

AUTHOR INDEX*

Volume 62

A

- A, D., 6485
 Aalders, M. C. G., 2024
 Aalders, T. W., 2695
 Aaltonen, L. A., 1166, 4352, 4554, 5989
 Aarts, W. M., 5770
 Abate-Shen, C., 2999
 Abbaszadegan, M., 2654
 Abbey, N. W., 5536
 Abbruzzese, J., 6070
 Abdelmohsen, K., 4922
 Abdurabbo, M. K., 6823
 Abecassis, J., 6211
 Abel, J., 99
 Abello, J., 4829
 Aboagye, E. O., 5912
 Abu-Khalil, E., 4325
 Abraham, D., 5317
 Abraham, J. M., 1148, 3493, 3641, 5637, 6820
 Abri, H., 5317
 Abrosimov, A. Y., 7031
 Aburatani, H., 233
 Accardi, L., 3654
 Achermann, R., 2962
 Ackerman, J. J. H., 1555
 Adam, B.-L., 3609
 Adam, R. M., 1549
 Adams, A. W., 4109
 Adams, D. M., 3159, 6552
 Adams, J., 4996
 Adams, M., 3289
 Adams, S., 6717
 Adem, C., 3587
 Adesomolu, A. A., 4007
 Adeyanju, M. O., 1481
 Adigun, Y. E., 4115
 Adini, A., 2749
 Agarwal, C., 3063
 Agarwal, R., 3063, 5280
 Agata, N., 789
 Aggarwal, B. B., 4945
 Aguilar-Cordova, E., 4968
 Aguzzi, A., 2592
 Aharinejad, S., 5317
 Ahmad, N., 6659
 Ahmadian M-R., 1718
 Ahmed, A., 5495, 6566
 Ahmed, F., 7166
 Ahn, D., 4514
 Ahn, E., 6385
 Ahn, K. Y., 1809
 Ahn, W.-S., 7234
 Ahranovitz, N., 2654
 Aicher, L. D., 5645
 Aimes, R. T., 7083
 Aittomäki, K., 4554
 Aizu, W., 3667
 Akagi, T., 6390
 Akaike, T., 3138
 Akasaka, T., 6224
 Akel, N. S., 5571
 Akgul, C., 6500
 Akhand, A. A., 2414
 Akhurst, R. J., 5627
 Akiyama, M., 3876
 Akiyama, S. K., 6837
 Akiyama, S.-I., 2834
 Akiyama, T., 3322

- Akiyama, Y., 4894
 Akslen, L. A., 6808
 Akunda, J., 3395
 Alain, T., 1696
 Alam, M., 2493
 Alaoui-Jamali, M. A., 5457
 Alazawi, W., 6959
 Albanese, C., 3997
 Albar, J. P., 3167
 Albelda, S. M., 6997
 Albert, M., 3466
 Albertson, D. G., 3636
 Albini, A., 2406
 Albor, A., 3264
 Aldape, K. D., 6205
 Aldaz, C. M., 4054
 Alder, H., 2258
 Ale-Agha, N., 4922
 Alemany, R., 1266, 4663, 5736
 Alexander, H. R., 3581
 Alexander, R. L., 1730
 Alfonso-De Matte, M. Y., 4575
 Alftahan, H., 5210
 Ali, S. Z., 135
 Alison, M., 5698
 Alitalo, K., 5580
 Allegri, P. R., 4015
 Allen, J. C., 2660
 Allen, J. D., 2294
 Allen, T. M., 7190
 Allen, W. L., 2644
 Alli, E., 6864
 Allred, C. D., 2474
 Allred, K. F., 2474
 Alroy, R., 5457
 Alpaugh, M. L., 3826
 Alpaugh, R. K., 4767
 Alson, S., 2761
 Al-Tassan, N., 363
 Altieri, D. C., 2462, 3093
 Álvarez, A., 5013
 Alvarez, R. D., 1266
 Álvarez-Tejado, M., 2929
 Alvey, R. F., 2423
 Alvord, W. G., 7305
 Alyea, E. P., 5517
 Al-Zoghaibi, F., 397
 Amadori, A., 6099
 Amalfitano, A., 801
 Aman, M. J., 1103
 Áman, P., 512
 Amann, G., 2986
 Ambros, I. M., 2986
 Ambros, P. F., 2986
 Ames, S. J., 7154
 Amin, K. M., 3438
 Amin, S., 2
 Amos, C. I., 3782
 Anastasi, J., 5523
 Ancelin, M., 4977
 Andenor, J., 5974
 Anderson, D. W., 1439
 Anderson, G. R., 6350, 6351
 Anderson, K. C., 2300, 3876, 4996, 5019
 Andersson, T., 409
 Ando, A., 1246
 Ando, T., 2385
 André, T., 4879
 Andreff, M., 3603, 7264
 Andrew, S. E., 359

- Andrews, J., 6070
 Ang, K. K., 6414, 7350
 Angeletti, C. A., 2535
 Angelo, L. S., 932
 Angulo, J. F., 5425
 Angus, S. P., 6587
 Anisimov, S. V., 3257
 Anklesaria, P., 6712
 Ansel, J. C., 4109
 Antel, J., 2131
 Antonescu, C. R., 135
 Anttila, M., 6410
 Anttonen, A., 5210
 Anver, M. R., 6724, 6944, 7305
 Aoki, H., 3850
 Aplenc, R., 4212
 Appella, E., 3521
 Arai, Y., 3850
 Arakawa, H., 1246, 2883
 Araki, N., 5859
 Arañes, M. J., 4791
 Arango, D., 4791, 6006
 Arap, W., 867
 Aras, R. A., 2385
 Arch, B., 6959
 Archer, D. R., 4109
 Archer, G. E., 3335
 Arden, K. C., 6981
 Ardini, E., 1321
 Argani, P., 5351
 Ariazi, E. A., 6510
 Arimori, K., 179
 Arlinghaus, R. B., 386
 Arlt, A., 910
 Arlt, M., 5543
 Armati, P., 781
 Armes, J. E., 1289
 Armstrong, C. A., 4109
 Armstrong, E. A., 4300
 Arnold, B., 1462
 Arnold, H., 3920
 Arnold, J. T., 79, 986
 Arola, J., 4554
 Aronow, B. J., 6587
 Arrigoni, G., 867, 941
 Arteaga, C., 5627
 Arteaga, C. L., 4132
 Arteaga, J. R., 5204
 Arús, C., 5672
 Aryee, D. N. T., 4583
 Asaki, E., 3581
 Asano, T., 4176, 4176
 Asemisen, A. M., 1743
 Ashfaq, R., 4985
 Ashmun, R. A., 5001
 Ashton, S. E., 5749
 Ashworth, L. K., 4100
 Asmann, Y. W., 3308
 Atencio, I., 6045
 Atkinson, E. N., 2715, 7264
 Atkinson, M. J., 3048
 Atsumi, T., 5881
 Attaix, D., 2771
 Attanucci, J., 2583
 Attoub, S., 4879
 Au, T., 4089
 Aubert, G., 764
 Auburn, K. J., 433
 Audouin, C., 3646
 Auer, G., 2365
 Augenlicht, L. H., 4791, 6006

- Aughton, K., 5158
 Aune, G., 4899
 Autrup, H. N., 4339
 Avanzini, J., 6045
 Aventin, A., 5408
 Avet-Loiseau, H., 2861
 Ávila, P., 2929
 Avila, S., 4519
 Avilés, M. J., 5013
 Avril, M. F., 7186
 Avula, R., 262
 Axworthy, D. B., 5755
 Ayala, G. E., 3298
 Ayres, M., 3100
 Azenshtain, E., 1093
 Aziz, R., 6857
 Azuhata, T., 3093
 Azuma, H., 1410
 Azuma, K., 3351
 Azumi, N., 3340
 Azzam, E. I., 5436

B

- Baas, F., 2024
 Baba, I., 5668
 Baba, M., 7004
 Bachelier, R. E., 7203
 Backlund, M., 901
 Badia, E., 6519
 Badizadegan, K., 682
 Baetens, D., 603
 Bagnato, A., 6381
 Bai, R., 4007
 Bai, R.-K., 972
 Bai, Y. X., 3226
 Bailey, E. C., 5867
 Bailey, R. J., 715
 Bailly, C., 7219
 Baird, A., 977
 Bais, A. J., 4599
 Baker, A. H., 1271
 Baker, C., 5106
 Baker, C. H., 1996
 Bakker, A., 2681
 Bakst, R., 6385
 Balachandran, S., 2239
 Balagué, C., 4663
 Balaguer, P., 6519
 Balas, A., 5013
 Baldwin, W. M., 1868
 Bales, E., 6231
 Bali, P., 5761
 Balibrea, J. L., 3855
 Balish, E., 6362
 Balkwill, F. R., 5930
 Baluk, P., 5381
 Bamberg, M., 789
 Banach-Petrosky, W. A., 2999
 Band, H., 3315
 Band, V., 3315, 4736
 Bandyopadhyay, A., 4690
 Bandyopadhyay, D., 6231
 Banerjee, D., 6909
 Banerjee, S., 4945
 Banerji, S., 1315
 Bange, J., 840
 Bankert, R. B., 2611, 7254
 Bansal, R., 3789
 Bao, J.-J., 7264
 Bapat, B., 3663, 4095

* For title of article and coauthors, see listing in Contents of Volume beginning on page at the end of this index issue.

AUTHOR INDEX*

Volume 62

A

- A, D., 6485
 Aalders, M. C. G., 2024
 Aalders, T. W., 2695
 Aaltonen, L. A., 1166, 4352, 4554,
 5989
 Aarts, W. M., 5770
 Abate-Shen, C., 2999
 Abbaszadegan, M., 2654
 Abbey, N. W., 5536
 Abbruzzese, J., 6070
 Abdelmohsen, K., 4922
 Abdurabbo, M. K., 6823
 Abecassis, J., 6211
 Abel, J., 99
 Abello, J., 4829
 Aboagye, E. O., 5912
 Abu-Khalil, E., 4325
 Abraham, D., 5317
 Abraham, J. M., 1148, 3493, 3641,
 5637, 6820
 Abri, H., 5317
 Abrosimov, A. Y., 7031
 Aburatani, H., 233
 Accardi, L., 3654
 Achermann, R., 2962
 Ackerman, J. J. H., 1555
 Adam, B.-L., 3609
 Adam, R. M., 1549
 Adams, A. W., 4109
 Adams, D. M., 3159, 6552
 Adams, J., 4996
 Adams, M., 3289
 Adams, S., 6717
 Adem, C., 3587
 Adesomolu, A. A., 4007
 Adeyanju, M. O., 1481
 Adigun, Y. E., 4115
 Adini, A., 2749
 Agarwal, C., 3063
 Agarwal, R., 3063, 5280
 Agata, N., 789
 Aggarwal, B. B., 4945
 Aguilar-Cordova, E., 4968
 Aguzzi, A., 2592
 Aharinejad, S., 5317
 Ahmad, N., 6659
 Ahmadian M-R., 1718
 Ahmed, A., 5495, 6566
 Ahmed, F., 7166
 Ahn, D., 4514
 Ahn, E., 6385
 Ahn, K. Y., 1809
 Ahn, W.-S., 7234
 Ahranovitz, N., 2654
 Aicher, L. D., 5645
 Aimes, R. T., 7083
 Aittomäki, K., 4554
 Aizu, W., 3667
 Akagi, T., 6390
 Akaike, T., 3138
 Akasaka, T., 6224
 Akel, N. S., 5571
 Akgul, C., 6500
 Akhand, A. A., 2414
 Akhurst, R. J., 5627
 Akiyama, M., 3876
 Akiyama, S. K., 6837
 Akiyama, S.-I., 2834
 Akiyama, T., 3322

- Akiyama, Y., 4894
 Akslen, L. A., 6808
 Akunda, J., 3395
 Alain, T., 1696
 Alam, M., 2493
 Alaoui-Jamali, M. A., 5457
 Alazawi, W., 6959
 Albanese, C., 3997
 Albar, J. P., 3167
 Albelda, S. M., 6997
 Albert, M., 3466
 Albertson, D. G., 3636
 Albini, A., 2406
 Albor, A., 3264
 Aldape, K. D., 6205
 Aldaz, C. M., 4054
 Alder, H., 2258
 Ale-Agha, N., 4922
 Alemany, R., 1266, 4663, 5736
 Alexander, H. R., 3581
 Alexander, R. L., 1730
 Alfonso-De Matte, M. Y., 4575
 Alftahan, H., 5210
 Ali, S. Z., 135
 Alison, M., 5698
 Alitalo, K., 5580
 Allegri, P. R., 4015
 Allen, J. C., 2660
 Allen, J. D., 2294
 Allen, T. M., 7190
 Allen, W. L., 2644
 Alli, E., 6864
 Allred, C. D., 2474
 Allred, K. F., 2474
 Alyoz, R., 5457
 Alpaugh, M. L., 3826
 Alpaugh, R. K., 4767
 Alson, S., 2761
 Al-Tassan, N., 363
 Altieri, D. C., 2462, 3093
 Álvarez, A., 5013
 Alvarez, R. D., 1266
 Álvarez-Tejado, M., 2929
 Alvey, R. F., 2423
 Alvord, W. G., 7305
 Alyea, E. P., 5517
 Al-Zoghaibi, F., 397
 Amadori, A., 6099
 Amalfitano, A., 801
 Aman, M. J., 1103
 Áman, P., 512
 Amann, G., 2986
 Ambros, I. M., 2986
 Ambros, P. F., 2986
 Ames, S. J., 7154
 Amin, K. M., 3438
 Amin, S., 2
 Amos, C. I., 3782
 Anastasi, J., 5523
 Ancelin, M., 4977
 Andenor, J., 5974
 Anderson, D. W., 1439
 Anderson, G. R., 6350, 6351
 Anderson, K. C., 2300, 3876, 4996,
 5019
 Andersson, T., 409
 Ando, A., 1246
 Ando, T., 2385
 André, T., 4879
 Andreff, M., 3603, 7264
 Andrew, S. E., 359

- Andrews, J., 6070
 Ang, K. K., 6414, 7350
 Angeletti, C. A., 2535
 Angelo, L. S., 932
 Angulo, J. F., 5425
 Angus, S. P., 6587
 Anisimov, S. V., 3257
 Anklesaria, P., 6712
 Ansel, J. C., 4109
 Antel, J., 2131
 Antonescu, C. R., 135
 Anttila, M., 6410
 Anttonen, A., 5210
 Anver, M. R., 6724, 6944, 7305
 Aoki, H., 3850
 Aplenc, R., 4212
 Appella, E., 3521
 Arai, Y., 3850
 Arakawa, H., 1246, 2883
 Araki, N., 5859
 Arañes, M. J., 4791
 Arango, D., 4791, 6006
 Arap, W., 867
 Aras, R. A., 2385
 Arch, B., 6959
 Archer, D. R., 4109
 Archer, G. E., 3335
 Arden, K. C., 6981
 Ardini, E., 1321
 Argani, P., 5351
 Ariazi, E. A., 6510
 Arimori, K., 179
 Arlinghaus, R. B., 386
 Arlt, A., 910
 Arlt, M., 5543
 Armati, P., 781
 Armes, J. E., 1289
 Armstrong, C. A., 4109
 Armstrong, E. A., 4300
 Arnold, B., 1462
 Arnold, H., 3920
 Arnold, J. T., 79, 986
 Arola, J., 4554
 Aronow, B. J., 6587
 Arrigoni, G., 867, 941
 Arteaga, C., 5627
 Arteaga, C. L., 4132
 Arteaga, J. R., 5204
 Arús, C., 5672
 Aryee, D. N. T., 4583
 Asaki, E., 3581
 Asano, T., 4176, 4176
 Asemisen, A. M., 1743
 Ashfaq, R., 4985
 Ashmun, R. A., 5001
 Ashton, S. E., 5749
 Ashworth, L. K., 4100
 Asmann, Y. W., 3308
 Atencio, I., 6045
 Atkinson, E. N., 2715, 7264
 Atkinson, M. J., 3048
 Atsumi, T., 5881
 Attaix, D., 2771
 Attanucci, J., 2583
 Attoub, S., 4879
 Au, T., 4089
 Aubert, G., 764
 Auburn, K. J., 433
 Audouin, C., 3646
 Auer, G., 2365
 Augenlicht, L. H., 4791, 6006

- Aughton, K., 5158
 Aune, G., 4899
 Autrup, H. N., 4339
 Avanzini, J., 6045
 Aventin, A., 5408
 Avet-Loiseau, H., 2861
 Ávila, P., 2929
 Avila, S., 4519
 Avilés, M. J., 5013
 Avril, M. F., 7186
 Avula, R., 262
 Axworthy, D. B., 5755
 Ayala, G. E., 3298
 Ayres, M., 3100
 Azenshtain, E., 1093
 Aziz, R., 6857
 Azuhata, T., 3093
 Azuma, H., 1410
 Azuma, K., 3351
 Azumi, N., 3340
 Azzam, E. I., 5436

B

- Baas, F., 2024
 Baba, I., 5668
 Baba, M., 7004
 Bachelter, R. E., 7203
 Backlund, M., 901
 Badia, E., 6519
 Badizadegan, K., 682
 Baetens, D., 603
 Bagnato, A., 6381
 Bai, R., 4007
 Bai, R.-K., 972
 Bai, Y. X., 3226
 Bailey, E. C., 5867
 Bailey, R. J., 715
 Bailly, C., 7219
 Baird, A., 977
 Bais, A. J., 4599
 Baker, A. H., 1271
 Baker, C., 5106
 Baker, C. H., 1996
 Bakker, A., 2681
 Bakst, R., 6385
 Balachandran, S., 2239
 Balagué, C., 4663
 Balaguer, P., 6519
 Balas, A., 5013
 Baldwin, W. M., 1868
 Bales, E., 6231
 Bali, P., 5761
 Balibrea, J. L., 3855
 Balish, E., 6362
 Balkwill, F. R., 5930
 Baluk, P., 5381
 Bamberg, M., 789
 Banach-Petrosky, W. A., 2999
 Band, H., 3315
 Band, V., 3315, 4736
 Bandyopadhyay, A., 4690
 Bandyopadhyay, D., 6231
 Banerjee, D., 6909
 Banerjee, S., 4945
 Banerji, S., 1315
 Bange, J., 840
 Bankert, R. B., 2611, 7254
 Bansal, R., 3789
 Bao, J.-J., 7264
 Bapat, B., 3663, 4095

* For title of article and coauthors, see listing in Contents of Volume beginning on page at the end of this index issue.

AUTHOR INDEX TO VOLUME

- Baranov, E., 1534
 Barazi, H. O., 1541
 Barber, G. N., 2239
 Barber, I., 1184
 Barbera-Guillem, E., 7042
 Barbieux, I., 1050
 Barcellos-Hoff, M. H., 5627
 Bardelmeijer, H. A., 6158
 Bar-Eli, M., 5106
 Barker, A. J., 5749
 Barnadas, R., 5672
 Barnes, C. J., 1251
 Barnes, M. N., 1266
 Barnhart, K., 43
 Barr, F. G., 135, 4711
 Barr, V., 6529
 Barrack, E. R., 2488
 Barracough, R., 3417
 Barrett, B. S., 6850
 Barrett, J. C., 367, 6784
 Barrette, T. R., 4427
 Barrois, M., 764
 Bar-Shira, A., 6803
 Barsky, S. H., 3826
 Bartels, K. E., 4295
 Bartelt, B., 1503
 Barth, R. F., 3159, 6552
 Barthel, B., 6850
 Barthel, H., 5912
 Bartholomeusz, C., 6712
 Bartolazzi, A., 3861
 Barton, K., 4968
 Basak, S., 5267
 Bash-Babula, J., 6864
 Bassi, R., 2567
 Basso, A. D., 3132
 Bast, R. C., Jr., 7264
 Bastian, B. C., 3200
 Batchu, R. B., 2982
 Bateman, A., 5495, 5590
 Bateman, A. R., 6566
 Bates, D. O., 4123
 Bates, S. E., 4331, 6108
 Batrla, R., 2052
 Battaglia, R., 2332
 Bauer, A. J., 2437
 Bauer, A. K., 6850
 Bauer, A. L., 1682
 Bauerschmitz, G. J., 1266, 1271
 Baum, C., 1768
 Bayani, J., 3466
 Baylin, S. B., 2157, 5902, 7213
 Bea, S., 619
 Bearss, D. J., 2077, 2890
 Beasley, N. J. P., 1315, 2493
 Beatty, J., 7175
 Beaudenon, S., 3315
 Beauileu, C., 4325
 Bechberger, J. F., 3544
 Becker, H., 1014
 Becker, J. C., 5664
 Becker, K. G., 2923
 Beckers, T., 3113
 Beckerl, A., 4061
 Bedford, J. S., 6400
 Bedford, M. T., 6475
 Bedi, A., 1583, 4180
 Bedin, M., 4879
 Bedolla, R., 2630
 Bee, J., 4562
 Beems, R. B., 1338
 Beer, D. G., 5273
 Bégin, L. R., 6808
 Beheshti, B., 3466
 Behnam, M., 18
 Beier, C., 2592
 Beijnen, J. H., 6158
 Beissert, T., 7050
 Bekesi, G., 6080
 Beland, F. A., 1978
 Belbin, T. J., 1184
 Belenkov, A. I., 5888
 Belinsky, M. G., 6172
 Belinsky, S. A., 2248, 2370
 Béliveau, R., 381
 Bell, A., 2064
 Bell, A. K., 2072
 Bell, C., 6750
 Bell, D. W., 2741
 Bell, S. C., 3289
 Bellamy, W. T., 5089
 Bello, L., 6884
 Bello, V., 5457
 Bellone, M., 1116
 Belon, J.-P., 1815
 Benali, N., 6124
 Ben-Aroya, N., 1036
 Ben-Baruch, A., 1093
 Bendahl, P.-O., 409
 Bendall, L. J., 283
 Bendre, M. S., 5571
 Benimetskaya, L., 2175
 Benito, M., 3855
 Benjamin, L. E., 2749, 6731
 Bennett, C. J., 2220, 6405
 Bennett, L. M., 990
 Bennett, P. F., 356
 Bennewith, K. L., 6827
 Benning, C. M., 597
 Bennouna, J., 213
 Bensasson, R. V., 6506
 Benson, D., 6717
 Bentley, D. L., 1420
 Ben-Ze'ev, A., 5947
 Beppu, H., 5955
 Beran, M., 5995
 Berenesi, K., 5267
 Berger, L., 721
 Berger, M., 1477
 Bergeron, C., 3646
 Bergeron, J., 5457
 Bergers, G., 2731
 Bergoglio, V., 3511
 Bergsmehd, A., 575
 Berkey, B. A., 7350
 Berkowitz, R. S., 3058
 Berlangier, I., 4169
 Bernard, M.-A., 1158
 Bernardin, F., 3904
 Bernassola, F., 5158
 Bernhard, E. J., 7316
 Bernhard, H., 2244
 Berns, A., 1862
 Bernt, K. M., 6089
 Berridge, M. V., 3356
 Bertino, J. R., 4244, 6909
 Bertolini, F., 3106
 Bérubé, G., 6625
 Besaratinia, A., 4331
 Beske, F., 1768
 Bessho, M., 1171
 Best, C. J. M., 5325
 Besterman, J. M., 4325
 Betel, D., 1284
 Betensky, R. A., 1790
 Bettaiab, A., 1815
 Beurdeley-Thomas, A., 1388
 Beyser, K., 3009
 Bhagwat, S. S., 1439
 Bhalla, K., 5761
 Bhalla, K. N., 466
 Bharara, S., 3347
 Bhatia, N., 5280
 Bhatia-Gaur, R., 2999
 Bhuiwalla, Z. M., 6731
 Bianchini, A., 7050
 Biard, D. S. F., 5425
 Bias, C., 4854
 Biassoni, R., 6178
 Bicciato, S., 7143
 Bichler, K.-H., 5818
 Bicknell, R., 1326, 5912
 Bidart, J.-M., 1020
 Bieberich, C. J., 338
 Bieche, I., 5874
 Biegel, J. A., 323
 Biesczad, C. K., 892
 Bieth, A., 3511
 Bigler, J., 3361
 Bigley, A. L., 4645
 Bignell, G. R., 6451
 Bikfalvi, A., 6884
 Bilhou-Nabera, C., 5408
 Billerey, C., 1815
 Bindra, R. S., 3014
 Bird, C. C., 3992
 Birebent, B., 5267
 Birkenkamp-Demtroder, K., 4352
 Birnstiel, M. L., 1477
 Birsner, A. E., 2300
 Bishop, J. S., 4023
 Bisi, J. E., 1171
 Bissell, M. J., 7102
 Bissonette, R., 6376
 Biswal, S., 5196
 Biunno, I., 567
 Black, K. L., 5657, 7170
 Blackwell, J. L., 4273
 Blackwood, M. A., 1481
 Blades, N. J., 819
 Blakey, D. C., 3711, 7247
 Blanco, C., 2660
 Blankenstein, T., 2856
 Blaschuk, O., 6688
 Blasco, M. A., 552
 Blaser, M. J., 2385
 Blaszyk, H., 6796
 Bleeker, E. R., 1784, 2253, 6485
 Blood, E. A., 715
 Bloome, E., 5267
 Blumenstock, J. E., 4963
 Blumenthal, R. D., 2029
 Blyth, K., 7181
 Bobiak, M. L., 1797
 Bocchinfuso, W. P., 2798
 Bocci, G., 2731, 6938
 Bocker-Edmonston, T., 6796
 Boczkowski, D., 5041
 Bode, A. M., 1300, 1343
 Bode, W., 5543
 Bodmer, W., 53, 4562
 Boecker, W., 1020
 Boehrer, S., 1768, 7050
 Boerman, O. C., 6146
 Boffey, S. J., 4645
 Bogin, L., 1948
 Boheler, K. R., 3257
 Bohlen, P., 2567, 2731
 Bohr, V. A., 1349
 Bois-Joyeux, B., 1158
 Boissier, S., 6538
 Boisson, C., 848
 Boivin, G. P., 6362
 Bok, D., 1654
 Bokmeyer, C., 2758
 Boklan, J., 2104
 Bol, D. K., 2516
 Boland, D., 4445
 Boldog, F. L., 3834
 Boldrini, R., 301
 Bolli, M., 3453
 Bolognesi, C., 5418
 Bonalaski, J. S., 5443
 Bonaccorsi, P., 4109
 Bondy, M. L., 4566
 Bonfils, C., 4325
 Bonham, M., 3920
 Bonney, P. L., 356
 Bonvini, P., 1559
 Bookstein, R., 5027, 6045
 Boon, E. M. J., 5126
 Boon, T., 5510
 Boone, C. W., 682, 5178, 6506
 Boonstra, H., 6146
 Boosalis, M., 4985
 Booth, K., 359
 Borden, E. C., 3453
 Bornmann, W. G., 4236, 4244
 Borras, E., 2058
 Borrebaeck, C. A. K., 4398
 Bosinco, G. M., 4459
 Bosl, G. J., 6218
 Bosserhoff, A. K., 5962
 Bostick, R., 3361
 Bottema, K. M., 4854
 Bottinger, E. P., 6278
 Bouadjar, B., 7186
 Boucher, D. L., 6606
 Boudreau, R., 7102
 Bou-Hanna, C., 2169
 Bouker, K. B., 3428
 Boulaires, A. H., 4439
 Bour, G., 6211
 Bouras, T., 1289
 Bourdon, V., 6218
 Bouscarel, B., 179
 Boustany, R.-M., 801
 Bouvet, M., 1534
 Bowden, G. T., 3044
 Bowen, W. C., 2064
 Bowen, W. D., 313
 Bowers, W. J., 6545
 Bowman, E. D., 3244
 Bowman, T., 6659
 Boyer, J., 2644
 Boyer, T. G., 3966
 Boykin, D. W., 7219
 Boynton, A., 2806
 Brabender, J., 371
 Brabletz, T., 3009
 Bracci, P. M., 4630
 Bracht, T., 542
 Bradstock, K. F., 283
 Brady, F., 5698, 5912
 Brady, H., 1439
 Brady, J. N., 3562
 Brammah, S., 1394
 Bramson, J., 5148
 Brand, K., 7139
 Brandenburg, S., 6442
 Brandt, B., 1020
 Brandt, G., 3626
 Brash, D. E., 1443
 Braun, K., 7018
 Bray, J., 7357
 Brechbiel, M. W., 560, 860, 5755

* For title of article and coauthors, see listing in Contents of Volume beginning on page at the end of this index issue.

AUTHOR INDEX TO VOLUME

- Breistøl, K., 3120
 Breitkreutz, B.-J., 3005
 Bremmes, R., 3971
 Brennan, M. F., 135, 6909
 Brenner, M. K., 1123, 7195
 Brenton, J. D., 3466, 5076
 Bressac-de Pailherets, B., 764
 Breton, C., 4623
 Brewer, G. J., 4854
 Brewster, S. F., 2942
 Bridge, J. A., 135, 4711
 Bridger, G., 5930
 Briehl, M. M., 5089
 Brignell, G., 6997
 Brinckerhoff, C. E., 7200
 Brinkley, W. R., 4115
 Briollais, L., 4095
 Briones, J., 3195
 Bristow, R., 6194
 Britt, W. J., 3347
 Bröcker, E.-B., 2125, 5664
 Brodeur, G. M., 1802, 6462, 6481, 6651
 Brodin, B., 3861
 Brodt, P., 5393
 Broët, P., 4685
 Broggini, M., 2332
 Bröker, L. E., 4081
 Bronder, J. L., 5236
 Bronk, S., 1648
 Bronson, R. T., 2281
 Bronstein, J. M., 2287
 Brooks, J. S. J., 135
 Brooks, M. W., 6348
 Brose, M. S., 6997
 Brossart, P., 5065
 Brouillard, S. R., 4746
 Brown, A. M. C., 5405
 Brown, E. B., 6831
 Brown, J., 4757
 Brown, J. M., 5248
 Brown, K. M., 2654
 Brown, L. F., 2004
 Brown, M., 89, 1045
 Brown, N. S., 1326
 Brown, P. H., 6376
 Brown, S., 4968
 Brown, S. L., 4202
 Brown, V. D., 967
 Browne, L. W., 2890
 Bruckheimer, E. M., 6712
 Brueckl, W. M., 3009
 Bruland, O. S., 3120
 Brünagel, G., 2437
 Brune, K. A., 3789
 Brunner, J., 6750
 Brünner, N., 3428
 Brusic, V., 213
 Bryneel, E., 4879
 Bubendorf, L., 1256
 Bucala, R., 5881
 Bucana, C., 5720
 Buchczyk, D. P., 4922
 Buchdunger, E., 5476
 Buchmann, A., 5685
 Buchsbaum, D. J., 773
 Buck, A. K., 3331
 Buckle, T., 6158
 Budach, V., 6621
 Budman, D., 290
 Bueno, R., 4963
 Bueren, J. A., 5013
 Buerger, H., 1020
 Bueso-Ramos, C., 4945
 Buetow, K., 3340
 Buettner, R., 5962, 6659
 Buettner, T. L., 445
 Buffinton, G. D., 2092
 Buisine, M.-P., 848
 Bulavin, D. V., 7305
 Bult, C. J., 1235
 Bunch, D., 990
 Bundred, N. J., 122
 Bunn, P. A., 3971
 Bunz, F., 1129
 Burbee, D., 2715
 Burg, M. A., 977
 Burgart, L. J., 1531
 Burger, A. M., 3113
 Burger, R. A., 5001
 Buricchi, F., 6489
 Burke, J., 2806
 Burke, P. A., 4263
 Burke, W., 376
 Burlingame, S. M., 1123
 Burlini, A., 3106
 Burnette, P. K., 5761
 Burns, P. N., 6371
 Burton, E. C., 6205
 Burton, J., 2029
 Buscail, L., 6124
 Busch, T. M., 7273
 Büschenthaler, C. M., 2244
 Buschle, M., 1477
 Bushell, M., 2272
 Bussink, J., 7066
 Bussolati, B., 2406
 Bussolati, G., 2406
 Busson, P., 1920
 Buteau-Lozano, H., 4977
 Buterin, T., 4229
 Butler, M. P., 4089
 Buttitta, F., 2535
 Byeon, M. K., 5083
 Byers, S. W., 6688
- C
- Cabañas, M. E., 5672
 Cabon, F., 6538
 Cachafeiro, C., 990
 Cai, D., 5267
 Cai, S., 6475
 Cai, S.-L., 3766
 Cai, Y., 5399
 Cairncross, J. G., 1790
 Cajal, S. R., 3855
 Calaluce, R., 2890
 Caldwell, C. W., 3214
 Caligiuri, M., 1261
 Caligiuri, M. A., 6552
 Calise, D., 6124
 Calvisi, D. F., 4459
 Calvo, A., 3934, 5325
 Camafeita, E., 3167
 Camarero, G., 6297
 Cameron, E., 7175
 Cameron, E. R., 7181
 Cameron, J. L., 1868
 Camoratto, A. M., 6462
 Camp, R. L., 497
 Campbell, K., 7102
 Campbell, R., 4109
 Campbell, R. B., 6831
 Campisi, J., 547, 4736
 Campo, E., 619
 Campo, L., 1326
 Canbay, A. E., 6500
- Canessa, P. A., 5418
 Canitrot, Y., 3511
 Canning, C., 5517
 Canron, X., 6884
 Canto, M., 1868
 Cantor, A., 6659
 Cantor, H., 2281
 Cao, B., 589
 Cao, D., 2313
 Cao, L., 4843
 Cao, X., 2856
 Capella, G., 4519, 5902
 Capello, D., 4089
 Caputo, L., 5267
 Caragine, T. A., 1110
 Carcangi, M.-L., 2778
 Cardenas, D. M., 2771
 Cardiff, R. D., 2999, 4812, 5096
 Cardinali, B., 1196
 Cardones, A. R., 7328
 Cardourel, A. J., 307
 Carducci, M., 2576, 5618
 Carey, D., 4273
 Carl, V. S., 4061
 Carles-Kinch, K., 2840
 Carlonamogno, F., 1077, 7284
 Carlo-Stella, C., 6152
 Carlson, B. L., 7291
 Carlton, P. S., 4376
 Carmella, S. G., 129
 Carmen, J. C., 7280
 Carmichael, J., 1669
 Carnot, F., 1868
 Caron, A., 1388
 Carpenter, J. D., 1784
 Carrabba, G., 6884
 Carrasquillo, J. A., 5755
 Carr-Locke, D. L., 682
 Carroll, J. S., 3126, 6916
 Carroll, V. A., 5912
 Carson, J. P., 18
 Carter, D., 6667
 Casaleto, J., 1196
 Casalini, P., 567
 Casanova, B., 3402
 Casanova, M. L., 3402
 Caspar, C. B., 5845
 Cassady, J., 6857
 Cassetti, M. C., 5792
 Cassoni, P., 2406
 Castedo, M., 1388
 Castelli, F., 213
 Castiglion, F., 1321
 Castiglion, P., 1116
 Casto, B. C., 5295
 Castranova, V., 5689
 Castrillon, D. H., 2761
 Catley, L. P., 4996
 Cattaneo, M., 567
 Caulee, K., 6211
 Cavalli, L. R., 6990
 Cavenee, W. K., 6764
 Cayre, A., 617
 Cazares, L. H., 3609
 Cazaux, C., 3511
 Celestino, J., 6376
 Celestino, J. C., 5551
 Celikkaya, G., 6634
 Celis, E., 5807
 Cerignoli, F., 1196
 Cermak, L., 6278
 Cernaianu, G., 4034
 Cerottini, J.-C., 1743, 2058
 Cerrano, P. G., 5418
- Certa, U., 3453
 Cervek, M., 2771
 Ceryak, S., 179
 Cevario, S., 7175
 Chabay, P. A., 4876
 Chace, D. F., 3736
 Chacko, S., 3340
 Chada, S., 2239
 Chadwell, B. A., 6817
 Chaganti, R. S. K., 4089, 6218
 Chaganti, S., 4089
 Chakladar, A., 4307
 Chakravarti, A., 200, 4307
 Chambers, A. F., 887, 2162
 Chambers, W. H., 2583
 Chames, P., 3184
 Chamorro, M., 6674
 Champlin, R. E., 3603
 Chan, A. S., 6451
 Chan, D. C. F., 3063
 Chan, D. W., 1868
 Chan, F. L., 6039
 Chan, K. C., 122
 Chan, K. Y. K., 4151
 Chan, S., 2761
 Chan, T. L., 6451
 Chandler, D. S., 1952
 Chandra, D., 2976
 Chandramouli, V. R., 6246
 Chandrasekaran, R., 1939
 Chang, A. C., 1289
 Chang, B.-L., 1784, 2253, 6485
 Chang, C., 6039
 Chang, C.-C., 6178
 Chang, C.-F., 4346
 Chang, D. D., 5358
 Chang, J., 801
 Chang, J.-Y., 3716
 Chang, L., 4491
 Chang, L. M., 6779
 Chang, P., 4566
 Chang, P.-L., 5336
 Chang, Q., 6035
 Chang, Y.-S., 6952
 Chaplin, D. J., 7247
 Chapman, J. M., 5083
 Chapman, W., 3663, 4095
 Chapoval, A., 1884
 Chappuis, P. O., 6808
 Charboneau, L., 3244
 Charbonnier, F., 848
 Charrier, L., 2169
 Charytonowicz, E., 6973
 Chatterjee, P., 3562
 Chatterjee, S., 3175
 Chattopadhyay, S., 6434
 Chaturvedi, P., 1797
 Chaudhary, P. M., 5897
 Chaudhri, N., 2365
 Chauhan, D., 3876
 Chauvet, C., 1158
 Chayvialle, J.-A., 4829
 Cheadle, C., 2923
 Cheadle, J. P., 363
 Cheburkin, Y., 840
 Chedorge, M., 2169
 Chella, A., 2535
 Chen, A., 1036
 Chen, B., 4419
 Chen, C., 3636
 Chen, C.-F., 5134
 Chen, C.-L., 6952
 Chen, C.-M., 3214
 Chen, C.-S., 6928

* For title of article and coauthors, see listing in Contents of Volume beginning on page at the end of this index issue.

AUTHOR INDEX TO VOLUME

- Chen, D., 967, 1178
 Chen, D. J., 2483
 Chen, D. Y.-S., 1613
 Chen, D. Z., 433
 Chen, D.-S., 4346
 Chen, E. J., 113
 Chen, F., 2468
 Chen, F.-A., 2611
 Chen, H., 338
 Chen, J., 589, 1305
 Chen, J. H., 3736
 Chen, J. Z., 6470
 Chen, J.-G., 1935
 Chen, L., 1761, 1884, 3459, 4413,
 5517
 Chen, L.-C., 1330
 Chen, L.-T., 3716
 Chen, N., 1300, 1343
 Chen, P.-J., 4346
 Chen, P.-L., 2498, 3966, 5134
 Chen, S., 6740
 Chen, S.-Y., 1123, 2600
 Chen, T.-H., 7001
 Chen, W. R., 4295
 Chen, X., 1213, 1458, 1737, 2430,
 4704
 Chen, Y., 391, 3743, 6246
 Chen, Y.-T., 4041
 Chen, Y.-W., 4346
 Chen, Z., 5049
 Chen, Z.-S., 3144, 6172
 Cheng, J., 4157
 Cheng, J. C., 2365
 Cheng, J. D., 4767
 Cheng, J. Q., 4575
 Cheng, L., 2232, 3904
 Cheng, S.-Y., 756
 Cheng, Y., 241
 Cheng, Y.-c., 459, 1624
 Cheng, Y.-F., 6952
 Cheng, Z.-J., 5223
 Cherrington, J. M., 1702
 Chesney, J., 5881
 Chester, R., 4645
 Cheung, A. L. M., 1662
 Cheung, A. M. Y., 6194
 Cheung, A. N. Y., 4151
 Cheung, N.-K., 2988
 Cheung, N.-K. V., 1761
 Cheung, S. T., 4704
 Chevallier, O., 4685
 Chevallier, P., 2861
 Cheville, J. C., 3308, 6796
 Chew, K. L., 3812
 Chia, M., 171
 Chiang, Y.-H., 756
 Chiao, J. W., 2
 Chiaraadonna, F., 7050
 Chiariugi, P., 6489
 Chiba, N., 4222
 Chiba, T., 506
 Chieco-Bianchi, L., 6099
 Chien, J., 262
 Childs, A. C., 4592
 Childs, G., 1184, 6973
 Chillakuru, R. A., 3834
 Chin, K., 3636
 Chinnadurai, G., 3373
 Chinnaian, A. M., 2337, 4427
 Chinratanalab, W., 4132
 Chiodoni, C., 4390
 Chiorazzi, N., 290
 Chirnomas, R. B., 113
 Chiu, P. P. L., 5828
- Chiu, S. W., 4464
 Chlenski, A., 7357
 Cho, B., 3233
 Cho, K. R., 4722
 Cho, Y.-M., 1956
 Choi, I.-H., 1809
 Choi, Y., 1275
 Chong, J.-M., 233
 Chong, T. W., 6924
 Chopra, D., 2976
 Chow, T.-C., 6909
 Chow, K. U., 1768
 Chow, T. Y. K., 5888
 Chrastina, A., 4469
 Christa, L., 1868
 Christensen, L. L., 4352
 Christiani, D. C., 1377, 2819
 Christie, N., 2141
 Christofori, G., 603
 Christopher, S. A., 6639
 Christov, K. T., 5178
 Chtarbova, S., 1718
 Chu, D., 1213
 Chu, P., 6667
 Chuang, L. S.-H., 1592
 Chuang, Y.-Y. E., 6246
 Chun, K.-H., 3530
 Chung, F.-L., 2
 Chung, L. P., 4464
 Chung, L. W. K., 3084
 Chung, M., 1275
 Chung, N. H. C., 7170
 Chung, Y.-L., 688
 Churchman, M., 4562
 Ciardiello, F., 7284
 Ciesielski, M., 3159
 Ciesielski, M. J., 6552
 Cifuentes, E., 2488
 Cin, P. D., 3980
 Ciolino, H. P., 3685
 Cirilli, A., 3654, 6381
 Cirri, P., 6489
 Civin, C. I., 2232, 3904
 Claesson-Welsh, L., 1944
 Clarijs, R., 7059
 Clark, B., 5049
 Clark, G. M., 6510
 Clark, J., 2798
 Clark, M. A., 5443
 Clarke, A. R., 6615
 Clarke, R., 3428
 Clarkson, B., 4236, 4244
 Claus, E. B., 6667
 Claypool, K., 5153
 Cleaveland, E. S., 892
 Cleaves, R., 2232, 3904
 Clemens, M. J., 2272
 Clements, M. A., 3609
 Clements, W. M., 3503
 Cleris, L., 6152
 Cleton-Jansen, A.-M., 48, 4599
 Cleveland, J. L., 2184
 Clevers, H., 5126
 Clézardin, P., 6538
 Clifford, R., 3340
 Clifford, S. C., 3803, 5906
 Cline, E. I., 7143
 Cobbs, C. G., 3347
 Cobbs, C. S., 3347
 Coderre, J. A., 3159
 Coffey, D. S., 647, 4029
 Coffin, D., 6246
 Cogen, P. H., 3794
 Cohen, B., 1330
- Cohen, C. J., 3184, 5835
 Cohen, H., 2660
 Cohen, M. B., 4812, 5096
 Cohen, P., 3530
 Cohn, S. L., 7357
 Coker, J. S., 4164
 Colau, D., 5510
 Colburn, N., 3044
 Colditz, G. A., 1045
 Cole, P. A., 2522, 6231
 Coleman, A. E., 1152
 Coleman, N., 6959
 Colgan, S. P., 3387
 Colgin, L., 4434
 Collard, J. G., 4484
 Collingridge, D. R., 5912
 Collins, C. C., 1939
 Collins, N. K., 990
 Collins, S. J., 48
 Collot, F., 2327
 Colombel, M., 6538
 Colombo, B., 941
 Colombo, M. P., 4390
 Colombo, T., 2332
 Colomer, D., 619
 Coman, W., 3759
 Combaret, L., 2771
 Combaret, V., 3646
 Comerford, K. M., 3387
 Comes, T., 3950
 Comoglio, P. M., 7025
 Compiont, A., 1609
 Conaway, C. C., 2
 Conaway, M. R., 6418
 Condeelis, J. S., 6278, 7166
 Connell, J. M., 445
 Connor, J. R., 165
 Conrad, S. E., 3985
 Constantini, O., 6901
 Contag, C. H., 5785
 Conte, R., 6178
 Conti, C. J., 3276, 3402
 Contreras, J. I., 5273
 Conway, K., 1987
 Conway, T. F., 2611
 Conway, T. F., Jr., 7254
 Cook, J. A., 6246
 Coomber, B. L., 1931
 Coon, C. I., 7200
 Cooney, M., 3408
 Cooper, C., 1832
 Cooper, C. S., 135
 Cooper, W. A., 1394
 Corao, D. A., 1014
 Corazzari, M., 5158
 Corbi, A. L., 3167
 Corbin, A. S., 7149
 Corbin, S., 3477
 Cordel, S., 1050
 Cordon-Cardo, C., 2988, 6973
 Cornelison, R., 1256
 Cornelisse, C., 4599
 Cornelisse, C. J., 48
 Corner, G. A., 4791
 Corstens, F. H., 6146
 Cortes, U., 6990
 Corti, A., 867, 941
 Corvalan, J. R. F., 2468
 Corveleyn, A., 5408
 Cosman, D., 6178
 Costa, M., 5689
 Cottam, H. B., 4007
 Couch, F. J., 3587
 Couch, V. L., 3587
- Couillard, M., 2210
 Coulie, P. G., 5510
 Coulombe, R. A., Jr., 105
 Couvé-Privat, S., 7186
 Coval, K., 213
 Cox, A. D., 4142
 Cox, C., 6451, 6997
 Cox, G., 1315
 Cox, G. J., 2493
 Cox, K., 5597
 Cozzi, G., 6489
 Cozzi, P., 2332
 Craddock, C. F., 4730
 Craig, B. A., 356
 Craig, R. W., 892
 Cramer, D. W., 3058
 Cramer, S. D., 6817
 Cranston, D., 2957
 Crawford, E. D., 5218
 Crawford, H. C., 5559
 Crawford, K. W., 313
 Crawford, S. E., 7357
 Creaney, J., 2766
 Cremesti, A., 2531
 Crémignon, C., 5425
 Cristiano, R. J., 3530
 Croce, C. M., 2258, 2398
 Croft, J., 6362
 Crook, T., 2072
 Crooks, H., 2744
 Crooks, L. A., 2370
 Cross, M., 1944
 Croucher, P. I., 1619
 Crowe, J., 5375
 Crowell, R. E., 2248, 2370
 Crum, C. P., 682
 Csizsar, K., 4478
 Cuevza, J. M., 6674
 Cui, H., 6442
 Cui, L., 603, 1987
 Cui, T.-G., 4123
 Cummings, J., 1876
 Cummins, A. B., 4169
 Cunha, G. R., 2999
 Curiel, D. T., 609, 1266, 1271,
 4273, 4663, 5736
 Curley, S. A., 1952, 3620
 Curnis, F., 867, 941
 Curry, B., 4645
 Curry, B. J., 5749
 Curwen, J. O., 4645
 Cuthbert-Heavens, D., 2957
 Czerwinski, D. K., 5845
 Czyzyk-Krzeska, M. F., 1682

D

- Dafni, H., 6731
 D'Agati, V., 2210
 Dagenais, S. L., 5273
 Dahler, A. L., 3759
 Dahlstrom, J. E., 2092
 Dahm, P., 5041
 Dai, C., 5551
 Dai, D., 881
 Dai, T., 1961
 Dai, W., 2
 Dai, Y., 1961
 Dairkee, S. H., 1000, 1939, 5980
 Daley, G. Q., 535
 Dall, P., 1266
 Dalla-Favera, R., 4089
 Dallol, A., 5874
 D'Amato, R. J., 2300

* For title of article and coauthors, see listing in Contents of Volume beginning on page at the end of this index issue.

AUTHOR INDEX TO VOLUME

- Dammann, R., 3698
 Dan, S., 1139
 Danan, J.-L., 1158
 Danenberg, K. D., 371
 Danenberg, P. V., 371
 Daneshvar, B., 4339
 Dang, J., 1222
 Dang, T. D., 3298, 6021
 Dangler, C. A., 696
 Daniel, J. J., 2092
 Daniel, L. W., 6817
 Danks, M. K., 5001
 Dannenberg, A. J., 2522, 5405
 Dannull, J., 5041
 Danska, J. S., 5828
 Dantzer, R., 4746
 Darling, G., 3005
 Darrah, D. M., 4722
 Dasari, R. R., 682, 5375
 Dasenbrock, C., 3448
 da Silva, N. F., 3803
 Dasnois, L., 2327
 Dassonneville, L., 7219
 Dauer, M., 2347
 Dauzon, D., 6506
 Davalos, A. R., 2637
 Davidoff, A. M., 3077
 Davidson, M. T. M., 887
 Davie, J. R., 75
 Davies, D. R., 2942
 Davies, E., 4164
 Davies, F., 5019
 Davies, H., 6451, 6997
 Davies, L., 1724
 Davies, M., 5564
 Davies, R., 4256
 Davis, A., 6080
 Davis, A. L. G., 2141
 Davis, B. J., 990
 Davis, B. M., 3070
 Davis, E. M., 3477, 5523
 Davis, G., 5058
 Davis, J. W., 3609
 Davis, M. A., 5463
 Davis, N., 3428
 Davis, P. D., 7247
 Davis, S. L., 7154
 Davis, T. W., 5778, 6706
 Davison, T. L., 6667
 Dawson, M., 3842
 Day, K. V., 4637
 Day, N. E., 3052
 Daya-Grosjean, L., 7186
 Daynes, R. A., 6870
 Deacu, E., 6820
 Deaglio, S., 2406
 Dearnaley, D. P., 3369
 Debes, J. D., 5632
 Debition, E., 2771
 Debruyne, P., 1718
 Debuire, B., 4685
 Debus, J., 7018
 De Carvalho, M., 4854
 Decaudin, D., 1388
 DeClue, J. E., 4507
 De Fabo, E. C., 6724
 de Felipe, C., 7343
 Degani, H., 1948, 1966
 Degen, J. L., 6966
 DeGortari, A. E., 356
 DeGraff, W., 6246
 DeGraffenreid, L., 6141
 de Gruijl, F. R., 1338
 de Heredia, M. L., 6674
 Deininger, M. W., 7149
 Dejana, E., 2567
 Dejmek, J., 409
 de Jong, A., 472
 Dejournett, R., 3782
 de Juan, C., 3855
 de Kok, J. B., 2695
 de la Chapelle, A., 4579
 Delahunt, B., 4554
 Delaney, M. A., 4307
 Delannoy, M. J., 6405
 De Latour, M., 1890
 DeLeo, A. B., 3521
 Delikatny, E. J., 1394
 Dell, J., 2516
 Dell'Agnola, C., 3106
 Delorme, D., 4325
 Del Piero, F., 7273
 Delsol, G., 1489, 3511
 Del Valle, L., 7093
 Delzenne, N., 3555
 De Marzo, A. M., 2220, 6405
 De Matteo, E., 4876
 DeMatteo, R. P., 5260
 Demeure, R. J., 3555
 Demidem, A., 1890
 De Miglio, M. R., 4459
 Demirpence, E., 6519
 Demopoulos, R., 2778
 Demou, Z. N., 5301
 DeNardo, G. L., 4263
 DeNardo, S. J., 4263
 Deng, J., 346
 Deng, M., 535
 Denis, M., 2169
 Denkberg, G., 3184
 Denmeade, S. R., 986
 Denner, L., 6080
 Dennis, J. L., 5999
 Denny, W. A., 1425
 Dent, P., 188
 Deora, A., 5405
 De Pascalis, R., 5049
 DePeralta-Venturina, M., 4968
 DePinho, R. A., 2761, 6724
 De Pinieux, G., 1388
 DeRisi, J., 4525
 Deryugina, E. I., 580
 Desai, K., 1148, 3493
 Desai, N., 2999
 Desai, S., 1439
 de Sauvage, F. J., 5308
 Desbaillets, I., 2962
 De Schrijver, E., 642
 de Silva Rudland, S., 3417
 Detmar, M., 2004
 de Toledo, S. M., 5436
 Devaux, B., 2546
 Devereux, T. R., 6424
 de Vere White, R. W., 1496
 De Vivo, I., 2819
 DeVries, G. H., 7357
 de Waal, R. M. W., 341, 7059
 Dewald, G. W., 715
 DeWeese, T. L., 7230
 De Wever, I., 3980
 de Wilde, P. C. M., 7066
 Dhanabal, M., 2468, 3834
 Dhanalakshmi, S., 3063
 Dhawan, P., 7335
 Diamandis, E. P., 295
 Diaz, J., 6659
 Diaz, R., 4514
 Diaz-Rubio, E., 3855
 DiBello, C., 7143
 DiBello, F., 3654
 Di Bonito, P., 3654
 Dichgans, J., 1915
 Dick, R. D., 4854
 Dicker, A. J., 3759
 Dickerson, W. M., 789
 Dickinson, C., 5470
 Dickson, C., 4562
 Dector, M., 4398
 Diegelman, P., 6639
 Dietmaier, W., 3009, 6796
 Dietrich, P.-Y., 1743
 Dietz, A., 6566
 Difez, J. L., 5013
 DiGiovanna, M. P., 6667
 DiGiovanni, J., 7207
 Dijkgraaf, I., 6146
 Dijkman, R., 5389
 Dilley, J., 3743
 Dimri, G. P., 4736
 Dimitchev, A., 6879
 D'Incalci, M., 2332
 Ding, Q., 5336
 Ding, W.-Q., 947, 5223
 Di Nicola, M., 6152
 Di Nicola, N., 1284
 Dinjens, W., 2758
 Dinjens, W. N. M., 1531
 Dinney, C. P., 5720
 Dinsdale, D., 4256
 DiRenzo, J., 89
 Dirks, A. J., 4592
 Dirven, C. M. F., 5736
 Divine, K. K., 2370
 Divoky, V., 5995
 Dixielius, J., 1944
 Dixon, K., 2766
 Dlugosz, A. A., 5308
 Dmitriev, I., 1266, 4273
 Dmitriev, I. P., 609
 Doerge, D. R., 1978, 2474
 Doetschman, T., 6362
 Dolan, J. P., 5069
 Dolmans, D. E. J. G. J., 2151, 4289
 Domann, F. E., 1205
 Dominici, C., 301
 Donà, M. G., 3654
 Donald, S., 4256
 Doñate, F., 5344, 5470
 Donfrancesco, A., 301
 Dong, B., 397
 Dong, D., 7207
 Dong, Y., 708
 Dong, Y. B., 1776
 Dong, Z., 1300, 1343
 Donnelly, E., 4671
 Donnelly, S., 5881
 Donnenberg, A. D., 3521
 Donnenberg, V. S., 3521
 Donovan, D. B., 3221
 Doody, J. F., 2567
 Dorion-Bonnet, F., 48
 Dorsey, R., 2606
 Dougherty, G. J., 7247
 Dougherty, R. H., 3257
 Doughty, J. M., 4123
 Dowle, A., 3369
 Dowlati, A., 3408
 Downes, A., 6132
 Dracheva, T., 2744, 3340
 Dragstedt, L. O., 4339
 Dralle, H., 3698
 Dranoff, G., 796, 5517
- Dreijerink, K., 3498
 Dressler, L., 1987
 Dreys, J., 4015
 Drijfhout, J. W., 472
 Dritschilo, A., 6879
 Drouin, S. S., 1987
 Drucker, B. J., 7149
 Du, B., 5405
 Du, C., 18
 Dubeau, L., 7207
 DuBois, R. N., 3282
 Dubois, V., 2327
 Duchesne, M.-J., 6519
 Duckett, A., 967
 Duell, E. J., 4630
 Duensing, S., 7075
 Duesberg, P., 6345
 Dugas, M., 251
 Duguay, D., 5148
 Duh, F.-M., 3498
 Duivenvoorden, W. C. M., 1588
 Dukes, M., 4645
 du Manoir, S., 6211
 Dunbrack, R. L. Jr., 4767
 Duncan, A. M. V., 5457
 Dunn, T. A., 2220
 Dunning, A. M., 3052
 Dunson, D. B., 3395
 Durand, R. E., 6827
 Duray, P., 6724
 Duray, P. H., 3581
 Durham, W. F., 5778
 Dutoit, V., 1743, 2058
 Dutriaux, A., 1129
 Dutchman, G. E., 1624
 Duval, A., 1609, 2447
 Duvall, J., 3562
 Dwyer-Nield, L. D., 6850
 Dyck, P. A., 4419
 Dyson, N. J., 200
- E
- Eads, C. A., 1296
 Easton, D. F., 3052, 3369
 Eaton, C. L., 1619
 Eberhard, D., 2546
 Eckard, J., 417
 Eckardt, K.-U., 3803
 Eckerdt, F., 4186
 Eddy, E. M., 990
 Edgington, T. S., 5470, 7118
 Edkins, S., 6451
 Edmiston, S. N., 1987
 Edmonston, T. B., 1014
 Edmund, N. A., 3868
 Edwards, D. R., 5543
 Edwards, D. S., 6146
 Edwards, E., 4671
 Edwards, E. M., 4478
 Edwards, R., 4256
 Edwards, S., 3369
 Edwards, S. W., 6500
 Eeles, R. A., 3369
 Eggert, A., 1802, 6462
 Egilmez, N. K., 2611, 7254
 Eguchi, S., 7213
 Egyed, A., 1477
 Ehemann, V., 5139
 Ehinger, M., 4398
 Ehninger, G., 4955
 Ehtesham, M., 5657, 7170
 Eiben, G. L., 5792
 Eichwald, E. J., 6870

* For title of article and coauthors, see listing in Contents of Volume beginning on page at the end of this index issue.

AUTHOR INDEX TO VOLUME

- Eigler, A., 2347
 Eils, R., 2993
 Einhorn, E., 6997
 Eischen, C. M., 1222, 2184
 Eisenbach, L., 5835
 Ek, S., 4398
 El-Alfy, M., 721
 Elbaggari, A., 5536
 El-Deiry, W. S., 7316
 Elder, D. E., 3992
 El-Gamil, M., 3630
 El-Hizawi, S., 3264
 Elia, A., 6194
 Elkahloun, A., 6240
 Elkahloun, A. G., 1256
 Ellenson, L. H., 4722
 Elliott, J., 2766
 Elliott, M. J., 1776
 Ellis, D. L., 7335
 Ellis, L. M., 2034
 Ellison, D. W., 5906
 El-Naggar, A., 1952
 El-Naggar, A. K., 6414
 El-Rifai, W., 2625, 4061, 6823
 El-Sheikh, A., 5470, 7118
 Elstrott, F., 1822
 El-Tanani, M., 3417
 Emanuele, M. J., 7273
 Emmell, E., 2824
 Emmert-Buck, M. R., 3498, 5325
 Enam, S., 7093
 Endres, S., 2347
 Enerbäck, C., 43
 Engbring, J. A., 3549
 Engle, S. J., 6362
 Engles, J., 371
 Engles, J. M., 3659
 Enholm, B. C., 1669
 Enjo, K., 636
 Ensor, C. M., 5443
 Entschladen, F., 6467
 Enzmann, T., 251
 Eppig, J. T., 1235
 Erban, J., 2741
 Erdos, M., 141
 Errf, M., 2583
 Eriksson, M., 5210
 Eriksson, S., 3100
 Ernst, M., 6779
 Errington, F., 5495
 Esche, H., 3598
 Eshhar, Z., 6803
 Eshleman, J. R., 7230
 Eshleman, J. S., 7291
 Espejo, A., 6475
 Espinosa, R. III, 3477, 5523
 Esposito, G., 6099
 Esser, N., 4015
 Esteban-Barragán, M. A., 2929
 Esteller, M., 1166, 3659, 4519,
 5902
 Evangelista, A., 7357
 Evans, A. E., 1802, 6462
 Evans, M. K., 1349
 Evans, M. S., 4575
 Evans, P. R., 3369
 Evans, S. M., 3626
 Ewan, K. B., 5627
 Ewing, C. M., 2220
- F
 Fages, C., 4805
 Fahrner, J. A., 7213
- Fairclough, R., 6659
 Faith, 6485
 Falcone, R., 6659
 Falini, B., 1559
 Falk, C. S., 480
 Fallavier, M., 4829
 Fallavollita, L., 5393
 Fan, A., 3221
 Fan, D., 5720
 Fan, H., 5611
 Fan, S., 141
 Fan, S. T., 4704
 Fang, B., 2715, 3620, 7264
 Fang, G., 3842
 Fang, H., 7328
 Fang, J., 3138, 4212
 Fang, J.-L., 1978
 Fang, Y., 7157
 Farago, M., 5835
 Farber, R. A., 6061
 Farhana, L., 3842
 Farley, K. M., 5035
 Farrell, P. J., 2072
 Farrer, R., 7357
 Faul, M. M., 5597
 Faure, P., 6124
 Faustman, D. L., 24
 Fauth, C., 1129
 Favrot, M.-C., 3646
 Fearon, E. R., 1613, 4722
 Fears, T. R., 3992
 Fedele, M., 2398
 Federoff, H. J., 6545
 Fedorov, L. M., 6297
 Fedowitz, M., 1356
 Fei, P., 7316
 Feil, A., 781
 Feinberg, A. P., 48, 6442, 6784
 Feld, M. S., 682, 5375
 Feldman, A. L., 3934
 Feldman, M., 6997
 Feldman, M. D., 747, 1481
 Felix, D. H., 4757
 Feltes, C. M., 6688
 Feng, H., 1662
 Feng, W.-h., 1920
 Feng, X., 2468, 5106
 Feng, Z., 3609
 Fenoglio-Preiser, C., 3503
 Fenstermaker, R. A., 3159, 6552
 Fenton, R. G., 450
 Feo, F., 4459
 Ferdinandusse, S., 2220
 Ferenczi, K., 528
 Ferguson, P. R., 2644
 Ferhle, W., 1256
 Fernald, A. A., 5523
 Fernandes Da Silva, N., 5874
 Fernandez, A.-M., 2327
 Fernández, P. L., 619
 Fernández-Aceñero, M. J., 3402
 Fernández de Velasco, J., 5013
 Fernando, G. J. P., 6438
 Fernando, H. C., 2681
 Ferner, R. E., 1573
 Feron, O., 3555
 Ferrara, J. L. M., 796
 Ferrario, A., 3956
 Ferreira, C. G., 4081
 Ferrer, F., 2576
 Ferrer-Miralles, N., 4514
 Ferrone, S., 6178
 Feuerstein, B. G., 6205
 Feunteun, J., 764, 3883
- Fiebring, H. H., 3113
 Fields, H. W., 5451
 Filiberti, R., 5418
 Filippova, G. N., 48
 Filleur, S., 6538
 Fillion, C., 721
 Filomenko, R., 1815
 Finan, D., 5076
 Finch, R. A., 3221
 Finelli, P., 2398
 Singleton, B., 5559
 Finkelstein, S., 2141
 Finkelstein, S. D., 2681, 3521
 Finnerty, B., 2567
 Finney, G. L., 6916
 Firat-Geier, E., 6901
 Firoozbakht, F., 2749
 Fischer, P., 4820
 Fischer, S. M., 1178, 2516
 Fischetti, L., 867
 Fishbein, M. C., 3207
 Fisher, R., 1014, 5988, 6796
 Fisher, C., 135
 Fisher, D., 2098
 Fisher, P. W., 1797
 Fishman, D. A., 5358
 Fitzmaurice, M., 5375
 Flanigan, R. C., 5218
 Flavell, R. A., 1343
 Flavia Di Renzo, M., 7025
 Fleitmann, J.-K., 1477
 Fleming, J., 4757
 Fleming, N., 363
 Fleshman, J. W., 445
 Fleschner, N. E., 2540
 Flesken-Nikitin, A., 2498, 5134
 Fletcher, C. D. M., 3980
 Fletcher, J. A., 6035
 Fletcher, L., 241
 Flies, D., 1884
 Flies, D. B., 4413
 Flora, R., 4730
 Flores, K. R., 4289
 Fluitter, K., 2024
 Foà, R., 5408
 Fodor, J., 4836
 Fodstad, O., 3120
 Foekens, J. A., 4617
 Foglieni, C., 941
 Fölsch, U. R., 910
 Fong, S. F. T., 4478
 Fonseca, R., 715
 Fontana, J. A., 3842
 Fontanini, G., 7284
 Ford, O. H., 2423
 Foreman, T. L., 2423
 Forman, S. J., 3175
 Formelli, F., 6152
 Formigli, L., 6489
 Fornace, A. J., Jr., 7305
 Forsyth, P., 6205
 Fosdick, L., 3361
 Fossá, S. D., 512, 2359
 Foster, C. J., 1952
 Foster, F. S., 6371
 Foster, P., 6462
 Foulkes, W. D., 6808
 Fournel, M., 4325
 Fournier, A., 721
- Fournier, P., 6538
 Fox, B. A., 3914
 Fox, E., 3485
 Fox, J. G., 696
 Fraga, M. F., 4519
 Fram, R., 789
 Francia, G., 2731
 Francisco, J. A., 3736
 Francisco, L. V., 3736
 Franco, S., 552
 Franconi, R., 3654
 Frankel, A. E., 1730
 Franken, K. L. M. C., 472, 6187
 Franklin, W. A., 3971
 Frantz, G., 2546
 Fränzel-Luiten, E., 7298
 Frati, L., 1196
 Frau, M., 4459
 Frazer, I. H., 6438
 Frazier, M., 1952
 Frebourg, T., 848
 Frechette, S., 4325
 Frederiksen, Z., 3587
 Frederiksen, C. M., 4352
 Freed, D. D., 3221
 Freeman, J., 2982
 Freeman, M. R., 1549, 2227
 Freeman, T., 6959
 Frei, E., 5678
 Freier, S., 219
 Frenkel, K., 417
 Freudenberg, M., 6901
 Freudenstein, J., 3448
 Freund, D., 4955
 Freund, G. G., 4746
 Frey, A. B., 1110
 Freytag, S. O., 4968
 Fricker, S., 5930
 Friebel-Hoffmann, U., 3521
 Friece, C. R., 7042
 Frieden, B. R., 3675
 Friedl, P., 2125
 Friedlander, D. R., 2660
 Friedlos, F., 1724
 Friedman, A. D., 2232, 3904
 Friedman, D., 3377
 Friedman, H. S., 3335
 Friedmann, P. S., 1757
 Friedrichs, W. E., 6141
 Frieling, C., 6146
 Friend, S., 3883
 Frierson, H., Jr., 2625
 Frierson, H. F., 6418
 Frierson, H. F., Jr., 4061, 6823
 Frieser, M., 3113
 Frilling, A., 3598
 Fritz, A., 3048
 Fritz, B., 2993
 Fritz, J., 1477
 Frödin, J.-E., 1364
 Frohlich, V. C., 6278
 Fry, R. D., 1014
 Fu, K. K., 7350
 Fu, T., 7195
 Fu, X., 2306
 Fuchs, E., 5664
 Fueyo, J., 5736
 Fuggle, S., 2493
 Fuhrman, U., 3766
 Fujibayashi, Y., 445
 Fujii, H., 5813
 Fujii, T., 3340
 Fujita, M., 5651
 Fujita, N., 2971

* For title of article and coauthors, see listing in Contents of Volume beginning on page at the end of this index issue.

AUTHOR INDEX TO VOLUME

- Fujiwara, H., 3751
 Fujiwara, M., 2236
 Fujiwara, O., 1956
 Fukai, Y., 7162
 Fukami, T., 5129
 Fukayama, M., 233
 Fuks, Z., 2531
 Fukuchi, M., 7162
 Fukuda, M., 4194
 Fukuda, M. N., 4194
 Fukuda, T., 5603
 Fukuda, Y., 2215
 Fukuhara, H., 5129
 Fukui, R., 1410
 Fukumura, D., 2151, 4289, 6831
 Fukushima, S., 3592
 Fulci, G., 2897
 Fuller, G. N., 5551
 Fulton, A. M., 2343, 2606
 Funahashi, Y., 6116
 Furge, K. A., 6598
 Furnari, F. B., 6764
 Fürstenberger, G., 4610
 Furukawa, M., 6337
 Furukawa, T., 2834
 Furukawa, Y., 518, 5651, 7012
 Furumai, R., 4916
 Furuta, T., 4899
 Fusco, A., 1077, 2398, 7284
 Futreal, P. A., 6451, 6997
 Fuxius, S., 4015
- G**
- Gaarde, W. A., 3257
 Gabari, I., 3167
 Gabrielli, B., 875
 Gabrielson, E., 3971
 Gaddy-Kurten, D., 5571
 Gadisetti, 6246
 Gaedike, S., 6901
 Gage, W. R., 2220
 Gaidano, G., 4089
 Gaikwad, A., 3030
 Gail, M. H., 3992
 Galambos, P., 2347
 Galanis, E., 4656, 6070
 Galanos, C., 6901
 Galappathi, K., 661, 1847
 Galbraith, S. M., 7247
 Galipeau, J., 5148
 Gallez, B., 3555
 Gallie, B. L., 967
 Galliera, E., 2323
 Gallinger, S., 1284
 Gallo, E., 4390
 Gallo, J. M., 1382
 Galm, O., 5902
 Gama, P., 2778
 Gambotto, A., 5853
 Gan, D.-D., 7093
 Gandhi, V., 3100
 Ganem, D., 4525
 Gannon, G., 603
 Gano, J., 2806
 Gansbacher, B., 5543
 Ganss, R., 1462
 Gant, T. W., 4256
 Ganther, H. E., 156, 708
 Gao, B., 734, 2715, 3971
 Gao, F. G., 6438
 Gao, P., 3751
 Gao, Q., 3315
 Garabedian, E. M., 1555
- Garattini, E., 2192
 Garber, J., 3485, 3925
 Garbow, J. R., 445
 Garcia, R., 4514, 6659
 García-Castro, J., 5013
 García-Pardo, A., 2929
 García-Sánchez, F., 5013
 Gardelle, O., 2962
 Gardiner, B. B., 226
 Gardner, A. E., 4599
 Garès, M., 3511
 Garmestani, K., 5755
 Garner, E. I. O., 3058
 Garrido, C., 1815
 Gärtner, S., 840
 Garvin, A. J., 6598
 Gasbarri, A., 3861
 Gasco, M., 2072
 Gascon, R., 5536
 Gascoyne, R. D., 4089
 Gasper, W. J., 5463
 Gassmann, M., 2962
 Gastaldi, T., 1559
 Gastineau, D., 1884
 Gastman, B. R., 4884
 Gatenby, R. A., 3675, 5218
 Gates, J., 5564
 Gatter, K., 2493
 Gatter, K. C., 1326, 2957
 Gatto, S., 5995
 Gattuso, P., 4876
 Gaudet, J., 43
 Gault, E., 7175
 Gaunat, F., 5685
 Gauny, S. S., 1279
 Gautam, S., 2488
 Gawlinski, E. T., 5218
 Gay, J., 4115
 Gaymes, T. J., 2791
 Gayo-Fung, L. M., 1439
 Gazdar, A., 3945
 Gazdar, A. F., 3382, 5897, 6820
 Gazit, A., 1077
 Gazit, G., 2468
 Gazzoli, I., 3925
 Ge, S., 6270
 Geacintov, N. E., 4229
 Gebhardt, R., 5685
 Gee, J. M., 122
 Gee, M. S., 747
 Geenen, V., 4623
 Geil, L., 3498
 Geissinger, E., 4820
 Gelmann, E. P., 2654
 Geluk, A., 472
 Geng, L., 4671
 Geng, Y., 4540
 Geoerger, B., 764, 5736
 Georgakoudi, I., 682
 Gera, J., 5027
 Geraci, M., 3971
 Geraci, M. W., 734
 Geraldts, J., 1987
 Gerald, W. L., 1761, 2988, 4499
 Gerber, J. N., 4289
 Gerber, P. A., 4922
 Gerbin, C. S., 5358
 Gere, S., 4191
 Gerhard, B., 1730
 Gernert, K. M., 2897
 Geroni, C., 2332
 Guerrero, R., 6997
 Gerritsen, W. R., 5736, 6165
 Gerson, S. L., 3070
- Gescher, A. J., 4256
 Geschwind, J.-F. H., 3909
 Gesell, T. L., 734
 Gespach, C., 4879
 Gessain, A., 3562
 Getzenberg, R. H., 2437
 Gevrey, J.-C., 4829
 Ghali, L. R., 4773
 Ghidomi, R., 2455
 Ghilardi, J. R., 7343
 Ghirelli, C., 1321
 Gho, Y. S., 6312
 Ghosh, D., 4427
 Ghosh, P. M., 2630
 Giaccone, G., 4081
 Giannini, M., 2192
 Gianni, M. A., 6152
 Giannini, G., 1196
 Giannoni, E., 6489
 Giardina, C., 3667
 Giardino, D., 2398
 Gibbs, R., 3369
 Gibril, F., 3702
 Gibson, E. M., 488
 Gibson, J. J., 7200
 Gibson, K. H., 5749
 Gibson, S. B., 488
 Giese, N. A., 3729
 Gilbert, M. R., 4364
 Gilboa, E., 5041
 Gildea, J. J., 982, 6418, 6981
 Gildea, J. W., 6981
 Gillan, L., 5358
 Gillatt, D., 4123
 Gillespie, G. Y., 773, 2699, 3347
 Gillespie, J. W., 3498
 Gilliland, F. D., 2248, 2370
 Gillis, A. J. M., 1822, 2758
 Gilmour, S. K., 67
 Gimmo, O., 3698
 Gimmi, C. D., 437
 Gingras, D., 381
 Gioldini, A., 2462
 Giordano, T. J., 4722
 Giorgi, C., 3654
 Giraudier, S., 4685
 Gisselsson, D., 2675, 5939
 Giuliano, R. E., 6545
 Giussani, C., 6884
 Gladson, C. L., 2699, 5336
 Gladu, J., 2390
 Glaser, M., 5912
 Glatstein, E., 7273
 Glating, G., 3331
 Glazer, C. A., 3335
 Glazer, R. I., 3538
 Glickman, N. W., 356
 Glover, T. W., 5273
 Glüsenkamp, K.-H., 1718
 Glynne, R., 1289
 Go, V. L. W., 741
 Gobbi, A., 3106
 Goebel, S. U., 3702
 Goepfert, T. M., 4115
 Goertz, D. E., 6371
 Gofin, J. R., 6808
 Gofman, I., 5536
 Goggins, M., 1868
 Goich, S., 5308
 Gokden, N., 6470
 Gold, L. I., 2778
 Goldberg, I. D., 141
 Goldberger, N., 1256
 Goldblum, J. R., 135
- Goldenberg, D. M., 2029
 Golding, M., 5698
 Goldman, I. D., 6434
 Goldschmidt, E., 4685
 Goldsmith, J. D., 135
 Goldstein, A. M., 4191
 Goldstein, L. A., 4884
 Goldstein, M., 6803
 Golembieski, W. A., 6270
 Golnick, S. O., 1604
 Golob, M., 5962
 Goloubeva, O., 4996
 Golpon, H. A., 734
 Gomer, C. J., 1458, 3956
 Gomez, D., 3365
 Gómez-Pineda, A., 5013
 Gonzales, F. A., 961, 2378, 6456
 Gonzales, M. I., 5505
 Gonzalez, A. M., 977
 Gonzalez, F. J., 3030
 González-Quevedo, R., 3855
 Goode, E. L., 3052
 Gooderham, N., 4605
 Gopalakrishnan, R., 4376
 Gorbsky, G. J., 2462
 Gordon, C. M., 4041
 Gordon, G. J., 4963
 Gordon, J. I., 1555
 Gordon, J. R., 2043
 Gore, S. D., 5618
 Gorelik, E., 5727
 Gores, G. J., 1648, 6500
 Gorfajn, B., 3377
 Gorny, I., 1477
 Gorospe, M., 3257
 Gosink, M., 2913
 Gotanda, T., 2834
 Goto, H., 3711, 5967
 Goto, M., 7004
 Gottenger, E., 5974
 Gotthard, S., 4955
 Gottlieb, D. J., 283
 Götz, R., 6297
 Gouble, A., 1489
 Gough, M., 5495
 Gough, M. J., 6566
 Gould, M. N., 1241
 Gould, V. E., 4876
 Goulding, E. H., 990
 Goulet, B., 6625
 Goutefangeas, C., 5818
 Gozzetti, A., 5523
 Grachitchouk, M., 5308
 Graff, B. A., 661, 1847
 Graham, G., 359
 Graham, G. A., 4645
 Gramatzki, M., 2848
 Grammer, J. R., 2699, 5336
 Grana, T. M., 4142
 Grant, S., 188
 Grass, L., 295
 Graw, J., 3048
 Gray, J. W., 1000, 1939, 3636
 Gray, P., 6870
 Grazide, S., 1489
 Greaves, P., 4256
 Greco, M. A., 2660
 Green, J. E., 3934, 5325
 Green, L., 5106
 Green, S. J., 3691
 Green, S. K., 2731, 6891
 Greenberg, N. M., 7135
 Greene, G. F., 6470
 Greenwald, B. D., 3493

* For title of article and coauthors, see listing in Contents of Volume beginning on page at the end of this index issue.

AUTHOR INDEX TO VOLUME

- Grégoire, M., 1050, 2861
 Grégoire, V., 3555
 Gregory, C. W., 2423
 Greil, J., 2848
 Greiner, J. W., 5049, 5058, 6944
 Greipp, P. R., 715
 Grenier, J., 721
 Gri, G., 4390
 Griffin, C., 3789
 Griffin, C. A., 647
 Griffin, C. S., 6263
 Griffin, J. D., 5019
 Griffin, R. J., 1702
 Griffith, T. S., 3093, 7170
 Griffiths, J. R., 688
 Grill, J., 764, 5736, 6165
 Grimes, M. J., 2370
 Grimwade, D., 4730
 Grinstein, S., 4876
 Groden, J., 2766, 3503
 Groom, A. C., 887, 2162
 Grossman, D. A., 3826
 Grossschmidt, K., 5317
 Grotzer, M. A., 1802
 Gruman, L. M., 665
 Grundy, P. E., 48
 Grünebach, F., 5065
 Grünwald, V., 6141
 Grupp, S. A., 4212
 Grushko, T. A., 1481
 Gryfe, R., 1284
 Gschwendt, B., 6698
 Gschwind, A., 6329
 Gu, J., 3620
 Gu, X., 3782
 Gu, Z., 3428
 Guadagni, F., 5049
 Guan, J., 1598
 Guan, X., 5344
 Guan, X. Y., 4704
 Guan, X.-Y., 7157
 Guan, Y., 6909
 Guba, M., 4034
 Gubish, C. T., 2141
 Gückel, B., 2052
 Guda, K., 3667
 Gudas, J. M., 113, 5106
 Gudas, L. J., 1196, 1654
 Guerry, D. P., IV, 3992
 Guglielmi, J., 6538
 Guha, S., 1632
 Guichard, S. M., 5001
 Guida, T., 1077, 7284
 Guillaume, P., 1743
 Guillaume, R., 2210
 Guillaume, T., 4985
 Guillemette, C., 1978
 Guillerm, C., 3562
 Guiot, M.-C., 2131
 Guldung, K. M., 982
 Gulino, A., 1196
 Gullans, S. R., 4963
 Gumbiner-Russo, L., 3782
 Gumin, G. J., 2318
 Gunawardena, R. W., 6587
 Gunn, R. N., 5698
 Gunning, W. T., 4199
 Gunz, D., 4229
 Guo, C., 6481, 6651
 Guo, H.-B., 6837
 Guo, M., 1166, 4023, 4637, 5902
 Guo, P., 756
 Guo, S., 652
 Guo, W.-X., 801
- Guo, X., 589, 1196, 1654
 Guo, Y., 4413
 Guo, Y. J., 4678
 Gupta, A., 4376
 Gupta, D., 4996, 5019
 Gupta, K., 4491
 Gupta, S. K., 4484
 Gure, A. O., 4041
 Gustafsson, J.-A., 4849
 Gusterson, B., 2072
 Gutierrez, M. A. R., 7170
 Gutierrez, M. D., 2929
 Gutkind, J. S., 1401
 Gutmann, D. H., 1573, 2085
 Guy, S. P., 5749
 Gwdry, F. G., 1688
 Gwyn, K., 1676
- H**
- Ha, L., 179
 Ha, S., 1275
 Haaf, T., 219
 Haapasalo, H., 3798
 Habeler, W., 6099
 Haber, D. A., 2741
 Habib, S., 4376
 Haddad, B. R., 6990
 Haffty, B. G., 497
 Hagedorn, M., 6884
 Hagelstein, M.-T., 4623
 Hagemann, R., 4352
 Hagemeyer, A., 5408
 Hagibara, N., 1433
 Hagiwara, K., 63
 Haglund, C., 632
 Hagos, F. G., 1481
 Hahn, W. C., 6348
 Haiman, C. A., 1045
 Hainaut, P., 2897
 Hait, W. N., 6864
 Hajra, K. M., 1613
 Haka, A. S., 5375
 Hakem, R., 6194
 Half, E., 1676, 4903, 6323
 Halford, S., 53
 Hall, J. A., 58
 Hallahan, D. E., 4671
 Halloum, A., 397
 Halmos, B., 528
 Halmos, G., 781
 Halpern, A., 3992
 Halsor, E. F., 661
 Halter, G., 3331
 Halvorsen, O. J., 6808
 Ham, A.-J. L., 5189
 Hamada, K., 3939
 Hamaguchi, M., 2215, 2414, 3929,
 3962
 Hamamoto, R., 5651
 Hamamoto, T., 5955
 Hamamoto, Y., 3939
 Hamaoka, S., 6116
 Hamaoka, T., 3751
 Hamburger, A. W., 1004
 Hamdy, F. C., 1619
 Hamel, E., 4007
 Hamelin, R., 1609, 2447
 Hamidi, H., 6108
 Hamilton, T. A., 2606
 Hammer, J., 2600
 Hämerling, G. J., 1462
 Hammond, E. H., 7350
 Hampel, H., 4579
- Hampton, G. M., 6418
 Han, C., 2957
 Han, F.-Y., 5457
 Han, H., 2890, 4843
 Han, S. W., 3226
 Han, S.-J., 1809
 Han, X., 5336
 Han, Z.-B., 5168
 Hana, K., 2236
 Hanada, R., 333, 4571
 Hanagiri, T., 1751
 Hanahan, D., 2731
 Hanash, S. M., 4722, 5273
 Hanawalt, P. C., 5288
 Hande, M. P., 6194, 6990
 Haneda, T., 6116
 Haney, N., 488
 Hankinson, S. E., 1045
 Hann, B., 3812
 Hannay, J. A. F., 2034
 Hansbury, M. J., 4909
 Hansen, G. B., 2675, 5939
 Hansen, M., 4339
 Hansen-Petrikk, M. B., 403
 Haq, R., 5076
 Haque, S. J., 1103
 Hara, A., 6367
 Hara, Y., 4445, 7241
 Harada, H., 2013
 Harada, K., 3382, 5897
 Harada, M., 1471
 Harada, N., 1971
 Harada, T., 835
 Haraguchi, M., 2834
 Harano, T., 271
 Harari, P. M., 4300
 Harbeck, N., 840, 4617
 Harbor, P. C., 1103
 Harden, S., 371
 Harders, C., 2856
 Harding, M. A., 982, 6418, 6981
 Häring, H.-U., 840
 Harkin, D. P., 2644
 Harkins, L., 3347
 Härikönen, P. L., 2708
 Harms, H. J., 2248, 2370
 Harousseau, J.-L., 2861
 Harpaz, N., 1148, 6820
 Harper, J., 6823
 Harper, S. J., 4123
 Harrell, C., 2798
 Harrington, D., 715
 Harrington, K. J., 5495, 6566
 Harris, A. L., 688, 1315, 1326,
 2493, 2957, 5912, 6924
 Harris, C. C., 3244
 Harris, D. M., 741
 Harris, L. C., 5001
 Harrison, C., 4065
 Harrison, D. J., 6615
 Harrison, P. R., 4757
 Hart, A. A. M., 7110
 Hartge, P., 3992
 Hartmann, A., 809, 6796
 Hartmann, C., 4100
 Hartmann, L., 3587
 Hartmann, L. C., 4656
 Hasegawa, S., 7012
 Haseman, J., 990
 Hasemeier, B., 6634
 Haslam, K., 3861
 Hasmann, M., 1057
 Hassan, K. A., 6414
 Hastie, N. D., 6615
- Haston, C. K., 3782
 Hasumi, Y., 2019
 Hata, K., 6367
 Hatfield, M., 6070
 Hatsukami, D. K., 129
 Hattori, T., 4938
 Hauck, W. W., 4054, 5413
 Haukaas, S. A., 6808
 Hautaniemi, S., 6240
 Havaux, N., 2327
 Haviv, Y. S., 4273
 Havre, P. A., 1443
 Hawighorst, T., 2004
 Hawk, N., 386
 Hawkins, A. L., 647
 Hawkins, G. A., 1784, 2253, 6485
 Hawkins, N., 53
 Hay, R. J., 5897
 Hayakawa, M., 4176
 Hayakawa, T., 2203
 Hayashi, K., 6390
 Hayashi, N., 1567
 Hayashi, S., 2203
 Hayashi, S.-i., 4849
 Hayashi, T., 24, 3876
 Hayashi, Y., 33, 333, 4075, 4571,
 4849
 Hayes, R. B., 2654
 Haynl, A., 3009
 Hayward, S. W., 2999
 Hazel-Martin, D., 6598
 He, H., 669
 He, M., 1987
 He, P., 3244
 He, Z., 5590
 Healey, C. S., 3052
 Healey, J. H., 135
 Heath, V., 2072
 Hebbel, R. P., 4491
 Heber, D., 741, 5204
 Heberer, M., 3453
 Hebert, F., 781
 Hecht, D., 5370
 Hecht, S. S., 129
 Hecker, T. P., 2699
 Heckford, S. E., 854
 Heckl, S., 7018
 Hedrick, N. M., 2085
 Heere-Ress, E., 2098
 Hegerfeldt, Y., 2125
 Hehlsgåns, T., 4034
 Heidt, M., 4610
 Heike, Y., 560, 860
 Hein, C., 1503
 Heise, C., 6070
 Heldin, C.-H., 5476
 Helén, P., 3798
 Helenius, H., 7364
 Helferich, W. G., 2474
 Hellawell, G. O., 2942
 Helmbach, H., 6698
 Helsby, N. A., 1425
 Hemenway, D., 4169
 Hemminki, A., 1266, 1271, 4273
 Hempen, P. M., 5351
 Henderson, B. W., 1604
 Henderson, K. J., 715
 Henderson, K. W., 5083
 Henderson, M. A., 1289
 Henderson, R., 1737
 Hendrick, J.-C., 4623
 Hendriks, J. A., 6187
 Hendrix, M. J. C., 665, 4478
 Heng, H., 2115

* For title of article and coauthors, see listing in *Contents of Volume* beginning on page at the end of this index issue.

AUTHOR INDEX TO VOLUME

- Hennequin, L. F., 4645
 Hennig, J., 4015
 Hennighausen, L., 1030, 7166
 Henriksen, G., 3120
 Henry, F., 1050
 Henry, M., 7102
 Hensel, C. H., 2637
 Hensen, K., 1510
 Henshall-Powell, R. L., 5627
 Henson, E. S., 488
 Herbrand, U., 1718
 Herbstritt, C. J., 3691
 Herlyn, D., 5267
 Herlyn, M., 226, 3200, 3581, 6997
 Herman, J. G., 1166, 2157, 3659,
 4519, 5902, 7213
 Hermann, C., 2244
 Hermanson, G., 5845
 Hermeking, H., 6255
 Herndier, B. G., 5536
 Herrmann, J., 2468, 3834
 Herter, P., 1718
 Herva, R., 4554
 Herzog, C. R., 6424
 Heselmeyer-Haddad, K., 2365
 Heslop, H. E., 7195
 Hess, M. T., 4229
 Hess, S. D., 2611
 Hessels, D., 2695
 Hetzel, M., 3331
 Hewett, P. W., 1669
 Hewitt, S. C., 2798
 Hewson, Q. D. C., 5158
 Heylen, N., 2327
 Heyns, W., 642
 Hicke, B. J., 4029
 Hicklin, D. J., 2034, 2567, 2731
 Hicks, J. L., 2220, 6405
 Hicks, K. O., 1425
 Hicks, M. J., 1123
 Hickson, J. A., 6717
 Hidalgo, M., 6141
 Hidemitsu, T., 3876, 4996, 5019
 Hiendlmeyer, E., 3009
 Hietanen, S., 7364
 Higashibata, Y., 3751
 Higashiyama, S., 6289
 Higgins, J., 5041
 Higuchi, H., 1648, 6500
 Hii, G., 6651
 Hildesheim, J., 7305
 Hill, A. E., 5867
 Hill, H. C., 7254
 Hill, J., 6376
 Hill, J. S., 2151, 4289
 Hill, S. A., 7247
 Hillan, K., 2546
 Hiller, L., 2072
 Hilsenbeck, S. G., 6376
 Hiltunen, E. L. J., 6410
 Himmelsbach, J., 5230
 Hinze, S. J., 4599
 Hippo, Y., 233
 Hiraga, A., 860
 Hirai, K., 1641
 Hiraiwa, Y., 3962
 Hirakawa, M., 1450
 Hirao, A., 6194
 Hiraoka, M., 2013
 Hirasawa, A., 4860
 Hirasawa, K., 1696
 Hirata, A., 2554
 Hirata, K., 518
 Hirata, M., 1025
 Hirata, Y., 13
 Hirohashi, S., 2971, 4860
 Hirose, Y., 6367
 Hirsch, F. R., 3971
 Hirt, U. A., 7139
 Hirte, H. W., 1588
 Hisa, Y., 6289
 Hisatomi, H., 13
 Hisatsune, A., 6579
 Hiscott, J., 5148
 Hishiki, T., 6462
 Hitii, A. L., 3826
 Ho, C.-P., 2516
 Ho, H. T. B., 4890
 Ho, J. W., 6451
 Ho, R., 6462
 Hoa, M., 7154
 Hoang-Vu, C., 3698
 Hobart, P., 5845
 Hobbs, C. A., 67
 Hockemeyer, J., 3113
 Hodek, P., 5678
 Hodge, J. W., 5058, 5770
 Hodges, A. K., 363
 Hoelzer, D., 1768, 7050
 Hoey, T., 5420
 Hofbauer, R., 5317
 Hoffman, M. P., 3549, 5370
 Hoffman, R. M., 1534, 4685
 Hoffmann, J.-S., 3511
 Hoffmann, N., 5835
 Hoffmann, T. K., 3521
 Hoffmeyer, S., 1503
 Höfle, H., 840, 3048
 Hofmann, J., 1087
 Hofmann, M., 5317
 Hofmann, U. B., 7059
 Hofstaedter, F., 809, 6796
 Hofstetter, A., 809
 Hogan, V., 4484
 Hogarty, M. D., 6481, 6651
 Högerkopf, C.-M., 4398
 Hogg, A., 1425
 Hogge, D. E., 1730
 Höglund, M., 2675, 5939
 Hogue, C. W. V., 1284
 Holbrook, N. J., 3257
 Holcomb, I., 2546
 Holder, A. L., 7247
 Holen, I., 1619
 Holland, E. C., 4364, 5551
 Holland, J. F., 6080
 Hollander, M. C., 7305
 Hollenbach, S. J., 3729
 Hollingsworth, M. A., 819
 Holly, E. A., 3992, 4630
 Holm, R., 512
 Holmgren, L., 575
 Holtsberg, F. W., 5443
 Holzner, A., 6559
 Hong, J., 7241
 Hong, M.-H., 589
 Hong, S.-I., 6318
 Hong, W. K., 351, 2430, 2813,
 3530, 4992, 5119, 6414
 Hong, Y. J., 5365
 Hongo, J. A., 2546
 Honn, K. V., 2721
 Hood, K. A., 3356
 Hoogenboom, H. R., 3184, 5835
 Hooper, J. D., 7083
 Hooshdaran, M. Z., 1370
 Höpfel, G., 2962
 Hopkins, T. M., 2141
 Hori, M., 1567
 Horiguchi, S.-i., 4849
 Horinouchi, S., 4916
 Horsfall, D. J., 854
 Hortobagyi, G., 5703
 Horton, J., 5778
 Horwitz, L. D., 6924
 Horwitz, S. B., 1935
 Hosaka, T., 5859
 Hoshi, S., 3850
 Hoshiga, M., 1410
 Hoshikawa, Y., 734
 Hosoda, M., 2203
 Hostetter, G., 1256
 Hotchkiss, K. A., 4791
 Hou, W., 3702
 Houghton, R., 2058
 Houghton, P. J., 5001
 Houle, C. D., 990
 Houlston, R. S., 1166, 3803
 Houseknecht, V., 6545
 Howard, B., 424
 Howard, M., 2332
 Howarth, D. J. C., 295
 Howe, C. L., 6667
 Howe, L. R., 5405
 Howell, S. B., 6559
 Howell, W. M., 3369
 Howitt, R., 3417
 Hrobowski, Y., 6717
 Hruban, R. H., 819, 1868, 3789
 Hsiao, L.-L., 4963
 Hsieh, C.-L., 3084, 6442
 Hsu, H.-C., 4346
 Hsu, J.-h., 5027
 Hsu, L.-C., 6357
 Hu, B., 1598
 Hu, H.-M., 3914
 Hu, L., 1087, 5027
 Hu, N., 4191
 Hu, Q., 7219
 Hu, W., 6857
 Hu, Y. J., 48
 Hu, Z., 3377
 Hua, L., 7230
 Huang, C., 5689, 6857
 Huang, C. C., 5867
 Huang, C.-f., 3226
 Huang, D., 171
 Huang, H., 1008, 2043, 2592, 4157,
 5470, 5632, 7118
 Huang, H.-J. S., 6764
 Huang, J., 4812, 6039
 Huang, J. J., 3226
 Huang, L., 6712
 Huang, M., 5761
 Huang, R., 2806
 Huang, R.-P., 2806
 Huang, S., 547, 5106
 Huang, S. F., 5720
 Huang, S.-M., 4300
 Huang, T. H.-M., 3214
 Huang, X., 3620, 5727
 Huang, X. F., 2600
 Huang, Y., 2913, 6857
 Huang, Z., 466
 Hubalek, M., 4535
 Huber, C., 2856, 6750
 Hudis, C., 5405
 Huebner, K., 4054
 Huerta, S., 741, 5204
 Huet, T., 2318
 Huettinger, C. S., 528
 Hufsky, H., 3113
 Hug, B. A., 2906
 Hugenschmidt, H., 4015
 Hughes, G. D., 4645
 Hui, C.-c., 5308
 Hui, R., 6916
 Huibregtse, J. M., 3315
 Huisman, C., 4081
 Huisman, M. T., 6158
 Hukin, J., 2660
 Hung, M.-C., 8, 346, 1311, 5703,
 6712
 Hungerhuber, E., 809
 Hunt, D. F., 18
 Hunt, K. K., 2239
 Hunter, D. J., 1045
 Hunter, D. S., 3766
 Huo, D., 6717
 Huo, K.-K., 7157
 Hurlbert, M. S., 6385
 Hurle, M. R., 1797
 Husain, S. R., 3575
 Husenet, T., 6211
 Hutchinson, O. C., 5912
 Hüttelmaier, S., 6278
 Huttunen, H. J., 4805
 Hwang, S. T., 7328
 Hwang, S.-L., 6952
 Hwu, P., 5144
 Hylander, B. L., 5800
 Hyman, E., 6240
 Hynes, N. E., 3151
 Hytioglou, P., 6820

I

- Iacobelli, S., 840, 2535
 Iacobuzio-Donahue, C. A., 5351
 Iacono, I., 3646
 Iacopetta, B., 1609
 Iavarone, A., 301
 Ichigotani, Y., 2215, 3929, 3962
 Ichihara, F., 5813
 Ichikawa, T., 367
 Ichimaru, N., 1410
 Ichinose, M., 1433
 Idezawa, T., 5611
 Iglehart, J. D., 2267
 Ihrig, M., 696
 Iida, S., 4089
 Iizumi, M., 1246
 Iizuka, N., 3939
 Ijpenberg, A., 6615
 Ikawa, S., 636
 Ikebuchi, Y., 6015
 Ikeda, R., 2834
 Ikegaki, N., 1802, 6462
 Ikegami, T., 179
 Ikezoe, T., 5204
 Ilagan, J., 2281
 Ilangovan, G., 307
 Iliakis, G., 1598, 2483, 6031
 Illei, P., 2988
 Illmer, T., 4955
 Ilyas, M., 4562
 Im, S.-Y., 1809
 Imaida, K., 1956
 Imamura, M., 4549, 5859
 Imanishi, T., 3751
 Imoto, I., 4860
 Inyanitov, E., 840
 Inaguma, S., 1956
 Inazawa, J., 4860
 Indraccolo, S., 6099
 Indranie, C., 165

* For title of article and coauthors, see listing in Contents of Volume beginning on page at the end of this index issue.

AUTHOR INDEX TO VOLUME

- Ingle, J. N., 3587
 Ings, S. J., 4730
 Iniesta, P., 3855
 Ino, K., 2753
 Inokuchi, J., 5668
 Inoue, H., 2937, 3819
 Inserra, A., 301
 Ioffe, O. B., 5463
 Ip, C., 708, 4383
 Ip, M. M., 4383
 Irani, J., 4854
 Irani, R., 3782
 Irby, R. B., 2669
 Irie, T., 1567
 Irwin, R. W., 741, 5204
 Isaacs, J. T., 986
 Isaacs, S. D., 1784, 2253, 6485
 Isaacs, W. B., 647, 1784, 2220,
 2253, 6485
 Ishihara, T., 1410
 Ishii, A., 3850
 Ishii, N., 2897
 Ishikawa, S., 7124
 Ishikawa, T.-o., 506, 2261
 Ishimoto, O., 636
 Ismail, A., 5590
 Isohama, Y., 6579
 Isola, J., 632, 4554
 Israel, B., 1920
 Israel, M. A., 3729
 Israeli, T., 6731
 Itahana, K., 4736
 Ito, A., 1025
 Ito, E., 33
 Ito, T., 4282
 Ito, Y., 1450
 Itoh, Y., 1410
 Ivakine, E., 5828
 Iwamoto, M., 3702
 Iwanaga, T., 560
 Iwanaga, Y., 2618
 Iwashita, T., 2414
 Izumi, Y., 6831
- J**
- Jäättelä, M., 7139
 Jabbour, H. N., 424
 Jablons, D. M., 3636
 Jablonski, S. A., 1797
 Jabolin, J., 6108, 6756
 Jackson, D. G., 1315, 6966
 Jackson, J. A., 4645
 Jackson, M. W., 854
 Jackson, S. C., 2294
 Jacob, L., 5267
 Jacobs, B., 3453
 Jacobs, J. J. L., 4736
 Jacobson, B. C., 682
 Jacquemin-Sablon, A., 4453
 Jaffe, R. B., 1087
 Jäger, D., 4041
 Jäger, E., 4041
 Jain, A. N., 957, 3636
 Jain, R. K., 2151, 4289, 6831
 Jaiswal, A. K., 3030
 Jalali, F., 6194
 Jallo, G. I., 2660
 Janek, K., 2875
 Jänicke, F., 4617
 Jänne, P. A., 5242
 Jansen, B., 2098
 Jansen, P. J., 801
 Janssen, H., 5408
- Janssen, M. L., 6146
 Jardine, L., 1876
 Jarry, A., 2169
 Järvinen, H., 1166, 4554
 Jasim, M., 1279
 Jass, J. R., 5988, 6011
 Jeang, K.-T., 2618
 Jeffers, M., 2468, 3834
 Jefferson, A. M., 1152
 Jeffrey, I. W., 2272
 Jeffy, B. D., 113
 Jen, J., 2744, 3340
 Jena, N., 535
 Jenkins, R. B., 3587, 4100, 6205
 Jenkins, W. T., 3626
 Jenne, J., 7018
 Jensen, E. R., 2287
 Jensen, J. A., 129
 Jensen, R. T., 3702
 Jensen, R. V., 4963
 Jensen-Pergakes, K., 977
 Jerónimo, C., 371
 Jesberger, J., 3408
 Jetten, A. M., 901
 Ji, L., 2715
 Jia, X.-C., 2468
 Jiang, B.-H., 5689
 Jiang, J.-D., 6080
 Jiang, P., 1534
 Jiang, W., 156, 1178, 5280
 Jiang, Y., 924, 1910
 Jiang, Z., 1624
 Jin, D.-Y., 1662
 Jin, X., 376, 1330
 Jing, D. D., 3226
 Jo, M., 5564
 Joel, S. P., 1876
 Joensuu, H., 632, 5210
 John, L., 4100
 Johnson, A. C., 827
 Johnson, A. J., 4413
 Johnson, B. E., 5242, 6304
 Johnson, D. G., 3276
 Johnson, G., 3971
 Johnson, J. P., 5920
 Johnson, J. R., 6485
 Johnson, M., 3587
 Johnson, M. R., 5867
 Johnson, R. L., 5867
 Johnston, M., 3005
 Johnston, P. G., 2644
 Johnston, R., 4445
 Johnstone, C. N., 6779
 Jolicœur, P., 6625
 Jones, A., 2957
 Jones, J., 819, 5351, 7166
 Jones, J. L., 3289
 Jones, P. A., 961, 2378, 6456
 Jones, R. T., 3244
 Jones, T., 5698
 Jong, Y. S., 7254
 Jongen, J. L. M., 7343
 Jonkers, J., 1862
 Jönsson, M., 409
 Joos, S., 2993
 Jorcano, J. L., 3402
 Jorycyk, C., 5325
 Jordan, B. F., 3555
 Jordan, V. C., 4419
 Jorgenson, P., 3005
 Joseph, J., 6467
 Joseph, P., 703
 Joshi, H. C., 4109
 Josien, R., 1050
- Jost, B., 6211
 Jothy, S., 2731
 Jouault, H., 4685
 Jovanovic, B. D., 4419
 Jovanovic, V. P., 3438
 Jove, R., 5761, 6659
 Joyner, A. L., 6385
 Ju, Y. H., 2474
 Juang, S.-H., 3716
 Juarez, J. C., 5344
 Jucker, R., 3507
 Judah, D. J., 4256
 Juhola, M., 6410
 Jull, B., 403
 Jung, A., 3009
 Jung, D., 5370
 Jung, G., 2592
 Jung, M., 6879
 Jung, M. W., 4169
 Jungbluth, A. A., 4041
 Junker, K., 6796
 Jurisica, I., 3005
- K**
- Kaanders, J. H. A. M., 7066
 Kabos, P., 5657, 7170
 Kabosova, A., 5657
 Kadambi, A., 2151, 4289
 Kadlubar, F. F., 6470
 Kaganovsky, E., 1036
 Kagawa, S., 6598
 Kai, H., 6579
 Kaina, B., 1524
 Kaiser, S. A., 4419
 Kajiyama, H., 2753
 Kakiuchi, Y., 1567
 Kakkanaiai, V. N., 4007
 Kalat, M., 5489
 Kalita, A., 4325
 Kallie, K. R., 4656
 Kallio, M. J., 2462
 Kallioniemi, A., 2359, 2625, 6240
 Kallioniemi, O.-P., 1256, 2359, 6240
 Kalluri, R., 789
 Kalpana, G., 323
 Kaluz, S., 4469
 Kaluzová, M., 4469
 Kamar, M., 6837
 Kamata, J., 6116
 Kamberov, Y. G., 277
 Kamibayashi, C., 2715
 Kaminiishi, M., 6645
 Kampfhaus, G. D., 789
 Kandasamy, K., 4929
 Kandouz, M., 2721
 Kanduri, C., 4545
 Kanduri, M., 4545
 Kaneda, A., 6645
 Kanerva, A., 1266, 1271, 4273
 Kang, C., 6312
 Kang, H.-S., 6318
 Kang, J., 5325
 Kang, T., 675
 Kang, X., 5144
 Kannagi, R., 6289
 Kanno, H., 7004
 Kanno, J., 2236
 Kantarjian, H. M., 5995
 Kantoff, P., 5517
 Kantoff, P. W., 1045
 Kantor, J. A., 5049
 Kanugula, S., 3037
 Kanzaki, T., 2834
- Kao, C., 3084
 Kaplan, D. R., 2131, 6756
 Kaplan, L. S., 6966
 Kapp, L., 5536
 Karagas, M. R., 152
 Karaguni, I.-M., 1718
 Karashima, T., 5720
 Karaskova, J., 3466, 6194
 Kardia, S. L. R., 4722
 Karhausen, J., 3387
 Karhu, A., 4554
 Karlann, B. Y., 5358
 Karlsson, A., 2650
 Karlsson, M. C. I., 6891
 Karmand, A. J., 3549
 Karp, D. D., 528
 Karras, J., 6659
 Garrison, T., 6717
 Kas, K., 1510
 Kaser-Hotz, B., 2962
 Kashentseva, E. A., 609
 Kasprzynski, A., 1718
 Kass, E. S., 5049
 Kast, W. M., 5792
 Kastan, M. B., 4588
 Kastner, B. D., 7291
 Kasumi, F., 560
 Katagiri, T., 518, 1139, 3244, 5859,
 7012
 Katano, K., 6559
 Kataoka, Y., 5603
 Katayama, H., 5168
 Kates, R. E., 4617
 Katiyar, S., 1370
 Kato, H., 7162
 Kato, M., 2203, 2414, 5955
 Kato, T., 7012
 Katsuoka, Y., 1410
 Kattan, M. W., 5974
 Katz, A. A., 424
 Katz, R., 7350
 Katz-Bruell, R., 1966
 Kaufman, D. G., 79
 Kaufmann, D., 1503
 Kaufmann, M., 4186
 Kaufmann, S. H., 6500
 Kaul, S. C., 4434
 Kaur, B., 2478, 2897
 Kauraniemi, P., 6240
 Kavanagh, K. T., 652
 Kawa, K., 333
 Kawabata, M., 5955
 Kawagishi, R., 6015
 Kawaguchi, H., 333
 Kawahara, C., 636
 Kawai, A., 135
 Kawai, N., 1567
 Kawai, T., 4176
 Kawakami, K., 3575
 Kawakami, M., 3575
 Kawakami, T., 2690
 Kawakami, Y., 4836
 Kawakami-Kimura, N., 6289
 Kawamori, T., 28
 Kawamoto, S., 560, 860, 7004
 Kawamoto, Y., 2414
 Kawano, S., 1567
 Kawano, Y., 7124
 Kawata, R., 6289
 Kay, N. E., 715
 Kazim, L., 1737
 Kazuki, Y., 3322
 Ke, L. D., 1854

* For title of article and coauthors, see listing in *Contents of Volume* beginning on page at the end of this index issue.

AUTHOR INDEX TO VOLUME

- Ke, Q., 5689
 Keblusek, P., 4736
 Keck-Waggoner, C. L., 4054
 Kedar, D., 5720
 Keilholz, U., 1743
 Keith, R. L., 734
 Keith, W. N., 5999
 Keller, E. T., 1832
 Keller, G. A., 2546
 Kelley, K. W., 4746
 Kelloff, G. J., 5178
 Kelsey, K. T., 152, 4630
 Kemming, D., 1020
 Kempkes, B., 2267
 Kendrew, J., 4645
 Kenerson, H. L., 5645
 Kennedy, R., 5495
 Kennel, M., 2824
 Kenner, O., 1503
 Kenney, S. C., 1920
 Kensler, T. W., 5196
 Kenter, G., 472
 Kerbel, R. S., 1838, 1931, 2731,
 6371, 6891, 6938
 Kere, J., 3798
 Kerkvliet, N., 2162
 Kern, S. E., 819, 3789, 5351
 Keshavjee, S., 3005
 Keski-Oja, J., 5580
 Ketchen, A.-M., 4065
 Keydar, I., 1093
 Keyes, K., 5597
 Keyser, C. P., 7343
 Khaletzkiy, A., 1213
 Khalili, K., 7093
 Khammanivong, V., 6438
 Khammadkhune, S., 1439
 Khanna, C., 6108
 Kharbanda, S., 789
 Khatib, A.-M., 5393
 Khil, M., 4968
 Khodavirdi, A. C., 4812
 Khokha, R., 5543
 Khong, H. T., 3020
 Khoo, U.-S., 4151
 Kiaris, H., 781
 Kickhoefer, V. A., 7298
 Kiechle, M., 4617
 Kiemeny, L. A., 2695
 Kiguchi, K., 2516
 Kijima, T., 6304
 Kikkawa, F., 2753
 Kikuchi, A., 4571
 Kikuchi, T., 3244
 Kilbey, A., 7181
 Killary, A. M. N., 1952
 Killion, J. J., 5720
 Kilpatrick, K. E., 2840
 Kim, B.-C., 3649, 5365
 Kim, C. J., 6108, 6756
 Kim, C. W., 6312
 Kim, D. C., 747
 Kim, H., 6674
 Kim, H.-T., 5365, 6376
 Kim, I. Y., 3649, 5365
 Kim, J., 1549, 5267
 Kim, J. H., 4202, 4968
 Kim, J. M., 4212
 Kim, J.-H., 38, 7234
 Kim, J.-S., 2744
 Kim, K., 1241
 Kim, K.-M., 1166
 Kim, M. J., 2999
 Kim, M.-S., 6318
 Kim, O. J., 3503
 Kim, R. B., 4955
 Kim, S.-J., 3649, 5365, 5720, 7135
 Kim, S.-T., 4588
 Kim, T.-G., 7234
 Kimchi, A., 5618
 Kimos, M. C., 3493, 3641, 6820
 Kimura, A., 1567
 Kimura, J., 4282
 Kinch, M. S., 2840
 King, P. H., 3347
 King, W., 4132
 Kiniwa, Y., 4836
 Kinnula, V., 5210
 Kinsler, E. L., 2906
 Kinugawa, N., 4048
 Kinzler, K. W., 1129, 4579
 Kioschis, P., 6698
 Kirchner, T., 3009
 Kirkwood, J. M., 213
 Kirlappos, H., 1477
 Kirn, D., 6070
 Kirn, D. H., 764
 Kirschmann, D. A., 4478
 Kirschner, M. W., 3842
 Kisley, L. R., 6850
 Kitagawa, T., 4282
 Kitahara, O., 518, 1139
 Kitakata, H., 6682
 Kitamura, T., 28, 5955
 Kitamura, Y., 3751
 Kitange, G., 4100
 Kitazawa, J., 33
 Kiuru, M., 4554
 Kizaka-Kondoh, S., 2013
 Klamut, H., 171
 Klar, E., 1462
 Klausner, R. D., 3014
 Kleer, C. G., 4854
 Klein, P. S., 277
 Klein, R., 2516
 Kleiner, H., 7207
 Kleinman, H. K., 3549, 5370, 6312
 Klement, G., 1838
 Klenova, E. M., 48
 Klijn, J. G. M., 4617
 Kloetzel, P.-M., 2875
 Kloosterboer, F., 346
 Klos, K., 5703
 Klotz, L. H., 2540
 Klotz, L.-O., 4922
 Klotzbücher, M., 3766
 Klussman, K., 3736
 Knapp, D. W., 356
 Knayzev, P., 840
 Knee, D. A., 1904
 Knight, J., 3663
 Knobloch, T. J., 5295
 Knoepp, S. M., 5083
 Knowlton, M., 6740
 Knox, W. F., 122
 Knudsen, B. S., 1654
 Knudsen, E. S., 323, 6587
 Knuechel, R., 809, 6796
 Knuth, A., 4041
 Knuutila, S., 2625, 4061, 4554
 Knyazeva, T., 840
 Ko, B., 7207
 Ko, H., 7207
 Ko, H.-M., 1809
 Ko, Y. H., 3909
 Kobashi, N., 4916
 Kobayashi, H., 560, 860, 4075
 Kobayashi, K., 28, 179
 Kobayashi, M., 28, 333
 Koc, H., 5183
 Koch, C., 3009
 Koch, C. J., 3626, 7273
 Koch, H. B., 6255
 Koch, Y., 1036
 Kocher, O., 528
 Kochetkova, M., 4599
 Kodama, T., 233
 Koefller, H. P., 741, 5204
 Koeppen, H., 2546
 Koh, G. Y., 1809
 Kohn, K. W., 1688, 5743
 Kohno, T., 2019
 Kohonen-Corish, M. R. J., 2092
 Kohu, K., 3322
 Koike, L., 1025
 Koivisto, P., 1256
 Koivusalo, R., 7364
 Koki, A. T., 625
 Kokkola, A., 2625
 Kolb, E. A., 3377
 Kolesnick, R., 2531
 Koller, B., 901
 Kölleremann, M. W., 251
 Kolodner, R. D., 3485, 3925
 Kolozsvary, A., 4202
 Komatsu, Y., 4916
 Kometani, T., 2554
 Komiya, A., 48
 Komiyama, S., 3351
 Komori, M., 1567
 Kondo, A., 6559
 Kondo, E., 6390
 Kondo, M., 2715, 4282
 Kondo, T., 6682
 Kondoh, S., 835
 Kondrat, N., 2115
 Kondziolka, D., 2583
 Konerding, M. A., 4015
 Konishi, F., 560
 Konishi, H., 271
 Konishi, J., 860
 Kono, K., 5813
 Kononen, J., 1256
 Koonce, L., 2798
 Kopitz, C., 5543
 Korach, K. S., 2798
 Koratkar, R., 5413
 Korc, M., 5611
 Korn, B., 6698
 Kornacker, M., 5785
 Kornaga, T., 2749
 Kornprobst, M., 4879
 Kormsley, S. J., 2184
 Kort, E. J., 589
 Korz, C., 2993
 Kosaka, T., 4176
 Kosari, F., 3308
 Koslowski, M., 6750
 Kosma, V.-M., 6410
 Kossakowska, A., 1696
 Kosuge, D., 1669
 Kothari, N. H., 5611
 Kotke, T., 6566
 Kough, E. C., 3691
 Koul, S., 6218
 Kouprina, N., 367
 Koutalos, Y., 1420
 Kovacs, G., 957
 Kovar, H., 4583
 Kovats, S., 262
 Koyama, M., 6390
 Kraemer, K. H., 4899
 Kraggerud, S. M., 512
 Kragh, M., 1191
 Krajewska, M., 6674
 Krajewski, S., 6674
 Kral, S., 2875
 Krämer, A., 4186
 Kramer, P. M., 4199
 Krasna, M. J., 3493
 Krasnykh, V., 1266, 4273
 Krause, P., 6750
 Kraus, E., 7364
 Krawczak, M., 363
 Kreipe, H., 6634
 Kreisberg, J. I., 2630
 Krell, H.-W., 5543
 Kremen, T. J., 2287
 Kresty, L. A., 5295
 Kriahev, L., 5590
 Krieg, P., 4610
 Krishna, M. C., 307
 Kristjansen, P. E. G., 1191
 Kroemer, G., 1388
 Kronenberg, A., 1279
 Krouse, R. S., 3175
 Krüger, A., 4617, 5543
 Kruger, W. D., 6639
 Kruh, G. D., 3144, 6172
 Krusk, P. A., 4575
 Krupke, D. M., 1235
 Kruse, P., 1503
 Kruszewski, M., 2576
 Krutzsch, H., 6740
 Krutzsch, H. C., 1541
 Krut, F. A. E., 4081
 Krystal, G., 188
 Kshirsagar, S., 4491
 Kuang, J., 6870
 Kuang, X., 5153
 Kubin, M., 6178
 Kucherlapati, R., 2993
 Kucherlapati, R. S., 6218
 Kudo, A., 6688
 Kudoh, M., 1904
 Kufe, D., 789
 Kufer, P., 251
 Kugoh, H., 3766
 Kuick, R., 4722
 Kuja-Panula, J., 4805
 Kukoc-Zivojinov, N., 1768
 Kulesz-Martin, M., 3264
 Kulik, G., 18
 Kultti, A., 6410
 Kumamoto, K., 6289
 Kumar, A., 3315, 7219
 Kumar, M., 6997
 Kumar, R., 1251
 Kume, A., 2019
 Kundu, N., 2343, 2606
 Kundu, S. D., 7135
 Kung, H.-f., 3226
 Kung, H.-J., 1496, 6606
 Kuno, T., 2203, 6367
 Kuntz, S. M., 947, 5223
 Kuo, M. T., 4903, 6323
 Kuo, M.-L., 1222
 Kuo, W.-L., 1939, 3636
 Kuo, Y.-M., 6559
 Küpcü, Z., 5489
 Küpers, H., 2848
 Kuppusamy, P., 307
 Kuramochi, M., 5129
 Kuramoto, T., 3592
 Kurata, M., 6224

* For title of article and coauthors, see listing in Contents of Volume beginning on page at the end of this index issue.

AUTHOR INDEX TO VOLUME

- Kuratomi, Y., 3351
 Kurebayashi, S., 901
 Kurek, R., 5685, 5818, 6740
 Kurie, J. M., 3530, 3945
 Kuriyama, K., 5603
 Kuriyan, J., 4236, 4244
 Kurland, A. R., 6006
 Kuroki, T., 2258
 Kuronen, A. T., 6410
 Kurooka, M., 1261
 Kurzrock, R., 932
 Kusano, N., 835
 Kuschel, B., 3052
 Kushner, D., 397
 Kushner, P. J., 141
 Kuske, M. A., 5920
 Kussie, P., 2567
 Küsters, B., 341
 Kusugami, K., 2385
 Kusuzaki, K., 5859
 Kuwada, S. K., 6870
 Kuwajerwala, N., 2488
 Kuwano, H., 7162
 Kuwano, M., 2554, 2834, 3144, 4048
 Kuwano, T., 2554
 Kuzdal, S., 1868
 Kuzmin, I., 3498
 Kwappenberg, K. M. C., 472
 Kwon, E., 7135
 Kyi, A. T., 7328
 Kyprianou, N., 597
- L**
- Laboisse, C. L., 2169
 Labrie, C., 721
 Labrie, Y., 721
 Lacroix-Triki, M., 3511
 Ladanyi, M., 135, 2988
 Ladner, R. D., 4909
 Ladu, S., 4459
 Laframboise, S., 3466
 Lagowski, J. P., 3264
 Lahermo, P., 1166, 3798
 Lahrech, H., 5672
 Lahrs, S., 5260
 Lahti-Domenici, J., 4540
 Lahusen, T., 1401
 Laiho, P., 1166, 4352, 5989
 Laird, A. D., 5727
 Laird, P. W., 1296
 Lake, R. A., 2353
 Lakkakorpi, P. T., 2708
 Lal, A., 3335
 Lam, C. L., 4464
 Lam, J. T., 1266
 Lam, W., 459, 1624
 Lam, W. K., 4464
 Lam, W. L., 6447
 Lambek, C. L., 4244
 Lamborn, K. R., 4263, 6205
 Lamfers, M. L. M., 5736
 Lamph, W. W., 6376
 Lamy, S., 381
 Lan, K-H., 5703
 Land, S., 213
 Landázuri, M. O., 2929
 Landen, J. W., 4109
 Landesman-Bollag, E., 6770
 Landini, E., 5418
 Lane, H. A., 3151
 Lang, F. F., 1069, 2318
 Lang, R., 4109
- Lang, S. H., 58
 Lange-Asschenfeldt, B., 2004
 Langenbach, R., 3395
 Länger, F., 6634
 Langland, G., 2766
 Lansdorp, P. M., 6990
 Lansiaux, A., 7219
 Lansita, J. A., 6791
 Lantry, L. E., 3024
 Lantvit, D. D., 5178
 Lapadat, R., 3971
 Lapointe, D. S., 3233
 Lapointe, R., 5144
 LaPushin, R., 7264
 Lara, C., 7093
 Larcher, F., 3402
 Lardeux, B., 4977
 Larionov, V., 367
 Larizza, L., 2398
 Larocca, D., 977
 LaRochelle, W. J., 2468, 3834
 La Rose, J. H., 5743
 La Rosée, P., 7149
 Larsen, R. H., 3120
 Larsson, O., 135, 3861
 Larsson, R., 4206
 Lasarev, M., 1518
 Lasky, A., 2546
 Lasorella, A., 301
 La Starza, R., 5408
 Latham, D. E., 4307
 Latham, P., 179
 Latif, F., 3803, 5874, 5906
 Latif, T., 2644
 LaTulippe, E., 4499
 Lau, A., 4890
 Launonen, V., 1166, 4554
 Laurberg, S., 4352
 LaVallee, T. M., 3691
 Lavery, T. T., 6598
 Law, P-Y., 4491
 Lawlor, E. R., 4711
 Lawrence, T. S., 2337
 Lazar, M. A., 2906
 Lazaro, L. L., 4256
 Lazarus, P., 1978
 Le, J. L., 3812
 Le, K-a., 129
 Le, N. D., 6447
 Le, X-F., 7264
 Leach, F., 3649
 Leahy, K. M., 625
 Le Beau, M. M., 3477, 5523
 LeBlanc, R., 2131, 2300, 4996
 Le Bricon, T., 2771
 Lebrun, J-J., 4678
 Lebtahi, K., 2327
 Lechner, J. F., 2370
 Leder, P., 4781
 Leduy, L., 6625
 Lee, A. S., 1458, 7207
 Lee, A. T., 5720
 Lee, C., 7135
 Lee, C. A., 3395
 Lee, C. M., 4282
 Lee, C. S. L., 6916
 Lee, C-C., 589
 Lee, D. K., 3649, 5365
 Lee, H. M., 6312
 Lee, H-K., 1809
 Lee, H-Y., 3530, 3945
 Lee, I., 6837
 Lee, J., 262
 Lee, J. C., 747
- Lee, J. I., 6414
 Lee, J. J., 351, 1178, 2813
 Lee, J. S., 3893
 Lee, K., 3144
 Lee, K-H., 4916
 Lee, L. M. L., 665
 Lee, L-F., 6606
 Lee, M. P., 4191
 Lee, M. W., 466
 Lee, N. C., 4696
 Lee, P. W. K., 1696
 Lee, P-H., 4346
 Lee, R. J., 2077
 Lee, R. Y., 3428
 Lee, S., 1275, 5703
 Lee, S. P., 6952
 Lee, S. Y. D., 2906
 Lee, S-H., 6318
 Lee, T. H., 6312
 Lee, T-H., 6952
 Lee, W. M. F., 747
 Lee, W. S., 6385
 Lee, W-H., 2498, 3773, 3966, 5134
 Lee, Y., 6395
 Lee, Y-F., 6039
 Lee, Y-P., 5564
 Leek, R. D., 688, 1315, 1326, 2493, 2957
 Leenders, W. P. J., 341
 Leeuwenburgh, C., 4592
 Leffert, J. J., 2313
 Leggett, G. R., 6438
 Leggett, B., 3641, 5988, 6820
 Leggett, B. A., 6011
 Legros, J-J., 4623
 Lehmann, U., 6634
 Lehr, H-A., 6750
 Lehtonen, R., 4554
 Lei, X., 4273
 Lei, Y-X., 703
 Leist, M., 7139
 Leistner, W., 1503
 Leit, S., 4325
 Leitch, A., 6615
 Leitner, W. W., 5144
 Leiva, I., 5325
 Lemke, N., 6270
 Leng, L., 5881
 Lengauer, C., 1129
 Lentzsch, S., 2300, 4996, 5019
 Leonard, S. S., 5689
 Leonessa, F., 3428
 Leoni, L., 4007
 Leppä, S., 5210
 Lerman, M. I., 2715, 3498, 4469
 Lerner, A., 5711
 LeRoith, D., 1030, 6529
 Leslie, K. K., 881
 Lessey, B. A., 79
 Leung, D. H., 135
 Leung, K. M., 4890
 Leung, S. Y., 6451
 Lev, A., 3184
 Levenson, A. S., 4419
 Levin, E., 5947
 Levine, B. D., 5778
 Levitt, R. J., 7372
 Levitzki, A., 1077
 Levsky, J. M., 6006
 Levy, D., 7102
 Levy, R., 3195, 5845
 Lew, Y. S., 4202
 Lewin, J. S., 3408
 Lewis, J. S., 445
- Leygue, E., 2736
 Leytin, A., 1148
 Lhoták, S., 1588
 Li, B. F-L., 1592
 Li, C., 5019
 Li, D., 4023, 4566, 4637
 Li, F., 1251, 2043, 5035
 Li, G., 1330, 4061
 Li, G. C., 2483, 6031
 Li, H., 307, 2029, 4507
 Li, J., 756, 2085, 3024, 4300, 5420, 5689, 6857
 Li, J-H., 171
 Li, J-J., 1213
 Li, J-N., 6080
 Li, K., 1330
 Li, M., 7012, 7124
 Li, R., 6345
 Li, R. J., 6447
 Li, S., 2337, 3722, 5019, 6712
 Li, W., 5027
 Li, W. W., 6909
 Li, X., 338, 417, 5867
 Li, Y., 1330, 1737, 2576, 2766, 3630, 3743, 6035, 6080
 Li, Y. F., 5144
 Li, Y-F., 2248
 Li, Z., 1000, 1939, 4325, 5980
 Li, Z-Y., 1063, 6089
 Liang, G., 961, 6430, 6456
 Liang, Y., 4867
 Liao, F., 2567
 Liau, L. M., 2287
 Liber, H. L., 6400
 Libutti, S. K., 3934
 Lichenstein, H. S., 2468, 3834
 Lichtenstein, A., 5027
 Lichter, P., 2993, 6698
 Lieber, A., 1063, 6089
 Lieberman, J. R., 5564
 Liénard, D., 1743
 Lieubeau, B., 1050
 Liew, F. Y., 4390
 Liewald, F., 3331
 Lillemoe, K. D., 1868
 Lillie, J., 262
 Lillo, R., 5013
 Lim, J. T. E., 3997
 Lin, B., 2806, 5019
 Lin, C-L., 6952
 Lin, D., 6430
 Lin, E. Y., 7166
 Lin, H-J., 376
 Lin, J., 376, 1305, 2227, 3226
 Lin, J. C. Y., 6456
 Lin, K., 5308
 Lin, L., 5273
 Lin, M. C., 3226
 Lin, R., 5148
 Lin, S-Z., 756
 Lin, T., 3620
 Lin, W-J., 6039
 Lin, Y., 2806, 4029
 Linardakis, E., 5495, 6566
 Linch, D. C., 4730
 Lindblom, A., 48
 Lindner, G., 6724
 Lindsey, J. C., 5906
 Lindstrom, M. J., 1241
 Linehan, W. M., 3014, 3498
 Ling, X. B., 5420
 Ling, Y-H., 6080
 Lingen, M. W., 7143
 Lingnau, K., 1477

* For title of article and coauthors, see listing in Contents of Volume beginning on page at the end of this index issue.

AUTHOR INDEX TO VOLUME

- Linnebacher, M., 2052
 Liotta, L. A., 3244
 Liou, J-Y., 1624
 Lipp, M., 1743
 Lippman, S. M., 1178, 2813, 5119
 Lips, J., 1524
 Liston, B. W., 4376
 Litman, E. S., 881
 Little, J. B., 2531, 5436
 Litwin, S., 3200
 Liu, A., 3428
 Liu, B., 3530
 Liu, C., 796, 4244, 5470, 7118
 Liu, C-Y., 5134
 Liu, D., 6414
 Liu, D. D., 351
 Liu, E. T., 1688, 1987, 3581, 6246
 Liu, F-F., 171
 Liu, G., 1377, 2819
 Liu, H., 4295
 Liu, J., 386
 Liu, J. R., 924
 Liu, J-F., 3716
 Liu, J-W., 2976
 Liu, K., 433
 Liu, L., 3037, 3070, 4545
 Liu, M., 5399
 Liu, M. Y., 6475
 Liu, N., 3005
 Liu, S., 4023, 4637, 7357
 Liu, T. C., 3493
 Liu, T-J., 1069
 Liu, T-W., 3716
 Liu, V. C., 7135
 Liu, W. J., 6438
 Liu, X., 6481
 Liu, X-g., 1802
 Liu, X-H., 1433
 Liu, Y., 3459, 6357
 Livingston, S., 6659
 Ljung, B-M., 1000, 5980
 Ljungkvist, A. S. E., 7066
 Lloyd, D. R., 5288
 Lloyd, M., 5295
 Lo, H. S., 4191
 Lo, S. H., 4217
 Lo, T. B., 4217
 Lo, W-F., 6952
 Lobanenkov, V. V., 48
 Lobl, T. J., 2327
 Lockman, J., 4579
 Lo Coco, F., 5618
 Loda, M., 89, 3485, 3925
 Loeb, L. A., 3511
 Loeffler, J. S., 200, 4307
 Loeppen, S., 5685
 Loeser, W., 5818
 Loft, S., 4339
 Loftin, C. D., 3395
 Lofton-Day, C., 3214
 Logan, T., 213
 Lohse, C. M., 6566
 Lokker, N. A., 3729
 Lomonosova, E., 3373
 Long, D. J., II, 3030
 Longley, D. B., 2644
 Longoni, P., 6152
 Lootjenga, L. H. J., 1822, 2758
 Look, A. T., 6481
 Look, M. P., 4617
 Lopez-Barcons, L., 4514
 López-Casillas, F., 4690
 Lorenzato, A., 7025
 Losa, M., 2398
 Löscher, W., 1356
 Löser, R., 1057
 Lotan, R., 1178, 2430
 Lothe, R. A., 512, 2359
 Lott, S. T., 1952
 Loughran, T., 5761
 Louie, D. C., 4089
 Louis, D. N., 1790, 4100
 Louis, N. A., 3387
 Loukinov, D. I., 48
 Louro, I. D., 5867
 Louvet, C., 4879
 Lovat, P. E., 5158
 Lövborg, H., 4206
 Lovell, M., 1952
 Lowe, L., 5308
 Lowler, K. P., 796
 Lowry, D. T., 1152
 Lowy, A. M., 3503
 Lu, C., 3005
 Lu, H., 7241
 Lu, J., 1884, 3428, 5807
 Lu, M., 4968, 6973
 Lu, M. L., 2227
 Lu, N., 4191
 Lu, W., 1305
 Lu, Y., 1087
 Lubet, R. A., 3024, 5178
 Luboshits, G., 1093
 Lucas, T., 2098
 Lucchiani-Hartz, M., 6901
 Lucroy, M. D., 4295
 Lue, J., 4514
 Luger, N. M., 7343
 Luker, G. D., 2195
 Luketicz, J. D., 2141, 2681
 Luna, M., 3956
 Luna, M. C., 1458
 Lundin, J., 632
 Lundin, M., 632
 Luo, J., 2220
 Luo, L-Y., 295
 Luong, M. X., 3233
 Lupold, S. E., 4029
 Lusher, M. E., 5906
 Lushnikov, E. F., 7031
 Luthora, S. K., 5912
 Lutterbaugh, J., 1134
 Lutterbüse, R., 251
 Lutz, R. J., 2546
 Lyakhovich, A., 2115
 Lynch, M., 2644
 Lynch, T. J., 1377, 2819
 Lynn, W. S., 5153
 Lyons, S., 1862
- M
- Ma, A-H., 1496, 6606
 Ma, H-I., 756
 Ma, J., 1382, 2654
 Ma, P. C., 6304
 Ma, W., 5399
 Ma, Y., 892
 Ma, Y. X., 141
 Mabjeesh, N. J., 2478
 Macaluso, J., 2468
 Macaulay, V. M., 2942
 Maccarrone, M., 5158
 MacDonald, C. J., 3685
 MacDonald, D. G., 4757
 MacDonald, I. C., 887, 2162
 MacDonald, J., 3503, 7175
 Macé, K., 105
 MacGowan, J., 3044
 Macgregor, P. F., 3466
 Mach, D. B., 7343
 Machida, K., 3929, 3962
 Machida, N., 233
 Machover, D., 4685
 Mack, D., 1134
 MacKenzie, K. L., 2104
 MacLeod, A. R., 4325
 Macris, M. H., 4711
 Madelmont, J. C., 1890
 Madelmont, J-C., 2771
 Maeda, H., 3138
 Maeda, M., 5168
 Maemondo, M., 63
 Maesako, Y., 6224
 Magee, C., 3909
 Magnaldo, T., 4685
 Magni, F., 1116
 Magni, M., 6152
 Magnusson, C. G. M., 1364
 Mahboobi, S., 3113
 Maher, E. R., 3803, 5874
 Mahieux, R., 3562
 Mai, K. H., 5196
 Mai, M., 6682
 Mai, W-Y., 589
 Mailleire, B., 213
 Maitland, N. J., 58
 Maitra, A., 5897
 Mak, T. W., 2281, 6194
 Makarla, P., 3382
 Maki, W., 7328
 Makita, T., 4812
 Makita, Z., 5881
 Makitaro, R., 5210
 Makkar, V., 3408
 Malapetsa, A., 5457
 Malik, S. N., 4690
 Malkinson, A. M., 734, 1152, 6850
 Mallery, S. R., 5295, 5451
 Mallett, R. W., 5755
 Malluck, C., 417
 Malphurs, J., 990
 Malumbres, M., 4514
 Mambo, E., 1349
 Man, S., 2731
 Manabe, R-i., 5603
 Mancuso, P., 3106
 Manda, R., 7162
 Mandahl, N., 3861, 3980
 Mandal, M., 1251
 Mandriota, S. J., 603
 Manfioletti, G., 3766
 Mangues, R., 4514
 Manjili, M. H., 1737
 Mann, K. K., 3945
 Mann, L., 5597
 Männel, D. N., 4034
 Manning, B. M., 6870
 Manning, C. B., 4169
 Manning, P. T., 165
 Mantyh, P. W., 7343
 Mao, C., 7207
 Mao, L., 351, 4992, 6414
 Marais, R., 1724
 Marcelli, M., 6080
 Marcenaro, S., 6178
 March, G. E., 6405
 Marchenko, N. D., 7083
 Marchetti, A., 2535
 Marchini, S., 2332
 Marchion, D. C., 3132
 Marchisio, P. C., 2462
- Marconato, L., 7273
 Mareel, M., 1718, 4879
 Mariadason, J. M., 4791
 Marincola, F., 5267
 Marincola, F. M., 3581
 Marini, F. C., 3603
 Maris, J. M., 6481, 6651
 Markey, M. P., 6587
 Markowitz, S., 1134
 Marks, F., 4610
 Marmé, D., 4015
 Marques, M. M., 1978
 Marres, H. A. M., 7066
 Mars, W. M., 2064
 Martens, H., 4623
 Marth, C., 4535
 Martin, C., 848
 Martin, G. M., 367
 Martin, J., 1724
 Martin, J. M., 4599
 Martineau, D., 5148
 Martínek, V., 5678
 Martinelli, G., 3106
 Martinez, J-L., 4736
 Martínez-Palacio, J., 3402
 Martin-Fontercha, A., 1116
 Martini, A., 5408
 Martinson, H. M., 3335
 Marusawa, H., 6674
 Maruta, H., 669
 Maruyama, T., 28, 5129
 Marynen, P., 5408
 Masferrer, J. L., 625, 5405, 5778, 6706
 Mashino, K., 2937
 Massé, D., 1050
 Massion, P. P., 3636
 Masso-Welch, P. A., 4383
 Massuger, L. F., 6146
 Mastrangelo, D., 5897
 Mastrangelo, M., 5267
 Masuda, A., 271
 Masuda, K., 1450
 Masuda, M., 3351, 3997, 5129
 Masuda, N., 7162
 Masuda, T-a., 3819
 Matei, D., 5358
 Mathiesen, B., 661, 1847
 Mathiowitz, E., 7254
 Matranga, C. B., 1707
 Matrisian, L. M., 5559
 Matsubara, N., 3641, 5988
 Matsuda, H., 271, 4282
 Matsuda, K., 2004, 2883, 5611
 Matsuda, S., 2215, 3929, 3962
 Matsumori, Y., 3711
 Matsumoto, T., 1944
 Matsumoto, Y., 5813
 Matsushima, K., 3751
 Matsushita, S., 2834
 Matsuyama, A., 4916
 Matsuzaki, Y., 179
 Matta, H., 5897
 Mattern, K., 1057
 Mattern, M. R., 1797
 Mattfeldt, T., 3331
 Mattner, F., 1477
 Matusik, R. J., 5096
 Matzku, S., 4263
 Maublant, J., 617
 Maulik, G., 6304
 Maurici, D., 2897
 Maxwell, P. H., 2957
 Maxwell, P. J., 2644

* For title of article and coauthors, see listing in Contents of Volume beginning on page at the end of this index issue.

AUTHOR INDEX TO VOLUME

- May, C., 2104
 May, K. F., Jr., 3459
 Mayer, F., 2758
 Mayotte, J., 2468
 Mazar, A. P., 4678, 5344
 Mazurchuk, R., 2561
 Mazeure, N. M., 1158
 Mazzola, L. M., 6831
 Mazzolini, G., 3167
 Mazzoni, I. E., 2131
 McAlhany, S. J., 3298, 6021
 McAllister, K. A., 990
 McBride, W. H., 5230
 McCadden, J., 2576
 McCarron, S. L., 3369
 McCarty, M., 5106
 McCauley, L. K., 1832
 McCormick, F., 3812
 McCormick, J. J., 1443
 McCrae, K. R., 3408, 5344
 McCue, P. A., 4054
 McCulloch, T., 1669
 McDermott, U., 2644
 McDonald, D. M., 5381
 McDonald, W. F., 3834
 McElhinney, J., 5223
 McEntee, M. F., 403
 McGarvey, K., 6740
 McGrath, M. S., 5536
 McGregor, F., 4757
 McIntire, L. V., 5301
 McJilton, M. A., 2423
 McKeehan, K., 1898
 McKeehan, W. L., 1898
 McKeithan, T. W., 3477
 McKenzie, O. L. D., 4599
 McKie, J. A., 1439
 McKie-Bell, P. R., 5867
 McKinnon, P. J., 6395
 McKinstry, R., 188
 McLean, K., 6740
 McLeod, R., 359
 McMahon, S. J., 4109
 McMasters, K. M., 1776
 McNeil, E. A., 3826
 McPherson, J. P., 6194
 McQueeney, K. D., 3834
 McSheehy, P. M. J., 688
 Mebel, E., 6712
 Mechtersheimer, G., 2993
 Mecklenburg, I., 251
 Mecklin, J.-P., 1166
 Mecucci, C., 5408
 Medina, D., 4115
 Medrano, E. E., 6231
 Meeker, A. K., 6405
 Meflah, K., 1050, 2861
 Meggetto, F., 1489
 Meier, F., 226
 Meijer, C. J. L. M., 618
 Meijer-van Gelder, M. E., 4617
 Melcher, A., 5495
 Melcher, A. A., 6566
 Melero, I., 3167
 Melief, C. J. M., 472, 6187
 Melikian, A. A., 1330
 Melillo, G., 4316
 Melino, G., 5158
 Mellinghoff, I. K., 5254
 Mellor, R., 7083
 Mellstedt, H., 1364
 Melnyk, N., 4711
 Melton, D. W., 4065
 Meltzer, S. J., 1148, 3382, 3493,
 3641, 5637, 5988, 6011, 6820
 Ménard, S., 567, 1321
 Mendoza, N., 5485
 Mendoza, V., 4690
 Meng, Q., 141
 Meng, X., 7241
 Meng, Z. H., 1000, 1939, 5980
 Menke, A. L., 6615
 Menon, M., 2488, 4968
 Menssen, A., 6255
 Merajver, S. D., 4854
 Meram, A., 2721
 Mercier, F., 5148
 Mercier, P., 1489
 Mercurio, A. M., 7203
 Mergny, J.-L., 3365
 Merino, M. J., 6740
 Merlano, M., 2072
 Merlino, G., 2951, 6724
 Merok, J. R., 6791
 Mertens, F., 3980
 Mertens, J. C., 497
 Mertz, J. E., 6510
 Mesri, E. A., 4854
 Messiaen, L., 1503
 Messing, E. M., 6039
 Mester, J., 4879
 Meterissian, S., 6625
 Metz, C., 5881
 Metzger, G., 4685
 Meyer, A. M., 6850
 Meyers, D. A., 1784, 2253, 6485
 Meyerson, M., 7001
 Mhashilkar, A. M., 2239
 Mian, B., 5720
 Miao, L., 3084
 Miccoli, L., 5425
 Michaelsson, J., 1116
 Michailidis, G., 4722
 Michalickova, K., 1284
 Michalopoulos, G. K., 2064
 Miele, L., 665
 Miers, L. A., 4263
 Mihich, E., 3883
 Mikami, T., 2236
 Mikesch, J.-H., 1020
 Mikhailova, M., 2630
 Mikheeva, G. V., 1266
 Miki, H., 669, 2503
 Miki, K., 5967
 Miki, T., 5967
 Miksicek, R. J., 2736
 Milan, G., 1116
 Milanesi, M., 6152
 Milanini, J., 4977
 Milas, L., 7350
 Milbrandt, J., 1555
 Millhollen, M., 789
 Millán, J. L., 1822
 Millar, D. P., 3663, 4095
 Millar, R. P., 424
 Millard, P., 2493
 Miller, C. R., 773
 Miller, C. T., 5273
 Miller, D. P., 1377, 2819
 Miller, G., 5260
 Miller, G. J., 5096
 Miller, J. F., 2287
 Miller, J. H., 3356
 Miller, L. D., 1688, 3581
 Miller, L. J., 947, 5223
 Miller, W. H., Jr., 3893, 3945
 Miller, W. T., 4236
 Miller, Y. E., 734
 Millikan, R., 1987
 Mills, G. B., 1087
 Mills, L., 5106
 Millward, C., 5536
 Milpied, N., 2861
 Mimaki, Y., 1025
 Mimori, K., 2258
 Min, H.-Q., 589
 Minamishima, Y. A., 995
 Mine, S., 3819
 Minna, J., 6997
 Minna, J. D., 2715, 3498, 5874
 Minskoff, S. A., 3834
 Minturn, J. E., 6462
 Mir, L., 4453
 Mirensky, T., 6651
 Misek, D. E., 4722, 5273
 Mishal, Z., 4685, 7219
 Mishima, K., 6764
 Mishima, M., 6559
 Mitchell, B. S., 3100
 Mitchell, J. B., 307, 6246
 Mitchell, R., 5881
 Mitelman, F., 2675, 3980, 5939
 Mitrou, P. S., 1768
 Mitsiades, C. S., 3876, 4996
 Mitsiades, N., 3876, 4996
 Mitsui, S., 295
 Miura, K., 3244
 Miura, M., 4860
 Miwa, N., 5651
 Mixson, A. J., 5463
 Miyahara, R., 7124
 Miyajima, A., 4176
 Miyajima, K., 3382, 5897
 Miyamoto, T., 3939
 Miyasaka, M., 4282
 Miyata, Y., 1025
 Miyazaki, J.-i., 7166
 Miyazaki, K., 2203
 Miyazaki, T., 7162
 Miyazono, K., 5955
 Miyoshi, E., 1567
 Miyoshi, H., 1971, 2261, 4549
 Mizuguchi, H., 2203
 Mizukami, H., 2019, 3244
 Mizuno, K., 271
 Mizuno-Horikawa, Y., 5603
 Mizushima, T., 277
 Mizutani, K., 669
 Mizutani, S., 2753
 Mladek, A. C., 7291
 Mo, R., 5308
 Mocellin, S., 3581
 Mochida, Y., 4048
 Modugno, M., 1321
 Moerland, E. W., 48
 Mohammed, S. I., 356
 Mohandas, T. K., 892
 Mohler, J. L., 2423
 Mohsin, S. K., 6376
 Mok, S. C., 3058, 6218
 Möck, A. M., 4339
 Molenkamp, G., 2131
 Mollenhauer, J., 6698
 Moller, P., 4339
 Molnar-Kimber, K., 3438
 Momoeida, M., 2019
 Monestioli, S., 3106
 Mon-Foote, T., 5571
 Monga, S. P. S., 2064
 Monia, B. P., 5393, 5888
 Monni, O., 2359, 2625, 6240
 Monno, A., 941
 Monos, D., 5267
 Montag, A., 251, 6598, 6717
 Montalto, M. C., 3387
 Montgomery, B., 3920
 Montgomery, C. A., 3030
 Montgomery, E., 4061
 Montgomery, K., 2993
 Montiel, J. L., 4690
 Moon, E.-Y., 5711
 Moon, I.-S., 7234
 Moon, R. C., 5178
 Moore, D. H., 957, 1000
 Moore, D. T., 3868
 Moore, J., 1315
 Moore, J. M., 48
 Moore, J. W., 2957, 6924
 Moore, M. A. S., 2104
 Moore, M. D., 734
 Moossa, A. R., 1534
 Moots, P. P., 2370
 Mora, J., 1761, 2988
 Mora, L. B., 6659
 Morán, A., 3855
 Moran, R. G., 5236
 Morello, D., 1489
 Moreno, V., 5902
 Moretta, A., 6178
 Moretta, L., 6178
 Morgan, W. T., 5344
 Morham, S. G., 3395
 Mori, H., 6367
 Mori, M., 2258, 2937, 3819
 Mori, N., 3939
 Mori, T., 1246
 Mori, Y., 1148, 3493, 3641, 5637,
 6820
 Morilla, R., 4730
 Morimoto, J., 1410
 Morimura, K., 3592
 Morin, P. J., 2923
 Morneau, N., 2861
 Morinello, E. J., 5183, 5189
 Morishige, K.-i., 6015
 Morita, A., 1471
 Morizet, J., 764
 Morley, S., 2272
 Möröy, T., 1718
 Morris, J., 122
 Morris, M. R., 3803
 Morris, V. L., 2162
 Morrison, L., 2365
 Morse, H. C., III, 48
 Morse, M. A., 4376, 5451
 Mortini, P., 2398
 Mortin-Toth, S., 5828
 Morton, C. C., 43
 Morton, C. L., 5001
 Morton, R. A., 3649, 5365
 Morvan, D., 1890
 Moskaluk, C., 2625
 Moskaluk, C. A., 4061, 6418, 6823
 Mosse, Y., 6651
 Mossink, M. H., 7298
 Mossman, B. T., 4169, 6065
 Mota, S. C. F., 6167
 Motoyama, A. B., 3151
 Mott, L. A., 152
 Motwani, M., 3950
 Moul, J. W., 6812
 Mousses, S., 1256, 2359, 6240
 Mu, R., 1330
 Mucilli, F., 2535
 Müerköster, S., 910
 Mufti, G. J., 2791

* For title of article and coauthors, see listing in *Contents of Volume* beginning on page at the end of this index issue.

AUTHOR INDEX TO VOLUME

- Muga, S., 2516
 Mukai, T., 3751
 Mukaida, N., 6682
 Mukunyadzi, P., 6470
 Mulé, K., 2064
 Mullen, C. A., 208
 Mullen, J. P., 3766
 Mullenders, L. H., 4229
 Müller, A., 1014, 3654, 6381
 Müller, D., 6211
 Müller, H. M., 4535
 Müller, J., 6545
 Müller, K., 4610
 Müller, M. G., 682
 Müller, O., 1718
 Müller, P., 4034
 Müller, S., 840
 Müller, W. J., 5405
 Müller-Driver, R., 4015
 Müller-Holzner, E., 4535
 Multani, A., 3030
 Munarom, L., 2406
 Munger, J. S., 2778
 Münger, K., 7075
 Muniappan, B. P., 3271
 Munn, L. L., 6831
 Munshi, N. C., 2982, 3876, 4996,
 5019
 Munson, P. J., 5370
 Münster, P. N., 3132
 Münstermann, E., 6698
 Muntoni, A., 4757
 Murai, M., 3751
 Murai, N., 1971
 Murai, T., 4282
 Murakami, T., 7328
 Murakami, Y., 5129
 Murata, H., 1567, 7004
 Murata, Y., 6015
 Murillas, R., 3402
 Muro-Cacho, C., 6659
 Muroni, M. R., 4459
 Murono, S., 6337
 Murphy, J., 3466
 Murphy, K. M., 3789
 Murphy, L. C., 2736
 Murray, J. C., 1669
 Murty, V. V. S., 6218
 Muschel, R. J., 241, 1910
 Muschler, J., 7102
 Musgrove, E. A., 3126, 6916
 Musgrove, H. L., 4645
 Mutoh, M., 28
 Mutsaers, A. J., 356
 Mutti, L., 5418
 Myal, Y., 2736
 Myers, E. N., 3521
 Myers, P., 2798
 Myoung, H.-J., 7234
- N**
- Nabel, G. J., 1261
 Nabors, L. B., 3347
 Nacer-Chérif, H., 1158
 Naderi, A., 3587
 Nadkarni, K. V., 887, 2162
 Naef, F., 6218
 Naegeli, H., 4229
 Naf, D., 1235
 Nafziger, D., 4968
 Nagane, M., 6764
 Nagar, B., 4236, 4244
 Nagarajan, R., 2085
 Nagarajan, S., 2869
 Nagasawa, H., 2531, 6400
 Nagase, H., 675
 Nagashima, Y., 7004
 Nagayama, S., 5859
 Nagi, P., 4273
 Nagle, R. B., 2890
 Nagorsen, D., 1743
 Nagy, A., 781
 Nahta, R., 2267
 Naito, S., 2554, 4048, 4273, 5668
 Naito, Y., 3962
 Naka, T., 5800
 Nakada, M. T., 2824
 Nakagawa, H., 277, 4579
 Nakagawa, T., 271, 2203
 Nakagawara, A., 2203
 Nakajima, H., 4916
 Nakajima, M., 7162
 Nakajima, Y., 2834
 Nakamura, J., 5189
 Nakamura, K., 2883
 Nakamura, N., 89
 Nakamura, T., 295, 3322, 5859
 Nakamura, Y., 518, 1139, 1246,
 2883, 3244, 5651, 5859, 7012
 Nakanishi, K., 2971
 Nakashima, I., 2414
 Nakashima, T., 3351
 Nakashima, Y., 5859
 Nakatani, Y., 6390
 Nakau, M., 2261, 4549
 Nakayama, E., 1471
 Nakayama, H., 3939
 Nakayama, J., 4194
 Nakayama, K., 995, 3819
 Nakayama, K.-I., 995, 3819
 Nakayama, T., 5859
 Nallainathan, D., 3466
 Nallasivam, P., 4089
 Namba, H., 7031
 Nambiar, P. R., 3667
 Nandi, A. K., 338
 Nanjangud, G., 2104
 Nanus, D. M., 1654
 Naoki, K., 7001
 Napolitano, M., 1077
 Nara, K., 6116
 Nardin, S. R., 1534
 Narita, Y., 6764
 Narumiya, S., 28, 506
 Nascimento, L., 6231
 Nasi, S., 3507
 Nassirpour, R., 1534
 Natali, P. G., 6381
 Nathwani, A. C., 3077
 Nattel, S., 4843
 Naumov, G. N., 2162
 Naus, C. G., 3544
 Nawrocky, M. M., 3159
 Naylor, M. A., 7247
 Naylor, S. L., 542, 2637
 Nchekwube, E. J., 4007
 Nederlof, P. M., 7110
 Nedospasov, S. A., 4034
 Neef, R., 5920
 Neeman, M., 6731
 Neff, J. R., 135
 Negrin, R. S., 5785
 Neil, J. C., 7175, 7181
 Neill, G. W., 4773
 Neilly, M. E., 3477
 Neiman, P. E., 48
 Nelson, H. H., 152
 Nelson, J. L., 7280
 Nelson, P. S., 3920
 Nelson, W. G., 7230
 Nemati, F., 1388
 Nemenoff, R. A., 734
 Nemoto-Sasaki, Y., 6682
 Nepveu, A., 6625
 Neri, M., 5418
 Nervi, C., 7050
 Nesbit, M., 3200
 Nesland, J. M., 512
 Nessling, M., 2993, 6698
 Nestle, F. O., 6750, 7328
 Nettelbeck, D. M., 1266, 1271,
 4663
 Neuberg, D., 4996
 Neumaier, B., 3331
 Neuman, T., 5657
 Neumark, E., 1093
 Newman, B., 1987
 Ng, C. Y. C., 3077
 Ng, I. O. L., 4704
 Ng, R. W. M., 1662
 Ngan, H. Y. S., 4151
 Ngo, D., 171
 Nguyen, C., 5974
 Nguyen, C. T., 2378, 6456
 Nguyen, K. C. Q., 5420
 Ni, S., 1063, 6089
 Nicholas, R. W., 5571
 Nichols, P., 7207
 Nicholson, A., 6997
 Nicholson, R. I., 122
 Nickel, A. E., 1296
 Nickoloff, B. J., 665
 Nicolaou, K. C., 6938
 Nicolas, J.-C., 6519
 Nicolò, G., 2455
 Nicotra, M. R., 6381
 Niculescu-Duvaz, I., 1724
 Nieder, M., 2327
 Niedermann, G., 6901
 Nieva, D. R. C., 4478
 Niewolna, M., 917
 Nigemann, B., 6467
 Nihei, N., 367
 Nijman, H. W., 6187
 Nikitakis, N. G., 1004
 Nikitin, A. Y., 5134
 Nilbert, M., 5939
 Nilssen, K., 661, 1847
 Nilsson, G., 3861
 Nimmanapalli, R., 5761
 Nimura, Y., 3929
 Nishanian, T. G., 2744
 Nishi, H., 827
 Nishi, K. H., 827
 Nishikawa, S. G., 1696
 Nishikori, M., 6224
 Nishino, N., 4916
 Nishiyama, M., 4916
 Nishizaki, M., 2715
 NiBlein, T., 3448
 Noessner, E., 480
 Nolan, J., 7247
 Nomoto, S., 3659
 Nomura, S., 3751
 Nomura, T., 518
 Nonomura, N., 1410
 Nooj, M., 2024
 Noonan, F. P., 6724
 Nordenskjold, A., 6598
 Nordquist, R. E., 4295
 Norman, K. L., 1696
 Northcote, P. T., 3356
 Norton, J. A., 4696, 5069
 Nosrati, A., 1134
 Notario, V., 2690
 Nowak, A. K., 2353
 Nuchtern, J. G., 1123
 Nukiwa, T., 63, 636, 3641
 Numico, G., 2072
 Nuñez, G., 924
 Nunez, N. P., 6529
 Nuovo, G. J., 1261
 Nussbaum, A. K., 2875
 Nyaga, S. G., 1349
 Nyati, M. K., 2337
 Nyhus, J. K., 7042
 Nylander, K. D., 4867
 Nylandsted, J., 7139
- O**
- Obata, Y., 1751
 Oberley, L. W., 1205
 Obermayr, F., 5818
 Obika, S., 3751
 Obinata, M., 636
 Obradovic, D., 7050
 O'Brien, S. J., 7175
 O'Bryan, E., 5761
 O'Callaghan, N. J., 4599
 Ochiya, T., 1641
 Ochs, K., 1524
 Odesa, S. K., 2287
 O'Donnell, A. H., 4588
 Offringa, R., 472, 6187
 O'Flaherty, J. T., 6817
 Ogama, Y., 6390
 Ogawa, H., 3711, 5967
 Ogawa, M., 5651
 Ogawa, S.-i., 2554
 Ogilvie, D. J., 4645
 Ogilvie, L. M., 1724
 Ogiso, Y., 5008
 Oh, D. S., 6052
 Oh, H.-K., 1592
 Oh, J. J., 3207
 O'Hara, J., 3555
 Ohara, N., 6390
 Ohgaki, H., 2592, 6990
 Ohira, M., 2203
 Ohki, M., 3592
 Ohlsson, R., 4545
 Ohnishi, Y., 518
 Ohnmacht, G. A., 3581
 Ohno, H., 6224
 Ohta, M., 2937
 Ohta, T., 3592
 Ohtsuru, A., 7031
 Ohuchida, S., 28
 Ohwada, S., 3322
 Ohyama, C., 3850, 4194
 Oien, K. A., 5999
 Oike, M., 1450
 Ojo-Amaize, E. A., 4007
 Oka, M., 3939, 4894
 Oka, T., 6390
 Okabe, T., 6116
 Okada, H., 2583, 5955
 Okada, N., 1110
 Okada, T., 3939
 Okamoto, M., 2834
 Okamura, T., 333
 Okan, N. A., 6231
 Okayasu, I., 2236
 Okayasu, R., 6400

* For title of article and coauthors, see listing in Contents of Volume beginning on page at the end of this index issue.

AUTHOR INDEX TO VOLUME

- Oken, M. M., 715
 Okita, K., 835
 Okochi, E., 3592
 Okogun, J. I., 4007
 Okon, E., 1036
 Okorokov, A. L., 1876
 Okuda, K., 7004
 Okui, A., 295
 Okumura, K., 5668
 Okuyama, A., 1410
 Olaru, A., 3493, 3641, 5637, 6820
 Old, L. J., 4041
 O'Leary, E., 1439
 Olesen, S. H., 4352
 Oleynikov, Y., 6278
 Oliaro, A., 7025
 Oliva, J., 6519
 Olive, P. L., 4469
 Oliver, D. H., 7230
 Oliverio, S., 5158
 Olivero, M., 7025
 Olivier, A., 2131
 Olivier, K., 5495
 Oliyai, C., 2327
 Ollikainen, V., 3798
 Olopade, O. I., 1481
 Olschwang, S., 848
 Olshen, A. B., 957, 3636
 Olsson, P. G., 1822
 O'Malley, B. W., Jr., 4023, 4637
 O'Meally, R. N., 7230
 Omoto, Y., 4849
 on der Heide, M., 3331
 Ong, T.-m., 703
 Onida, F., 5995
 Onishko, H., 4671
 Onkamo, P., 3798
 Ono, M., 2554, 2834
 Ono, R., 333, 4075
 Ono, T., 1471
 Onyango, P., 6442
 Ooms, M. E., 6187
 Oosterhuis, J. W., 1822, 2758
 Oipari, A. W., 924
 Oplanich, S., 1761
 Pololon, P., 764
 Oprysko, P. R., 3626
 O'Reilly, S., 1443
 Oren, M., 5947
 Orlandi, R., 567
 Orlowski, R. Z., 3868
 Ormsby, I., 6362
 Ornberg, R. L., 625, 6706
 Orntoft, T. F., 961, 4352
 Orrico, M., 4685
 Orringer, M. B., 5273
 Orr-Urtreger, A., 6803
 Ortiz-Hidalgo, C., 7093
 Osada, H., 271
 Oshima, H., 506, 1971
 Oshima, J., 367, 547
 Oshima, K., 3929
 Oshima, M., 506, 1971, 2261, 4549,
 6846
 Oshimura, M., 3322, 6784
 Osman, S., 5698, 5912
 Ossendorp, F., 6187
 Östman, A., 5476
 Ostrand-Rosenberg, S., 4406
 O'Sullivan, M. J., 4065
 Oswald, U., 3009
 Ota, S., 1471
 Ota, T., 5168
 Otake, Y., 7124
 Otava, A., 1477
 Otsuki, Y., 1410
 Otte, A. P., 618
 Ottey, M., 4054
 Ottmann, O. G., 7050
 Ouchida, M., 6390
 Outram, S. V., 4730
 Ouwehand, M., 6158
 Overall, C. M., 283
 Overholser, J., 2567
 Overmoyer, B., 3408
 Owa, T., 6116
 Owen, J. S., 6817
 Oxford, G., 6418
 Oyemade, O. A., 4007
 Oyen, W. J., 6146
 Ozaki, T., 2203
 Ozawa, K., 2019
 Ozawa, Y., 6116
 Ozçelik, H., 4151
 Ozog, M. A., 3544
- P**
- Packeisen, J., 1020
 Packer, R. J., 323
 Padigaru, M., 3834
 Padley, D., 1884
 Padovan, E., 3453
 Pae, C., 547
 Páez, J. G., 2690
 Pagano, J. S., 6337
 Paielli, D., 4968
 Paiment, J.-P., 5888
 Paik, C. H., 5755
 Pajares, M. J., 5627
 Pajonk, F., 5230
 Pajovic, S., 967
 Palazzo, J., 4054
 Palazzo, J. P., 1014, 7093
 Palmer, C., 4169
 Palmisano, W. A., 2370
 Pals, S. T., 5126
 Palumbo, J. S., 6966
 Pan, K., 6430
 Pan, Q., 4854
 Panacchia, L., 3507
 Panasci, L., 5457
 Panasci, L. C., 5888
 Pandeya, N., 6011
 Pang, J., 1987
 Pant, A. C., 391
 Pantel, K., 251
 Panzarella, G., 7083
 Pao, A. Y., 1311
 Papadopoulos, T., 6297
 Papon, J., 1890
 Parada, L. F., 4507
 Paranawithana, S. R., 466
 Parekh, H. K., 2193
 Parekh, T. V., 2778
 Parikh, D., 1069
 Park, C. W., 5755
 Park, H., 1702
 Park, I.-C., 6318
 Park, J., 1284
 Park, J. P., 892
 Park, J.-G., 38
 Park, L., 5755
 Park, M.-J., 6318
 Park, S. H., 6318
 Park, S.-Y., 459
 Parker, A. R., 7230
 Parkinson, E. K., 4757
 Parmigiani, G., 819
 Parr, T., 7207
 Parrella, P., 3659
 Parrish, R. S., 3722
 Parry, G. C., 5344
 Parvin, J. D., 4222
 Pascale, R. M., 4459
 Pascasio, L., 1439
 Paschen, A., 2875
 Pasqualini, R., 867
 Passe, S., 6205
 Passlick, P., 251
 Pastan, I., 5755
 Paster, W., 5489
 Pastorek, J., 4469
 Pastoreková, S., 4469
 Pataer, A., 2239
 Patak, P., 4922
 Patané, S., 7025
 Patel, A., 5058
 Patel, J., 5405
 Patel, V., 1401
 Pathak, S., 3030
 Paul, B. A., 67
 Paul, R., 6712
 Paulding, W. R., 1682
 Paulus, P., 5317
 Paunu, N., 3798
 Pavey, S., 875
 Pawlowski, S., 6362
 Paz, M. F., 4519
 Peabody, J., 4968
 Peale, F., 2546
 Pearson, A. D. J., 5158, 5906
 Pease, K. M., 4419
 Pease, L. R., 4413
 Peat, D., 4123
 Pedersen, P. L., 3909
 Pediaditakis, P., 2064
 Peehl, D. M., 1654
 Peek, R. M., Jr., 2385
 Pegg, A. E., 3037
 Pegg, J., 4968
 Pehamberger, H., 2098
 Pei, D., 675
 Pei, L., 5420
 Pei, P., 5451
 Peinado, M. A., 4519, 5902
 Peipp, M., 2848
 Pellicci, P. G., 7050
 Pellicena, P., 4236
 Pellicer, A., 4157, 4514
 Penault-Llorca, F., 617
 Pendle, D., 6178
 Peng, A. C., 3244
 Peng, H., 8, 3773
 Peng, K.-W., 4656
 Peng, Y., 5420, 6400
 Pennington, C., 5543
 Pennisi, P. A., 6529
 Penttinen, J., 6410
 Pepper, M. S., 603
 Péqueux, C., 4623
 Pequignot, E., 4054, 5413
 Pereira, M. A., 4199
 Pérez, Y., 5672
 Perez de Castro, I., 4514
 Perez-Diez, A., 3581
 Perez-Soler, R., 4514, 6080
 Peric-Hupkes, D., 3233
 Peritt, D., 5267
 Perlman, E. J., 6981
 Perrone, E., 5418
 Perrot-Appanat, M., 4977
 Perry, A., 2085
 Perry, K., 3493, 3641, 5637
 Persaud-Sawin, D.-A., 801
 Perucho, M., 1961
 Peschel, C., 2244
 Pestell, R. G., 141, 2077, 3997
 Petermann, R., 4583
 Peters, C. M., 7343
 Peters, J. P. W., 341
 Peters, K. B., 5248
 Petersen, D., 3581
 Petersen, G. M., 3789
 Peterson, T., 6566
 Petricoin, E. F., III, 6740
 Petros, W. P., 3408
 Petrus, E., 4566
 Pett, M., 6959
 Pezo, R. C., 6006
 Pezzella, F., 1326
 Pezzuto, J. M., 5178
 Pfeffer, K., 4034
 Pfeifer, G. P., 3698, 4331
 Pfeifer, S., 4545
 Phan, V., 5495
 Phaneuf, S. L., 4592
 Pharoah, P. P. D., 3052
 Phillips, G. L., 5485
 Phillips, T., 4592
 Philpott, M. P., 4773
 Piacentini, M., 5158
 Pianetti, S., 652
 Pidgeon, G. P., 2721
 Pien, C. S., 4996
 Pienta, K. J., 1832
 Pierantoni, G. M., 2398
 Pierce, A. J., 1279
 Pierce, M., 6837
 Pieters, R., 2157
 Pietras, K., 5476
 Pili, R., 2455
 Pillaire, M.-J., 3511
 Pillarisett, V. G., 5260
 Pilz, B., 2516
 Pinedo, H. M., 5736, 6165
 Pinilla, C., 2058
 Pinkas, J., 4781
 Pinkel, D., 3200, 3636
 Pinski, J., 986
 Pintus, J. H., 6803
 Pintilie, M., 3005
 Piotrowska, K., 3048
 Piovan, E., 6099
 Pipkorn, R., 7018
 Pise-Masison, C. A., 3562
 Pistrutto, G., 3200
 Pitt, W. G., 7280
 Pittman, B., 6424
 Pitts, R. L., 43
 Pizzey, A. R., 4730
 Pizzorno, G., 2313
 Platt-Higgins, A., 3417
 Platz, E. A., 2220, 6405
 Platzer, P., 1134
 Player, A., 3340
 Plon, S. E., 1123
 Pluder, M., 6884
 Plunkett, M. L., 5344
 Po, L. S., 4890
 Podar, K., 5019
 Poehlein, C. H., 3914
 Poh, C., 6447
 Poirier, M., 6625
 Poiron-Bichat, F., 1815
 Polikoff, D., 3636

* For title of article and coauthors, see listing in *Contents of Volume* beginning on page at the end of this index issue.

AUTHOR INDEX TO VOLUME

- Pollack, I. F., 2583
 Pollak, M., 7372
 Pollan, M., 4519
 Pollard, J. W., 7166
 Pollegioni, L., 1321
 Pollock, R. E., 2034
 Polson, A. G., 4525
 Polyak, K., 43, 4540
 Pommier, Y., 1688, 4899, 5743
 Ponder, B. A. J., 3052
 Pongratz, H., 3113
 Ponomareva, O. N., 1518
 Pons, M., 6519
 Poon, R. Y. C., 4890
 Pop, L. A. M., 7066
 Popa, C., 3759
 Popescu, N., 6348
 Popescu, N. C., 4054
 Popović, S. V., 1588
 Porter, C. W., 6639
 Porter, D., 4540
 Porter, D. A., 43
 Poser, I., 5962
 Post, D. E., 2478
 Potapova, O., 3257
 Potoczek, M., 4054
 Potten, C. S., 122
 Potter, D., 3221
 Potter, J. D., 3361
 Potter, J. M., 6966
 Potter, P. M., 5001
 Pouch, M-N., 2771
 Pouillart, P., 1388
 Poulsen, H. E., 4339
 Poulsom, R., 2942
 Poupon, M-F., 1388
 Poustka, A., 6698
 Pouvelle-Moratille, S., 213
 Powell, J. A., 4599
 Powell, J. I., 3581
 Powell, R. L., 3971
 Powell, S. M., 2625, 4061, 6823
 Powell, W. C., 4812, 5096
 Powers, S., 5420
 Powis, G., 5089
 Pow-Sang, J., 6659
 Prabhu, V. V., 5370
 Pradayrol, L., 6124
 Pradono, P., 63
 Prados, M., 6205
 Prang, N., 251
 Precht, D., 840
 Preciado, M. V., 4876
 Prendergast, G. C., 450
 Prenzel, N., 6329
 Prescott, M. S., 5273
 Presti, J. C., Jr., 957
 Pretlow, T. G., 6606
 Prevo, R., 1315
 Pribluda, V. S., 3691
 Price, P., 5698, 5912
 Priddy, R., 6447
 Prieto, J., 3167
 Prince, C. W., 5336
 Pringle, J. H., 3289
 Profittlich, S., 1524
 Proia, A. D., 801
 Pröls, E., 5920
 Protopopov, A., 3498
 Pruner, G., 3106
 Prystowsky, M., 6973
 Prystowsky, M. B., 1184
 Puccetti, E., 1768, 7050
 Pugacheva, E. M., 48
- Puisieux, A., 848, 3646
 Pulaski, B. A., 4406
 Pullen, J. K., 5792
 Pullen, S. M., 1425
 Pumphrey, C. Y., 3722
 Puntoni, R., 5418
 Purdie, D., 6011
 Puri, R. K., 3575
 Pützer, B. M., 3598
- Q**
- Qi, C.-F., 48
 Qi, H., 721
 Qi, M., 433
 Qian, C.-N., 589
 Qiang, W., 5153
 Qin, Z., 2856
 Qu, Q., 1330
 Qu, Y., 3609
 Qu, Z., 1555
 Qualman, S. J., 4711
 Quigley, J. P., 7083
 Quinn, A. G., 4773
 Quistorff, B., 1191
- R**
- Ra, M. S., 1809
 Raab-Traub, N., 1920
 Raaphorst, F. M., 618
 Rabascio, C., 3106
 Rabbani, S. A., 2390, 4678, 5344
 Rabinowich, H., 4884
 Radcliffe, J. N., 1757
 Raderschall, E., 219
 Radonovich, M., 3562
 Radovanovic, I., 2592
 Radulovich, N., 3005
 Raderschall, E., 219
 Radonovich, M., 3562
 Radovanovic, I., 2592
 Radulovich, N., 3005
 Raffeld, M., 1256, 3702
 Raffo, A. J., 2175
 Rafie, N., 3408
 Raftogianis, R. B., 3144
 Ragg, E., 2332
 Raghaw, S., 1370
 Rahaman, S. O., 1103
 Rahimpour, S., 1036
 Rahman, A., 6045
 Rahmani, M., 188
 Rahmatpanah, F., 3214
 Rainbow, A. J., 5528
 Raja, R., 3667
 Rajagopal, A., 391
 Rajapaksa, R., 5845
 Rajkumar, S. V., 715
 Rajopadhye, M., 6146
 Raju, U., 2318
 Rak, J., 1931
 Rak, J. W., 1838
 Raleigh, J. A., 6827, 7066
 Ramachandra, M., 6045
 Ramaswamy, S., 4963
 Ramesh, N., 3743
 Ramirez, M., 5013
 Ramirez, R. A., 4383
 Ramirez-Solis, R., 3221
 Rammensee, H-G., 2592, 5818
 Ramos-Nino, M. E., 6065
 Ramponi, G., 6489
 Ran, S., 6132
 Ranalli, M., 5158
 Ranasinghe, A., 5183, 5189
 Randlev, B., 6070
 Rando, R. R., 1654
- Rangell, L., 2546
 Rangnekar, V. M., 1768
 Ranicar, A. S., 5698
 Rantala, I., 3798
 Ranzani, G. N., 1609
 Rao, A., 6817
 Rao, C. V., 165, 6506
 Rao, P. H., 4089, 6218
 Rapisarda, A., 4316
 Rapp, U. R., 6297
 Rappaport, S. M., 1330
 Rasey, J., 1518
 Rasmussen, H., 1847
 Rasnick, D., 6345
 Raso, E., 2824
 Rassool, F. V., 2791
 Rastelli, L., 3834
 Rastert, R., 7018
 Ratcliffe, P. J., 2957
 Rattel, B., 1057
 Rauen, K. A., 3812
 Raugei, G., 6489
 Rauscher, F. J., III, 1, 3773
 Rauvala, H., 4805
 Ravani, S. A., 5627
 Ravetch, J. V., 6891
 Ravey, P., 977
 Ravi, R., 1583, 4180
 Ray, R. B., 6141
 Raynaud-Messina, B., 3511
 Raz, A., 4484
 Re, G. G., 6598
 Reali, E., 5058
 Rebbeck, T. R., 6651
 Rebel, H., 1338
 Recio, J. A., 2690, 6724
 Reddel, R. R., 1289, 4434
 Reddy, B. S., 165
 Reddy, J. L., 5897
 Reddy, R. K., 7207
 Redfern, C. P. F., 5158
 Redhead, N. J., 4065
 Redon, R., 6211
 Redston, M., 1284
 Ree, A. H., 4165
 Reed, H., 4722
 Reed, J. C., 1904, 6674
 Reed, K. A., 1382
 Reed, S. I., 4535
 Rehemtulla, A., 2337
 Rehg, J. E., 2184
 Reichardt, P., 251
 Reichert, J., 5065
 Reichert, U., 3842
 Reid, T., 6070
 Reimer, C. L., 789
 Reimers, J. M., 5641
 Reinders, M. J. T., 7110
 Reinhardt, J., 2
 Reinhold, W. C., 1688
 Reis, J., 5536
 Reiss, D. J., 497
 Reiss, M., 497, 2778
 Reissmann, T., 3113
 Reiter, Y., 3184, 5835
 Rellosa, M., 3167
 Remaley, A. T., 3649
 Remick, S. C., 3408
 Rempel, S. A., 6270
 Rémy, C., 5672
 Ren, M., 2455
 Ren, Y., 6952
 Renner, R. J., 5451
 Repasky, E., 1737
- Repasky, E. A., 5800
 Reperant, M., 1609
 Resau, J. H., 589
 Reschke, D. K., 5641
 Reschner, A., 3453
 Reske, S. N., 3331
 Restifo, N. P., 3581, 5144
 Reuter, V., 4499, 6218
 Rey, O., 1632
 Reynolds, P. N., 1271
 Reynolds, S. H., 1152
 Rhee, C. H., 6318
 Rheingold, S., 4212
 Rhim, J. S., 1654, 3498, 6812
 Rhodes, D. R., 4427
 Riabowol, K., 4445
 Ricci, C., 5995
 Ricciardelli, C., 854
 Richards, F. M., 3803
 Richards, W. G., 4963, 7001
 Richardson, A., 4540
 Richardson, P., 3876
 Richardson, P. G., 4996, 5019
 Richmond, A., 7335
 Richmond, G. H. P., 4645
 Rickinson, A. B., 6952
 Ricordy, R., 3507
 Riddle, D., 6566
 Rideout, D. C., 1394
 Ridley, A. J., 4805
 Ried, T., 1134, 2365
 Riegman, P. H. J., 1531
 Rieker, R. J., 2993
 Riese, H. H., 552
 Riess, K., 5230
 Riethmüller, G., 251
 Riggins, G. J., 3335, 6823
 Riley, J., 4256
 Rimm, D. L., 497
 Rimner, A., 2592
 Rimoldi, D., 1743
 Rinaldi, A. L., 5451
 Rinaldi, C., 1196
 Ringnér, M., 6240
 Rinker-Schaeffer, C. W., 6717
 Rinkes, I. H. M. B., 4289
 Riou, J-F., 3365
 Risdon, G., 3736
 Rishi, A. K., 3842
 Rishi, I., 6997
 Risinger, J. I., 3251
 Risom, L., 4339
 Ristumäki, A., 632
 Ritchey, J. W., 4295
 Ritter, C. A., 4132
 Ritter, G., 4041
 Rittman, B., 2468
 Ritz, J., 5517
 Rivat, C., 4879
 Rivenson-Segal, D., 1966
 Rivera, A. A., 4663
 Rivera, P., 6178
 Rivera-Gonzalez, R., 89
 Robbins, P. D., 5853
 Robbins, P. F., 3630, 5144
 Röbe, J., 2347
 Roberts, C. W. M., 323
 Roberts, D. D., 1541
 Roberts, J. S., 854
 Robertson, E. J., 4558
 Robertson, K., 3408
 Robey, R., 6108
 Robey, R. W., 5035
 Robins, D. M., 4854

* For title of article and coauthors, see listing in Contents of Volume beginning on page at the end of this index issue.

AUTHOR INDEX TO VOLUME

- Robinson, B. C., 2151
 Robinson, B. W. S., 2353
 Robinson, S. P., 688
 Robles, A. I., 3244
 Roboz, J., 6080
 Rochdi, M., 6559
 Rodemann, H. P., 1915
 Rodeschini, O., 2398
 Rodolfo, C., 5158
 Rodrigo, K. A., 5451
 Rodrigues, S., 4879
 Rodriguez, C. O., Jr., 3100
 Rodriguez, J. A., 4081
 Rodriguez, M., 351, 4413
 Rodriguez, R., 2576
 Rodriguez-Calvillo, M., 3167
 Roeder, B. L., 7280
 Roelofs, R. W., 2695
 Roetger, A., 1020
 Roffler, S. R., 6089
 Rofstad, E. K., 661, 1847
 Rogan, E. G., 3395
 Rogan, P. K., 3251
 Rogatko, A., 4767
 Rogers, L. A. C., 6817
 Rogers, M. S., 2300
 Rogers, P. M., 3276
 Rogers, S. D., 7343
 Rogounovitch, T. I., 7031
 Rohde, M., 7139
 Rollins, B., 6304
 Roloff, F., 7280
 Romagnolo, D. F., 113
 Rome, L., 6070
 Romero, P., 1743, 2058
 Romieu-Mourez, R., 6770
 Ronchini, C., 567
 Ronson, B., 4023
 Rood, B. R., 3794
 Rook, S. L., 789
 Rooney, C. M., 7195
 Ropponen, K., 6410
 Rosai, J., 3980
 Rosato, A., 1116
 Rose, D. G., 1014
 Rose, J. A., 1518
 Rosemann, M., 3048
 Rosen, B., 3466
 Rosen, E. M., 141
 Rosen, N., 2982, 3132
 Rosenberg, D. W., 3667
 Rosenberg, S. A., 3020, 3581, 3630, 5144
 Rosenblatt, J. D., 6545
 Rosenblum, M. K., 5551
 Rosenthal, D., 6879
 Rosin, M. P., 6447
 Rosolen, A., 1559
 Ross, D., 1420
 Ross, S., 2546
 Ross, S. R., 747
 Rossant, J., 3005
 Rossi, D., 4089
 Rosso, E., 7025
 Rusty, C., 1868
 Rotaru, J. H., 3159
 Roth, J. A., 2239, 2715, 6997
 Roth, R. B., 656
 Rothas, D. A., 5451
 Rothenfusser, S., 2347
 Rothen-Rutishauser, B., 437
 Rothman, K., 376
 Rottapel, R., 5076
 Rouillard, D., 1388
- Roumiantsev, P. O., 7031
 Rounbehler, R. J., 3276
 Roussel, M. F., 1222
 Rouwé, B., 3356
 Rowan, A., 53
 Rowley, D. R., 3298, 6021
 Rowley, R. B., 2516
 Roy-Burman, P., 4812, 5096
 Rozenblum, E., 6240
 Rozengurt, E., 1632
 Rozovsky, U., 6803
 Rubin, H., 6350
 Rubin, J., 6070
 Rubin, K., 5476
 Rubin, M., 5420
 Rubin, M. A., 2546, 4427
 Rubinstein, D. B., 4985
 Rubio-Godoy, V., 1743, 2058
 Rucker, N., 1458
 Ruckert, S., 3009
 Rudin, C. M., 3515
 Rudland, P. S., 3417
 Rudy, W., 2052
 Rueschhoff, J., 1014, 6796
 Rugarli, C., 1116
 Ruggiero, J., 6385
 Ruiter, D. J., 341, 7059
 Ruiz, A., 1654
 Ruotsalainen, P., 7364
 Ruppert, J. M., 5867
 Rusan, N. M., 4109
 Rüschoff, J., 3009
 Rush, W. L., 6724
 Rushkin, E., 1966
 Russel, D., 6141
 Russell, J. S., 2318
 Russell, R. L., 2313
 Russell, S. J., 4656
 Russo, A., 6246
 Rustgi, A. K., 277
 Rustum, Y. M., 5800
 Rusyn, E. V., 4142
 Rutgers, J., 6717
 Ruthardt, M., 1768, 7050
 Rux, J. J., 3773
 Ryan, A. J., 7284
 Ryan, P. E., 6606
 Rydhholm, A., 3980
 Rydlová, H., 5678
 Rylova, S. N., 801
 Rynkiewicz, S. D., 2337
 Ryschich, E., 1462
 Ryu, B., 819
 Ryu, J.-H., 7241
- S
- Saad, S., 283
 Sabel, M. S., 7254
 Sabés, M., 5672
 Sabino, M. A. C., 7343
 Sacchi, A., 867
 Sacchi, N., 2455
 Sacco, R., 2535
 Sadanaga, N., 2937
 Sadelain, M., 2104
 Sadvakassova, G., 5590
 Saenko, V. A., 7031
 Safaei, R., 6559
 Saffroy, R., 4685
 Saga, T., 860
 Sagebiel, R. W., 3992
 Sahin, A., 1676, 6740
 Sahin, A. A., 1251, 4566
- Sahin, U., 6750
 Saito, Y., 63
 Saito, H., 271
 Saito, I., 1641
 Saito, M., 3850
 Saito, S., 3850
 Sajii, S., 4849
 Sak, A., 6621
 Saka, A., 3663
 Sakamoto, H., 1641
 Sakamoto, M., 2971, 4860
 Sakaue, M., 901
 Salani, D., 6381
 Salazar, V. S., 5778
 Sales, K. J., 424
 Salgia, R., 5242, 6304
 Säll, T., 2675, 5939
 Salminen, T., 632
 Salomons, G. S., 2157
 Salovaara, R., 4554
 Salowsky, R., 6698
 Salvesen, H. B., 6808
 Salwen, H. R., 7357
 Samanta, M., 3347
 Samimi, G., 6559
 Sampsel, J. W., 7042
 Sampson, J. H., 3335
 Sampson, J. R., 363
 Samson, L. D., 656
 Samuels, S. E., 2771
 Sanchez-Carbayo, M., 6973
 Sanchez-Cespedes, M., 3659, 4519
 Sanchez-Madrid, F., 2929
 Sanchez-Pernaute, A., 3855
 Sanders, M. O., 1481
 Sanders, S., 2690
 Sanderson, R. D., 3722
 Sandler, A. D., 3093
 Sands, A. T., 3221
 Sangfelt, O., 4535
 Santamaría, G., 6674
 Santoro, M., 1077, 7284
 Santos, S., 5013
 Santucci, R., 5470
 Sanz, G., 4453
 Sapino, A., 2406
 Sapra, P., 7190
 Sarasini, A., 4899, 7186
 Sargent, L. M., 1152
 Sarkaria, J. N., 7291
 Sarnaik, A., 3503
 Sartor, C. I., 4142
 Sasaki, H., 1641, 1641, 1790, 5308
 Sasaki, K., 835, 4894
 Sasaki, T., 1944
 Sasaki, Y., 1567
 Sasatomi, E., 2681
 Sasazuki, T., 5668
 Sashida, Y., 1025
 Sasiéni, P., 53
 Satagopan, J., 4499
 Sathasivam, N., 1394
 Sathyaranayana, U. G., 3382
 Sato, F., 1148, 3382, 3493, 3641,
 5637, 6820
 Sato, K., 4894
 Sato, M., 5603
 Sato, N., 860
 Sato, T., 1025
 Sato, M., 3850
 Satoh, S., 7012
 Sattler, M., 6304
 Satyamoorthy, K., 226
 Sauk, J. J., 1004
- Saul, D., 2848
 Saunders, H. M., 747, 2962
 Saunders, N. A., 3759
 Saurin, J.-C., 4829
 Sausville, E. A., 1401, 4316
 Sauter, E. R., 3200
 Sauter, G., 1256, 6240
 Sawa, T., 3138
 Sawada, K., 6015
 Sawiris, G. P., 2923
 Sawyers, C. L., 5254
 Sayeed, A., 5980
 Scaife, C. L., 6870
 Scanlan, M. J., 4041
 Scanlon, I., 1724
 Scappini, B., 5995
 Scardino, P., 4499
 Schadendorf, D., 1743, 2875, 6698
 Schaefer, T. S., 1069
 Schäfer, H., 910
 Schäfer, R., 5317
 Schäffer, E., 3048
 Schagdarsurenjin, U., 3698
 Schaich, M., 4955
 Schaid, D., 3587
 Schäkel, U., 4955
 Schalken, J. A., 2695
 Schalkwijk, L., 7059
 Schally, A. V., 781
 Schartl, M., 4820
 Schatteman, G. C., 665
 Scheffler, G. L., 7298
 Scheffold, C., 5785
 Scheffold, Y. C., 5785
 Scheibenbogen, C., 1743
 Schell, M., 3646
 Schellens, J. H. M., 6158
 Schellhammer, P. F., 3609
 Schemainda, I., 1057
 Schendel, D. J., 480
 Schepher, R. J., 7298
 Scher, H., 4499
 Scherf, U., 1688
 Schiavetti, F., 5510
 Schick, M., 6698
 Schier, K., 1020
 Schiestl, R. H., 547
 Schild, H., 2875
 Schindler, T., 4236, 4244
 Schinkel, A. H., 2294
 Schipper, H. M., 3893
 Schirle, M., 2875, 5818
 Schirrmeister, H., 3331
 Schlake, G., 809
 Schlegel, W., 2098
 Schlierf, B., 2848
 Schlom, J., 5049, 5058, 5770, 6944
 Schlossman, R. L., 5019
 Schmeits, J., 3485
 Schmid, J. A., 4583
 Schmidt, B., 2244
 Schmidt, E. V., 2267
 Schmidt, K. H., 5641
 Schmidt, L. J., 1008, 5632
 Schmidt, M., 3113
 Schmidt, W., 1477
 Schmidt, W. E., 910
 Schmits, R., 2281
 Schmitt, L. D., 3812
 Schmitt, M., 840, 4617
 Schmitz, J., 5058
 Schmitz, V., 3167
 Schneider, D., 5685
 Schneider, E., 5035

* For title of article and coauthors, see listing in Contents of Volume beginning on page at the end of this index issue.

AUTHOR INDEX TO VOLUME

- Schnell, P. O., 1682
 Schnitt, S., 43
 Schnurr, M., 2347
 Schoen, R. E., 2437
 Schoester, M., 7298
 Scholz, C., 2347
 Schoor, O., 5818
 Schor, N. F., 4867
 Schouten, R., 1338
 Schow, P., 2546
 Schrama, D., 5664
 Schreiber, H., 5792
 Schroeder, G., 6621
 Schroers, R., 2600
 Schubert, F., 2993
 Schuler, U. S., 4955
 Schüller, S., 5489
 Schultz, C., 6270
 Schulz, J. B., 1915, 2592
 Schum, P. L., 1481
 Schürkes, C., 99
 Schwab, M., 5139
 Schwaen, C., 2993
 Schwall, R., 5485
 Schwaninger, R., 437
 Schwartz, D. R., 4722
 Schwartz, G. K., 3950
 Schwartz, P. S., 6928
 Schwartz, R., 4491
 Schwartz, S., 3070
 Schwarz, E. M., 5564
 Schwarz, M., 5685
 Schwarz, U. I., 4955
 Schwei, M. J., 7343
 Schweiger, S., 219
 Schweighoffer, T., 5489
 Schweinfest, C. W., 5083
 Sciot, R., 3980
 Scott, D. L., 3093
 Scott, J., 6205
 Scott, K., 5930
 Scott, L., 6959
 Scott, K. W., 3377, 6909
 Scotton, C. J., 5930
 Serepanti, I., 1196
 Scudiero, D. A., 4316
 Secker, G. A., 4599
 Seddai, M. A., 4459
 Sedivy, J. M., 1129
 Seelig, S., 4132
 Seftor, E. A., 665, 4478
 Seftor, R. E. B., 665
 Segal, J. G., 4696
 Segall, J. E., 6278, 7166
 Seger, D., 1966
 Segura, I., 552
 Sehgal, C. M., 747
 Seiden, I., 3005
 Seidlitz, E., 1588
 Seigne, J., 6659
 Seitz, G., 6750
 Seki, N., 2203
 Seki, T., 609
 Seki, Y., 6579
 Sekido, M., 3159
 Sekiguchi, K., 5603
 Sekiya, T., 3322
 Selaru, F., 5637
 Selaru, F. M., 1148, 3493, 3641, 6820
 Selby, M., 4316
 Seldin, D. C., 6770
 Seldin, M. F., 2261, 4549
 Seliger, B., 2856
 Sellappan, S., 5703
 Sellers, T. A., 3587
 Sellers, W., 89
 Sellers, W. R., 6803
 Selvaraj, P., 2869
 Selzer, E., 2098
 Semba, T., 6116
 Semlali, A., 6519
 Semmes, O. J., 3609
 Sen, A., 262
 Senderowicz, A. M., 1401
 Senft, J. R., 1152
 Senga, T., 2414, 3962
 Senger, D. L., 2131
 Senitzer, D., 3175
 Seno, H., 506
 Seo, J.-M., 5365
 Seo, K. H., 1809
 Seong, D. H., 3649, 5365
 Seppälä, M., 79
 Seraj, M. J., 982, 6418
 Serewko, M. M., 3759
 Serrano, J., 3702
 Seruca, R., 1609
 Servant, M., 5148
 Seshadri, R., 4599
 Sessions, A., 3395
 Seta, K., 4176
 Seth, P., 43, 4540
 Sette, A., 3630
 Sevignani, C., 4054
 Sgroi, D., 43
 Sgroi, D. C., 2741, 6740
 Shabram, P., 6045
 Shafer-Peltier, K. E., 5375
 Shah, A. B., 5260
 Shah, A. H., 7135
 Shah, J. H., 2300
 Shah, R., 417
 Shahbazian, D., 1093
 Shalaby, R., 5980
 Sham, J. S. T., 7157
 Shames, D., 2175
 Shamma, M. A., 2982
 Shan, J., 290
 Shao, J., 3282
 Shao, R., 1311
 Shapiro, E., 4157
 Shapiro, G. I., 1707
 Shariat, S. F., 5974
 Sharma, P., 1103
 Sharpless, N. E., 2761
 Shaw, W.-Y., 4346
 Shaw, D. E., 5344
 Shaw, J. L., 208
 Shayakhmetov, D. M., 1063
 Shchaveleva, I., 6172
 She, Q.-B., 1300, 1343
 She, Y., 3950
 Shedd, K. A., 4722
 Sheets, E. E., 682
 Shekhar, M. P. V., 2115
 Shen, B., 1213, 6026
 Shen, H., 4992
 Shen, J., 5153
 Shen, M. M., 2999
 Shen, W.-H., 4746
 Sheng, H., 3282, 5308
 Shenoy, S. M., 6006
 Shepherd, D., 5720
 Shepherd, F. A., 3005
 Sheppard, B. J., 696
 Sheriff, Z. A., 4439
 Sheriff, D. D., 665
 Sherley, J. L., 6791
 Sherman-Baust, C. A., 2923
 Sherr, C. J., 1222
 Shi, G., 4637
 Shi, H., 403, 3214
 Shi, M., 3221
 Shi, Q., 2806
 Shi, W., 171
 Shi, X., 5689
 Shi-X-B., 1496
 Shi, Y., 5027
 Shi, Y. Y., 3868
 Shi, Y.-X., 1854
 Shibata, D., 1148, 1166, 3493, 3641, 6820
 Shibata, D. M., 5637
 Shibata, K., 2753
 Shibata, K., 2937
 Shibuya, M., 2019, 5129
 Shibuya, N., 33, 4571
 Shichiri, M., 13
 Shide, K. L., 7291
 Shields, J. D., 4123
 Shiff, B., 2660
 Shih, C., 5597
 Shimada, H., 2987
 Shimizu, C., 4849
 Shimizu, K., 6390
 Shimizu-Yoshida, Y., 7031
 Shimkets, R. A., 3834
 Shimokawa, T., 5651
 Shin, J.-H., 38
 Shin, K.-H., 38
 Shina, S., 1093
 Shipley, J., 135
 Shipolina, N. V., 5344
 Shirafuji, N., 3929
 Shiraga, M., 5967
 Shirai, T., 1956
 Shiraishi, K., 835
 Shiraishi, T., 2258
 Shirakawa, K., 560, 860
 Shirasawa, S., 5668
 Shivapurkar, N., 3382, 5897
 Shochat, D., 2327
 Shoemaker, R. H., 4316
 Shoemaker, S., 4383
 Shohet, J. M., 1123
 Shoji, Y., 28
 Shono, T., 1069
 Shore, R., 1330
 Shridhar, V., 262
 Shutman, M., 5947
 Shu, H., 6740
 Shukla, S., 3159, 6552
 Shuman, A. L., 3626
 Shureiqi, I., 1178
 Shusterman, S., 6651
 Shustova, V., 3493
 Shuto, T., 6579
 Sicinska, E., 535
 Sicinski, P., 535
 Sidney, J., 3630
 Sidransky, D., 371, 3659
 Siebert, M., 4610
 Siegall, C. B., 3736
 Siegfried, J. M., 2141
 Siersema, P. D., 1531
 Sies, H., 4922
 Signoretti, S., 89
 Sijts, A. J. A. M., 2875
 Siligan, C., 4583
 Silva, J., 5485
 Silver, D. P., 2761
- Silverman, R. H., 397
 Simari, R., 6566
 Simeone, P., 3654, 6381
 Simi, B., 165
 Simile, M. M., 4459
 Simms, L. A., 6011
 Simola, K. O. J., 3798
 Simon, R., 2058, 3244, 3581
 Simon, S. M., 391
 Simonassi, C., 5418
 Simons, J., 2576
 Simons, J. W., 2478
 Simons, L. A., 4419
 Sims, P. J., 397
 Sin, J.-I., 7234
 Sinclair, C. S., 3587
 Singer, J., 3893
 Singer, R. H., 6006, 6278
 Singh, A. B., 7335
 Singh, B., 1184, 2744
 Singh, G., 1588, 5528, 5845
 Singh, L., 3315
 Singh, R. P., 3063
 Singh, S. V., 3615
 Singletary, S. E., 4566
 Singleton, B. K., 6263
 Sinicropie, F., 4903
 Sinicropie, F. A., 1676, 6323
 Sinn, B., 6621
 Siracusa, L. D., 5413
 Sircchia, S. M., 2455
 Sironi, E., 2455
 Sirotnak, F. M., 3950
 Sistonen, P., 1166
 Siu, W. Y., 4890
 Sivula, A., 632
 Sjöberg, J., 4554
 Sjöblom, T., 5476
 Sjöquist, M., 5476
 Skaar, T. C., 3428
 Skinner, R. A., 5571
 Skinnider, B., 6194
 Skorecki, K. L., 3184
 Skotheim, R. I., 2359
 Skytting, B., 135, 3861
 Slamon, D. J., 3207
 Slawin, K. M., 5974
 Slobos, R. J. C., 6052
 Slezak, J., 3587
 Small, G. W., 3868
 Smart, R. C., 3395
 Smit, D. J., 226
 Smith, A., 4499
 Smith, A. G., 4256
 Smith, D. L., 262
 Smith, L., 3759
 Smith, L. H., 1688
 Smith, L. R., 5792
 Smith, M., 323
 Smith, M. F., Jr., 4061
 Smith, P., 2072
 Smith, R., 1184
 Smith, T. M., 2370
 Smits, D., 341
 Smulson, M., 6879
 Smulson, M. E., 4439
 Smyth, M. J., 4406
 Sniecinski, I., 3175
 Snipes, G. J., 2131
 Snyder, P. W., 356
 So, S., 4704
 So, T., 1751
 Sobue, G., 2414
 Soccia, N., 1184

* For title of article and coauthors, see listing in Contents of Volume beginning on page at the end of this index issue.

AUTHOR INDEX TO VOLUME

- Socci, N. D., 6973
 Soderberg, C. L., 3587
 Söderhäll, S., 6598
 Söderkvist, P., 2650
 Soeters, R. P., 424
 Sohara, Y., 3962
 Sohda, M., 7162
 Soiffer, R. J., 5517
 Solarly, E., 1815
 Soldatenkov, V., 6879
 Sollenberger, J. E., 3789
 Solomon, E., 4730
 Solomon, K. R., 2227
 Solorzano, C. C., 1996
 Somasundaram, R., 5267
 Somasundaram, S., 3868
 Somenzi, G., 2455
 Somers, R., 5408
 Somerville, M. J., 359
 Sommer, A., 5230
 Sommer, P., 4478
 Sone, S., 3711, 5967
 Sonenschein, G. E., 652, 6770
 Song, C. W., 1702
 Song, H., 5267, 5295
 Song, M., 2875
 Song, S-K., 1555
 Song, W., 5974
 Song, Z., 5096
 Sonneveld, P., 7298
 Sonoda, H., 3819
 Sonoshita, M., 6846
 Sonveaux, P., 3555
 Soosaipillai, A., 295
 Sorcinelli, M. D., 4109
 Sordat, B., 4829
 Sørensen, F. B., 4352
 Sorensen, P. H. B., 4711
 Soria, J-C., 351
 Soroceanu, L., 580
 Soucek, L., 3507
 Soung, M. C., 2287
 South, L. S., 5867
 Southey, M. C., 1289
 Southgate, C., 3369
 Sowter, H. M., 6924
 Spagnoli, G., 3453
 Spahn, L., 4583
 Spalding, J., 3395
 Spanjaard, R. A., 7154
 Specht, K., 840
 Speicher, M. R., 1129
 Spencer, D. M., 5974
 Spencer, S. D., 2546
 Spendlove, H. E., 4599
 Spetz, A-L., 575
 Spiegelman, D., 1045
 Spisek, R., 2861
 Spitz, D. R., 5436
 Spitz, M. R., 2813, 4992
 Spooner, R. A., 1724
 Sporchia, B., 1321
 Spraggon, L., 6615
 Spring, H., 7018
 Spring, K., 5637
 Springer, C. J., 1724
 Spruck, C. H., 4535
 Spurbeck, W. W., 3077
 Squire, J., 6194
 Squire, J. A., 967, 3466
 Sreedharan, S., 4637
 Sreekumar, A., 2337
 Srikantan, V., 6812
 Srinivasan, S., 3315
 Srisuma, S., 5196
 Srivastava, R. K., 4929
 Srivastava, S., 6812
 Stabile, L. P., 2141
 Stafford, L. J., 5399
 Stagg, J., 5148
 Stahl, J., 854
 Stallmach, T., 2962
 Stamblar, B., 3408
 Stamp, G., 5930
 Stampfer, M. J., 2654
 StAMPL, J., 43
 Stanbridge, E. J., 4469
 Stanley, E. R., 5317
 Stanley, M. A., 6959
 Stannard, B., 65:9
 Starink, T. M., 5389
 Stass, S. A., 5463
 Staub, J., 262
 Steadman, D. J., 2654
 Stearmar, R., 3014
 Steckley, J. L., 359
 Steeg, P. S., 6740
 Steel, C., 5698
 Steele, V. E., 4199, 5178, 6506
 Steeves, R. M., 2546
 Stein, B., 1439
 Stein, C. A., 2175
 Stein, G. S., 2510, 3233
 Stein, J. L., 2510, 3233
 Stein, R., 2029
 Steinbach, J. P., 2592
 Steinbauer, M., 4034
 Steiner, M. S., 1370
 Steinwaelder, D. S., 6089
 Stenwig, A. E., 512
 Stepanova, L., 1222
 Stephen, A. E., 2004
 Stephen, D., 6385
 Stephens, C. E., 7219
 Stephens, L. C., 3620
 Stephens, P., 6451, 6997
 Stern, D. F., 6667
 Stevanovic, S., 2875, 5818
 Stevenson, F. K., 1757
 Stewart, A. L., 2239
 Stewart, C., 708
 Stewart, J., Jr., 2699, 5336
 Stewart, J. C., 2840
 Stewart, M., 7181
 Stiborová, M., 5678
 Stidley, C. A., 2370
 Stievano, L., 6099
 Stiwe, T., 3598
 Stine, O. C., 3641
 Stockert, E., 4041
 Stoehr, R., 6796
 Stoelcker, B., 4034
 Stoffregen, E. P., 7149
 Stokes, E. E., 3058
 Stokes, E. S. E., 4645
 Stokoe, D., 3636
 Stoltzfus, P., 2365
 Stoner, G. D., 4376, 6857
 Stoop, H., 1822
 Stopfer, P., 4034
 Stoppacciaro, A., 4390
 Storkus, W. J., 5853
 Stortchevoi, A., 4985
 Story, M. D., 6414
 Stout, K., 219
 Stower, M., 58
 Straign, C. M., 5001
 Strand, K., 2654
 Stratford, I. J., 688, 2962
 Stratford, M., 3408
 Stratford, M. R. L., 7247
 Strathee, C. A., 171
 Stratton, M. R., 6451, 6997
 Straub, J., 4562
 Straubinger, R. M., 2561
 Straume, O., 6808
 Strausberg, R. L., 3340
 Strehhardt, K., 4186
 Streit, M., 2004
 Strelkov, I. S., 75
 Stribbling, S. M., 1724
 Stricker, H., 4968
 Striet, J. B., 1682
 Strife, A., 4244
 Strigård, K., 1364
 Strobeck, M. W., 6587
 Strohmaier, H., 4535
 Strömborg, U., 3980
 Strome, S., 6566
 Strome, S. E., 1884
 Strong, L. C., 1952
 Strongin, A. Y., 580
 Strutton, G. M., 3759
 Strzelecki, D. M., 4711
 Stuart, S., 1123
 Stubbs, M., 688
 Stuccchi, C., 6152
 Studeny, M., 3603
 Stumm, S., 2052
 Sturm, R. A., 226
 Stuschke, M., 6621
 Su, H., 4191
 Su, L., 1377, 2819
 Su, L-K., 1311
 Su, W., 4282
 Su, Z., 5041
 Subbaramaiah, K., 2522, 5405
 Subjeck, J. R., 1737
 Suckow, V., 219
 Sucov, H. M., 4812
 Sudakin, V., 1797
 Sudilovsky, D., 3812
 Sugai, H., 5813
 Sugamura, K., 5800
 Sugarbaker, D. J., 4963, 7001
 Sugaya, M., 1751
 Sugi, N. H., 6116
 Sugie, S., 6367
 Sugihara, H., 4938
 Sugihara, K., 13
 Sugihara, K-i., 6846
 Sugimoto, Y., 28
 Sugimura, T., 28, 3592, 6645
 Sugio, K., 1751
 Sugiono, M., 4123
 Sugita, M., 3971
 Suh, Y-A., 3945
 Suico, M. A., 6579
 Sullivan, A., 2072
 Sullivan, C. M., 3729, 4478
 Sumizawa, T., 2834
 Sun, B., 781
 Sun, H., 2606
 Sun, J-Y., 3175
 Sun, L-Z., 4690
 Sun, N., 6857
 Sun, S-Y., 2430
 Sun, T., 386
 Sun, T-T., 4157
 Sun, X., 6026
 Sun, Y., 2875, 2913, 6323
 Sun, Y. J., 4903
- Sundberg, J. P., 1235
 Sures, I., 840
 Susini, C., 6124
 Sutherland, M. K., 1439
 Sutherland, R. L., 3126, 6916
 Sutmuller, R. P. M., 6187
 Suto, S., 5168
 Sutton, J. N., 18
 Suva, L. J., 5571
 Suzui, M., 3351, 3997
 Suzuki, A., 4194, 6194
 Suzuki, F., 5168
 Suzuki, H., 48
 Suzuki, I., 1961
 Suzuki, K., 1266, 1961
 Suzuki, M., 4194
 Suzuki, S., 1410
 Suzuki, T., 2753
 Svoboda, K. M., 4419
 Swalsky, P. A., 2681
 Swarbrick, A., 3126
 Sweeney, P., 5720
 Swenberg, J. A., 5183, 5189
 Swerdel, M., 2516
 Swinkels, D. W., 2695
 Swinnen, J. V., 642
 Swisher, S. G., 2239
 Swoboda, R., 5267
 Swope, S., 2654
 Sy, T., 1401
 Sykes, S. N., 2287
 Symons, M., 2462
 Syngal, S., 3485, 3925
 Sze, D., 6070
 Szeles, A., 575
 Szepeshazi, K., 781

T

- Taatjes, D. J., 4169
 Tabayoyong, W. B., 7135
 Tada, Y., 4048
 Taddei, M. L., 6489
 Taffaro, M. L., 5242
 Tagliabue, E., 1321
 Tago, K-i., 3322
 Taguchi, K-i., 4048
 Taguchi, O., 6289
 Tahara, M., 6015
 Tai, L. S., 4704
 Tai, Y-T., 3876, 5019
 Taichman, N. S., 1832
 Taichman, R. S., 1832
 Taidi, B., 5845
 Taillandier, D., 2771
 Taira, K., 4434
 Tajima, N., 7004
 Takada, S., 6390
 Takaha, N., 647
 Takahara, S., 1410
 Takahashi, A., 5813
 Takahashi, K., 6116, 6390
 Takahashi, M., 28, 2203, 2414,
 5076, 5651, 6598
 Takahashi, N., 6909
 Takahashi, S., 1956
 Takahashi, T., 271, 3850
 Takahashi, Y., 6682
 Takaku, K., 506, 4558, 6846
 Takamura, M., 2971
 Takayama, H., 6724
 Takayama, S., 1904
 Takeda, K., 2414
 Takemoto, N., 3939

* For title of article and coauthors, see listing in Contents of Volume beginning on page at the end of this index issue.

AUTHOR INDEX TO VOLUME

- Takemura, H., 5743
 Takenawa, T., 669, 2503
 Takenoyama, M., 1751
 Takeshi, F., 1641
 Taketani, T., 33, 333, 4075, 4571
 Taketani, Y., 2019
 Taketo, M. M., 506, 1971, 2261,
 4549, 4558, 6846
 Takeuchi, K., 2019
 Taki, T., 33, 333, 4075, 4571
 Takita, H., 2611
 Talbot, I., 53
 Talini, D., 6489
 Talks, K. L., 1326
 Tallini, G., 3980
 Talmage, K., 6966
 Talpaz, M., 932
 Tam, P. K. H., 6952
 Tamada, K., 1884, 4413
 Tamai, Y., 1971
 Tamaoki, N., 518
 Tamesa, T., 3939
 Tammam, J. G., 789
 Tammi, M., 6410
 Tammi, R., 6410
 Tamura, G., 3641
 Tan, C., 1083, 2546
 Tan-D.J., 972
 Tan, E. H-H., 1592
 Tan, J., 4671
 Tan, L., 924
 Tan, M., 2913
 Tan, W., 6430
 Tan, Y., 4685
 Tanaka, A., 4916
 Tanaka, F., 2937, 7124
 Tanaka, M., 63
 Tanaka, T., 4282, 6367, 6390
 Tang, D. G., 2976
 Tang, H., 376, 924
 Tang, M-s., 6857
 Tang, S-H., 2976
 Tang, T. C-M., 7157
 Tang, X., 4903
 Tang, X. M., 1676, 6323
 Tangen, C. M., 5218
 Tangoku, A., 3939
 Tanguy, M-L., 4685
 Tani, K., 28
 Tani, T., 4938
 Taniguchi, H., 233
 Taniguchi, N., 6289
 Tanimoto, M., 6390
 Tanino, M., 5168
 Tanious, F., 7219
 Taniwaki, M., 333, 4075
 Tanji, N., 2210
 Tannenbaum, C. S., 2606
 Tanwar, M. K., 4364
 Tasaka, K., 6015
 Tatò, F., 3507
 Tatsuka, M., 5168
 Tatsumi, T., 5853
 Tavassoli, M., 2072
 Taya, Y., 2883
 Taylor, A., 3408
 Taylor, C. F., 2957
 Taylor, J. A., 3251, 6052
 Taylor, J. M. G., 4722
 Taylor, M., 1326
 Taylor, P. R., 4191
 Tazawa, R., 63
 Teh, B. T., 589, 6598
 Teh, M-T., 4773
 Tei, K., 6289
 Teichberg, D., 2923
 Teichberg, S., 290
 Teicher, B. A., 5597
 Tellez, C., 5106
 Tellez, C. S., 2370
 Temparis, S., 2771
 Templeton, N. S., 1541
 Tenan, M., 1191
 ten Asbroek, A. L. M. A., 2024
 Tenen, D. G., 528
 TenEyck, C. J., 4656
 Tensen, C. P., 5389
 te Poele, R. H., 1876
 Tepper, C. G., 6606
 Tepperberg, J., 5761
 Terada, M., 560, 1641
 Terada, Y., 5168
 Terao, M., 2192
 te Riele, H., 2092
 Terleth, C., 1338
 Terracciano, L., 3453
 Terrian, D. M., 2423
 Terrier-Lacombe, M-J., 764
 Terry, A., 7175
 Terui, K., 33
 Teshima, T., 796
 Thacker, J., 6263
 Thakur, N., 4545
 Thaler, H. T., 5405
 Thant, A. A., 3962
 Theodorakis, P., 3373
 Theodore, L. J., 5755
 Theodoreescu, D., 982, 6418, 6981
 Theus, A. M., 3722
 Thiede, C., 4955
 Thiel, E., 1743
 Thiele, C. J., 323, 1196, 6108, 6756
 Thilly, W. G., 3271
 Thimmulappa, R. K., 5196
 Thirdborough, S. M., 1757
 Thomas, A. P., 4645
 Thomas, G., 3485
 Thomas, M., 2813
 Thomas, M. W., 363
 Thompson, D. C., 6850
 Thompson, E. J., 3044
 Thompson, H. J., 156, 5280
 Thompson, J. D., 3736
 Thompson, T. E., 3251
 Thonnard, J., 5510
 Thorpe, P. E., 6132
 thor Straten, P., 5664
 Thurston, S. W., 1377
 Thykjaer, T., 961
 Tian, H. F., 3395
 Tibaldi, E. V., 6304
 Tichansky, D. S., 3200
 Tilanus, H. W., 1531
 Tilignac, T., 2771
 Tilleray, V. J., 2272
 Tilley, W. D., 854
 Timar, J., 2824
 Timblin, C. R., 4169, 6065
 Timmerman, J., 3195
 Timmerman, J. M., 5845
 Timmons, C. F., 5897
 Timper, A., 3048
 Timpl, R., 1944
 Tin, R. T., 5096
 Tinari, N., 2535
 Tindall, D. J., 1008, 5632
 Tinkelenberg, B. A., 4909
 Tiraby, G., 6124
 Tirapu, I., 3167
 Tisato, V., 6099
 Tjarks, W., 3159, 6552
 Tobin, P., 2546
 Toda, K., 6289
 Todo, S., 2203, 2971
 Tofilon, P. J., 1069, 2318
 Togashi, K., 860
 Tognin, S., 2462
 Toguchida, J., 5859
 Toi, M., 4849
 Tokita, H., 2203
 Tokugawa, T., 4938
 Tolba, K. A., 6545
 Toma, S., 2455
 Tomajer, V., 1116
 Tomida, A., 5008
 Tomita, K., 3351
 Tomlinson, G. E., 5897
 Tomlinson, I., 53, 4562
 Tomlinson, S., 1110
 Tonetti, C., 4685
 Tong, W-M., 6990
 Tong, Z., 5528
 Topalian, S. L., 5505
 Toquet, C., 2169
 Torbenson, M. S., 3909
 Torchilin, V. P., 6831
 Toriyama-Baba, H., 1641
 Török, N. J., 1648
 Torres, A., 3855
 Torrisi, A., 2406
 Tortora, G., 7284
 Tosello, V., 6099
 Touloukian, C. E., 5144
 Toyama, T., 4445
 Toyooka, K. O., 3382
 Toyooka, S., 3382, 5897, 6820
 Tozer, G. M., 7247
 Tozer, R. G., 1588
 Trachy-Bourget, M-C., 4325
 Tran, C., 5254
 Trapasso, F., 2258
 Travis, E. L., 3782
 Travis, W. D., 3340
 Treadway, P., 5597
 Trent, J. M., 1784, 2220
 Treseler, P. A., 3636
 Treston, A. M., 2300
 Tretiakova, M., 6598
 Triche, T. J., 4711
 Trifan, O. C., 5778
 Trikha, M., 2824, 5336
 Trink, B., 3659
 Trivedi, C., 3842
 Trofimova, I., 6879
 Troglio, F., 567
 Trouet, A., 2327
 Trowbridge, D. B., 6870
 Troy, H., 688
 Troyer, D. A., 2077
 Trudel, M., 2210
 True, L. D., 5645
 Tsai, E.-M., 8
 Tsai, M.-H., 6246
 Tsai, Y. C., 2378
 Tsang, F. C., 4890
 Tsang, K. Y., 5049
 Tsao, M. S., 3005
 Tsao, M-S., 6194
 Tsao, S. W., 1662
 Tschumi, A. I., 2385
 Tse, C., 542, 2637
 Tse, C-K., 1987

U

- Uberla, K., 6099
 Uchimiya, H., 2834
 Uchimura, S., 3939
 Uchiyama, T., 6224
 Ueda, C., 6224
 Ueda, E., 901
 Ueda, N., 6116
 Ueda, T., 4899
 Uekusa, Y., 3751
 Uenaka, A., 1471
 Ueno, N. T., 6712
 Ueyama, Y., 518
 Uhrbom, L., 5551
 Ullenhag, G. J., 1364
 Ullrich, A., 840, 2535, 3402, 6329
 Ulmer, J. E., 48
 Ulrich, C. M., 3361
 Ulusakarya, A., 4685
 Umbach, D. M., 6052
 Unfried, K., 99
 Unger, C., 4015
 Untergasser, G., 6255
 Upender, M. B., 1134
 Uprichard, M., 6070
 Upton, P. B., 5189
 Urabe, M., 2019
 Uranchimeg, B., 4316
 Urba, W. J., 3914
 Urbanek, M., 6651

* For title of article and coauthors, see listing in Contents of Volume beginning on page at the end of this index issue.

AUTHOR INDEX TO VOLUME

Usadel, H., 371
Ushijima, T., 3592, 6645
Uskokovic, M. R., 741
Usui, K., 63
Uto, A., 6579
Uzgare, A. R., 986

V

Väinämönen, H. K., 2708
Vacanti, J. P., 2004
Vacek, P., 4169
Vaidya, B., 226
Vaillancourt, M., 6045
Vaillant, F., 7181
Vakkari, M.-L., 2625
Valent, P., 2098
Valentine, P. J., 4645
Valianou, M., 4767
Valladares, M., 6812
Valette, G., 2169
Valmori, D., 1743, 2058
Valtorta, E., 2398
van Beckhoven, A., 5845
van Beusechem, V. W., 5736, 6165
van Bezouw, S., 2157
Van Boexlaer, S., 4879
Van Buren, E., 3842
Van Dam, J., 682
van Dekken, H., 1531
van den Berg, J., 5736
Van den Berghe, H., 3980
van den Doel, P. B., 6165
van den Hoogen, F. J. A., 7066
van der Burg, S. H., 472, 6187
Vander Griend, D. J., 6717
Vander Heiden, M. G., 3515
van der Hulst, J. M., 472
van der Kogel, A. J., 341, 7066
van der Meijden, C. M., 2510
van der Meijden, C. M. J., 3233
van der Neut, R., 5126
Vandertop, W. P., 5736
Van de Sande, T., 642
Van de Ven, W. J. M., 1510
van de Wetering, M., 5126
Vande Woude, G. F., 589
van Doorn, L.-J., 2385
van Doorn, R., 5389
Van Echo, D. A., 4023
Vanegas, S., 2468
van Eydhoven, W. G., 5420
van Golen, K. L., 4854
van Groenigen, M., 2024
van Gurp, R. J. H. L. M., 1822
Vanhoef, U., 3113
Vanhulle, V. P., 3555
Vanim, E. F., 3077
van Lohuizen, M., 619, 4736
van Meijgaarden, K. E., 472
Van Meir, E. G., 1191, 2478, 2897
Van Ness, B., 715
Vanni, R., 3980
van Noesel, M. M., 2157
Van Parijs, L., 7135
van Steeg, H., 1338
van Tellingen, O., 6158
van Trappen, P., 1315
van't Veer, L. J., 7110
Van Valckenborgh, I. C. C., 1510
Van Vleet, T. R., 105
Van Waes, C., 5049
van Welsem, T., 7110
Van Wier, S. A., 715

van Wijnen, A. J., 2510, 3233
van Zon, A., 7298
Vardantan, L., 7305
Varghese, H. J., 887
Vargo-Gogola, T., 5559
Varis, A., 2625
Varma, H., 3985
Varner, J. A., 4007
Varticovski, L., 188
Vasmatzis, G., 3308
Vass, J. K., 5999
Vass, W. C., 4507
Vassal, G., 764, 5736
Vasselli, J. R., 3014
Vassileva, V., 4095
Vaughan, L., 1604
Vaughan, M. M., 4383
Veach, D. R., 4236, 4244
Vecchio, G., 1077, 7284
Veer Reddy, G. P., 2488
Velasco-Miguel, S., 4507
Velich, A., 6006
Velders, M. P., 5792
Velicescu, M., 2378, 6456
Veltman, J. A., 957
Venkateswaran, V., 2540
Venter, D. J., 1289
Venuti, A., 3654, 6381
Verdier-Pinard, P., 4007
Verhaegh, G. W., 2695
Verhoeven, G., 642
Vermeer, M. H., 5389
Vermeij, P., 472
Vernejoul, F., 6124
Verrijp, K., 341
Verschoyle, R. D., 4256
Versteeg, R., 2157
Verstovsek, S., 5995
Vessella, R., 5470
Viacava, P., 5874
Viars, C., 6981
Vicario, J. L., 5013
Vickroy, J. D., 2468
Vierboom, M. P. M., 6187
Vietmeier, B. N., 2437
Vieweg, J., 5041
Vieyra, D., 4445
Vile, R., 1884, 5495
Vile, R. G., 6566
Vilenchik, M., 2175
Villa, L., 2583
Villanueva, C., 3402
Villanueva, J., 488
Virdis, P., 4459
Virmani, A., 3945
Virshup, D. M., 6357
Virtanen, S. S., 2708
Visakorpi, T., 4554
Visscher, D. W., 2115
Vitagliano, D., 1077, 7284
Vocke, C. D., 3498
Voeller, H. J., 2654
Vogel, U., 4339
Vogel, W., 1503
Vogelbaum, M. A., 1103
Vogelstein, B., 1129, 4579
Vogelzang, N. J., 6598
Voisine, C., 1050
Volante, M., 2406
Volk, E. L., 5035
Volpe, P., 6997
Volpert, O. V., 7357
von der Lieth, C. W., 7018
Von Hoff, D. D., 2890

von Montfort, C., 4922
von Stemm, A., 3200
von Tiehl, K., 3956
Voo, K. S., 7195
Vooijs, M., 1862
Vorburger, S. A., 2239
Vormdamm, J., 910
Voss, S., 1884
Voute, P. A., 2157
Voz, M. L., 1510
Vrana, J. A., 892

W

Waas, J., 3408
Wacheck, V., 2098
Wada, H., 7124
Wada, M., 4048
Wada-Takahashi, Y., 6909
Wadhwani, R., 4434
Wadsworth, P., 4109
Wadsworth, P. F., 4645
Wadum, L., 3587
Waelti, E., 437
Wagner, L. M., 5001
Wagner, R., 6099
Wagner, U., 1256
Wahl, A. F., 3736
Wahlberg, S. S., 3485
Wайдынанта, С., 1330
Wain, J. C., 1377, 2819
Wakabayashi, K., 28
Wakabayashi, T., 6116
Wakasugi, H., 560, 860
Wakefield, S. J., 3356
Wakefield, T. L., 1884
Wakeham, A., 6194
Wakeling, A. E., 5749
Wakisaka, N., 6337
Walch, A., 3048
Walcott, F. L., 4566
Waldeck, W., 7018
Waldman, F. M., 957
Waldman, T., 2744
Waldmann, T. A., 1083, 5755
Walker, C., 2736
Walker, C. L., 3766, 6475
Walker, J. P., 2151, 4289
Walker, R. A., 3289
Wall, N. R., 2462, 3093
Wallace, T. J., 3387
Wallin, H., 4339
Wallwiener, D., 2052, 6740
Walsh, M. D., 6011
Walsh, P. C., 1784, 2253, 6485
Walter, S., 5818
Walther, S., 3144
Wancewicz, E. V., 5393
Wanders, R. J., 2220
Wang, A., 5308
Wang, C., 141
Wang, C. C., 2806
Wang, C.-X., 2
Wang, C.-Y., 3221
Wang, D., 4525
Wang, E., 3581, 4464
Wang, F., 1898
Wang, G.-Q., 4884
Wang, H., 840, 2483, 4413, 4843
Wang, H.-G., 466
Wang, J., 208, 1534, 1956, 3503,
 4843
Wang, J. D., 1410
Wang, J. Y., 2982

Wang, J.-A., 141
Wang, K., 3308
Wang, K. K., 1531
Wang, K. K. W., 2913
Wang, L., 4992, 7264
Wang, L.-G., 6080
Wang, L.-M., 589
Wang, M., 4273
Wang, Q., 848
Wang, R.-F., 3630, 5505, 7195
Wang, R.-Y., 7264
Wang, S., 1148, 3493, 3641, 5637,
 6820
Wang, S.-C., 8, 1311
Wang, T. C., 696
Wang, W., 2232, 6278, 7166
Wang, X., 18, 1598, 1662, 2064,
 2483, 5505, 6031
Wang, X.-Y., 1737
Wang, Y., 386, 625, 917, 1598,
 2483, 2999, 3024, 3428, 6031,
 6080, 6434, 7166
Wang, Z., 4843
Wang, Z.-Q., 6990
Wani, M. C., 7377
Ward, M. D., 48, 3609
Ward, R., 53
Ward, T., 990
Ward, Y., 5505
Warner, M., 4849
Warren, W. H., 4876
Warters, R., 5627
Wasan, H., 53
Washburn, B., 7050
Waskewich, C., 2029
Wassenaar, T. M., 2385
Wasserman, R., 4212
Watanabe, I., 860
Watanabe, K., 28
Watanabe, K.-i., 2203
Watanabe, N., 3592
Watanabe, R., 3850
Watanabe, T., 4849, 7012
Waters, C. A., 2151
Wathen, K., 1676
Watkins, S., 2583, 5727
Watson, K. L. M., 5543
Watson, M. A., 2085
Watson, P., 6625
Watson, P. H., 2736
Waxman, D. J., 6928
Waxman, S., 3893, 5618
Wazer, D. E., 3315, 4736
Webb, P., 141
Weber, B. L., 1481, 6997
Weber, G. F., 2281
Weber, K., 3048
Weber, M. J., 18
Weckermann, D., 251
Wedge, S. R., 4645
Weeraratna, A., 986
Weghorst, C. M., 5295
Wegmann, N., 437
Wei, Q., 4992
Wei, Q. V., 2813
Weidmann, E., 1768
Weidner, M., 5962
Weil, M., 1093, 3782
Weilbaecher, K. N., 2098
Wein, L. M., 6070
Weinberg, R. A., 6348
Weinberg, V., 3812
Weiner, H. L., 6385
Weiner, L. M., 4767

* For title of article and coauthors, see listing in Contents of Volume beginning on page at the end of this index issue.

AUTHOR INDEX TO VOLUME

- Weinmeister, P. M., 2162
 Weinschenk, T., 5818
 Weinstein, I. B., 3351, 3997
 Weinstein, J. N., 1688
 Weinstein, M. D., 5536
 Weisberg, E., 5019
 Weisenberger, D. J., 2378, 6456
 Weiss, E. H., 480
 Weiss, M. J., 6651
 Weisser, C., 4820
 Weissman, B., 323
 Weitman, D. M., 3794
 Weizer, A. Z., 5041
 Welch, J. N., 3428
 Welch, M. J., 445
 Wellbrock, C., 4820
 Weller, E., 5019
 Weller, M., 1915, 2592, 7139
 Wells, P., 5698
 Welsh, S. J., 5089
 Welt, S., 4041
 Wen, X., 2778
 Wen, Y., 8
 Wendt, M. A., 7203
 Wenger, R. H., 2962
 Wenig, B., 1184
 Weremowicz, S., 43
 Wergin, M., 2962
 Werneburg, N. W., 6500
 Wernet, D., 5818
 Wescott, G. G., 2423
 Wesierska-Gudek, J., 4206
 Wesseling, P., 341
 Wessels, L. F. A., 7110
 Wessendorf, S., 2993
 West, A. R., 3207
 West, C. R., 3417
 West, L. M., 3356
 Westermann, J., 1356
 Westra, W. H., 3659
 Wetterwald, A., 437
 Wettstein, P., 1884
 Whary, M. T., 696
 Wheeler, T. M., 5974
 Whelan, J., 403
 White, J. D., 1669
 White, J. G., 6278
 White, M. F., 6035
 White, M. J., 881
 White, P. S., 6481, 6651
 White, R. L., 6357
 Whiteford, C., 3562
 Whitehall, V. L. J., 5988, 6011
 Whiteside, D., 359
 Whiteside, T. L., 3521
 Whong, W.-Z., 703
 Whysner, J., 2
 Wick, A., 1915
 Wick, W., 1915, 7139
 Wickramasinghe, D., 5485
 Wickström, S. A., 5580
 Widmer, M. B., 5800
 Widmer, W. R., 356
 Widschwendter, M., 4535
 Wieckowski, E., 4884
 Wiedmer, T., 397
 Wiehle, S. A., 3530
 Wieland, W., 6796
 Wiemer, E. A. C., 7298
 Wiencke, J. K., 4630
 Wiener, D., 1978
 Wiese, C., 1279
 Wiesener, M. S., 3803
 Wiewrodt, R., 3438
 Wigle, D. A., 3005
 Wigler, N., 1093
 Wijdenes, J., 1388
 Wijfels, K. I. E. M., 7066
 Wilbanks, G. D., 5930
 Wilber, K., 2365
 Wilcox, R., 1884
 Wilcox, R. A., 4413
 Wild, J., 6108
 Wild, R., 1702
 Wilder, E. L., 277
 Wilding, G., 6039
 Wilding, J., 4562
 Wildner, G., 3048
 Wiley, K. E., 1784, 2253, 6485
 Wileyto, E. P., 7273
 Wilhelm, M., 957
 Will, R. D., 6698
 Willard, M. T., 2478
 Willemze, R., 5389
 Willén, H., 3980
 Willett, W. C., 1045
 Willhite, D., 1289
 Willi, N., 1256
 Williams, B. O., 6598
 Williams, B. W., 1702
 Williams, C. R., 773
 Williams, E., 213
 Williams, K. J., 688, 2962
 Williams, P. J., 917
 Williams, R. D., 3093
 Williams, S. L., 6587
 Williamson, K. A., 6615
 Willink, R., 2248
 Willis, J., 1134
 Wills, J. C., 6870
 Wills, K., 6045
 Willson, J. K. V., 1134
 Wilson, A. J., 6006
 Wilson, D. R., 2318
 Wilson, J. L., 5930
 Wilson, K., 1134
 Wilson, S. M., 887, 2162
 Wilson, W. D., 7219
 Wilson, W. R., 1425
 Wilting, J., 6884
 Winde, G., 1718
 Windle, J. J., 2077
 Wingenfeld, C., 437
 Wink-Godschalk, J. C. J., 1531
 Winkler, M., 4123
 Winkler, R., 4623
 Winski, S. L., 1420
 Winstanley, J. H. R., 3417
 Winter, C. L., 6481
 Winters, S. A., 2370
 Winton, T., 3005
 Wirths, S., 5065
 Wischhusen, J., 2592
 Wiseman, R. W., 990, 3024
 Wisniewski, D., 4244
 Wit, E. C., 5999
 Witham, T. F., 2583
 Wittig, C., 4015
 Wittig, R., 6698
 Wittmann, B., 1477
 Wojciechowski, J., 4206
 Wolf, D. M., 881
 Wolf, G., 6621
 Wolf, M., 2625, 6240
 Wolf, S. F., 5727
 Wolford, C. C., 7042
 Wong, B. C. Y., 3226
 Wong, J., 3945
 Wong, J. Y. C., 1213
 Wong, K. J., 5755
 Wong, K. K., Jr., 3175
 Wong, L.-J. C., 972
 Wong, M. K., 5727
 Wong, M. P., 4464
 Wong, P. K. Y., 5153
 Wong, S., 1458, 3956
 Wong, S. Y., 4704
 Wong, S.-T., 4773
 Wong, Y. C., 1662
 Woo, S.-H., 4325
 Wood, J., 4015, 5019
 Woodburn, J. R., 5749
 Woodgett, J., 3005
 Woodruff, J. M., 135
 Woods, J. D., 2681
 Wooster, R., 6451, 6997
 Working, P., 3743
 Wosikowski, K., 1057
 Wotton, S., 7181
 Wrana, J. L., 4558
 Wrba, F., 2098
 Wright, B. E., 5641
 Wright, G. L., Jr., 3609
 Wright, M., 3511
 Wrobel, G., 2993
 Wu, C. J., 5517
 Wu, D., 2423
 Wu, F., 2468, 3834
 Wu, J., 4812, 5564
 Wu, K., 6376
 Wu, M., 2098
 Wu, Q.-L., 7157
 Wu, R., 4722, 5273
 Wu, X., 2813, 5096
 Wu, X.-R., 4157
 Wu, Y., 386, 1030, 2567, 4100,
 5035, 6442
 Wulfkuhle, J. D., 6740
 Wurm, R., 6621
 Wyatt, C. A., 7200
 Wyckoff, J., 7166
 Wyckoff, J. B., 6278
 Wynter, C. V. A., 6011
- X
- Xia, C., 5399
 Xia, L., 1213, 1496, 6606
 Xia, W., 346, 6712
 Xiang, J., 2043
 Xiang, R. H., 542, 2637
 Xiao, D., 3615
 Xiao, N., 5325
 Xiao, Q., 290
 Xiao, S., 6035
 Xiao, X., 756
 Xie, D., 7157
 Xie, R.-L., 2510
 Xie, S., 386
 Xie, W., 497
 Xie, Y., 3861
 Xing, D., 6430
 Xiong, Y., 1171
 Xu, B., 1330, 3226, 4588
 Xu, H., 3538
 Xu, H.-p., 290
 Xu, J., 1784, 2253, 6485
 Xu, K., 2715
 Xu, L. L., 1377
 Xu, X., 1178
 Xu, X.-C., 6376
 Xu, Y., 1148, 3493, 3641, 4637,
- Y
- Yageta, M., 5129
 Yaguchi, T., 4434
 Yakar, S., 1030
 Yakes, F. M., 4132
 Yakovlev, A. G., 4439
 Yamada, K., 307
 Yamada, N. A., 6061
 Yamada, S. D., 6717
 Yamada, Y., 6367
 Yamada-Okabe, H., 3939
 Yamaguchi, H., 466, 2503, 2937
 Yamaguchi, K., 4894
 Yamaguchi, N., 295, 3751
 Yamamoto, A., 5967
 Yamamoto, H., 1641
 Yamamoto, I., 7004
 Yamamoto, M., 2414, 5196
 Yamamoto, Y., 6116
 Yamaoka, Y., 7012
 Yamashita, K., 1961
 Yamashita, S., 3592, 7031
 Yamazaki, K., 1139
 Yamori, T., 1139
 Yan, C., 4867
 Yan, H., 1330, 4579, 6246
 Yan, M., 5153
 Yan, P. S., 3214
 Yan, P. T., 4325
 Yan, Y., 5457
 Yanagawa, R., 518, 1139
 Yanagihara, K., 4894, 6645, 7124
 Yancey, D., 5041
 Yang, B., 4843
 Yang, C. S., 7241
 Yang, F., 6021
 Yang, H., 3084, 4575
 Yang, H. L., 1776
 Yang, J., 4690
 Yang, J.-M., 6864
 Yang, L., 3084
 Yang, M., 1534, 3834
 Yang, Q., 2606, 7357
 Yang, S., 371
 Yang, T., 2583
 Yang, W., 3159, 4791, 5703, 6552
 Yang, X. J., 6598
 Yang, X.-D., 2468
 Yang, X.-F., 5517
 Yang, Y., 2232, 3498, 3904, 5420
 Yang, Y.-M., 2
 Yang, Z., 1251
 Yano, M., 1025
 Yano, S., 3711, 5967
 Yao, M., 7004
 Yao, Z., 5755
 Yarbrough, W. G., 1171
 Yaron, Y., 6803
 Yarranton, G. T., 2327
 Yasuda, J., 2971
 Yasuda, M., 1751
 Yasui, N., 5603
 Yasui, Y., 3609
 Yasumaru, M., 1567
 Yasumatu, R., 3351
 Yasumoto, K., 1751
 Yau, E. K., 5755
 Ye, M., 129
 Ye, Y., 3826

* For title of article and coauthors, see listing in Contents of Volume beginning on page at the end of this index issue.

AUTHOR INDEX TO VOLUME

- Yeatman, T. J., 2669
 Yee, D., 4369, 4491
 Yee, J., 5273
 Yeh, G. C., 3685
 Yeh, S.-H., 4346
 Yen, N., 2715
 Yen, T. J., 1797
 Yeo, C. J., 1868
 Yeo, U.-C., 3200
 Yeung, F., 3084
 Yeung, R. S., 5645
 Yi, B., 917
 Yi, H., 5727
 Yin, J., 1148, 3382, 3493, 3641,
 5637, 6820
 Yin, S., 1330
 Yliskoski, M., 6410
 Yo, G. H., 6712
 Yoder, B. K., 5867
 Yokota, Y., 301
 Yokozaki, S., 2215
 Yonaga, M., 6116
 Yoneda, T., 917
 Yoo, H., 6318
 Yoon, J.-H., 6500
 Yoshida, C., 6823
 Yoshida, K., 2883
 Yoshida, M., 4916
 Yoshida, N., 5603
 Yoshida, T., 1641, 2236
 Yoshikawa, H., 2019
 Yoshikawa, Y., 3819
 Yoshimatsu, K., 6116
 Yoshimi, N., 6367
 Yoshinaga, K., 13
 Yoshino, T., 6390
 Yoshizaki, T., 6337
 You, M., 3024, 6424
 You, X. J., 5611
 Youle, R. J., 1433
 Young, J., 3641, 5637, 5988, 6011,
 6820
 Young, M. A., 4244
 Young, M. R., 3044
 Yousem, S. A., 2681
- You-Ten, A., 6194
 Yu, C., 188, 1898, 6430
 Yu, D., 1020, 2034, 5703
 Yu, D.-C., 3743
 Yu, H., 910
 Yu, J. L., 1838, 1931, 6371
 Yu, J. S., 5657, 7170
 Yu, Q., 5743
 Yu, S., 4637
 Yu, W.-G., 3751
 Yu, Y., 2951, 7264
 Yuan, J., 4186, 7264
 Yuan, L., 290
 Yuan, R.-Q., 141
 Yue, P., 2430
 Yuen, S. T., 6451
 Yulug, I., 2072
 Yung, W. K. A., 1854
 Yvon, A.-M., 4109
- Z**
- Zaak, D., 809
 Zabarovsky, E., 3498
 Zaenker, K. S., 6467
 Zafarana, G., 1822
 Zagzag, D., 2660, 6385
 Zahurak, M., 2232, 3904
 Zahurak, M. L., 1868
 Zalusky, D., 5489
 Zambowicz, B. P., 3221
 Zanardo, L., 6796
 Zanation, A., 1171
 Zangani, D., 4383
 Zanke, B., 3466, 5076
 Zapata, J. M., 6674
 Zarnegar, R., 2064
 Zarour, H. M., 213
 Zatyka, M., 3803
 Zauner, W., 1477
 Zavadil, J., 6278
 Zegarra-Moro, O. L., 1008
 Zehetner, M., 5489
 Zelent, A., 5618
 Zembutsu, H., 518, 1139
- Zemel, M. B., 403
 Zeng, G., 3630
 Zeng, H., 3144, 6172
 Zeng, T., 6447
 Zeng, X., 3538
 Zenger, E., 5536
 Zeytin, H., 6944
 Zha, S., 2220
 Zhai, J., 2798
 Zhai, Y., 4722
 Zhan, X. H., 3691
 Zhang, B., 450
 Zhang, D., 2313
 Zhang, H., 3711, 3794, 5743, 5967
 Zhang, H. J., 1205
 Zhang, H.-Z., 7350
 Zhang, J., 2600, 2906, 3743, 4194
 Zhang, J.-C., 5344
 Zhang, L., 2034, 3620, 5463, 6430,
 6447
 Zhang, M., 2337, 5755
 Zhang, N., 3221
 Zhang, Q., 6400
 Zhang, S., 1311
 Zhang, W., 4566
 Zhang, X., 1330, 2306, 4369, 5564
 Zhang, Y., 924, 1205, 3842, 3962,
 4843, 6376
 Zhang, Z., 3024
 Zhang, Z.-T., 4157
 Zhao, J., 397
 Zhao, L., 1030
 Zhao, R., 6434
 Zhao, S., 6246
 Zhao, W., 1205
 Zhao, Y., 2058, 3581, 6740
 Zhou, H. E., 3084
 Zheng, L., 2498, 3773, 6026
 Zheng, P., 3459
 Zheng, S. L., 1784, 2253, 6485
 Zhong, H., 2478
 Zhong, L., 4115
 Zhong, Q., 3966
 Zhong, X.-S., 5689
 Zhou, A., 397
- Zhou, B., 8
 Zhou, B.-B. S., 1797
 Zhou, H., 4142
 Zhou, J., 3077
 Zhou, J.-H., 4746
 Zhou, L., 1541
 Zhou, Q., 397
 Zhou, R., 2561, 3515
 Zhou, W., 1377
 Zhou, X., 3782
 Zhou, X.-J., 2637
 Zhou, X.-Y., 1598, 2483
 Zhou, Y., 1688
 Zhou, Z., 2824
 Zhu, H., 4605
 Zhu, J., 4566
 Zhu, W., 3200
 Zhu, Y., 1797, 2813, 3428
 Zhu, Z., 156, 5280
 Zhuang, L., 2227
 Zhuang, S.-M., 2650
 Zhurinsky, J., 5947
 Ziegler, U., 2962
 Zijlstra, A., 7083
 Zilberberg, L., 6884
 Zimmerman, C. L., 129
 Zimmerman, S., 3598
 Zimonjic, D. B., 4054, 6348
 Zippelius, A., 251
 Zittoun, J., 4685
 Zitzmann, S., 5139
 Zoltoski, A. J., 4439
 Zompetta, C., 3603
 Zou, A., 6045
 Zou, T. T., 3493
 Zou, T.-T., 1148, 3641
 Zou, Y., 8
 Zou-Yang, H., 2239
 Zunino, S. J., 2848
 Zwaveling, S., 6187
 Zweier, J. L., 307
 Zweifel, B. S., 625, 5778, 6706
 Zysman, M., 3663

* For title of article and coauthors, see listing in Contents of Volume beginning on page at the end of this index issue.

SUBJECT INDEX

Volume 62

A

- A1 protein** mINGh interactions, 1275
- A6** combined with tamoxifen, breast cancer, 4678
- Agg** -null mice bone marrow alkylation resistance, 656
- 17-AAG:** *See* 17-Allylamino-17-demethoxy-geldanamycin
- ABCC6:** *See* Multidrug resistance protein 6
- Abl** imatinib-resistant Abl mutants PD180970 activity against, 7149
- N-Acetylglucosaminyltransferase V** and β_1 integrin glycosylation, 6837
- N-Acetyl-l-cysteine** benzyl and phenethyl conjugates, dietary B(a)P-induced lung tumorigenesis inhibition, A/J mice, 2
- Acinar differentiation** promotion by metallothionein, 5370
- β -Actin** β -actin/AUF1 transgenic mice sarcoma, 1489
- Acyclic retinoid** growth inhibition, hepatoma, 3997
- Adeno-associated virus** -encoded angiostatin tumor growth inhibition, glioma, 756 rAAV-mediated tsFlk-1 expression growth inhibition, renal tumors, 3077 Rb protein protection, 2982 recombinant rAAV dendritic cell-targeted candidate vaccine, chronic myelogenous leukemia, 3175
- Adenocarcinoma** colon EGCG stability, uptake, metabolism and efflux, 7241 endometrial Ishikawa stromal regulation, 79 esophageal *HNF3 α (FOXA1)* amplification and over-expression, 5273 gastric *HPP1* and *hMLH1* hypermethylation, 5637 inhibition by *semaphorin 3B*, 542 lung allelic imbalance, nonsmokers, 4464 *BRAF* mutations, 7001 expression analysis, 3244 *HNF3 α (FOXA1)* amplification and over-expression, 5273 *LKB1/STK11* inactivation, 3659 pulmonary metastases ZD6126 effects, 3711 molecular markers, 5999 pancreatic peptidomic marker peptide discovery, 4894 risk *XRCC1 Arg399Gln* polymorphism and, 4630 pancreatic ductal *HIP/PAP-I*, 1868
- Adenoma** colorectal *CDH13* promoter region methylation, 3382

- T5* polymorphisms and, 3361 pituitary *HMG2* overexpression, 2398
- Adenomatous polyposis coli (APC) gene** *APCDD1* upregulation, colon cancer, 5651 *Apc $^{\Delta 716}$* knockout mice malignant intestinal polyp progression *Smad2* null mutation and, 4558 *Apc $^{Min^+}$* mice CEA-based vaccine antitumor activity, 6944 tumor load reduction by vitamin D₃ compounds, 741 *Apc $^{Min^+}$* mice microadenomatous lesions, colon, 6367 PGE₂ modulation of NSAID effects, 403 *Apc $^{Min^{\text{fl}}}$* , *CASTB6F1 Mom1 VS* mice polyp multiplicity, 5413 *Apc $^{Min^+}$* , *Dnmt1*-hypomorphic mice polyp inhibition, 1296 *Apc/Smad2* compound mutant mice invasive tumors, 5955 methylation lung cancer, 371 MSI+ endometrial cancers, 3663 mutations growth advantages, colorectal tumors, 363 polymerase β and, colon tumors, 3271
- Adenosine triphosphate** β -F1-ATPase inhibition, carcinoma, 6674
- Adenovirus** *c-erbB-2* oncoprotein-targeting, 609 combined with enzyme-activated prodrug therapy, 6089 conditionally replicative Ad $\Delta 24$ -p53 oncolytic potency, 6165 dendritic cell activation, 5260 double suicide gene therapy, locally recurrent prostate cancer, 4968 DT-A gene transfer, 2576 E2F-1 gene transfer combined with chemotherapy, melanoma, 1776 replication-selective, 3438 endostatin growth inhibition, mammary tumors, 3934 liver metastasis-specific, 1063 mda-7, mechanism of action, 2239 oncolytic *dl1520* hepatic arterial administration, 6070 p53 gene transfer phosphorylation, glioma, 1069 purging, autologous PBSC transplantation, 5013 RB94 treatment, head and neck squamous cell carcinoma, 4637 renal cell carcinoma gene therapy, 4273 replication enhancement by vitamin D₃, 3084 type 5 conditionally replicative Ad5- $\Delta 24$ RGD combined with radiotherapy, glioma, 5736 ovarian cancer treatment, 1266 type 5 E1A oncolytic mutations, melanoma-targeted, 4663 systemic gene therapy, 6712 tumor inhibition mechanisms, 346
- ADI:** *See* Arginine deiminase
- Aflatoxins B₁** metabolism and cytotoxicity, bronchial cells, 105
- Age** ING1 properties and, 4445
- Aggressiveness** associated genomic alterations, bladder cancer, 6981
- AIM-1/aurora-B** overexpression and cancer, 5168
- Akt** Akt/PKB tumor progression, melanoma, 7335 cholesterol and, prostate cancer, 2227 *AEFR/PI3-K/Akt/p27* signaling, glioblastoma, 6764 herceptin-induced inhibition, 4132 phosphorylation sites 14-3-3 and tuberin interactions, 6475
- Albumin** adducts and benzene metabolism, 1330
- Alendronate** lysophosphatidic acid-induced migration inhibition, ovarian cancer, 6015
- O⁶-Alkyguanine DNA alkyltransferase** Lys-165 mutations chemotherapy-induced, colon cancer, 3070 NO-induced inactivation and degradation, 3037
- Alleles** separation and splicing alterations, 4579 -specific tumor growth inhibition, 2024
- Allelic deletions:** *See* Deletions
- Allelic imbalance** lung adenocarcinoma, nonsmokers, 4464
- Allelotype** neuroblastoma, 1761
- 17-Allylamino-17-demethoxygeldanamycin** and HER2 status, 3132 NPM-ALK expression downregulation, anaplastic large cell lymphoma, 1559
- α -particle-irradiation** bystander effects oxidative metabolism and, fibroblasts, 5436 radionuclide ²²³Ra antitumor effects, skeletal metastases, 3120
- Alternate reading frame** *ARF L Bax L* mice tumor spectrum, 2184 ARF-p53 pathway, colon tumors, 3667 *Ink4a/Arf* gene deficiency gliogenesis, mouse, 5551 and UV-induced melanogenesis, 6724 p53-independent S-phase delay, 1171
- Alveolar rhabdomyosarcoma** fusion-negative, 4704
- American Association for Cancer Research (AACR)** Special Conference on Molecular Imaging in Cancer: Linking Biology, Function, and Clinical Applications *In Vivo*, meeting report, 2195 special meeting "Colon Cancer: Genetics to Prevention," 6779
- γ -Aminobutyric acid** cell migration inhibition, SW 480 colon cancer cells, 6467
- S-3-Amino-phthalimido-glutarimide** angiogenesis and tumor growth inhibition, mice, 2300
- AML:** *See* Leukemia, acute myeloid
- AML1-ETO** cooperative domains, bone marrow cell ex-

- pansion, 2906
- Amphotericin**
RAGE-binding motif
metastasis blockade, 4805
- AN-238**
and colon cancer, 781
- Analytical tools**
meeting report, 3883
- Androgen-induced bZIP**
expression and regulation, prostate cancer, 721
- Androgen receptor**
AR mutations
prostate cancer, 1496
relapsed CWR22 prostate cancer cell growth, 6606
CAG repeat
HBV-related female hepatocarcinogenesis, 4346
polymorphism
and breast cancer risk, 1045
cell proliferation, androgen-refractory prostate cancer, 1008
transactivation by IL-6
mediation by p300, 5632
- Aneuploidy**
DNA polymerase β and, 3511
- Angiogenesis**
EGFR-dependent, skin carcinogenesis, 3402
GPIIb/IIIa and $\alpha v\beta 3$ integrins and, 2824
HIF-2 α breast tumor macrophage expression and, 1326
induction
lymphotoxin- β receptor, 4034
morphine, 4491
inhibition
angioarrestin, 3834
bisphosphonates, prostate, 6538
celecoxib, mechanism, 625
combination urokinase-derived $\tilde{\text{A}}$ and tamoxifen, breast cancer, 4678
conjugated linoleic acid, 4383
and EGFR-targeting, 2554
IL-12, mammary carcinoma, 747
modified PF-4 peptides, 6884
S-3APG, mice, 2300
SPARC, neuroblastoma, 7357
tetraethylomolybdate, 4854
thrombospondin 2, cell-based antiangiogenic gene therapy, 2004
TrkA, neuroblastoma, 1802
mouse intestinal tumor models, 506
platelet-activating factor-induced
nuclear factor κB , 1809
selectin and integrin roles, nude rats, 6289
short-telomere mice, 552
TGF- β and, prostate cancer-reactive stroma, 6021
tumor cell extracellular membrane vesicle activity, 6312
tumor growth dependence, review, 1931
tumor-infiltrating macrophages and, 7042
ZD1839 effects, 4300
- Angiogenic factors**
expression after chemotherapy, 5597
- Angiopoietins**
expression, non-small cell lung cancer, 7124
- Angiotatin**
AAV-encoded
tumor growth inhibition, glioma, 756
- Angiotensin II**
type I
antagonist
pulmonary metastasis prevention, renal cell carcinoma, 4176
- Anionic phospholipids**
exposure, tumor blood vessels, 6132
- Anoikis**
induction by Smad4, 6045
- Anti-angiogenic compounds**
synergistic activity
prediction by gene expression profiling, 7143
- Antibodies:** *See also Monoclonal antibodies*
anti-adhesive
and antibody-dependent cellular cytotoxicity, 6891
colon cancer antigen recognition, 4041
EphA2 targeting
malignant cell inhibition, 2840
human anti-MUC18
growth and metastasis inhibition, melanoma, 5106
human TCR-like MUC1-specific recombinant, 5835
internalizing
antibody-targeted liposomal drug targeting, 7190
recombinant
TCR-like telomerase-specific, 3184
vascular endothelial-cadherin E4G10
tumor growth inhibition, 2567
- Antibody-dependent cellular cytotoxicity**
anti-adhesive antibody and, 6891
- Anticancer agents**
apoptosis-induced delivery, 1382
ErbB-targeted
and EGF-related ligands, 3151
sensitivity
expression profiles, 518
- Antiestrogen**
sensitivity
cyclin D1 overexpression and, breast cancer, 6916
- Antifolate**
toxicity
uracil misincorporation, 4909
- Antigen**
cancer/testis
gene expression, lung cancer, 3971
carinoembryonic
anti-rhCEA IgG subclass response, immunized colorectal cancer patients, 1364
-based vaccine
antitumor activity, MIN mice, 6944
head and neck cancer immunotherapy target, 5049
colon cancer
antibody recognition, 4041
HLA-DP3
-restricted EBNA1 peptides, T helper, 7195
- HLA-DR7**
-restricted epitopes
and hTERT, 2600
- melanoma**
isolation by SEREX, 4836
retroviral, CTL-recognized, 5510
- presentation**
transporter for antigen presentation (TAP)
1-deficient tumors, 2856
- prostate stem cell**
therapy target, 2546
- "self"**
tumor expression
and CD4 $^+$ T-cell function, 5144
- serological analysis**
new SEREX approach, lung cancer, 1751
- sialyl Lewis**
COX-2 and, colon cancer, 1567
- sialyl Lewis X**
-dependent lung colonization, melanoma, 4194
- tumor-associated**
melanoma with vitiligo
isolation by SEREX, 4836
-primed dendritic cells, cancer vaccines, 1884
- SOX10**, 3020
- T-cell response, poly-L-arginine vaccination, 1477
- Antigen-presenting cells**
CD8 $^+$ T cell interactions, 5065
- Antimicrotubule drugs**
statin and, breast cancer, 6864
- Antioxidants**
thiol
apoptosis induction, tumor cells, 1443
- Antisense**
colony-stimulating factor 1
growth inhibition, solid tumors, 5317
oligodeoxyribonucleotides
DNA-PKcs inactivation, 6621
- oligonucleotides**
c-myc
growth inhibition, MCF-7 breast cancer cells, 3126
- C-raf**
colorectal cancer liver metastasis inhibition, 5393
- Ku86**
effects, malignant glioma, 5888
- RNA**
bel-xL expression downregulation, 2175
- Antivascular therapy**
monitoring, high-frequency Doppler ultrasound, 6371
- AP-1**
asbestos-induced, mesothelioma, 6065
BPDE-induced transactivation
inhibition by berry extracts, 6857
- Apo-2 ligand**
apoptosis
sensitization by casein kinase II inhibition, 4180
- TRAIL/Apo2L-induced apoptosis**, colorectal cancer, 1583
- Apoptosis:** *See also Anoikis*
adhesion-dependent
NF- κB inhibitors, colon cancer, 6870
 β -pol deficiency and, 1524
- calpain-dependent
induction by *ARHI*, ovarian and breast cancer, 7264
- chemotherapy-induced
BDNF-TrkB-PI3K pathway protection, neuroblastoma, 6756
inhibition by curcumin, breast cancer, 3868
- c-myc*-induced, polycystic kidney disease, 2210
- discoidermolide and epothilone B, non-small cell lung cancer, 4081
- drug delivery, 1382
- epithelial cells
BAX, 3373
- fenretinide-induced, neuroblastoma, 5158
- flavopiridol-induced, S-phase, 1707
- induction
Ad-mda-7, lung cancer, 2239
- Bad (S112D S136A)-DTTR protein, 1433
- Bcr/Abl-expressing leukemia, 188
- CD437, lung cancer, 2430
- endothelial irradiation-induced NO, 1450
- glioma-associated hyaluronan, dendritic cells, 2583
- HDAC5, 2913
- 2-methoxyestradiol, ER α/β -independent, 3691
- neoglycans, 3722

SUBJECT INDEX TO VOLUME 62

- neural stem cell-mediated TRAIL therapy, glioblastoma, 7170
 quinazolines, prostate cancer, 597
 Rac inhibition, glioma, 2131
 raloxifene
 androgen-independent prostate cancer, 5365
 prostate cancer LNCaP cells, 3649
 saquinavir, 5230
 sigma-2 receptor agonists, 313
 thiol antioxidants, tumor cells, 1443
 WK175, leukemia, 1057
 inhibition by nitric oxide, 1648
in vivo doxorubicin-induced, cardiomyocytes, 4592
 modulation by inhibitor of caspase-3-activated DNase, colon cancer, 2169
 Myc-induced
 Omomyc and, 3507
 PEITC-induced
 ERKs, prostate cancer, 3615
 protein synthesis
 inhibition, 2272
 regulation
 HERG K⁺ channel, 4843
 p53AIP1, 2884
 resistance
 COX-2 expression, colon cancer, 6323
 matrilysin selection, mammary cells, 5555
 reversal by mPBR ligands, 1388
 RhoA-dependent, prostate cancer, 2630
 Smac, prostate cancer LNCaP cells, 18
 steroid-induced, pre-B cells, 4212
 T-cell activation, pancreatic cancer, 2347
 TRAIL/Apo2L-induced
 colorectal cancer, 1583
 COX-2 and, colon cancer, 4903
 PI3K/PTEN/Akt kinase pathway, non-small cell lung cancer, 4929
 renal cell carcinoma, 3093
 sensitization by casein kinase II inhibition, 4180
- Aptosome**
 activation, ovarian cancer, 924
- Apoptotic factors**
 and P450 gene therapy, 6928
- Aptamers**
 prostate-specific RNA, 4029
- 9-β-d-Arabinosylguanine**
 phosphorylation by dCK and dGK, 3100
- Arginine deiminase**
 melanoma and hepatocellular carcinoma inhibition, 5443
- Arginine-glycine-aspartic acid (Arg-Gly-Asp) (RGD) peptides**
 radiolabeled, tumor targeting, 6146
 tumor cell binding, 5139
- ARHI gene**
 calpain-dependent apoptosis induction, ovarian and breast cancer, 7264
- 2-Aroylindoles**
 small molecule tubulin inhibitors, 3113
- Arsenic trioxide**
 mechanism of action, review, 3893
 and tumor radiation response, 4202
- Artificial neural networks**
 esophageal lesions, 3493
- Asbestos**
 -induced AP-1 and Fra-1, mesothelioma, 6065
 -induced proliferation
 inhibition by mutant EGFR, lung epithelium, 4169
- Ascites**
 carcinomatous
 inhibition by sFlt-1, 2019
- Astrocytoma**
 anaplastic
- focal adhesion kinase signaling *in vivo*, 2699
 cell migration promotion by brain osteopontin, 5336
 pilocytic
 gene expression analysis, 2085
 progression
 p53 functional loss, 2897
- Ataxia and Rad3-related/CHK1 pathway**
 S checkpoint
 Ku and, 2483
- Ataxia telangiectasia mutated**
Atm-/- mice
 thymic lymphoma prevention by dexamethasone, 5153
- AUFI/heterogeneous nuclear ribonucleoprotein D (hnRNP D)**
 β-actin/AUFI transgenic mice, sarcoma, 1489
 overexpression, mice tumorigenesis, 1489
- Aurora A**
 mammary tumorigenesis, rat, 4115
- Aurora B:** See AIM-1
- Autocrine motility factor**
 Rho-like GTPase changes, 4484
- 5-Aza-2'-deoxycytidine**
 gene induction, fibroblasts, 961
- Azotemia**
 postoperative
 and metastatic renal cell carcinoma, 5218
- B**
- B7.2**
 B7.2-IgG fusion protein
 combined with SU6668, breast tumor therapy, 5727
- Bad**
 diphtheria toxin transport domain fusion protein Bad (S112D S136A)-DTTR
 apoptosis induction, 1433
- Bag1 proteins**
 growth regulation, breast cancer, 1904
- Barrett's esophagus**
 artificial neural networks and cDNA microarrays, 3493
 7q13.2-q36.1 loss, 1531
- Basal cell carcinoma**
 FOXM1 expression, 4773
 xeroderma pigmentosum
 smoothened mutations, 7186
- Bax**
 ARF^{-/-} Bax^{-/-} mice
 tumor spectrum, 2184
 conformational change by BMS-247550, breast cancer, 466
 epithelial cell apoptosis, 3373
- Bel-2**
 homology 3 (BH3)-only proteins
 Bim splice variant Bimγ, identification and characterization, 2976
 oncogenesis, rat, 6297
- BCL-6 gene**
 alternative breakpoint region, B-cell non-Hodgkin's lymphoma, 4089
H4/BCL6 fusion gene, B-cell non-Hodgkin's lymphoma, 6224
- bel-xL**
 downregulation by antisense RNA, 2175
- Ber-Abl**
 cyclin D2 induction, 535
 inhibition by Ber
 Ser 354 requirement, 386
 inhibitors, characterization, 4244
 leukemia
 apoptosis induction, 188
 acute
 leukemia, acute
 STI-571 and, 5761
- mutations, leukemia, 5995
BCRP: See Breast cancer resistance protein
- Benzene**
 albumin adducts
 and metabolism, 1330
- Benz(a)pyrene**
 lung tumorigenesis
 inhibition by dietary BITC-NAC and PEITC-NAC, A/J mice, 2
 neoplastic transformation, lung fibroblasts, 4605
- Benz(a)pyrene diol-epoxide**
 -induced AP-1 and NFκB
 inhibition by berry extracts, 6857
- Benz(a)pyrene-trans-7,8-dihydrodiol**
 glucuronidation, characterization, 1978
- Benzodiazepine receptor**
 peripheral
 ligands
 apoptosis resistance reversal, 1388
- Benz(g)chrysene-DNA adducts**
 global nucleotide excision repair
 regulation by p53, fibroblasts, 5288
- Benzylamide sulindac analogues**
 effects, chronic lymphocytic leukemia, 5711
- Berry extracts**
 effects on BPDE-induced AP-1 and NFκB, 6857
- β-cell carcinogenesis**
 VEGF and tumor progression, 603
- Betaglycan**
 recombinant soluble sBG
 antitumor activity, breast cancer, 4690
- BH3 (Bcl-2 homology 3)-only proteins**
 Bim splice variant Bimγ, identification and characterization, 2976
- bik gene**
 systemic tumor inhibition, 8
- Bile acids**
 Mcl-1 protein degradation inhibition, 6500
- Bim**
 BH3-only Bim splice variant, 2976
- Biotin**
⁹⁰Y-labeled DOTA-biotin
 pretargeted
 radioimmunotherapy, mice, 5755
- Bisphosphonates**
 angiogenesis inhibition, prostate, 6538
- Black raspberry extracts**
 effects on BPDE-induced AP-1 and NFκB, 6857
- Bladder cancer**
 aggressiveness
 associated genomic alterations, 6981
de novo methylation
 cell division requirements, 2378
 DNA polymerase β splice variants, 3251
 G_{M3} antitumor effects, 3850
 invasive
 piroximac effects, canine model, 356
 molecular profiling, 6973
 recurrence
 DAPK hypermethylation and, 4048
- Bladder tumorigenesis**
 epidermal growth factor receptor and, 4157
- Bleomycin**
 resistance
 SRPK1 inhibition and, 4453
- BLM helicase**
 DNA double-strand break repair, 2766
- Blood, peripheral**
 lymphocytes
 micronuclei
 and pleural malignant mesothelioma susceptibility, 5418
 progenitor cells
 mobilization by combination defibrotide

SUBJECT INDEX TO VOLUME 62

- and rhG-CSF, mice, 6152
stem cells
transplantation, autologous
adenoviral purging, 5013
- Blood flow**
antivascular therapy and
monitoring, high-frequency Doppler ultrasound, 6371
- Blood vessels**
leakiness, meeting report, 5381
patterning
VEGF isoforms and, melanoma, 1838
tumor
anionic phospholipid exposure, 6132
phosphatidylserine marker, 6132
- B lymphocytes**
leukemia, acute lymphoblastic
early
steroid-induced apoptosis, 4212
- lymphoma
cancer tumor suppressor gene, chromosome 15q15, 7175
CD40L-transduced tumor cell vaccine, 3195
DNA vaccination, 5845
lymphoma, non-Hodgkin's
BCL-6 alternative breakpoint region, 4089
cryptic *IGH* rearrangements, novel, 5523
H4/BCL6 fusion gene, 6224
translocation t(3;6)(q27 a1) breakpoints, 6224
- neoplasia
growth inhibition by S-3APG, mice, 2300
- Bmi-1 gene**
amplification and overexpression, hematological malignancies, 618
mammary epithelial cell immortalization, 4736
- BMS-247550**
Bax conformational change induction, breast cancer, 466
- Bombesin**
invasion stimulation, colon cancer, 4829
- Bone**
breast cancer metastasis
IL-8 expression and, 5571
osteosclerotic
PDGF-BB and, 917
tumor burden reduction by doxycycline, 1588
- prostate cancer metastasis
stromal cell-derived factor-1/CXCR4, 1832
- Bone cancer pain**
blockade by COX-2 inhibitors, 7343
- Bone marrow**
alkylation
resistance, *Aag* null mice, 656
expansion
AML1-ETO cooperative domains, 2906
mesenchymal stem cells
IFN- β tumor delivery, 3603
neuroblastoma purging
virus-directed enzyme prodrug therapy, 5001
- TGF- β signaling
blockade, cancer gene therapy, 7135
transplantation, allogeneic
relapse, hematological malignancy, 208
- Bone morphogenetic protein 4**
expression
 β -catenin and, cancer, 2744
- BRAF gene**
mutations
colorectal tumors, 6451
lung adenocarcinoma, 7001
lung cancer and melanoma, 6997
- Brain**
malignant melanoma metastasis
VEGF-A₁₆₅ vascularity effects, 341
- osteopontin
astrocytoma cell migration promotion, 5336
vinyl chloride-induced adducts, rat, 5183
- Brain-derived neurotrophic factor**
BDNF-TrkB-PI3K pathway
protection against chemotherapy, neuroblastoma, 6756
- Brain tumors**
antivascular liposomal doxorubicin effects, rat model, 2561
- BRCA1 gene**
-associated breast cancer
HER-2/neu, 1481
TBX2 amplification, 3587
-associated RING domain protein BARD1
EWS and *EWS-FLI1* interactions, 4583
and RNA polymerase II holoenzyme, 4222
epigenetic factors and, ovarian cancer, 4151
estrogen receptor inhibition
modulation by p300, 141
mutation carriers
breast cancer, 2741
tumor gene profiling, 7110
-null fibroblasts
nonhomologous end-joining activity, 3966
protein phosphatase 1 α interactions, 6357
and RNA polymerase II holoenzyme, 4222
S-phase checkpoint requirements, 4588
transcriptional inhibition, 113
- BRCA2 gene**
cancer cell growth inhibition, 1311
epigenetic factors and, ovarian cancer, 4151
mutation carriers
breast cancer, 2741
mutations
familial pancreatic cancer, 3789
genomic instability, 6194
homozygous
cancer susceptibility, mice, 990
-related breast tumors
TBX2 amplification, 3587
- Breast**
epithelial cell proliferation
EGFR tyrosine kinase inhibition effects, 122
estrogen targets, 4540
microcalcifications, Raman spectroscopy, 5375
ribosomal phosphoproteins
downregulation by GnRH, 1036
- Breast cancer**
antiestrogen sensitivity
cyclin D1 overexpression and, 6916
anticancer drug sensitivity
stathmin and, 6959
autologous PBSC transplantation
adenoviral purging, 5013
Bax conformational change induction by BMS-247550, 466
- BRCA1-associated**
HER-2/neu, 1481
- BRCA1-BRCA2 mutation carrier**, 2741
- BRCA1 mutation carriers**
genetic profiling, 7110
calpain-dependent apoptosis
induction by *ARH1*, 7264
- cell motility inhibition by IGFBP-1, 4369
chemoprevention by selenium, mechanisms, /08
- chemotherapy-induced apoptosis inhibition
by curcumin, 3868
- choline, 1966
- combination cilengitide and radioimmuno-therapy, 4263
combination ET-743 and paclitaxel, 6909
- COX-2 expression, 1676
- DAPK gene methylation**, 6634
- diagnosis, genetic
fine-needle aspiration, 2365
- early stage
TRB1 inactivation, 1939
- E-cadherin inhibition by *SLUG*, 1613
- estrogen receptor α -positive
 β ex protein, 4849
- estrogen-related receptors, 6510
- G3BP induction by heregulin, 1251
- gene expression patterns
DNA amplification and, 6240
- genistein and tamoxifen interactions, 2474
- growth enhancement by complement inhibitor, rat model, 1110
- growth inhibition
c-myc antisense oligonucleotides, MCF-7 cells, 3126
combination urokinase-derived $\ddot{\Lambda}$ 6 and tamoxifen, 4678
- growth prevention by FTY720, mouse, 1410
- growth regulation by Bag1 proteins, 1904
- hereditary nonpolyposis colorectal cancer
tumor exclusion, 1014
- HER-2/neu-induced**
inhibition by EGCG, 652
reduction by celecoxib, 5405
- hormonal VEGF regulation, 1948
- IGF-IR signaling**
blockade by proinflammatory cytokines, 4746
and metastatic phenotype, 6529
- infiltrating
desmoplastic response, 5351
- inflammatory
herceptin rapid accumulation and internalization, 860
- vasculogenic mimicry hemodynamics, 560
- invasive
cadherin-11 and, 6688
- lysyl oxidase, 4478
- promotion by VEGF CXCR4 regulation, 7203
- Wnt-5 α loss of expression, 409
- karyotypes, multivariate analysis, 2675
- metastasis
blockade by COX-1 or COX-2 inhibitors, murine, 2343
- coml expression, 4164
- and IGF-IRs, 6529
- prevention by FTY720, mouse, 1410
- metastasis to bone
IL-8 expression and, 5571
- osteosclerotic
PDGF-BB and, 917
- tumor burden reduction by doxycycline, 1588
- metastasis to liver
-specific adenovirus vector, 1063
- MTAP tumor suppressor activity, 6639
- NF- κ B activation promotion by protein kinase CK2, 6770
- 8-oxoG repair defects, 1349
- p53* mutations and smoking, 1987
- predictive uPA/PAI-1 impact, 4617
- prognosis
COX-2 expression and, 632
- osteopontin and, 3417
- putative tumor suppressor gene *CBFA2T3*, 4599
- RANTES promalignant activity, 1093
- RAR β reactivation, 2455
- recurrent

SUBJECT INDEX TO VOLUME 62

- early molecular marker, 1000
risk
androgen receptor CAG repeat polymorphism and, 1045
carcinogen exposure and, 4566
sBG antitumor activity, 4690
SERM-ER complexes
gene expression profiles, 4419
Smad signaling alterations, 497
somatic mtDNA mutations, 972
SP500263 effects against, 1439
stanniocalcin 2 expression, 1289
STAT3 activity modulation by p53, 376
superchemosensitization by Herceptin pre-treatment, 5703
survival
genotype and, 3052
tenascin-C isoform expression, 3289
TSP50 activation, 290
tumor xenograft eradication by Hsp70 depletion, 7139
VEGF regulation by estrogen, 4977
- Breast cancer resistance protein**
Bcrp1 (Abcg2)
mutation hot spot
and doxorubicin resistance, 2294
wild-type
and methotrexate resistance, 5035
- Breast carcinogenesis**
early events, new *in vitro* model, 5980
- Breast ductal carcinoma *in situ***
COX-2 expression, 1676
proteomics, 6740
- Breast tumors**
BRCA1- and *BRCA2*-related
TBX2 amplification, 3587
cell aggressiveness
SEL1L expression and, 567
combination SU6668 and B7.2-IgG therapy, 5727
epithelial polarization by dystroglycan, 7102
fractionated photodynamic therapy, 4289
macrophage HIF-2 α expression
and angiogenesis, 1326
SBEM biomarker, 2736
- 3-Bromopyruvate**
intraarterial, liver cancer therapy, 3909
- Bronchial cells**
aflatoxin B₁ metabolism and cytotoxicity, 105
- Bronchial epithelium**
hypermethylation, smokers, 2370
- Bronchioloalveolar lung carcinoma**
feline, comparative studies, 3826
- Brostallicin**
anticancer activity
glutathione and, 2332
- Budding uninhibited by benzimidazole**
human *hBUB1* and *hBUBR1*
inactivation, 13
- Burkitt lymphoma**
MCL1-overexpressing
response to death stimuli, 892
- Bystander effects**
 α -particle-irradiation
oxidative metabolism and, fibroblasts, 5436
radiation
membrane signaling, 2531
3D cell cultures, 1425
- C**
- CABC1 gene**
isolation, 1246
- c-Abl**
kinase domain crystal structures, 4236
- Cadherin**
vascular endothelial-cadherin antibody
- E4G10
tumor growth inhibition, 2567
- Cadherin-11**
and breast cancer invasion, 6688
- Cadmium**
-responsive proto-oncogene, novel, 703
- Café-au-lait spots**
hMSH2 germ-line mutations, 359
- Calcium binding proteins**
S100A
overexpression, gastric cancer, 6823
- Calpain**
-dependent apoptosis
induction by *ARHI*, ovarian and breast cancer, 7264
- Camptothecin**
gene expression changes, 1688
resistance
XRCC1, 459
- Cancer:** *See also specific cells, sites, types*
advanced
combrestatin A-4 phosphate, phase I trial, 3408
analytical tools, meeting report, 3883
CD40-expressing
T-cell activation inhibition, 2052
- cell tracking
fully automated, collagen gels, 5301
- diagnosis
gene ratios, 4963
- H19* imprinting control region
de novo methylation, 4545
- prognosis
glomeruloid microvascular proliferations and, 6808
- progression
FGFR4 Arg³⁸⁸ allele and, 840
- susceptibility
homozygous mutant *Bra2* mice, 990
- Cancer-inducible transgenes**
expression by *Grp94* promoter, 7207
- Cancer prevention:** *See also Chemoprevention*
science and practice, perspectives, 5119
- Cancer Research**
future directions, 1
- Cancer/testis antigen**
gene expression, lung cancer, 3971
- Candidate of metastasis-1**
expression, breast cancer cells with metastatic potential, 4164
- Carbamate**
lung tumors
chemoprevention, mice, 4199
- Carbohydrate**
-dependent melanoma, melanoma, 4194
- Carbonic anhydrase IX**
activation by PI3K
oxygen levels, 4469
- Carboxypeptidase G2**
suicide gene therapy
prodrugs, 1724
- Carcinoembryonic antigen**
anti-rhCEA IgG subclass response, immunized colorectal cancer patients, 1364
-based vaccine
antitumor activity, MIN mice, 6944
head and neck cancer immunotherapy target, 5049
promoter
yeast cytosine deaminase expression, 2337
- Carcinogen**
adducts
nonrepairable, 4229
exposure
and breast cancer risk, 4566
loss of heterozygosity, lung tumorigenesis, 6424
oral mucosa bioactivation
inhibition by curcumin, 5451
- Carcinogen-activating enzymes**
inhibition by fluasterone, 3685
- Carcinogenesis**
information degradation and, 3675
ultraviolet
inhibition by DFMO, *Xpa*^{-/-} mice, 1338
- Carcinoma *in situ***
ductal
active HER-2/neu signaling, 6667
breast
COX-2 expression, 1676
proteomics, 6740
- Carcinomatous ascites**
inhibition by sFlt-1, 2019
- Cardiomyocytes**
in vivo doxorubicin-induced apoptosis, 4592
- Carnosol**
COX-2 induction inhibition, 2522
- Casein kinase II**
inhibition
TRAIL/Apo2L-induced apoptosis sensitization, 4180
- Caspase 3**
inhibitor of caspase-3-activated DNase and colon cancer, 2169
TAT-ODD-Casp3^{WT} fusion protein antitumor effects, 2013
- Caspase 8**
expression, pediatric tumors, 5897
- Caspase 9**
nitrosylation, 1648
- Caspase 10**
expression, pediatric tumors, 5897
- Caspases**
translation regulation, 2272
- Catecholamines**
regulation pVHL, PC12 cells, 1682
- Catechol-O-methyltransferase**
COMT gene polymorphisms and ovarian cancer risk, 3058
- B*-Catenin**
and bone morphogenetic protein 4 expression, cancer, 2744
low-molecular-weight protein tyrosine phosphatase interactions, cell-cell adhesion, 6489
mutations
gastric cancer, 3503
stable, mouse liver, 1971
nuclear translocation induction by HGF, 2064
PML induction, 5947
transcription regulation by Wnt-1, esophageal cancer, 277
tumor suppression, 5947
- Caveolin-1**
endothelin association, endothelial cells, 5580
- CBFA2T3 (MTG16)* gene**
putative tumor suppressor, breast cancer, 4599
- CBF β -SMMHC:* *See Core binding factor***
 β -smooth muscle myosin heavy chain
- CCAAT-displacement protein/cut homeobox CDP/Cux p75**
characterization, 6625
- CCAAT/enhancer binding protein α**
downregulation, lung cancer, 528
- C6 cells**
mobile lipid compartment dimensions, 5672
- CCI-779**
efficacy, multiple myeloma, 5027
- CD2**
regulation, acute promyelocytic leukemia, 7420

SUBJECT INDEX TO VOLUME 62

- 4730
- CD4**
T cells
EBNA1 peptide helpers, 7195
indirect tumor killing mediation, 2611
“self-” antigen tumor expression and,
5144
wtp53-specific, antitumor efficacy, 6187
- CD7**
CD7-exotoxin, scFv immunotoxin, 2848
- CD8**
T cells
antigen-presenting cell interactions, 5065
memory
activation, 6438
tumor killing
IFN- γ and, mice, 5058
tumor targeting, 5785
- CD13**
isoforms
differential expression, 860
- CD40**
ligand
combined SLC/CD40L-mediated immuno-
therapy, antitumor activity, 6545
 α -transduced lymphoma cell vaccine, 3195
T-cell activation inhibition, carcinoma, 2052
- CD44**
metastasis effects, sarcoma, 2281
standard form CD44s
HA-CD44s
and MMP-2 secretion, lung cancer,
3962
- CD45**
CD45RA⁺CCR7⁺ cytotoxic T lymphocytes,
melanoma, 1743
- CD70**
immune escape pathway, glioblastoma, 2592
- CD95**
inhibition by Ras
reversal by farnesyltransferase inhibitors,
450
ligand
monocyte expression, tumors, 1261
- CD102**
anti-ICAM-2 mAb, ICAM-2⁻ colon cancer,
3167
- CD137**
antitumor effects
IFN- γ , 4413
- CD437**
apoptosis induction, lung cancer, 2430
cross-resistance, paclitaxel-resistant ovarian
carcinoma, 2192
E2F-1 and cyclin B modulation, prostate
cancer, 3842
- cdc2**
regulation, radiation-induced G₂ delay, 241
- CDC4**
human *hCDC4* mutations, endometrial can-
cer, 4535
- CDH13 (H-cadherin)**
promoter region methylation, colorectal tu-
mors, 3382
- C/EBP α :** See **CCAAT/enhancer binding
protein α**
- Celecoxib**
angiogenesis inhibition, mechanism, 625
combined with CPT-11, anticancer/antidiar-
rhea effects, 5778
combined with iNOS inhibitor, chemopre-
ventive effects, 165
growth inhibition, cancer cells, 2029
HER-2/neu-induced breast cancer reduction,
5405
- Cell adhesion**
anti-adhesive antibody
- and antibody-dependent cellular cytotoxic-
ity, 6891
- β -catenin and low-molecular-weight protein
tyrosine phosphatase interactions, 6489
- dependent apoptosis
NF- κ B inhibitors, colon cancer, 6870
- fibrillar
formation by β 1-integrin
VHL role, 2929
- homotypic
disruption by Src activity, colon cancer,
2669
- regulation by CXCR4 and c-Kit, 6304
- regulation by endostatin, 1944
- Cell aggressiveness**
SEL1L expression and, breast tumors, 567
- Cell cycle**
arrest
methyleselinic acid, mechanisms, 156
perifosine, squamous cell carcinoma, 1401
- G₂ checkpoint
defect, small cell lung cancer, 271
Ku effects, ionizing radiation, 6031
- G₁ phase
acceleration
cooperation with CBF β -SMMHC, leu-
kemogenesis, 2232
- G₂ phase
radiation-induced delay
cdc2 regulation, 241
- G₁-S transition and M phase blockade by
3-IAABE, 6080
- progression
gene profiling, 3233
- S checkpoint
Ataxia and Rad3-related/CHK1-dependent
Ku and, 2483
- Brcal requirements, 4588
- S phase
ATM-independent checkpoint pathway,
1598
- flavopiridol-induced apoptosis, 1707
- p53-independent delay by ARF, 1171
- resveratrol and prostate cancer cells, 2488
- Cell death:** See also **Apoptosis**
discodermolide and epothilone B, non-small
cell lung cancer, 4081
- Cell differentiation**
blockade by leukemia-associated fusion pro-
teins, 7050
- induction
acute promyelocytic leukemia treatment,
meeting report, 5618
- neuroendocrine
activation by ERK, 1549
- regulation
metallothionein, 5370
- Cell growth:** See also **Tumor growth**
anchorage-independent
PI3K/Akt pathway, hepatocellular carci-
noma, 2971
- deregulation
interferon regulatory factor 2-dependent,
2510
- EDB-containing fibronectin-absent mice,
5603
- Her-2-induced
inhibition by EGCG, breast cancer, 652
- inhibition
acyclic retinoid, hepatoma, 3997
- BRCA2, 1311
- celecoxib, cancer cells, 2029
- ciliary neurotrophic factor, C6 glioma
cells, 3544
- c-myc antisense oligonucleotides, MCF-7
breast cancer cells, 3126
- connexin 43, glioblastoma, 2806
- CuZnSOD, glioma, 1205
- DRA*-induced, 5083
- endothelin A receptor blockade, cervical
cancer, 6381
- HDAC5, 2913
- HEPSIN*, prostate cancer, 6812
- Icat* gene, colon cancer, 3322
- ICI 182,780
and IGF-I signaling, 3985
- IGFBP-3, non-small cell lung cancer,
3530
- phospholipid scramblase 1, ovarian can-
cer, 397
- PKI-166, prostate cancer, 5254
- progesterone, endometrial cancer, 881
- silibinin, prostate cancer, 3063
- modulation by selenium, prostate cancer,
2540
- promotion by K-ras, head and neck squa-
mous cell carcinoma, 7154
- regulation
Bag1 proteins, breast cancer, 1904
- Ras, micrometastasis, 887
- relapse
AR mutations, CWR22 cells, 6606
- Cell immortalization**
Bmi-1, mammary epithelial cells, 4736
- E6/E7
combination HPV-16 E7 and CpG-ODN
immune therapy, 7234
- immortal DNA strand co-segregation, 6791
- mammary epithelial, characterization, 89
- Cell killing**
viral fusogenic membrane glycoproteins,
solid tumors, 6566
- Cell lineage**
and *Msh2*⁺/*Rb*⁺ mice, 5134
- Cell migration:** See also **Invasion**
collective melanoma
plasticity, 2125
- inhibition by GABA, SW 480 colon cancer
cells, 6467
- inhibition by NESH, 2215
- lysophosphatidic acid-induced
inhibition by alendronate, ovarian cancer,
6015
- microvascular
promotion by tenascin-C, 2660
- promotion by brain osteopontin, astrocy-
toma, 5336
- promotion by periostin, epithelial ovarian
carcinoma, 5358
- regulation by CXCR4 and c-Kit, 6304
- stimulation by bombesin, colon cancer, 4829
- T cell to tumor masses
CCR5, 3751
- Cell motility**
EGF receptor-regulated
Ral A, 982
- inhibition by IGFBP-1, breast cancer, 4369
- 67-kDa laminin receptor and, 1321
- Cell proliferation:** See also **Cell growth**
androgen receptor, androgen-refractory pros-
tate cancer, 1008
- asbestos-induced
inhibition by mutant EGFR, lung epithe-
lium, 4169
- endothelial
metronomic chemotherapy and, 6938
- epithelial
EGFR tyrosine kinase inhibition effects,
breast, 122
- glomeruloid microvascular, prognostic value,
6808
- hsMAD1 and, 2618
- inhibition
COX-2 inhibitors

SUBJECT INDEX TO VOLUME 62

- IGF-I and, pancreatic cancer, 7372
 Mdm2 isoforms, 1222
 2-methoxyestradiol, ER α / β -independent, 3691
 neoglycans, 3722
 polo-like kinase 1, cancer, 4186
 magnetic field-induced, rat mammary gland, 1356
 RhoA-dependent, prostate cancer, 2630
- Cell transformation**
 HER-2
 cyclin D1 rate-limiting effects, 2267
 K-Ras
 modulation by PPARs, intestinal epithelial cells, 3282
 malignant
 Δ TA-p73, 3598
 mediation by MEK1 signaling, EpH4 mammary epithelial cells, 4781
 neoplastic
 benzo(a)pyrene-induced, lung fibroblasts, 4605
 neuroblastoma to neuronal cells
 VHL protein, 7004
 PDK1, mammary epithelial cells, 3538
 Ras-induced
 reversal by IND 12, 1718
 RET
 inhibition by PP1, 1077
- Cellular cytotoxicity**
 antibody-dependent
 anti-adhesive antibody and, 6891
- Cellular phones**
 electromagnetic near field
 $lacZ$ mutations, mice, 1956
- Cellular retin-binding protein 1 gene**
 hypermethylation-associated inactivation, cancer, 5902
- Cellular stress response**
PCPH oncogene and, 2690
- Central nervous system**
 tumor immunity
 induction by *L. monocytogenes* vaccine, 2287
- CENU:** See **Chloroethylnitrosourea**
- c-erbB-2**
 adenovirus targeting, 609
 early placenta insulin-like growth factor and, 1020
- Cervical cancer**
 chemoradiation response
 p53 and, 7364
 cIAP1 expression, 4860
 COX-1 upregulation, 424
 growth inhibition by endothelin A receptor blockade, 6381
- Checkpoint kinase**
 Chk1
 ATM-independent S-phase checkpoint pathway, 1598
 -dependent G₂ checkpoint
 Ku effects, ionizing radiation, 6031
 -dependent S checkpoint
 Ku and, 2483
 Chk2
 inhibition by UCN-01, 5743
- Chemical carcinogenesis**
 germ-line p53 mutations and, mice, 3024
- Chemokines**
 receptor CCR5
 T-cell migration to tumor masses, 3751
 receptor CCR7
 CD45RA⁺CCR7⁺ cytotoxic T lymphocytes, melanoma, 1743
 lymph node metastasis, gastric cancer, 2937
 receptor CXCR4
- and B16 lung metastases, murine, 7328
 cell migration and adhesion regulation, small cell lung cancer, 6304
 neutralization, non-Hodgkin's lymphoma, 3106
 prostate cancer metastasis to bone, 1832
 regulation by VEGF
 invasion promotion, breast cancer, 7203
- Chemoprevention**
 carbamate-induced lung tumors, mice, 4199
 9-cis-retinoic acid, prostate carcinogenesis, 5178
 combination iNOS and COX-2 inhibitors, colon cancer, 165
 COX-2 induction inhibition, 2522
 Nrf2-regulated genes, 5196
 prostaglandin I₂ synthase overexpression, murine lung cancer, 734
 selenium, breast cancer, 708
 tamoxifen, prostate cancer, 1370
- Chemoradiation**
 response
 p53 and, cervical cancer, 7364
- Chemoresistance**
 IL-1 β and, pancreatic cancer, 910
 mediation by EGFR, glioblastoma, 4307
 mediation by TrkB, neuroblastoma, 6462
 modulation by rapamycin, prostate cancer, 6141
- Chemosensitivity**
 and gene expression, cancer cells, 1139
 modulation by Drg1, 3950
 superchemosensitization
 Herceptin pretreatment, breast cancer, 5703
- Chemotherapy**
 angiogenic factor expression, 5597
 apoptosis
 inhibition by curcumin, breast cancer, 3868
 BDNF-TrkB-PI3K pathway protection, neuroblastoma, 6756
 combined with Ad-E2F-1 gene transfer, melanoma, 1776
 combined with enzyme-activated prodrug therapy, 6089
 combined with ganciclovir, EBV⁺ tumors, 1920
 combined with NM-3, antineoplastic effects, 789
 combined with TRAIL, colon tumors, 5800
 enhancement by PDGF receptor antagonists, 5476
 Lys-165 alkyltransferase mutations, colon cancer, 3070
 metronomic
 selectivity for endothelial cells, 6938
 skeletal muscle ubiquitin-proteasome-dependent proteolysis inhibition, 2771
 transcription-targeted agent ET-743, 3377
 ultrasonically activated delivery, rat model, 7280
- Chfr**
 ubiquitin ligase activity, 1797
- Childhood tumors**
 atypical teratoid/rhabdoid tumors, workshop meeting report, 323
 caspase 8 and caspase 10 expression, 5897
 solid tumors
 MS-27-275 antitumor activity, 6108
- Chimeric idiotype**
 DNA vaccination, B-cell lymphoma, 5845
- Chloroethylnitrosourea**
 adaptive phospholipid metabolism changes, melanoma, 1890
- 1,3-bis(2-Chloroethyl)-1-nitrosourea**
 combined with radiation
- resistance
 mediation EGFR, glioblastoma, 4307
- Cholecytokinin B**
 missplicing, pancreatic cancer, 947
- Cholesterol**
 and Akt signaling, prostate cancer, 2227
- Choline**
 breast cancer, 1966
- Chondroitin sulfate**
 -binding cationic liposomes, novel liver metastasis inhibition, 4282
- Chromogranin A**
 and tumor growth, mouse models, 941
- Chromosome 1p36.3**
 imprinting absence, neuroblastoma, 6481
- Chromosome 3p14.2**
 genetically unstable sequences, 3477
- Chromosome 3p21.3**
 H37 lung cancer tumor suppressor gene, 3207
 homozygous deletion region
 tumor suppressor genes, 2715
- Chromosome 7q13.2-q36.1**
 loss, Barrett's esophagus, 1531
- Chromosome 8p**
 metastasis suppressor gene, rat prostate cancer, 367
- Chromosome 9**
 alterations, flat urothelial neoplasia, 809
- Chromosome 12p11-p12**
 EST array analysis, 6218
- Chromosome 13**
 abnormalities, multiple myeloma, 715
- Chromosome 15q15**
 B-cell lymphoma candidate tumor suppressor gene, 7175
- Chromosome 16p12-13**
 familial neuroblastoma mapping, 6651
- Chromosome 17q**
 gastric cancer, 2625
- Chromosome 20q13**
 genes
 and prostate tumorigenesis, 6803
- Chromosome 19q13.1**
 candidate cervical cancer oncogene *SEI-1*, identification, 7157
- Chromosome 19q13.3**
D19S12-D19S246 transcript map, 4100
- Chromosomes**
 alterations
 colorectal cancer, 6350
 HMGI(Y) and, prostate cancer, 647
 lung adenocarcinoma, 1152
 prognostic value, soft tissue sarcoma, 3980
 amplification silence, colon cancer, 1134
 immortal DNA strand co-segregation, 6791
 instability
 AIM-1 overexpression and, 5168
 DNA polymerase β and, 3511
 HPV-16 and, 7075
 induction by Rad6 overexpression, 2115
 lymphocytes
 and oral premalignant lesions, 2813
 translocation t(2;11)-acute myeloid leukemia
 NUP98-HOXD11 fusion gene, 28
 translocation t(11;12)(p15; q13)-acute myeloid leukemia
 NUP98-HOXC11 fusion gene, 4571
 translocation t(3;6)(q27 a]1)-B-cell non-Hodgkin's lymphoma, 6224
 translocation t(X;11)(q24;q23)-acute myeloid leukemia, infant
 MLL-SEPTIN6 fusion gene, 333
- CHS 828**
 sensitivity, PARP-1 fibroblasts, 4206
- Cilengitide**
 combined with radioimmunotherapy, breast

SUBJECT INDEX TO VOLUME 62

- cancer, 4263
Ciliary neurotrophic factor
 growth inhibition, C6 glioma cells, 3544
Cimicifuga racemosa extract
 estrogen-dependent mammary tumor effects, 3448
Cisplatin
 combined with IL-2 gene therapy, head and neck squamous cell carcinoma, 4023
 resistance
 copper homeostasis and, 6559
 regulation by *XPD*, 5457
 sensitivity
 transcription-coupled nucleotide excision repair and, 4899
CIZ/NMP4
EWSR1 and *TAF15* fusions, acute leukemia, 5408
c-jun
 dominant negative TAM-67
 okadaic acid-induced tumor promotion blockade, 3044
c-Jun NH₂-terminal kinase
 telomerase regulation, ovarian surface epithelial cells, 4575
c-Jun NH₂-terminal kinase 1
 skin tumor development, mice, 1343
c-Jun NH₂-terminal kinase 2
 gene expression regulation, 3257
c-Kit receptor tyrosine kinase
 cell migration and adhesion regulation, small cell lung cancer, 6304
 characterization, 4244
CLN3 gene
 novel molecular cancer target, 801
Clonality delineation
 metastasis-associated genes, hepatocellular carcinoma, 4711
c-Met
 signaling, nonautocrine
 metastasis promotion, 2951
CML28
 overexpression, tumor cells, 5517
c-myc
 antisense oligonucleotides
 growth inhibition, MCF-7 breast cancer cells, 3126
 apoptosis, polycystic kidney disease, 2210
 transcription sites
 novel detection, colon cancer, 6006
Colitis-associated tumors
HPP1 aberrant methylation, 6820
Msh2-deficient mice, 2092
p14^{ARF} hypermethylation, 1148
Collagen
 epithelial precancer fluorescent biomarker, 682
Collagen gels
 fully automated cancer cell tracking, 5301
 type 1
 prostate cell interactions, 58
Colon
Apc^{Min/+} mice
 microadenomatous lesions, 6367
 maturation
 gene expression profile, 4791
 mutated crypts
 ulcerative colitis, 2236
 sucrose-rich diet-induced mutations, rat, 4339
Colon adenocarcinoma
 EGCG stability, uptake, metabolism and efflux, 7241
Colon cancer
 adhesion-dependent apoptosis
 NF-κB inhibitors, 6870
 AN-238 and, 781
 antigen
 antibody recognition, 4041
 apoptosis resistance
 COX-2 expression, 6323
 cell migration inhibition by GABA, SW 480 cells, 6467
 chemotherapy
 Lys-165 alkyltransferase mutations, 3070
 chromosomal amplification silence, 1134
 c-myc transcription sites, novel detection, 6006
 COX-2 and sialyl Lewis antigens, 1567
 elimination, germ-free TGF-β1-deficient mice, 6362
 growth inhibition
 Icat, 3322
 PC-SPEs, 5204
 growth regulation by IGF-I, 1030
 homotypic adhesion disruption by Src activity, 2669
 human papillomavirus JCV and, 7093
 ICAM-2
 anti-ICAM-2 mAb therapy, 3167
 inhibitor of caspase-3-activated DNase and, 2169
 invasion stimulation by bombesin, 4829
 metastasis regulation by IGF-I, 1030
 nuclear matrix protein alterations, 2437
 prevention
 combination iNOS and COX-2 inhibitors, 165
 electron-donating ability and, 6506
 genetics, meeting report, 6779
 prostaglandin I₂ synthase gene transfer, 63
 reovirus therapy, 1696
 thromboxane A₂ synthase gene transfer, 63
 TRAIL-induced apoptosis
 COX-2 and, 4903
 tumor xenograft eradication by Hsp70 depletion, 7139
Colon cancer, hereditary nonpolyposis
 germ-line *MSH2* and *MLH1* mutations, prediction, 3485
Colon carcinogenesis
 prostaglandin E receptor EP₄, 28
Colon tumors
 APC mutations
 polymerase β and, 3271
 ARF-p53 pathway, mouse, 3667
 combination TRAIL and chemotherapy, SCID mice, 5800
Colon-stimulating factor 1
 antisense
 growth inhibition, solid tumors, 5317
Colorctal adenomas
CDH13 promoter region methylation, 3382
TS polymorphisms and, 3361
Colorctal cancer
 anti-rhCEA IgG subclass response, immunized patients, 1364
 apoptosis
 TRAIL/Apo2L-induced, 1583
CDH13 promoter region methylation, 3382
 cytotoxic T cell inhibition by regulatory T cells, 5267
 defective 8-oxo-G repair, 7230
 early onset
 hMSH2 and *hMLH1* promoter region germ-line mutations, 38
 gene expression, 4352
 intrachromosomal genomic instability, 6350
 karyotypic patterns, multivariate analysis, 5939
 loss of imprinting, 6442
 low-level microsatellite instability, 53, 1166, 5988
 metastasis to liver
 inhibition by C-raf antisense oligonucleotides, 5393
 Met expression regulation by Wnt signaling, 5126
 microsatellite instability-high
 frameshift TCF-4 mutations, 3009
 MMP-3 promoter mutations, 3855
 MMR-deficient
 mutation profiling, 1284
 non-microsatellite instability-high heterogeneity, 6011
 NSAIDs and GATA-6, 1178
 prognosis
 VEGF-D expression and, 1669
 ST1571 therapy, 4879
 ulcerative colitis-associated
 HPP1 aberrant methylation, 6820
 p14^{ARF} hypermethylation, 1148
Colorctal cancer, hereditary nonpolyposis
 breast cancer tumor exclusion, 1014
hExo1 mutation alterations, 6026
hMSH2 and *hMLH1* promoter region germline mutations, 38
MLH1 hypermethylation, 3925
MSH2 inactivation, 848
Colorctal carcinogenesis
APCDD1 upregulation, 5651
Colorctal tumors
BRAF and *KRAS* mutations, 6451
 growth
 APC mutations and, 363
Combrestatin A-4 phosphate
 phase I trial, advanced cancer, 3408
Comparative genomic hybridization
 array-based
 non-small cell lung cancer analysis, 3636
 renal cell carcinoma diagnosis, 957
BRCA1 breast cancer tumor profiling, 7110
 glioblastoma analysis and survival, 6205
 interglandular heterogeneity, pancreatic cancer, 835
 sporadic ovarian cancer analysis, 3466
Complementary DNA
 microarrays
 epithelial ovarian cancer, 2923
 esophageal lesions, 3493
 head and neck squamous cell carcinoma, 1184
 molecular profiling, bladder cancer, 6973
 pancreatic cancer, 2890
 serological identification of tumor antigens by cDNA expression cloning
 melanoma antigen isolation, 4836
Complement inhibitor
 tumor growth enhancement, breast cancer, 1110
Conjugated linoleic acid
 angiogenesis inhibition, 4383
Connexin43
 growth inhibition, glioblastoma, 2806
 increase by ciliary neurotrophic factor, C6 glioma cells, 3544
Convective-enhanced delivery
 boronated epidermal growth factor, glioma, 6552
COOH-terminal binding protein
 MIA downregulation, malignant melanoma, 5962
Copper
 homeostasis
 and cisplatin resistance, 6559
Copper-64-pyruvaldehyde-bis(N⁴-methylthiosemicarbazone)
 tumor growth inhibition, 445
Copper zinc superoxide dismutase
 growth inhibition, glioma, 1205

Core binding factor β -smooth muscle myo-sin heavy chain cooperation with G₁ acceleration, leukemogenesis, 2232

Corticosterone and energy restriction, 5280

Coxsackie adenovirus receptor expression, prostate cancer, 3812

CpG islands expressed sequence Tags, 3214

CpG-oligodeoxynucleotide combined with HPV-16 E7, immune therapy, 7234

CPI-0004Na toxicity, activity, and tissue distribution, 2327

CPT-11: *See Irinotecan*

C-raf antisense oligonucleotides colorectal cancer liver metastasis inhibition, 5393

Crocidolite asbestos mutagenicity, 99

CTCF functional change, cancer, 48

Cten downregulation, prostate cancer, 4217

Curcumin chemotherapy-induced apoptosis inhibition, breast cancer, 3868 oral mucosa carcinogen bioactivation inhibition, 5451

Cutaneous melanoma cyclin D1 candidate oncogene, 3200 progression VEGFR-3 marker, 7059

Cutaneous T-cell lymphoma *Fas* splice variant, 5389

CWR22 cells relapsed growth *AR* mutations, 6606

CXC chemokine receptor CXCR-4 and B16 lung metastases, murine, 7328 cell migration and adhesion regulation, small cell lung cancer, 6304 neutralization, non-Hodgkin's lymphoma, 3106 prostate cancer metastasis to bone, 1832 regulation by VEGF invasion promotion, breast cancer, 7203

CXCL12 ovarian cancer role, 5930

Cyclic AMP response element binding protein and faslodex resistance, 3428

Cyclic AMP response element binding protein-binding protein downregulation and melanocyte senescence, 6231

Cyclin B modulation by CD437, prostate cancer, 3842

Cyclin B1 and radiotherapy resistance, head and neck squamous cell carcinoma, 6414

Cyclin D1 and antiestrogen sensitivity, breast cancer, 6916 candidate oncogene, cutaneous melanoma, 3200 intestinal tumorigenesis, Min mice, 4562 modifier, VHL disease, 3803 rate-limiting effects, HER-2 transformation, 2268 regulation by hypoxia VHL-mediated, renal cell carcinoma, 3014 skin carcinogenesis enhancement, 1641 *SYT-SSX* and, synovial sarcoma, 3861

Cyclin D2 induction by BCR/ABL, 535

Cyclin E and antiestrogen sensitivity, breast cancer, 6916

Cyclin L candidate head and neck cancer oncogene, 6211

Cyclooxygenase 1 deficiency skin tumorigenesis reduction, 3395 inhibitors metastasis blockade, murine breast cancer, 2343 upregulation, cervical cancer, 424

Cyclooxygenase 2 deficiency skin tumorigenesis reduction, 3395 -derived PGE₂ tumor growth promotion, head and neck cancer, 6706 expression apoptosis resistance, colon cancer, 6323 breast cancer, 1676 intestinal polyps, 6846 prognostic value, breast cancer, 632 inhibitors bone cancer pain blockade, 7343 combined with iNOS inhibitor, chemopreventive effects, 165 combined with photodynamic therapy, 3956 IGF-I and, pancreatic cancer, 7372 metastasis blockade, murine breast cancer, 2343 retinoids and carnosol, 2522 and sialyl Lewis antigens, colon cancer, 1567 and TRAIL-induced apoptosis, colon cancer, 4903 tumorigenesis inhibition, skin, 2516

Cyclophosphamide low-dose antitumor effects, mice, 2731

Cysteine secreted protein acidic and rich in cysteine (SPARC) glioma invasion promotion, 6270

Cysteumustine adaptive phospholipid metabolism changes, melanoma, 1890

Cytochrome c TRAIL-mediated release blockade by epidermal growth factor, 488

Cytochrome P450 1A1 inhibition by fluasterone, 3685 Sudan I metabolism, 5678 1B1 inhibition by fluasterone, 3685 *CYP17* polymorphisms and ovarian cancer risk, 3058 gene therapy apoptotic factors and, 6928

Cytokines combined with vector-based vaccines, 5770 -encapsulated microspheres tumor immunotherapy, 7254 gene polymorphisms and prostate cancer, 3369 proinflammatory IGF-IR blockade, 4746 telomerase activity modulation, multiple myeloma, 3876

Cytomegalovirus human infection and expression, malignant glioma, 3347

Cytosine deaminase CD45-FC gene therapy, glioma, 773 yeast expression under CEA promoter, 2337

Cytotoxicity aflatoxin B₁, bronchial cells, 105 antibody-dependent cellular anti-adhesive antibody and, 6891 discodermolide and epithilone B, non-small cell lung cancer, 4081 DT₃₈₈IL3, acute myeloid leukemia stem cells, 1730 glycaminidase ribonucleotide formyltransferase inhibitors, 5236

Cytotoxic T lymphocytes CD45RA⁺CCR7⁺, melanoma, 1743 epitope presentation rescue by PA28, melanoma, 2875 inhibition by regulatory T cells, colorectal cancer, 5267 memory activation, 6438 prostate cancer-reactive, 5807 retroviral melanoma antigen recognition, 5510 tyrosinase-specific PS-SCL recognition, 2058

D

DAL-1 TSLC1 association, lung cancer, 5129

D-amino acid oxidase pegylated tumor-targeted H₂O₂ generation, 3138

DAO: *See D-amino acid oxidase*

DARPP-32 (dopamine and cAMP-regulated phosphoprotein of M_r32,000) overexpression, gastric cancer, 4061 truncated tDARPP overexpression, gastric cancer, 4061

DDATHF: *See (6R)-Dideazatetrahydrofolate*

DDC^{CCAF} gene prostate tumor marker, 2695

Death-associated protein kinase (DAPK) gene hypermethylation, bladder cancer, 4048 methylation breast cancer, 6634 former smokers, 351

Death stimuli MC1L-overexpressing Burkitt lymphoma response, 892

Decoy adducts nonrepairable, 4229

Defender against apoptotic cell death (DAD-R) gene and testicular germ cell tumors, 1822

Defibrotide combined with rhG-CSF stem cell mobilization, mice, 6152

Deleted in malignant brain tumors 1 (DMBT1) gene peptideomic marker peptide discovery, pancreatic adenocarcinoma, 4894 polymorphisms, malignant glioma, 1790

Deletions *I4-3-3 ϵ* , small cell lung cancer, 271 mtDNA, thyroid tumors, 7031 plasmid-based assay, Werner syndrome fibroblasts, 547 stage II non-small cell lung cancer, 2681 *Znfl1al/Ikaros* gene, murine lymphoma, 2650

Dendritic cells activation by adenovirus, 5260 EBV peptide-pulsed immunotherapy, nasopharyngeal carcinoma, 6952

- iNOS induction by glioma-associated hyaluronan, 2583
- phenotype**
interferon stimulated gene 15 and, melanoma, 3453
- pulsed**
leukemic blast cross-presentation, 2861
- rAAV-targeted candidate vaccine**, chronic myelogenous leukemia, 3175
- telomerase RNA-transfected, 5041
- tumor-primed**
cancer vaccine, 1884
- vaccines**
IL-18 gene-transduced, immunotherapy, 5853
- Dendritic-like cells**
silica-induced, 1050
- Deoxycytidine analogue monophosphates**
l-form
phosphorylation, 1624
- Deoxycytidine kinase**
ara-G phosphorylation, 3100
- 2-Deoxy-d-ribose**
2-deoxy-L-ribose functional effects, 2834
- 3-Deoxy-3-[¹⁸F]fluorothymidine-position emission tomography**
lung nodules, 3331
- Deoxyguanosine kinase**
ara-G phosphorylation, 3100
- 2-Deoxy-L-ribose**
thymidine phosphorylase and dRib functional effects, 2834
- Depsipeptide**: *See* FK228
- Desferri-exochelin**
HIF, VEGF and NIP3 induction, 6924
- Desmoplasia**
gene expression, 5351
- Development**
Id2 and, 301
- Dexamethasone**
apoptosis, pre-B cells, 4212
thymic lymphoma prevention, *Atm*-/- mice, 5153
- Diabetes**
lymphoid neoplasia, immunodeficient nonobese diabetic mice, 5828
- Diarrhea**
celecoxib and CPT-11 effects, 5778
CPT-11-induced prevention, 179
- (6R)-Dideazatetrahydrofolate**
cytotoxicity, 5236
- Diet**
sucrose-rich
mutations, rat colon, 4339
- Difluoromethylornithine**
UV carcinogenesis inhibition, *Xpa*^{-/-} mice, 1338
- 7,12-Dimethylbenz(a)anthracene**
IL-1 α induction, 417
mammary carcinogenesis
inhibition by resveratrol, rats, 4945
- 1,2-Dimethylhydrazine**
uterine sarcoma, p53 transgenic mice, 3024
- Dipeptidyl peptidase IV**
overexpression
and survival, ovarian cancer, 2753
- Diphtheria toxin**
A chain
adenoviral gene transfer, 2576
- DT₃₈₈IL3 fusion protein
acute myeloid leukemia stem cell cytotoxicity, 1730
- transport domain
Bad fusion protein Bad (S112D S136A)-DTTR
apoptosis induction, 1433
- Discodermolide**
cytotoxicity, non-small cell lung cancer,
- Disease**
epigenetic mechanisms, meeting report, 6784
- dI1520**
hepatic arterial administration, 6070
- DMBA**: *See* 7,12-Dimethylbenz(a)anthracene
- DNA**
amplification
and gene expression patterns, breast cancer, 6240
- complementary microarrays
epithelial ovarian cancer, 2923
esophageal lesions, 3493
head and neck squamous cell carcinoma, 1184
molecular profiling, bladder cancer, 6973
pancreatic cancer, 2890
serological identification of tumor antigens by cDNA expression cloning
melanoma antigen isolation, 4836
- CpG islands
expressed sequence Tags, 3214
electrovaccination, melanoma, 5489
hypermethylation, histone modifications and
gene expression dependent on, 7213
hypomethylation by methioninase, 4685
immortal strand co-segregation, 6791
methylation *de novo*
cell division requirements, bladder cancer, 2378
- mitochondrial
deletions, thyroid tumors, 7031
mutations, prostate cancer, 6470
somatic mutations, breast cancer, 972
- replication inhibition by Kin17, 5425
- secondary structures
p53 hypermutable base positions, 5641
- SZF1 binding, 3773
vaccination, B-cell lymphoma, 5845
vaccines, T-cell lymphoma, 1757
- DNA adducts**
benzo(g)chrysene
global nucleotide excision repair
regulation by p53, fibroblasts, 5288
nonrepairable, 4229
- DNA-binding protein B**
expression, vascular endothelial growth factor, 4985
- DNA damage**
clustered
complex rearrangements, 6263
double-strand breaks
aberrant repair, myeloid leukemia, 2791
homology-directed repair, 1279
repair
BLM helicase, 2766
metabolic inhibition response, 3515
p53 response mediation by TGF- β 1, 5627
senescence induction, tumor cells, 1876
tetranucleotide repeat mutations, 6052
VP-16-induced fragmentation
DNASIL3, osteosarcoma, 4439
- DNA-dependent protein kinase**
catalytic subunit DNA-PKcs
inactivation with antisense oligodeoxynucleotides, 6621
silencing by siRNAs, 6400
- DNA ligase I gene**
point mutation, mice, 4065
- DNA ligase IV**
medulloblastoma inhibition, 6395
- DNA-methyltransferase**
Apc^{Mnd/+} *Dnmt1*-hypomorphic mice
polyp inhibition, 1296
Dnmt1 protein
- depletion by methylating agents, 1592
- DNA-methyltransferase-3B promoter**
polymorphism
and lung cancer risk, 4992
- DNA polymerase β**
and aneuploidy and tumorigenesis, 3511
deficiency
and apoptosis, 1524
and low-level microsatellite instability, 6061
replication error spectrum, *APC* mutations, 3271
splice variants, bladder cancer, 3251
- DNA repair**
deficiency
FHIT/FRA3B locus and, 4054
double-strand break
aberrant, myeloid leukemia, 2791
BLM helicase, 2766
- genes
mutations, MSI+ endometrial cancer, 4095
- homology-directed, 1279
- mismatch
deficiency
mutations, colorectal cancer, 1284
mutations, review, 2447
target gene mutation profiles, 1609
target genes for instability, review, 2447
- gene rearrangements, hereditary nonpolyposis colorectal cancer, 848
- nucleotide excision
global
regulation by p53, fibroblasts, 5288
transcription-coupled
and cisplatin sensitivity, 4899
- 8-oxo-G
defective, colorectal cancer, 7230
- DNASIL3**
VP-16-induced fragmentation, osteosarcoma, 4439
- DNAzymes**
VEGFR2, 5463
- DNp73**
oncogenic potential, 636
- Docetaxel**
combined with pegylated IFN- α -2b
prostate cancer inhibition, nude mice, 5720
systemic exposure
ritonavir-boosted, mice, 6158
- Dodecafluoropentane**
hypoxic tumor cell radiosensitization, 3626
- Donor leukocyte infusion**
immunized
tumor vaccine enhancement, 796
- Doppler ultrasound**
high-frequency
antivascular therapy monitoring, 6371
- Dormancy**
tumor
solitary cells and, 2162
- DOTA**: *See* 1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid
- Down-regulated in adenoma (DRA) gene**
growth inhibition, 5083
- Doxorubicin**
combined with anti-flk-1 mAb, soft tissue sarcoma, 2034
- in vivo*
apoptosis, cardiomyocytes, 4592
- liposomal
antivascular effects, rat brain tumor model, 2561
- resistance
Bcrp1 mutation hot spot and, 2294
modulation by rapamycin, prostate cancer, 6141

SUBJECT INDEX TO VOLUME 62

- Doxycycline** bone metastasis tumor burden reduction, breast cancer, 1588
- Drg1** chemosensitivity modulation, 3950
- dRib:** *See* 2-Deoxy-d-ribose
- Drug delivery** apoptosis-induced, 1382
ultrasonically activated, rat model, 7280
- Drug resistance** melanoma, 6698
multidrug resistance protein 6 properties, 6172
murine major vault protein MVP/LRP and, 7298
nuclear proteasome and, 5008
- Drug transport** multidrug resistance protein 6 properties, 6172
- ΔTA-p73** malignant transformation, 3598
- Ductal carcinoma *in situ*** active HER-2/neu signaling, 6667
breast
COX-2 expression, 1676
proteomics, 6740
- Dysplasia** oral
molecular analysis, 4757
oral epithelial, severe
p16^{INK4a} and *p14^{ARF}* alterations, 5295
- Dystroglycan** epithelial polarization, breast tumor cells, 7102
- E**
- E7820** integrin α2 inhibition, endothelium, 6116
- E1A** oncolytic mutations, melanoma-targeted, 4663
systemic gene therapy, 6712
tumor inhibition mechanisms, 346
- E6AP ubiquitin ligase** EG-induced E6TP1 degradation mediation, 3315
- Early growth response-1 gene** *EGFR* gene expression induction, hypoxia, 827
- Early placenta insulin-like growth factor** and c-erbB-2-positive cells, 1020
- E-cadherin** inhibition by *SLUG*, breast cancer, 1613
- Ecteinascidin-743** combined with paclitaxel, breast cancer, 6909
hepatotoxicity, female rat, 4256
transcription-targeted chemotherapy agent, 3377
- EDB-containing fibronectin** mice lacking, 5603
- E2F-1** Ad-E2F-1 gene transfer
combined with chemotherapy, melanoma, 1776
modulation by CD437, prostate cancer, 3842
Myc-induced tumorigenesis inhibition, 3276
-targeted replication-selective adenovirus, 3438
- E4G10** tumor growth inhibition, 2567
- Electromagnetic near field** *lacI* mutations, mice, 1956
- Electron-donating ability** and colon cancer prevention, 6506
- Electronic expression profiling** prostate cancer, 3308
- Electrovaccination** DNA
melanoma, 5489
- ELF4:** *See* MEF
- Endocrine neoplasia, multiple** function-impaired RET-MEN2A repair, 2414
- Endometrial adenocarcinoma** Ishikawa
stromal regulation, 79
- Endometrial cancer** early TGF-β signaling loss, 2778
growth inhibition by progesterone, 881
hCDC4 mutations, 4535
microsatellite instability
APC methylation, 3663
DNA repair gene mutations, 4095
- Endometrial tumors** mismatch repair-deficient
target gene mutation profiles, 1609
- Endostatin** adenoviral
growth inhibition, mammary tumors, 3934
cell adhesion regulation, 1944
extracellular matrix interactions, endothelial cells, 5580
- Endothelial cells** adhesion
regulation by endostatin, 1944
COX-2 expression, intestinal polyps, 6846
extracellular matrix
endostatin interactions, 5580
metronomic chemotherapy selectivity, 6938
tumor
placental growth factor survival factor, 2749
- Endothelin A** receptor
blockade
growth inhibition, cervical cancer, 6381
- Endothelium** integrin α2 inhibition by E7820, 6116
irradiated
PI3K/Akt signaling response, 4671
irradiation-induced NO
apoptosis induction, 1450
tumor
heparin-binding VEGF substructure binding, 7118
- Energy restriction** mechanisms, 5280
- Enzyme-activated prodrug therapy** combined adenoviral and cytostatic therapy, 6089
P450 gene-directed
apoptotic factors and, 6928
- EphA2** antibody targeting
malignant cell inhibition, 2840
- Epidermal growth factor** boronated
convection-enhanced delivery, glioma, 6552
receptor
anti-EGFR therapy resistance
mediation by IGFR-1, glioblastoma, 200
and bladder tumorigenesis, 4157
ΔEGFR/PI3-K/Akt/p27 signaling, glioblastoma, 6764
-dependent angiogenesis, skin carcinogenesis, 3402
expression
head and neck squamous cell carcinoma, 7350
induction by *Egr-1*, hypoxia, 827
inhibition
- antiangiogenic effects, 2554
effects, breast epithelial proliferation, 122
malignant pleural mesothelioma, 5242
metastatic pancreatic cancer, 1996
molecular targeting, neutron capture therapy, 3159
mutations
asbestos-induced proliferation inhibition, lung epithelium, 4169
radiation and BCNU resistance mediation, glioblastoma, 4307
-regulated cell motility
Ral A, 982
signaling
inhibition by ZD1839, 5749
Nfl/p53 mouse tumor cells, 4507
signal transactivation, head and neck squamous cell carcinoma, 6329
truncated trEGFR
mitogenic blockade, pancreatic cancer, 5611
receptor 2
human: *See* HER-2/neu
receptor VIII
invasion gene activation, 3335
-related ligands
ErbB-targeted anticancer agents and, 3151
TRAIL-mediated cytochrome c release blockade, 488
- Epigallocatechin-3 gallate** Her-2-induced cell growth inhibition, breast cancer, 652
stability, uptake, metabolism and efflux, colon adenocarcinoma, 7241
- Epigenetics** disease mechanisms, meeting report, 6784
- Epithelial cancer** apoptosis
BAX, 3373
ovarian
cDNA array and, 2923
cell migration promotion by periostin, 5358
malignant
hyaluronan levels, 6410
risk
CYP17 and *COMT* polymorphisms and, 3058
- Epithelial cells** breast
proliferation
EGFR tyrosine kinase inhibition effects, 122
intestinal
K-Ras transformation
modulation by PPARs, 3282
mammary
immortalization by *Bmi-1*, 4736
ING1 target gene detection by cDNA microarrays, mouse, 2203
MEK1 signaling and, EpH4 cells, 4781
psoriasis expression, 43
transformation by PDK1, 3538
ovarian surface
telomerase regulation by JNK, 4575
polarization by dystroglycan, breast tumors, 7102
prostate
senescence characterization by SAGE, 6255
RK3E
GLI-regulated transcripts, 5867
- Epithelial cell tumors** Epstein-Barr virus-positive combination chemotherapy and ganciclovir, 1920

- Epithelial dysplasia**
oral
severe
p16^{INK4a} and *p14^{ARF}* alterations, 5295
- Epithelial neoplasia**
stromal regulation, 79
- Epithelial precursor**
NAD(P)H/collagen fluorescent biomarkers, 682
- Epithelial tumors**
ovarian
malignant
hyaluronidase activity, 6410
- Epithelium**
bronchial
hypermethylation, smokers, 2370
- lung
asbestos-induced proliferation
inhibition by mutant EGFR, 4169
- prostate
EGF88 overexpression, mouse, 5096
RXR α allele inactivation, prostatic intraepithelial neoplasia, 4812
- Epothilone B**
cytotoxicity, non-small cell lung cancer, 4081
- Epothilone B analogue BMS-247550**
Bax conformational change induction, breast cancer, 466
- Epstein-Barr virus**
carcinoma, 4876
-encoded nuclear antigen 1 (EBNA1)
T helper peptides, 7195
- epithelial cell tumors
combination chemotherapy and ganciclovir, 1920
- latent membrane protein 1
FGF-2 induction and release, 6337
- peptide-pulsed dendritic cell immunotherapy, nasopharyngeal carcinoma, 6952
- ErBB**
-targeted anticancer agents
and EGF-related ligands, 3151
- erbB-2:** See HER-2/neu
- ERCC2 gene**
polymorphisms
and smoking, lung cancer, 1377
- Esophageal adenocarcinoma**
HNF3 α (*FOXA1*) amplification and overexpression, 5273
- Esophageal cancer**
artificial neural networks and cDNA microarrays, 3493
- squamous cell
p16 silencing modes, 4938
RNF6 mutations, 4191
Smurf2 expression, 7162
WWOX alterations, 2258
- T cell factor transcription regulation by Wnt-1, 277
- Esophageal tumorigenesis**
piroxicam effects, rat, 4376
- Esophagus, Barrett's**
artificial neural networks and cDNA microarrays, 3493
7q13.2-3q36.1 loss, 1531
- Estradiol**
VEGF regulation, breast cancer, 4977
- Estrogen**
estrogen-responsive element-targeted histone deacetylase antiestrogen activity, 6519
- lung cancer, 2141
- mammary tumors
Cimicifuga extract effects, 3448
- receptor
 β cx protein, ER α -positive breast cancer, 4849
- inhibition by BRCA1
modulation by p300, 141
- SER-MR complexes, breast cancer, 4419
- receptor α
absent, mammary tumor onset delay, 2798
- breast cancer
 β cx protein, 4849
- lung cancer, 2141
- receptor β , lung cancer, 2141
- targets, breast tissue, 4540
- VEGF regulation, breast cancer, 4977
- Estrogen-related receptor α**
breast cancer, 6510
- Estrogen-related receptor γ**
breast cancer, 6510
- Estrogen-responsive element**
-targeted histone deacetylase
antiestrogen activity, 6519
- N^{2,3}-Ethenoguanine**
vinyl chloride-induced
molecular dosimetry and repair, rats, 5189
rat brain and liver, 5183
- Etoposide**
-induced fragmentation
DNASIL3, osteosarcoma, 4439
- E6TP1**
EG-induced degradation
mediation by E6AP ubiquitin ligase, 3315
- Ewing's sarcoma**
EWS-*FLI1* fusion gene
BARD1 interactions, 4583
- EWSR1*-*CIZ* fusion gene, acute leukemia, 5408
- Exonuclease 1**
human *hExo1*
mutations, hereditary nonpolyposis colorectal cancer, 6026
- Exotoxins**
CD7-exotoxin, acute leukemia, 2848
- Expressed sequence tag (EST) arrays**
12p11-p12 amplicon analysis, 6218
- Extracellular matrix**
endostatin interactions, endothelial cells, 5580
- Extracellular membrane vesicles**
tumor cell
angiogenic activity, 6312
- Extracellular signal-regulated kinase**
inhibitors
apoptosis induction, Bcr/Abl-expressing leukemia, 188
- neuroendocrine differentiation activation, 1549
- PEITC-induced apoptosis, prostate cancer, 3615
- and photodynamic therapy sensitivity, 5528
- F**
- Familial glioma**
linkage analysis, 3798
- Familial neuroblastoma**
chromosome 16p12-13 mapping, 6651
- Familial pancreatic cancer**
BRCA2 mutations, 3789
- Farnesyltransferase inhibitors**
Ras CD95 expression inhibition reversal, 450
- Fas gene**
splice variant, cutaneous T-cell lymphoma, 5389
- Fas ligand**
monocyte expression, tumors, 1261
- Faslodex (ICI 182,780)**
growth inhibition
and IGF-1 signaling, 3985
- resistance
molecular analysis, 3428
- Fatty acid synthase**
PI3K/PTEN/Akt kinase and, LNCaP prostate cancer cells, 642
- Feline immunodeficiency virus**
and chromosome 15q15 candidate tumor suppressor gene, B-cell lymphoma, 7175
- Fenretinide**
apoptosis, neuroblastoma, 5158
GADD153 and 12-LOX induction, 5158
- Fetal liver kinase 1**
anti-flk-1 mAb
combined with doxorubicin, soft tissue sarcoma, 2034
- truncated soluble tsFlk-1 rAAV-mediated expression
growth inhibition, renal tumors, 3077
- α -Fetoprotein**
afp gene expression downregulation by hypoxia, 1158
- Fibrillar-type adhesions**
formation by β 1-integrin VHL role, 2929
- Fibrinogen**
deficiency
lymphatic metastasis, mice, 6966
- Fibroblast activation protein**
tumor growth promotion, 4767
- Fibroblast growth factor**
basic bFGF
prognostic value, lung cancer, 5210
- receptor
FGFR4 Arg³⁸⁸ allele
and tumor progression, 840
- receptor 1
phosphotyrosine 766, prostate tumor progression, 1898
- Fibroblast growth factor 2**
induction and release by EBV LMP1, 6337
- Fibroblast growth factor 8b**
overexpression, prostate epithelium, 5096
- Fibroblasts**
 α -particle irradiation bystander effects
oxidative metabolism and, fibroblasts, 5436
- Brcal-null
nonhomologous end-joining activity, 3966
- COX-2 expression, intestinal polyps, 6846
- gene induction by methylation inhibitors, 961
- global nucleotide excision repair regulation by p53, 5288
- histone H3 phosphorylation, mouse, 75
- immortal
telomerase inhibition, 2104
- Jnk1*- and *Jnk2*-deficient
gene expression profile, murine cells, 1300
- MMP-2 release, malignant cell contact, 283
- PARP-1
CHS 828 sensitivity, 4206
- plasmid-based deletion assay, Werner syndrome, 547
- Fibronectin**
EDB-containing, mice lacking, 5603
matrix assembly, EDB segment-absent mice, 5603
- Fibrosarcoma**
invasion inhibition by nobiletin, 1025
- Fibrosis**
pulmonary
radiation-induced, murine, 3782
- Fine-needle aspiration**
breast cancer diagnosis, genetic, 2365
- FK228 (depsipeptide)**
HDAC inhibition, mechanism, 4916
- Flavopiridol**
apoptosis induction, S-phase, 1707

SUBJECT INDEX TO VOLUME 62

- FLII gene**
EWS-FLII fusion gene
 BARD1 interactions, 4583
- Flt-1**
 promoter
 transcriptional targeting, teratocarcinoma, 1271
- soluble sFlt-1
 carcinomatous ascites inhibition, 2019
- Fluasterone:** *See 16 α -Fluoro-5-androsten-17-one*
- Fluorescence imaging**
 tumor growth and metastasis, pancreatic cancer, 1534
- 16 α -Fluoro-5-androsten-17-one**
 carcinogen-activating enzyme inhibition, 3685
- 5-Fluorcytosine**
 cytosine deaminase/5-FC gene therapy, glioma, 773
- Focal adhesion kinase**
 tumor signaling *in vivo*, 2699
- Folate**
 transport by MRP4, 3144
- Forkhead box FOXM1**
 expression, basal cell carcinoma, 4773
- 4-1BB**
 anti-4-1BB mAb
 and large tumor immunotherapy, 3459
- 14-3-3**
 tuberin interactions, 6475
- 14-3-3 ϵ**
 deletion, small cell lung cancer, 271
- 14-3-3 σ**
 methylation, oral carcinoma, 2072
- Fra-1**
 asbestos-induced, mesothelioma, 6065
- Fragile histidine triad (FHIT) gene**
FHIT/FRA3B locus
 genetically unstable sequences, 3477
 and repair-deficient cancers, 4054
 testicular germ cell tumorigenesis, 512
- Fructose-2,6-bisphosphatase**
 inducible
 expression, cancer, 5881
- FTY720**
 tumor growth and metastasis prevention, mouse breast cancer, 1410
- Fumarate hydratase (fumarase, FH) gene**
 mutations, hereditary leiomyomatosis and renal cell cancer, 4554
- Furamidine analogues**
 cellular distribution, 7219
- Furin**
 proMT3-MMP processing, Madin-Darby canine kidney cells, 675
- Fusion genes**
EWS-FLII fusion gene
 BARD1 interactions, 4583
- EWSR1-CIZ*, acute leukemia, 5408
- H4/BCL6* fusion gene, B-cell non-Hodgkin's lymphoma, 6224
- MLL-LCX*, acute myeloid leukemia with trilineage dysplasia, 4075
- MLL-SEPTIN6*, infant t(X;11)(q24;q23)
 acute myeloid leukemia, 333
- NUP98-HOXC11*, t(11;12) acute myeloid leukemia, 4571
- NUP98-HOXD11*, t(2;11)-acute myeloid leukemia, 33
- SYT-SSX*
 and cyclin D1 expression, synovial sarcoma, 3861
 and synovial sarcoma, 135
- TAF15-CIZ*, acute leukemia, 5408
- Fusion proteins**
 Bad (S112D S136A)-DTTR

- apoptosis induction, 1433
- B7.2-IgG**
 combined with SU6668, breast tumor therapy, 5727
- DT₃₈₈IL3** fusion protein
 acute myeloid leukemia stem cell cytotoxicity, 1730
- green fluorescent protein/TRAIL**
 targeted expression, hepatocytes, 3620
- leukemia-associated differentiation blockade**, 7050
- TAT-ODD**, antitumor effects, 2013
- Fusion vaccines**
 melanoma, 5495
- Fusogenic membrane glycoproteins**
 viral
 solid tumor cell killing, 6566
- Fv antibody fragment**
 single-chain
 anti-Ras
 radiation-induced NF- κ B activation inhibition, 2318
- CD7-exotoxin, acute leukemia, 2848
- G**
- GABA:** *See* γ -Aminobutyric acid
- Gadd45a**
 -dependent stress MAPK and p53 activation, 7305
- GADD153**
 induction by fenretinide, 5158
- Ganciclovir**
 combined with chemotherapy, EBV⁺ tumors, 1920
- Ganglioside G_{M3}**
 antitumor effects, bladder cancer, 3850
- Gap junctional intercellular communication**
 menadione and, 4922
- GART:** *See* γ -Glycine ribonucleotide formyltransferase
- Gastric adenocarcinoma**
HPPI and *hMLH1* hypermethylation, 5637
- Gastric cancer**
 β -catenin mutations, 3503
 chromosome 17q characterization, 2625
 DARPP-32 and tDARPP overexpression, 4061
 gene expression analysis by oligonucleotide microarrays, 233
 gene silencing, 6645
Helicobacter-induced
 inhibition by p53-targeted disruption, 696
 herceptin, 5813
hrgA and, Asians, 2385
 instabiliotyping, 3641
 intestinal-type
 gene expression profiles, 7012
 metastasis to lymph nodes
 CCR7 expression, 2937
- S100A** calcium binding protein overexpression, 6823
 serial analysis of gene expression, 6823
 Skp2 expression, 3819
- Gastrin**
CCK-B/gastrin receptor missplicing, pancreatic cancer, 947
- Gastrinoma**
HER-2/neu expression, 3702
- Gastrointestinal cancer**
 length polymorphisms, short mononucleotide tract, 1961
 mismatch repair-deficient
 target gene mutation profiles, 1609
- Gastrointestinal hamartoma**
Lkb1 knockout mice, 2261
- GATA-6**
 NSAIDs and, colorectal cancer, 1178
- G3BP**
 induction by heregulin, breast cancer, 1251
- Gelatinase**
 MMP inhibitor specificity/efficacy correlation, T-cell lymphoma, 5543
- Geldanamycin**
 HIF-1 α inhibition, prostate cancer, 2478
- Gemcitabine**
 effects on humoral immune response, 2353
- Gene amplification**
 induction by mutant p53, 3264
- Gene-directed enzyme prodrug therapy**
 P450 gene
 apoptotic factors and, 6928
- Gene expression**
 analysis
 sensitivity to anticancer drugs, 518
 cDNA microarrays
 artificial neural networks and, esophageal lesions, 3493
 pancreatic cancer, 2890
 chemosensitivity and, cancer cells, 1139
 colorectal cancer, 4352
 comprehensive analysis, prostate cancer, 4499
 CPT-induced changes, 1688
 desmoplasia, 5351
 electronic profiling, prostate cancer, 3308
 EST arrays
 12p11-p12 amplicon, 6218
 genome-wide analysis, synovial sarcoma, 5859
 histone modification and, dependence on DNA hypermethylation, 7213
 HPV16 integration and cervical keratinocytes, 6959
 JNK2-regulated, 3257
 modulation by Kaposi's sarcoma-associated herpesvirus viral G protein-coupled receptor, 4525
 oligonucleotide microarrays, gastric cancer, 233
 patterns
 DNA amplification and, breast cancer, 6240
 single cell behavior correlation, metastatic mammary cancer, 6278
 pilocytic astrocytoma, 2085
 profiles
 anti-angiogenic therapy and, 7143
 bladder cancer, 6973
BRCA1 breast cancer tumors, 7110
 cell cycle progression, 3233
 colon cell maturation, 4791
 etiology-specific, mammary cancer, 3592
 favorable histology Wilms' tumor, 6598
 head and neck squamous cell carcinoma, 1184
 HTLV-1 infection, 3562
 intestinal-type gastric cancer, 7012
Jnk1- and *Jnk2*-deficient murine fibroblasts, 1300
 liposarcoma, 2993
 lung adenocarcinoma, 3244
 MHC I ligand analysis and, 5818
 ovarian cancer, 4722
 oxidative stress, breast cancer, 6246
 prostate cancer, meta-analysis, 4427
 prostate cancer progression, 5325
 SERM-ER complexes, breast cancer, 4419
 testicular germ cell tumorigenesis, 2359
 ratios, cancer diagnosis, 4963
 serial analysis
 epithelial senescence characterization, prostate, 6255
 gastric cancer, 6823
 pancreatic cancer, 819

SUBJECT INDEX TO VOLUME 62

- squamous cell carcinoma progression, 3759
stromal cells
MMP-1 2G single nucleotide polymorphism and, 7200
virus type linkage, hepatocellular carcinoma, 3939

Gene polymorphisms
AR CAG repeat
and breast cancer risk, 1045
cytokine
and prostate cancer, 3369
DMBT1, malignant glioma, 1790
ERCC2
and smoking, lung cancer, 1377
germ-line
and sputum promoter methylation, 2248
glutathione *S*-transferase P1
and sputum promoter methylation, 2248
NAD(P)H:quinone oxidoreductase
and sputum promoter methylation, 2248
NKX-3.1 C154T, 2654
short mononucleotide tract length, gastrointestinal cancer, 1961
single nucleotide
2G
MMP-1 promoter, and gene expression, 7200
hOGGI
and prostate cancer, 2253
MDR1, acute myeloid leukemia, 4955
MMP2
and lung cancer risk, 6430
thymidylate synthase promoter
and colorectal adenomas, 3361

Genes
alterations, complex
clustered DNA damage, 6263
chromosome 20q13
and prostate tumorigenesis, 6803
colon cancer prevention, meeting report, 6779
cutaneous melanoma candidates
cyclin D1, 3200
head and neck cancer candidates
cyclin L, 6211
induction by methylation inhibitors, fibroblasts, 961
invasion
activation by EGFRvIII, 3335
invasion suppressor
RhoGDI2, 6418
metastasis-associated
hepatocellular carcinoma, clonality delineation, 4711
metastasis suppressor
rat prostate cancer, 367
RhoGDI2, 6418
methyl-group metabolism
germ-line variants, 4519
Nrf2-regulated
cancer chemoprevention, 5196
ovarian cancer oncogene candidate *SEI-1*, identification, 7157
p53-regulated
modulation by thymidylate synthase, 2644
silencing, gastric cancer, 6645
tumor suppressor
chromosome 3p21.3 homozygous deletion region, 2715
tumor suppressor candidates
chromosome 15q15, B-cell lymphoma, 7175

Gene therapy
adenoviral, renal cell carcinoma, 4273
adenoviral double suicide, locally recurrent prostate cancer, 4968
cell-based antiangiogenic, 2004

cytosine deaminase/5-FC, glioma, 773
IL-2
combined with cisplatin, head and neck squamous cell carcinoma, 4023
P450
apoptotic factors and, 6928
PARP-based, prostate cancer, 6879
retroviral
bone marrow TGF- β signaling blockade, 7135
suicide
carboxypeptidase G2
prodrugs, 1724
inducible
combined with photodynamic therapy, 1458
nitroreductase
bystander effects, 3D cell cultures, 1425
systemic *bik*, 8
systemic *E1A*, 6712
tumor-targeted, nasopharyngeal carcinoma, 171

Genetic stability
p53 and, 1129
Rb gene and, mouse, 2498

Gene transfer
adenoviral DT-A, 2576
adenoviral E2F-1
combined with chemotherapy, melanoma, 1776
adenoviral p53
phosphorylation, glioma, 1069
horizontal, 575
lymphocyte transgene *Lptn*
combined with adoptive T-cells, 2043
phagemid, carcinoma, 977
prostaglandin I₂ synthase, colon cancer, 63
retroviral vs lentiviral vectors, ovarian cancer, 6099
sst2
antitumor effects, pancreatic cancer, 6124
thromboxane A₂ synthase, colon cancer, 63

Genistein
tamoxifen interactions, breast cancer, 2474

Genome-wide allelotyping
early breast carcinogenesis events, new *in vitro* model, 5980

Genome-wide analysis
gene expression, synovial sarcoma, 5859

Genomic alterations
allele separation and, 4579
associated with aggressiveness, bladder cancer, 6981

Genomic expression
EST arrays
12p11-p12 amplicon, 6218
profiling, liposarcoma, 2993

Genomic instability
Brc2 and *p53* mutations, 6194
intrachromosomal, colorectal cancer, 6350
-null human tumor cells, 6345

Genotype
and breast cancer survival, 3052

Germ cell tumororigenesis
testicular
gene expression profiling, 2359

Germ cell tumors
refractory
microsatellite instability, 2758
testicular
DAD-R and, 1822
FHIT, 512

Gleevec: *See Imatinib*

GLI
-regulated transcripts
RK3E epithelial cells, 5867

Gli2
NH₂-terminal fragment
and skin tumor phenotype, 5308

Glioblastoma
anti-EGFR therapy resistance
mediation by IGFR-1, 200
apoptosis induction
neural stem cell-mediated TRAIL therapy, 7170
combination radiation and chemotherapy
resistance
mediation by EGFR, 4307
 Δ EGFR/PI3-K/Akt/p27 signaling, 6764
growth inhibition by connexin 43, 2806
IL-4 signaling inhibition by IL-13R α 2, 1103
invasion
inhibition by PTEN, 6318
malignant
CD70 immune escape pathway, 2592
PDGF autocrine signaling, 3729
radiosensitization by rapamycin, U87 xenografts, 7291
survival
genetic alterations and, 6205
tumor vascularity reduction by TSP-1 overexpression, 1191
tumor xenograft eradication by Hsp70 depletion, 7139

Glioma
boronated EGF delivery, convection-enhanced, 6552
CD5/FC gene therapy, 773
combination radiotherapy and Ad5- Δ 24RGD, 5736
familial
linkage analysis, 3798
growth inhibition
AAV-encoded angiostatin, 756
ciliary neurotrophic factor, C6 cells, 3544
CuZnSOD, 1205
SPARC, 6270
IL-12 neural stem cell therapy, 5657
invasion
promotion by SPARC, 6270
reduction by temozolomide, 1915
malignant
DMBT1 gene polymorphisms, 1790
HCMV infection and expression, 3347
ONYX-015, xenografts, 764
YKL-40 serum marker, 4364
neural stem cell-mediated TRAIL therapy, 7170
neutron capture therapy
molecular EGFR targeting, 3159
survival
regulation by Rac, 2131
tumorigenicity
VEGF and, 1854
VEGF regulation by MT1-MMP, 580

Glioma-associated hyaluronan
iNOS induction, dendritic cells, 2583

Gliomagenesis
Ink4a-Arf loss, mouse, 5551

Glomeruloid microvascular proliferations
prognostic value, cancer, 6808

Glucose
uptake and metabolism alterations
genotoxic exposure and, 3515

Glucose-regulated protein Grp94 promoter
cancer-inducible transgene expression, 7207

Glutamine synthetase
hepatocarcinogenesis promotion, mouse, 5685

Glutathione
and brostallicin anticancer activity, 2332
tissue levels
and tumor redox status, 307

SUBJECT INDEX TO VOLUME 62

- Glutathione S-transferase μ**
GSTM1
 and lung cancer risk, 2819
- Glutathione S-transferase π**
GSTP1
 and lung cancer risk, 2819
 methylation, former smokers, 351
 polymorphisms
 and sputum promoter methylation, 2248
- Glycinamide ribonucleotide formyltransferase inhibitors**
 cytotoxicity, 5236
- Glycolipid-anchored GPI-IL-12**
 antitumor immune response, 2869
- Glycoprotein**
 fusogenic membrane
 viral
 solid tumor cell killing, 6566
 histidine-profile-rich
 antiangiogenic activity, 5344
- Glycoprotein IIb/IIIa**
 tumor growth, angiogenesis, and metastasis, 2824
- Glycosaminoglycans**
 heparin-binding VEGF substructure binding, 7118
- GnT-V:** *See N-Acetylglucosaminyltransferase V*
- Gonadotropin-releasing hormone**
 breast ribosomal phosphoprotein downregulation, 1036
- G protein-coupled receptors**
KiSS1, identification and characterization, 5399
 viral
 Kaposi's sarcoma-associated herpesvirus gene expression modulation, 4525
- G-quadruplex ligands**
 -related telomerase inhibitors
 TRAP assay, 3365
- Granulocyte colony-stimulating factor**
 recombinant human rhG-CSF
 combined with defibrotide
 stem cell mobilization, mice, 6152
- Granulocyte-macrophage colony-stimulating factor**
 -encapsulated microspheres, tumor immunotherapy, 7254
- Granzyme B**
 -mediated TCR ζ chain degradation, 4884
- Green fluorescent protein**
 GFP/TRAIL fusion protein
 targeted expression, hepatocytes, 3620
 mammary tumor labeling, transgenic mice, 7166
- Green tea catechins**
 VEGF receptor phosphorylation inhibition, 381
- GTPase**
 Rho-like
 autocrine motility factor-induced changes, 4484
- GTPase-activating protein SH3 domain-binding protein G3BP**
 induction by heregulin, breast cancer, 1251
- H**
- H19**
 $de novo$ methylation, cancer, 4545
 hypomethylation, colorectal cancer, 6442
- H37**
 lung cancer tumor suppressor gene, 3207
- Hamartoma**
 gastrointestinal
Lkb1 knockout mice, 2261
- H-cadherin:** *See CDH13*
- Head and neck cancer**
 candidate oncogene *cyclin L*, 6211
- immunotherapy
 carcinoembryonic antigen target, 5049
- Head and neck squamous cell carcinoma**
 combination IL-2 gene therapy and cisplatin, 4023
 EGFR expression, 7350
 EGFR signal transactivation, 6329
 gene expression profiling, 1184
 growth promotion by COX-2-derived PGE₂, 6706
 growth promotion by *K-ras*, 7154
 hypoxia-inducible factors, 2493
 lymphangiogenesis, 1315
p53₂₆₄₋₂₇₂-specific T cells, 3521
 radiotherapy resistance
 cyclin B1 and, 6414
 retinoblastoma 94 treatment, 4637
Stat3, 3351
 treatment outcome
 pimonidazole binding and tumor vascularization and, 7066
- Heat shock protein 60**
 $\alpha\beta 1$ integrin activation, 1541
- Heat shock protein 70**
 depletion
 tumor xenograft eradication, 7139
- Heat shock protein 110**
 recombinant HSP110-HER-2/neu vaccine, 1737
- HeLa cells**
 telomere dysfunction by hTERT COOH-terminal fragment polypeptide, 3226
- Helicobacter-induced gastric cancer**
 inhibition by *p53*-targeted disruption, 696
- Helicobacter pylori restriction endonuclease-replacing gene hrGA**
 and gastric cancer, Asians, 2385
- Helper T lymphocytes**
CD4+
 EBNA1 peptides, 7195
 wtp53-specific, antitumor efficacy, 6187
HPV16 E2-specific responses, 472
NY-ESO-1 119–143 epitope, 213
- Hematological malignancy**
BMI-1 amplification and overexpression, 618
hMSH2 germ-line mutations, 359
 relapse after allogeneic bone marrow transplantation, 208
- Hemostatic factors**
 and metastasis, fibrinogen-deficient mice, 6966
- Heparin**
 -binding VEGF substructure
 glycosaminoglycans binding and tumor endothelial localization, 7118
- Hepatocyte**
 partial
 recovery, Skp2-deficient mice, 995
- Hepatic arterial infusion**
 oncolytic adenovirus *dl1520*, 6070
- Hepatitis B virus**
 gene expression and, hepatocellular carcinoma, 3939
 -related female hepatocarcinogenesis
 androgen receptor CAG repeat, 4346
- Hepatitis C virus**
 gene expression and, hepatocellular carcinoma, 3939
- Hepatocarcinogenesis**
 genetic control, rat, 4459
 HBV-related female
 androgen receptor CAG repeat, 4346
 promotion
 glutamine synthetase, mouse, 5685
- Hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I**
 pancreatic ductal adenocarcinoma, 1868
- Hepatocellular carcinoma**
 gene expression patterns
 virus type linkage, 3939
 growth
 anchorage-independent
 PI3K/Akt pathway, 2971
 inhibition by arginine deiminase, 5443
Ku80 heterozygosity and, PARP-1^{-/-} mice, 6990
Lkb1 knockout mice, 4549
 metastasis
 hematogenous
 PI3K/Akt pathway, 2971
 metastasis-associated genes, clonality delineation, 4711
 therapy
 intraarterial ATP production inhibitor, 3909
- Hepatocyte growth factor**
 β -catenin nuclear translocation induction, 2064
 tubulogenesis
N-WASP, 2503
- Hepatocyte nuclear factor 3 α gene (HNF3 α) (FOXA1)**
 amplification and overexpression, esophageal and lung adenocarcinoma, 5273
- Hepatocytes**
 targeted GFP/TRAIL expression, 3620
- Hepatoma**
 growth inhibition by acyclic retinoid, 3997
 HIF-1 β -deficient tumors, magnetic resonance studies, 688
- Hepatotoxicity**
ET-743, female rat, 4256
- HEPSIN gene**
 functions, prostate cancer, 6812
- HER-2/neu**
 17-AAG and, 3132
 active signaling, ductal carcinoma *in situ*, 6667
 androgen-independent prostate cancer, 5485
 anti-HER2 trastuzumab
 synergy with T cells, 2244
 antifrat new virosomes, cancer therapy, 437
BRCA1-associated breast cancer, 1481
 cell growth
 inhibition by EGCG, breast cancer, 652
 expression, gastrinoma, 3702
 induced breast cancer
 reduction by celecoxib, 5405
 recombinant HSP110-HER-2/neu protein, 1737
 transformation
 cyclin D1 rate-limiting effects, 2267
- Herceptin:** *See Trastuzumab*
- Heredity leiomyomatosis**
FH mutations, 4554
- Heredity nonpolyposis colorectal cancer**
 breast cancer tumor exclusion, 1014
hExo1 mutation alterations, 6026
hMSH2 and *hMLH1* promoter region germline mutations, 38
MLH1 hypermethylation, 3925
MSH2 inactivation, 848
- Heregulin**
 G3BP induction, breast cancer, 1251
- Herpes simplex virus**
 amplicon
 -mediated combined SLC/CD40L-mediated immunotherapy, antitumor activity, 6545
 oncolytic, antitumor effects, 2306
- Herpesvirus**
 Kaposi's sarcoma-associated
 viral G protein-coupled receptor
 gene expression modulation, 4525

- 5-HETE** PC-3 cell stimulation, 6817
- High mobility group A2** expression and TSC2 loss, uterine leiomyoma, 3766 overexpression, pituitary adenomas, 2398
- High mobility group I(Y)** and chromosomal rearrangements, prostate cancer, 647
- Histidine-profile-rich glycoprotein** antiangiogenic activity, 5344
- Histone acetyltransferase** p300/CBP downregulation and melanocyte senescence, 6231 regulation by polyamines, murine skin and tumors, 67
- Histone deacetylase** class I inhibition by FK228, mechanism, 4916 estrogen-responsive element-targeted antiestrogen activity, 6519 regulation by polyamines, murine skin and tumors, 67
- Histone deacetylase 5** growth inhibition and apoptosis induction, 2913
- Histone H3** phosphorylation, mouse fibroblasts, 75
- Histone H4** *H4/BCL6* fusion gene, B-cell non-Hodgkin's lymphoma, 6224
- Histone H3-lysine 9** methylation, cancer, 6456
- Histone modifications** dependence on DNA hypermethylation, 7213
- Hodgkin's disease** SGN-30 antitumor activity, 3736
- Homeobox gene HOXC11** *NUP98-HOXC11* fusion gene, t(11;12) acute myeloid leukemia, 4571
- Homeobox gene HOXD11** *NUP98-HOXD11* fusion gene, t(2;11)-acute myeloid leukemia, 33
- Homology-directed repair**, 1279
- Hormones** VEGF regulation, breast cancer, 1948
- Host-derived matrix metalloproteinase** expression, multiple-organ metastasis, 5967
- HPPI gene** aberrant methylation, ulcerative colitis-associated colorectal cancer, 6820 hypermethylation, gastric adenocarcinoma, 5637
- Human endogenous retrovirus** CTL-recognized retroviral melanoma antigen, 5510
- Human ether-a-go-go related gene (HERG) potassium channel** tumor cell apoptosis and growth regulation, 4843
- Human kallikrein hK2** preoperative RT-PCR-hK2 status and prostate cancer progression, 5974
- Human kallikrein hK11** prostate and ovarian carcinoma biomarker, 295
- Human lymphocyte antigen** class I LAK-T cell activity inhibition, 480
- Human lymphocyte antigen-A*0201** HPV16 tumor model, 5792
- Human lymphocyte antigen DP3** -restricted EBNA1 peptides, T helper, 7195
- Human lymphocyte antigen DR7** -restricted epitopes and hTRT, 2600
- Human papillomavirus 16** and chromosome instability, 7075 E6 E6TP1 degradation mediation by E6AP ubiquitin ligase, 3315 -immortalized tumor cells combination HPV-16 E7 and CpG-ODN immune therapy, 7234
- E7 combined with CpG-oligodeoxynucleotide, immune therapy, 7234 -immortalized tumor cells combination HPV-16 E7 and CpG-ODN immune therapy, 7234 plant-derived tumor protection, 3654
- E2-specific Th responses, 472 gene expression changes, cervical keratinocytes, 6959
- HLA-A*0201 HPV16 tumor model, 5792 PUFAAs and skin cancer, transgenic mice, 433
- Human papillomavirus JCV** and colon cancer, 7093
- Human T-cell leukemia virus type 1** infection gene expression profiles, 3562
- Humoral immune response** gemcitabine and, 2353
- Hyaluronan** glioma-associated iNOS induction, dendritic cells, 2583
- HA-CD44s and MMP-2 secretion, lung cancer, 3962 levels, malignant epithelial ovarian tumors, 6410
- Hyaluronic acid** -induced invasion inhibition by PTEN, glioblastoma, 6318
- Hyaluronidase** activity, malignant epithelial ovarian tumors, 6410
- Hydrogen-ATP synthase** β -catalytic subunit β -F1-ATPase inhibition, carcinoma, 6674
- Hydrogen peroxide** tumor-targeted generation with pegylated DAO, 3138
- N-Hydroxy-4-acetylaminobiphenyl** mutations, 4325
- Hydroxyflutamide** MAP kinase activation, prostate cancer, 6039
- 8-Hydroxyguanine** human *hOGG1* variants and prostate cancer, 2253 repair defects, breast cancer, 1349
- 8-Hydroxyguanosine** defective repair, colorectal cancer, 7230
- 7-Hydroxystauroporine** Chk2 activity inhibition, 5743
- 3 β -Hydroxysteroid dehydrogenase HSD3B genes** and prostate cancer susceptibility, 1784
- Hypermethylated in cancer (HIC-1) gene** hypermethylation, medulloblastoma, 3794
- Hypermethylation** -associated *CRB1* gene inactivation, cancer, 5902 bronchial epithelium and sputum, smokers, 2370
- DAPK*, bladder cancer, 4048
- HIC-1*, medulloblastoma, 3794
- hMLH1*, gastric adenocarcinoma, 5637
- HPPI*, gastric adenocarcinoma, 5637
- MLH1*, hereditary nonpolyposis colorectal cancer, 3925
- p14^{ARF}*, colitis-associated tumors, 1148
- TRAIL** decoy receptors DcR1 and DcR2, tumors, 2157
- Hyperplasia** myelogenous *NQO1* disruption, mice, 3030
- Hypoestoxide** mechanism of action, 4007
- Hypomethylation** methioninase, 4685
- Hypoxia** *afp* gene expression downregulation, 1158 cyclin D1 regulation VHL-mediated, renal cell carcinoma, 3014 *EGFR* gene expression induction by *Egr-1*, 827 and lymph node metastasis, melanoma, 1847 *MDRI* induction, 3387 tumor cell radiosensitization by dodecafluoropentane, 3626
- Hypoxia-inducible factor** expression, renal cell carcinoma, 2957
- Hypoxia-inducible factor 1** induction by desferri-exochelin, 6924 inhibitors, identification, 4316 *MDRI* regulation, 3387
- Hypoxia-inducible factor 1 α** head and neck squamous cell carcinoma, 2493 increase by thioredoxin-1, 5089 inhibition by geldanamycin, prostate cancer, 2478 tumorigenesis, 2962
- Hypoxia-inducible factor 1 β** -deficient tumors, magnetic resonance studies, 688
- Hypoxia-inducible factor 2** induction by desferri-exochelin, 6924
- Hypoxia-inducible factor 2 α** expression, breast tumor macrophages and angiogenesis, 1326 head and neck squamous cell carcinoma, 2493

I

- 3-IAABE:** *See* 3-Iodoacetamido benzoyl ethyl ester
- Icat gene** growth inhibition, colon cancer, 3322
- IC1 182,780:** *See* Faslodex
- Id2** development and neuroblastoma prognosis, 301
- Idiotype** chimeric DNA vaccination, B-cell lymphoma, 5845
- IGH gene** rearrangements, B-cell non-Hodgkin's lymphoma, 5523
- Imatinib (ST1-571, Gleevec)** apoptosis induction, Bcr/Abl-expressing leukemia, 188 and Bcr-Abl-positive acute leukemia, 5761 c-Abl complex kinase domain crystal structures, 4236 colorectal cancer therapy, 4879 -resistant Abl mutants PD180970 activity against, 7149
- Immortalization** *Bmi-1*, mammary epithelial cells, 4736
- E6/E7 combination HPV-16 E7 and CpG-ODN immune therapy, 7234
- immortal DNA strand co-segregation, 6791
- mammary epithelial cells, characterization, 89

- Immune responses**
 antitumor
 augmentation, lymphoplastic hosts, 3914
 GPI-IL-12, 2869
 humoral
 gemcitabine and, 2353
- Immunodeficiency**
 immunodeficient nonobese diabetic mice
 lymphoid neoplasia, 5828
- Immunoglobulin G**
 anti-rhCEA IgG subclass response, immunized colorectal cancer patients, 1364
 B7.2-IgG fusion protein
 combined with SU6668, breast tumor therapy, 5727
- Immunotherapy**
 antirat neuvirosomes, 437
 carcinoembryonic antigen target, head and neck cancer, 5049
 combination HPV-16 E7 and CpG-ODN, 7234
 combined secondary lymphoid tissue chemokine/CD40L-mediated, antitumor activity, 6545
 cytokine-encapsulated microspheres, 7254
 EBV peptide-pulsed dendritic cell, nasopharyngeal carcinoma, 6952
 IL-10
 mediation by Mig and IP-10, 2606
 IL-18 gene-transduced dendritic cell-based vaccines, 5853
 large tumor
 anti-4-1BB mAb and, 3459
 laser
 metastatic tumor treatment components, 4295
- Immunotoxins**
 scFv
 CD7-exotoxin, acute leukemia, 2848
- IND 12**
 Ras-induced cell transformation reversal, 1718
- Inducible protein 10**
 IL-10 tumor inhibition mediation, 2606
- Infant leukemia, acute myeloid**
 t(X;11)(q24;q23)
 MLL-SEPTIN6 fusion, 333
- Infarction**
 tumor
 selective, 5470
- Infection**
 HTLV-1
 gene expression profiles, 3562
 human cytomegalovirus, malignant glioma, 3347
- Infiltrating breast cancer**
 desmoplastic response, 5351
- Inflammation**
 microenvironment
 tumor therapy and, 1462
- Inflammatory breast cancer**
 herceptin rapid accumulation and internalization, 860
 vasculogenic mimicry hemodynamics, 560
- Information degradation**
 and carcinogenesis, 3675
- ING1**
 age-dependent properties, 4445
 detection by cDNA microarray, mouse mammary epithelial cells, 2203
 mouse homologue mINGh
 A1 interactions, 1275
- ING1b**
 p53 regulation, 4890
- Inhibitor of apoptosis IAP1**
 cIAP1
 expression, cervical cancer, 4860
- INII gene**
 rhabdoid tumors, meeting report, 323
- Ink4a/Arf gene**
 deficiency
 and UV-induced melanomagenesis, 6724
 loss, mouse gliomagenesis, 5551
- Instabilityotyping**
 gastric cancer, 3641
- Insulin**
 radiation response modulation, 3555
- Insulin-like growth factor**
 binding protein 1
 cell motility inhibition, breast cancer, 4369
 binding protein 3
 growth inhibition, non-small cell lung cancer, 3530
 receptor I
 anti-EGFR therapy resistance mediation, glioblastoma, 200
 expression, prostate cancer, 2942
 signaling blockade by proinflammatory cytokines, breast cancer, 4746
- Insulin-like growth factor I**
 and COX-2 inhibitor anti-proliferative effects, pancreatic cancer, 7372
 growth and metastasis regulation, colon cancer, 1030
 receptors
 metastatic phenotype and, breast cancer, 6529
 signaling
 ICI 182,780 growth inhibition and, 3985
- Insulin-like growth factor II**
 IGF2 hypomethylation
 loss of imprinting and, colorectal cancer, 6442
- Insulin receptor substrate 1**
 activation, tumors, 6035
- Integrin**
 tumor angiogenesis, nude rats, 6289
 $\alpha_5\beta_1$ Integrin
 activation by heat shock protein 60, 1541
 $\alpha_5\beta_1$ Integrin
 endostatin association, endothelial cells, 5580
 $\alpha_5\beta_3$ Integrin
 -binding peptides
 radiolabeled, tumor targeting, 6146
 tumor growth, angiogenesis, and metastasis, 2824
 α_2 Integrin
 inhibition by E7820, endothelium, 6116
 β_1 Integrin
 fibrillar adhesion formation
 VHL role, 2929
 glycosylation
 GnT-V and, 6837
 β_3 Integrin
 osteonectin induction, melanoma, 226
- Intercellular adhesion molecule-2**
 anti-ICAM-2 mAb, ICAM-2+ colon cancer, 3167
- Interferon α -2b**
 pegylated
 combined with docetaxel
 prostate cancer inhibition, nude mice, 5720
- Interferon β**
 tumor delivery
 mesenchymal stem cells, 3603
- Interferon γ**
 CD137 mAb-mediated antitumor effects, 4413
 and CD8 $^+$ T-cell-mediated tumor killing, mice, 5058
 -dependent phagocytic cells
- tumor growth regulation, metastatic mammary carcinoma, 4406
 IL-12-mediated tumor rejection, 4696
 monokine induced by (Mig)
 IL-10 tumor inhibition mediation, 2606
- Interferon regulatory factor 1**
 and faslodex resistance, 3428
- Interferon regulatory factor 2**
 cell growth deregulation, 2510
- Interferon regulatory factor 3**
 tumor suppressor activity, B16 melanoma, 5148
- Interferon stimulated gene 15**
 and dendritic cell phenotype, melanoma, 3453
- Interleukin 1 α**
 induction by DMBA, 417
- Interleukin 1 β**
 and chemoresistance, pancreatic cancer, 910
- Interleukin 2**
 gene therapy
 combined with cisplatin, head and neck squamous cell carcinoma, 4023
- Interleukin 3**
 DT₃₈₈IL3 fusion protein
 acute myeloid leukemia stem cell cytotoxicity, 1730
- Interleukin 4**
 inhibition by IL-13R α 2, glioblastoma, 1103
 receptors
 pancreatic cancer therapy, 3575
- Interleukin 6**
 androgen receptor transactivation
 mediation by p300, 5632
 production, renal cell carcinoma, 932
- Interleukin 8**
 and bone metastasis, breast cancer, 5571
- Interleukin 10**
 tumor inhibition
 mediation by Mig and IP-10, 2606
- Interleukin 12**
 antitumor effects absent IFN- γ , 4390
 -encapsulated microspheres, tumor immunotherapy, 7254
 glycolipid-anchored GPI-IL-12
 antitumor immune response, 2869
- Neural stem cells, glioma therapy, 5657**
- Tumor growth and angiogenesis inhibition, mammary carcinoma, 747**
- Tumor rejection**
 effector mechanism, 5069
 IFN- γ , 4696
- Interleukin 13**
 receptor α 2
 IL-4 signaling inhibition, glioblastoma, 1103
- Interleukin 18**
 gene transfer
 dendritic cell-based vaccine, immunotherapy, 5853
- International consensus statement**
 malignant peripheral nerve sheath tumors, neurofibromatosis 1, 1573
- Interstitial fluid pressure**
 and metastasis, melanoma, 661
- Intestinal epithelial cells**
 K-Ras transformation
 modulation by PPARs, 3282
- Intestinal neoplasia, multiple**
 Apc^{min} mice
 tumor load reduction by vitamin D₃ compounds, 741
 Apc^{Mut $^+$} mice
 microadenomatous lesions, colon, 6367
 PGE₂ modulation of NSAID effects, 403
 Apc^{Mut $^+$} , CASTB6F1 Mom1^{S/S} mice
 polyp multiplicity, 5413

SUBJECT INDEX TO VOLUME 62

- Apc^{Min/+} Dnmt1-hypomorphic mice**
polyp inhibition, 1296
- Min mice**
CEA-based vaccine antitumor activity, 6944
cyclin D1, 4562
- Intestinal polyps**
COX-2 expression, 6846
malignant progression
Smad2 null mutation and, *Apc*^{Δ716} knockout mice, 4558
- Intestinal tumorigenesis**
cyclin D1, Min mice, 4562
- Intestinal tumors**
angiogenesis, mouse models, 506
invasive, *Apc/Smad2* compound mutant mice, 5955
- Intestinal-type gastric cancer**
gene expression profiles, 7012
- Intra-abdominal malignancy**
advanced
proliferation assessment by PET, 5698
- Intraepithelial neoplasia, prostatic**
FGF8b mouse model, 5096
inhibition by 9-cis-retinoic acid, rats, 5178
RXRα allele inactivation, prostate epithelium, 4812
- Invasion:** See also **Cell migration**
Apc/Smad2 compound mutant mice, 5955
cadherin-11 and, breast cancer, 6688
genes
activation by EGFRvIII, 3335
hyaluronic acid-induced inhibition by PTEN, glioblastoma, 6318
inhibition
alendronate, prostate cancer, 2708
HEPSIN, prostate cancer, 6812
nobiletin, fibrosarcoma, 1025
temozolomide, glioma, 1915
lysyl oxidase, breast cancer, 4478
promotion
 bombesin, colon cancer, 4829
 SPARC, glioma, 6270
 VEGF CXCR4 regulation, breast cancer, 7203
suppressor gene RhoGDI2, 6418
- Invasive bladder cancer**
piroxicam effects, canine model, 356
- Invasive breast cancer**
Wnt-5a loss of expression, 409
- 3-Iodoacetamido benzoyl ethyl ester**
new cancercidal tubulin ligand, 6080
- Ionizing radiation:** See also **Radiation**
α-particle
 bystander effects
 oxidative metabolism and, fibroblasts, 5436
endothelium response
 PI3K/Akt signaling, 4671
-induced NO, endothelial apoptosis induction, 1450
Ku G₂ checkpoint effects, 6031
mutagenesis, solid tissue, 1518
sensitivity
 modulation by insulin, 3555
S-phase checkpoint
 Brcal requirements, 4588
- Irinotecan**
combined with celecoxib
anticancer/antidiarrhea effects, 5778
diarrhea
 prevention, 179
- Ishikawa endometrial adenocarcinoma**
stromal regulation, 79
- J**
- JCV**
and colon cancer, 7093
- Jnk1**
deficiency
 gene expression profile, murine fibroblasts, 1300
- Jnk2**
deficiency
 gene expression profile, murine fibroblasts, 1300
- K**
- Kallikrein**
human hK2
 preoperative RT-PCR-hK2 status and prostate cancer progression, 5974
- human hK11, prostate and ovarian carcinoma, 295
- Kaposi's sarcoma**
-associated herpesvirus viral G protein-coupled receptor
 gene expression modulation, 4525
oxytocin growth factor, 2406
- Karyotypes**
breast cancer, multivariate analysis, 2675
multivariate analysis, colorectal cancer, 5939
- Keratinocytes**
TP53-inactive
 NF-κB activation in, 1213
- Kidney disease**
polycystic
 c-myc-induced apoptosis, 2210
- Kin17**
T antigen interactions and replication inhibition, 5425
- Kiss1**
G protein-coupled receptor, identification and characterization, 5399
identification and characterization, 5399
- K-ras**
expression, head and neck squamous cell carcinoma, 7154
mutations, colorectal tumors, 6451
transformation
 modulation by PPARs, intestinal epithelial cells, 3282
- Ku**
and Ataxia and Rad3-related/CHK1-dependent S checkpoint, 2483
G₂ checkpoint effects, ionizing radiation, 6031
- Ku80**
heterozygosity
 and hepatocellular carcinoma, PARP-1^{-/-} mice, 6990
- Ku86**
antisense effects, malignant glioma, 5888
- KU-MEL-1**
identification, 4836
- L**
- LacI**
mutations
 electromagnetic near field, mice, 1956
- Lactate dehydrogenase C**
splice variants, cancer, 6750
tumor-specific transcripts, 6750
- Laminin**
metastasis, 3549
receptor
 67-kDa and cell motility, 1321
- Laminin-1**
-induced acinar differentiation
 promotion by metallothionein, 5370
- Large cell lymphoma**
anaplastic
 NPM-ALK expression downregulation by 17-AAG, 1559
- Laser capture microdissection**
mtDNA mutations, prostate cancer, 6470
- Laser immunotherapy**
metastatic tumor treatment components, 4295
- LCX (leukemia-associated protein with CXXC domain)**
MLL-LCX fusion, acute myeloid leukemia with trilineage dysplasia, 4075
- Lecithin:retinol acyltransferase**
reduction, prostate cancer, 1654
- Leiomyoma**
uterine
 HMGA2 expression and TSC2 loss, 3766
- Leiomysomatosis**
hereditary
 FH mutations, 4554
- Lentivirus**
gene transfer, ovarian cancer, 6099
- Letters to the editor**
- re: A. H. Ree *et al.*, 59: 4675–4680, 4164
 - re: A. Kumar *et al.*, 61: 7552–7555, 2192
 - re: C-H. Kao *et al.*, 61: 1412–1414, 617
 - re: D. Zimonjic *et al.*, 61: 8838–8844, 6345
 - re: G. Anderson *et al.*, 61: 8274–8283, 6350
 - re: J. Mora *et al.*, 61: 6892–6898, 2986
 - re: P. Laiho *et al.*, 62: 1166–1170, 5988
 - re: S. Beá *et al.*, 61: 2409–2412, 618
 - re: Y. Kiniwa *et al.*, 61: 7900–7907, 4836
- Leukemia**
- acute
 - Bcr-Abl-positive
 - ST1-571 and, 5761
 - CD7-exotoxin effects, 2848
 - EWSR1-CIZ* fusion, 5408
 - induction by TEL-AML1, mice, 3904
 - TAF15-CIZ* fusion, 5408
 - apoptosis induction by WK175, 1057
 - Bcr/Abl-expressing
 - apoptosis induction, 188
 - BCR/ABL mutations, 5995
 - blast cross-presentation by pulsed dendritic cells, 2861
 - myeloid
 - aberrant double-strand break repair, 2791
 - SHPI* aberrant methylation, 6390
 - T-cell
 - adult
 - PS-341 therapy, murine model, 1083
 - Leukemia, acute lymphoblastic**
 - B-cell
 - early
 - steroid-induced apoptosis, 4212
 - Leukemia, acute myeloid**
 - associated fusion proteins
 - differentiation blockade, 7050
 - MDRI* polymorphisms, 4955
 - Runx1/AML-1* gene
 - T-cell lymphoma role, 7181
 - stem cells
 - DT₃₈₈IL3* cytotoxicity, 1730
 - t(2;11)*
 - NUP98-HOXD11* fusion gene, 28
 - t(11;12)(p15; q13)*
 - NUP98-HOXC11* fusion gene, 4571
 - trilineage dysplasia
 - MLL-LCX* fusion gene, 4075
 - t(X;11)(q24;q23)*
 - infant
 - MLL-SEPTIN6* fusion, 333
 - Leukemia, acute promyelocytic**
 - CD2* gene expression regulation, 4730
 - differentiation induction treatment, meeting report, 5618
 - Leukemia, chronic lymphocytic**
benzylamide sulindac analogue effects, 5711

SUBJECT INDEX TO VOLUME 62

- Leukemia, chronic myelogenous**
candidate vaccine, rAAV dendritic cell-targeted, 3175
- Leukemogenesis**
core binding factor β -smooth muscle myosin heavy chain and G_i acceleration, mice, 2232
- Leukocytes**
immunized donor leukocyte infusion tumor vaccine enhancement, 796
- Leukotriene pathway inhibitors**
carbamate-induced lung tumor chemoprevention, mice, 4199
- LGD1069**
ER-negative mammary tumor development prevention, mice, 6376
- Lipids**
mobile compartment dimensions, C6 cells, 5672
NMR-visible accumulation, 1394
- Liposarcoma**
genomic and expression profiling, 2993
- Liposomes**
antibody-targeted drugs targeting to internalizing antibodies, 7190
cationic, novel liver metastasis inhibition, 4282
doxorubicin antivascular effects, rat brain tumor model, 2561
EIA gene, systemic therapy, 6712
tumor distribution, 6831
- Lipoxygenase**
carbamate-induced lung tumor chemoprevention, mice, 4199
- 12-Lipoxygenase**
induction by fenretinide, 5158
inhibition, prostate cancer, 2721
- 12S-Lipoxygenase**
epidermis-type e12S-LOX, mouse skin tumorigenesis, 4610
- 15-Lipoxygenase-1**
upregulation by NSAIDs, colorectal cancer, 1178
- Listeria monocytogenes vaccines**
CNS tumor immunity induction, 2287
- Liver**
breast cancer metastasis -specific adenovirus vector, 1063
 β -catenin mutation, stable, 1971
colorectal cancer metastasis inhibition by C-raf antisense oligonucleotides, 5393
metastasis inhibition by novel cationic liposomes, 4282
-specific adenovirus vector, 1063
TNF-Rp55 knockout mice, 6682
vinyl chloride-induced adducts, rat, 5183
- Lkb1 gene**
inactivation, lung adenocarcinoma, 3659
knockout mice gastrointestinal hamartoma, 2261
hepatocellular carcinoma, 4549
- LMP:** See **Low molecular mass polypeptide**
- LNCaP cells**
apoptosis Smac, 18
apoptosis induction by raloxifene, 3649
PI3k/PTEN/Akt kinase and fatty acid synthase, 642
- Lometrexol:** See **(6R)-Dideazatetrahydrofolate**
- Loss of heterozygosity:** See also **Deletions**
BRCA1-BRCA2 mutation carrier breast cancer, 2741
- carcinogen-induced, lung tumorigenesis, 6424
and second oral malignancy, oral cancer, 6447
stage II non-small cell lung cancer, 2681
VHL-associated pancreatic islet cell tumors, 1952
- Loss of imprinting**
colorectal cancer, 6442
- Low molecular mass polypeptide**
knockout mice uterine tumors, 24
- lRib:** See **2-Deoxy-l-ribose**
- Lung**
epithelium asbestos-induced proliferation inhibition by mutant EGFR, 4169
nodules FLT-PET, 3331
sialyl Lewis X antigen-dependent colonization, melanoma, 4194
- Lung adenocarcinoma**
allelic imbalance, nonsmokers, 4464
BRAF mutations, 7001
chromosomal alterations, mouse, 1152
expression analysis, 3244
HNF3 α (*FOXA1*) amplification and overexpression, 5273
LKB1/STK11 inactivation, 3659
metastases pulmonary ZD6126 effects, 3711
- Lung cancer**
APC promoter methylation, 371
apoptosis induction by Ad-mda-7, 2239
apoptosis induction by CD437, 2430
BRAF and RAS mutations, 6997
bronchioloalveolar feline, comparative studies, 3826
cancer/testis antigen gene expression, 3971
C/EBP α downregulation, 528
chemoprevention by prostaglandin I₂ synthesis overexpression, murine, 734
diagnosis gene ratios, 4963
ERCC2 polymorphisms and smoking and, 1377
HA-CD44s and MMP-2 secretion, QG90 cells, 3962
metastasis multiple-organ host-derived MMP expression, 5967
prognosis syndecan-1 and bFGF and, 5210
RAR β loss, 3945
risk DNA-methyltransferase-3B promoter polymorphism and, 4992
GSTM1, and *GSTM1*, and *p53* combinations and, 2819
MMP2 single nucleotide polymorphism and, 6430
SEREX approach, new, 1751
susceptibility *bcl-2* and, rat, 6297
- TSLC1** and DAL-1 association, 5129
- tumor suppressor gene *H37*, 3207
- Lung cancer, non-small cell**
angiopoietin expression, clinical significance, 7124
array-based comparative genomic hybridization, 3636
cell death by discodermolide and epothilone B, 4081
estrogens, 2141
growth inhibition by IGFBP-3, 3530
molecular classification, 3005
- 90K (Mac-2 binding protein), 2535
stage II allele loss, 2681
TRAIL-/induced apoptosis PI3K/PTEN/Akt kinase pathway, 4929
transcriptome map, 3340
- Lung cancer, small cell**
cell migration and adhesion regulation by CXCR4 and c-Kit, 6304
14-3-3 ϵ deletion and *G₂* checkpoint defects, 271
oxytocin functional signaling, 4623
- Lung tumorigenesis**
B(a)P-induced inhibition by dietary BITC-NAC and PEITC-NAC, A/J mice, 2
carcinogen-induced loss of heterozygosity, mouse, 6424
reduction by iNOS deficiency, mouse, 6850
- Lung tumors**
carbamate-induced chemoprevention, mice, 4199
- Lymphangiogenesis**
head and neck squamous cell carcinoma, 1315
- Lymphatic drain**
peritumor VEGF-induced, MR mapping, 6731
- Lymphatic metastasis**
fibrinogen-deficient mice, 6966
- Lymph nodes**
gastric cancer metastasis CCR7 expression, 2937
metastasis hypoxia and, melanoma, 1847
- Lymphocytes**
chromosome instability and oral premalignant lesions, 2813
peripheral blood micronuclei and pleural malignant mesothelioma susceptibility, 5418
- Lymphocyte transgene Lptn**
gene transfer combined with adoptive T-cells, 2043
- Lymphoid neoplasia**
immunodeficient nonobese diabetic mice, 5828
- Lymphokine-activated killer-derived T cells**
inhibition by HLA class I molecules, 480
- Lymphoma**
anaplastic large cell NPM-ALK expression downregulation by 17-AAG, 1559
- B-cell**
candidate tumor suppressor gene, chromosome 15q15, 7175
CD40L-transduced tumor cell vaccine, 3195
DNA vaccination, 5845
- Burkitt**
MCL1-overexpressing response to death stimuli, 892
- mantle cell**
BMI-1 amplification and overexpression, 618
- SHPI** aberrant methylation, 6390
- T-cell**
cutaneous *Fas* splice variant, 5389
DNA vaccines against, 1757
epitope hierarchy subversion, 1116
MMP inhibitor specificity/efficacy correlation, 5543
ROR γ -deficient mice, 901
Runx1/AML-1 role, 7181
- thymic

SUBJECT INDEX TO VOLUME 62

- prevention by dexamethasone, *Atm*-/- mice, 5153
- Znfl1a/Ilkaros* alterations, murine, 2650
- Lymphoma, non-Hodgkin's**
- B-cell
 - BCL-6* alternative breakpoint region, 4089
 - cryptic *IGH* rearrangements, novel, 5523
 - H4/BCL6* fusion gene, 6224
 - translocation t(3;6)(q27 aJ1) breakpoints, 6224
 - CXCR4 neutralization, 3106
- Lymphomagenesis**
- murine model, 5536
- Lymphoplastic hosts**
- antitumor immunity augmentation, 3914
- Lymphotxin- β receptor**
- angiogenesis induction, 4034
- Lysine 9**
- methylation, cancer, 6456
- Lysophosphatidic acid**
- cell migration
 - inhibition by alendronate, ovarian cancer, 6015
- Lysyl oxidase**
- breast cancer invasion, 4478
- M**
- Mac-2 binding protein**
- non-small cell lung cancer, 2535
- Macrophages**
- HIF-2 α expression
 - and angiogenesis, breast tumor, 1326
 - placental growth factor survival factor, 2749
 - tumor-infiltrating
 - and tumor angiogenesis, 7042
- Madin-Darby canine kidney cells**
- proMT3-MMP processing by furin, 675
- MAGE-A genes**
- expression, disseminated tumor cells, 251
- Magnetic field exposure**
- cell proliferation, rat mammary gland, 1356
- Magnetic resonance imaging**
- HIF-1 β -deficient tumor studies, 688
 - mapping
 - VEGF-induced peritumor lymphatic drain, 6731
 - pancreatic cancer, transgenic mouse model, 1555
- Major histocompatibility complex**
- class I
 - ligand analysis and gene expression profiling, 5818
 - related chain A recognition by NKG2D, tumors, 6178
 - class I and class II dual-specific peptides, 3630
 - class II-restricted mutated neo-PAP recognition, 5495
- Major vault protein MVP/LRP**
- and drug resistance, murine, 7298
- Malignancy**
- astrocytoma
 - cell migration promotion by brain os-teopontin, 5336
 - conversion, VHL tumorigenesis, 1952
 - epithelial ovarian cancer
 - hyaluronan levels, 6410
 - hyaluronidase activity, 6410
 - glioblastoma
 - CD70 immune escape pathway, 2592
 - glioma
 - DMBT1* gene polymorphisms, 1790
 - CMV infection and expression, 3347
 - ONYX-015, xenografts, 764
 - YKL-40 serum marker, 4364
 - hematological
 - BMI-1* amplification and overexpression, 618
- hMSH2** germ-line mutations, 359
- relapse after allogeneic bone marrow transplantation, 208
 - inhibition by EphA2 antibody targeting, 2840
- intestinal polyp progression
- Smad2* null mutation and, *Apc*^{Δ716} knockout mice, 4558
- intra-abdominal
- advanced
 - proliferation assessment by PET, 5698
- melanoma
- metastasis to brain
 - VEGF-A₁₆₅ vascularity effects, 341
 - MIA downregulation by COOH-terminal binding protein, 5962
- MMP-2 release from fibroblasts, 283
- peripheral nerve sheath tumors
- neurofibromatosis 1
 - international consensus statement, 1573
- pleural mesothelioma
- EGFR inhibition, 5242
 - susceptibility
 - peripheral blood lymphocyte micronuclei and, 5418
- prostate tumor progression
- FGFR1 phosphorylation 766, 1898
 - second oral
 - loss of heterozygosity and, 6447
 - transformation
 - ΔTA-p73, 3598
- Mammary carcinogenesis**
- inhibition by resveratrol, rats, 4945
- Mammary carcinoma:** *See also Breast cancer*
- gene expression profiles
 - etiology-specific, rat, 3592
 - growth and angiogenesis inhibition by IL-12, 747
 - metastatic
 - growth regulation by IFN- γ -dependent phagocytic cells, 4406
 - single cell behavior correlation with gene expression patterns, 6278
 - Ras organ specificity, 1241
 - solitary
 - and dormancy, 2162
- Mammary epithelial cells**
- immortalization by *Bmi-1*, 4736
 - immortalized, characterization, 89
 - ING1* target gene detection by cDNA microarrays, mouse, 2203
 - MEK1 signaling and, Eph4 cells, 4781
 - psoriasin expression, 43
 - transformation by PDK1, 3538
- Mammary gland**
- cell proliferation
 - magnetic field-induced, rat, 1356
 - matrilysin selection for apoptosis resistance, 5559
- Mammary tumorigenesis**
- aurora A, rat, 4115
- Mammary tumors**
- estrogen-dependent
 - Cimicifuga* extract effects, 3448
 - estrogen receptor-negative
 - development prevention by LGD1069, mice, 6376
 - green fluorescent protein labeling, transgenic mice, 7166
 - growth inhibition
 - adenoviral endostatin delivery, transgenic mice, 3934
 - onset delay by ER α removal, 2798
 - p21^{WAF1/CIP1} deficiency, mouse, 2077
 - photodynamic therapy
 - antivascular effects, 2151
- Mantle cell lymphoma**
- BMI-1* amplification and overexpression, 618
 - transcriptional profiling, 4398
- Mapping**
- magnetic resonance
 - VEGF-induced peritumor lymphatic drain, 6731
- redox**
- RIF-1 tumor tissue, 307
 - transcriptome, non-small cell lung cancer, 3340
- Matrilysin**
- apoptosis resistance selection, mammary cells, 5559
- Matrix metalloproteinase**
- host-derived, multiple-organ metastasis, 5967
 - inhibitors
 - specificity/efficacy correlation, T-cell lymphoma, 5543
 - membrane-type 1
 - VEGF regulation, glioma, 580
- Matrix metalloproteinase 1**
- 2G single nucleotide polymorphism, 7200
- Matrix metalloproteinase 2**
- release from fibroblasts on malignant cell contact, 283
 - secretion
 - HA-CD44s and, lung cancer, 3962
 - single nucleotide polymorphism and lung cancer risk, 6430
- Matrix metalloproteinase 7:** *See Matrilysin*
- Matrix metalloproteinase 9**
- regulation by translational efficiency, murine prostate cancer, 1910
- MCAM/MUC18**
- human anti-MUC18
 - growth and metastasis inhibition, melanoma, 5106
- Mel-1**
- degradation
 - inhibition by bile acids, 6500
 - overexpression
 - response to death stimuli, 892
- mdmx (mdm4)**
- p53 regulation, 3221
- Measles virus**
- ovarian cancer therapy, 4656
- Medulloblastoma**
- epigenetic *RASSF1A* gene inactivation, 5906
 - HIC-1* hypermethylation, 3794
 - induction by Shh, mice, 6385
 - inhibition by DNA ligase IV, 6395
- Meeting reports**
- AACR Special Conference on Molecular Imaging in Cancer: Linking Biology, Function, and Clinical Applications *In Vivo*, 2195
 - AACR special meeting "Colon Cancer: Genetics to Prevention," 6779
 - blood vessel leakiness in cancer, 5381
 - epigenetic disease mechanisms, 6784
 - international consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis 1, 1573
 - Joint International Conference on Acute Promyelocytic Leukemia and Differentiation Therapy, 5618
 - Thirteenth Annual Pezcoller Symposium, 3883
 - workshop on childhood atypical teratoid/rhabdoid tumors, 323
- MEF**
- X chromosome tumor suppressor gene, 6579
- MEK1**
- and Eph4 mammary epithelial cells, 4781

- Melanocytes**
senescence
p300 downregulation and, 6231
survival
osteopontin, 4820
- α-Melanocyte-stimulating hormone**
p16 expression and, 875
- Melanoma**
adaptive phospholipid metabolism changes to CENU, 1890
antigen
retroviral, CTL-recognized, 5510
BRAF and RAS mutations, 6997
CD45RA⁺CCR7⁺ CTLS, 1743
cell migration, collective
plasticity, 2125
combination Ad-E2F-1 gene transfer and chemotherapy, 1776
cutaneous
cyclin D1 candidate oncogene, 3200
progression
VEGFR-3 marker, 7059
DNA electrovaccination, 5489
drug resistance, 6698
fusion tumor cell vaccines, 5495
IFN-stimulated gene 15 and dendritic cell phenotype, 3453
inhibition
arginine deiminase, 5443
human anti-MUC18, 5106
IRF-3 tumor suppressor activity, B16 tumors, 5148
lymph node metastasis
hypoxia and, 1847
malignant
metastasis to brain
VEGF-A₁₆₅ vascularity effects, 341
MIA downregulation by COOH-terminal binding protein, 5962
metastasis
carbohydrate-dependent, 4194
immune responsiveness, 3581
inhibition
human anti-MUC18, 5106
interstitial fluid pressure and, 661
PHLDA1/TDAG51 function, 5920
T-cell receptor transcripts, 5664
transendothelial function, 665
metastasis to lung
CXCR4 expression and, murine B16 cells, 7328
sialyl Lewis X antigen-dependent colonization, 4194
nocapaine treatment, murine, 4109
oncolytic adenoviruses, 4663
osteonectin induction by β_3 integrin, 226
phenotype
microphthalmia transcription factor and, 2098
risk
UVB flux and time outdoors and, 3992
tumor epitope presentation rescue by PA28, 2875
tumor progression
Akt, 7335
tumor vessel patterning
VEGF isoforms and, 1838
- Melanoma-associated antigen**
isolation by SEREX, 4836
- Melanoma differentiation-associated gene 7 (mda7)**
Ad-mda-7, mechanism of action, 2239
- Melanogenesis**
UV-induced
Ink4a/Arf deficiency and, 6724
- Membrane signaling**
radiation bystander effects, 2531
- Membrane-type 1 matrix metalloproteinase**
VEGF regulation, glioma, 580
- Membrane-type matrix metalloproteinase 3**
proMT3-MMP
processing by furin, Madin-Darby canine kidney cells, 675
- Memoriam**
Monroe E. Wall, 7377
- Memory cytotoxic T lymphocytes**
activation, 6438
- Menadione:** See Vitamin K₃
- Menopause**
Cimicifuga extract treatment
estrogen-dependent mammary tumor effects, 3448
- Mesenchymal stem cells**
IFN- β tumor delivery, 3603
- Mesothelioma**
asbestos-induced AP-1 and Fra-1, 6065
diagnosis
gene ratios, 4963
pemetrexed transporter, novel, 6434
pleural malignant
EGFR inhibition, 5242
susceptibility, peripheral blood lymphocyte micronuclei and, 5418
- Met**
expression
late-stage nasopharyngeal carcinoma, 589
regulation by Wnt signaling, colorectal cancer, 5126
- Metabolism**
inhibition response to DNA damage, 3515
- Metallothionein**
tumor differentiation regulation, 5370
- Metastasis**
bone
IL-8 expression and, breast cancer, 5571
tumor burden reduction by doxycycline, breast cancer, 1588
breast cancer to liver
-specific adenovirus vector, 1063
candidate of (com1)
expression, breast cancer cells with metastatic potential, 4164
carbohydrate-dependent, melanoma, 4194
CD44 gene effects, sarcoma, 2281
fluorescence imaging, pancreatic cancer, 1534
GP1IIb/IIIa and $\alpha\beta\beta$ integrins and, 2824
hematogenous
PI3K/Akt pathway, hepatocellular carcinoma, 2971
immune responsiveness, melanoma, 3581
inhibition
amphoterin RAGE-binding motif, 4805
bone marrow TGF- β signaling blockade, gene therapy, 7135
combination pegylated IFN- α -2b and docetaxel, prostate cancer, 5720
combination urokinase-derived Å6 and tamoxifen, breast cancer, 4678
COX-1 or COX-2 inhibitors, murine breast cancer, 2343
human anti-MUC18, melanoma, 5106
MKK4 activity, ovarian cancer, 6717
NESH, 2215
tetraethylomolybdate, 4854
interstitial fluid pressure and, melanoma, 661
laminin peptide, 3549
laser immunotherapy components, rats, 4295
liver
inhibition by C-raf antisense oligonucleotides, colorectal cancer, 5393
inhibition by novel cationic liposomes, 4282
- specific adenovirus vector, 1063
TNF-Rp55 knockout mice, 6682
lymphatic, fibrinogen-deficient mice, 6966
lymph node
CCR7 expression, gastric cancer, 2937
hypoxia and, melanoma, 1847
malignant melanoma to brain
VEGF-A₁₆₅ vascularity effects, 341
mediation by MEK1 signaling, EphH4 mammary epithelial cells, 4781
- MET** somatic mutations, 7025
- micrometastasis
growth regulation by Ras, 887
MAGE-based diagnosis, 251
- multiple-organ
host-derived MMP expression, lung cancer, 5967
osteosclerotic
breast cancer to bone
PDGF-BB and, 917
- phenotype
and IGF-IRs, breast cancer, 6529
PHLDA1/TDAG51 function melanoma, 5920
postoperative azotemia and, renal cell carcinoma, 5218
- potential
com1 expression, breast cancer, 4164
prevention
FTY720, mouse breast cancer, 1410
promotion by nonautocrine c-Met signaling, 2951
- prostate cancer to bone
stromal cell-derived factor-1/CXCR4, 1832
- pulmonary
CXCR4 expression and, murine B16 melanoma cells, 7328
prevention by angiotensin II type I antagonist, renal cell carcinoma, 4176
ZD6126 effects, lung adenocarcinoma, 3711
rate-limiting steps, real-time PCR analysis, 7083
- regulation
IFN- γ -dependent phagocytic cells, mammary cancer, 4406
IGF-I, colon cancer, 1030
single cell behavior correlation with gene expression patterns, mammary cancer, 6278
- skeletal
²²³Ra antitumor effects, 3120
- T-cell receptor transcripts, melanoma, 5664
transendothelial function, melanoma, 665
urokinase and, *in vivo*, 2390
VEGF-R and EGF-R, pancreatic cancer, 1996
- Metastasis-associated genes**
hepatocellular carcinoma, clonality delineation, 4711
- Metastasis suppressor genes**
RhoGDI2, 6418
- Methioninase**
DNA hypomethylation, 4685
- Methotrexate**
resistance
BCRP and, 5035
transport by MRP4, 3144
- 2-Methoxyestradiol**
ER α / β -independent mechanism of action, 3691
- Methoxyisobutylisonitrile**
Tc-MIBI scintimammography
Pgp/MRP expression and, 617
- α-Methylacyl-CoA racemase**
AMACR sequence variants
and prostate cancer risk, 6485

SUBJECT INDEX TO VOLUME 62

- prostate cancer, 2220
- Methylating agents**
DNMT1 protein depletion, 1592
- Methylation:** *See also* **Hypermethylation**
aberrant
 HPPI gene, colitis-associated tumors, 6820
 SHPI gene, leukemias/lymphomas, 6390
- APC gene**
 lung cancer, 371
 MSI+ endometrial cancers, 3663
- CDH13** promoter region, colorectal adenoma, 3382
- DAPK gene**
 breast cancer, 6634
 former smokers, 351
- de novo**
 cell division requirements, bladder cancer, 2378
- H19** imprinting control region, 4545
- 14–3–3 σ , oral carcinoma, 2072
- GSTP1** gene, former smokers, 351
- hypomethylation
 methioninase, 4685
- MGMT** promoter
 sputum
 germ-line polymorphisms and, 2248
- p16*, former smokers, 351
- p16^{INK4a}* promoter
 sputum
 germ-line polymorphisms and, 2248
- RASSF1A** gene, prostate cancer, 3498
- Methylation inhibitors**
 gene induction, fibroblasts, 961
- Methyl-group metabolism genes**
 germ-line variants, 4519
- O⁶-Methylguanine DNA methyltransferase**
 promoter methylation
 sputum
 germ-line polymorphisms and, 2248
- 2-Methyl-1,4-naphthoquinone:** *See* **Vitamin K₃**
- 4-(Methylnitrosamo)-1-(3-pyridyl)-1-butanoate**
 metabolites, smokeless cessation, 129
- Methylseleninic acid**
 cell cycle arrest mechanisms, 156
- Methylthioadenosine phosphorylase gene (MTAP)**
 tumor suppressor activity, breast cancer, 6639
- MET oncogene**
 somatic mutations, carcinoma metastases, 7025
- Mevalonate**
 alendronate invasion inhibition and, prostate cancer, 2708
- MIA**
 downregulation by COOH-terminal binding protein, malignant melanoma, 5962
- Microadenomatous lesions**
 colon, *Apc^{Min/+}* mice, 6367
- Microarrays**
 cDNA
 differential gene expression, pancreatic cancer, 2890
 epithelial ovarian cancer, 2923
 esophageal lesions, 3493
 gene expression profiling, head and neck squamous cell carcinoma, 1184
 ING1 target gene detection, mouse mammary epithelial cells, 2203
 molecular profiling, bladder cancer, 6973
 gene expression ratios, cancer diagnosis, 4963
- oligonucleotide
 gene expression analysis, gastric cancer, 233
- prostate cancer analysis, meta-analysis, 4427
- sporadic ovarian cancer analysis, 3466
- Tag**
 expressed CpG island sequence, 3214
- Microcalcifications**
 breast, Raman spectroscopy, 5375
- Microenvironment**
 and tumor therapy, 1462
- Micrometastasis**
 growth regulation by Ras, 887
 MAGE-based diagnosis, 251
- Micronuclei**
 peripheral blood lymphocyte
 and pleural malignant mesothelioma susceptibility, 5418
- Microphthalmia transcription factor**
 and melanoma phenotype, 2098
- Microsatellite instability**
 APC methylation, endometrial cancers, 3663
 DNA repair gene mutations, endometrial cancer, 4095
 high-level, colorectal cancer
 frameshift TCF-4 mutations, 3009
 MMP-3 promoter mutations, 3855
 low-level
 colorectal cancer, 53
 DNA polymerase β and, 6061
 refractory germ cell tumors, 2758
 upper urinary tract cancer, 6796
- Microsatellite mutator phenotype**
 short mononucleotide tract length polymorphisms, gastrointestinal cancer, 1961
- Microspheres**
 cytokine-encapsulated
 tumor immunotherapy, 7254
- Microtubule agents**
 mitotic responses, differential, 1935
- Microtubule inhibitors**
 2-aryliindoles, 3113
- Microtubules**
 stability
 regulation by survivin, 2462
 *-*stabilizing agent peloruside A, 3356
- Microvascular endothelium**
 tumor
 heparin-binding VEGF substructure binding, 7118
- Microvascular proliferations**
 glomeruloid, prognostic value, 6808
- Mig-6**
 NF- κ B activation, 5668
- Minichromosome maintenance protein MCM7**
 transactivation by MYCN, neuroblastoma, 1123
- Mismatch repair**
 deficiency
 mutations
 colorectal cancer, 1284
 review, 2447
 target gene mutation profiles, 1609
 target genes for instability, review, 2447
 gene rearrangements, hereditary nonpolyposis colorectal cancer, 848
- Mitochondrial DNA**
 deletions, thyroid tumors, 7031
 mutations
 prostate cancer, 6470
 somatic, breast cancer, 972
- Mitogen-activated protein kinase**
 activation
 Gadd45a-dependent, 7305
 hydroxyflutamide, prostate cancer, 6039
- ERK pathway**
 neuroendocrine differentiation activation, 1549
- inhibitors
 apoptosis induction, Bcr/Abl-expressing leukemia, 188
 p38^{HOG}
 senescence role, 5076
- Mitogen-activated protein kinase kinase 4**
 metastasis suppressor activity, ovarian cancer, 77
- Mitogenesis**
 blockade by trEGFR, pancreatic cancer, 5611
- Mitosis**
 checkpoint control, ovarian cancer, 1662
 microtubule agent responses, 1935
 regulation by survivin, 2462
- Mitotic arrest deficiency protein 1**
 human hSMAD1
 and cell proliferation, 2618
- Mitotic arrest deficiency protein 2**
 MAD2 expression, ovarian cancer, 1662
- MKT-077**
 and telomerase activity, 4434
- MLL-LCX fusion gene**
 acute myeloid leukemia with trilineage dysplasia, 4075
- MLL-SEPTIN6 fusion gene**
 infant t(X;11)(q24;q23) acute myeloid leukemia, 333
- MN/carbonic anhydrase IX**
 activation by PI3K
 oxygen levels, 4469
- Modifier of Min 1 (Momi^{LR}) gene**
 CASTB6F1 *Momi^{SG}*, *Apc^{Min/+}* mice
 polyp multiplicity, 5413
- Molecular imaging**
 meeting report, 2195
- Molecular profiling**
 bladder cancer, 6973
 non-small cell lung cancer, 3005
- Monoclonal antibodies**
 anti-4-1BB mAb
 and large tumor immunotherapy, 3459
 anti-flk-1
 combined with doxorubicin, soft tissue sarcoma, 2034
 anti-HER2 trastuzumab
 synergy with T cells, 2244
 anti-ICAM-2 mAb, ICAM-2⁺ colon cancer, 3167
- CD137
 -mediated antitumor effects
 IFN- γ , 4413
- Monocytes**
 CD95L expression, tumors, 1261
- Monokine induced by IFN- γ**
 IL-10 tumor inhibition mediation, 2606
- Morphine**
 angiogenesis and tumor growth promotion, 4491
- Mouse double minute 2**
 isoforms
 cell proliferation inhibition, 1222
- Mouse double minute 4**
 p53 regulation, 3221
- Mouse Tumor Biology Database (MTB),**
 1235
- MRP6:** *See* **Multidrug resistance protein 6 MS-27-275**
- antitumor activity, pediatric solid tumors, 6108
- MSI:** *See* **Microsatellite instability**
- MTG16 gene:** *See* **CBFA2T3 gene**
- Mucins**
 MUC1
 human TCR-like MUC1-specific recombinant antibodies, 5835
- MUC18

SUBJECT INDEX TO VOLUME 62

- human anti-MUC18
growth and metastasis inhibition, melanoma, 5106
- Mucosa**
oral
carcinogen bioactivation inhibition by curcumin, 5451
- Multidrug resistance 1 gene MDR1**
polymorphisms, acute myeloid leukemia, 4955
- regulation
HIF-1-dependent, 3387
- Multidrug resistance protein**
expression
and Te-MIBI scintimammography, 617
- Multidrug resistance protein 1**
activity
in vivo analysis, 391
- Multidrug resistance protein 4**
methotrexate and folate transport, 3144
- Multidrug resistance protein 6**
drug resistance and transport properties, 6172
- Multiple antigen peptide**
cellular processing, 1471
- Multiple endocrine neoplasia**
function-impaired RET-MEN2A
repair, 2414
recessive syndrome, rat, 3048
- Multiple intestinal neoplasia**
Apc^{mm} mice
tumor load reduction by vitamin D₃, compounds, 741
Apc^{Min/+} mice
microadenomatous lesions, colon, 6367
PGE₂ modulation of NSAID effects, 403
Apc^{Min/+}, CASTB6F1 *Mom1^{tg}* mice
polyp multiplicity, 5413
Apc^{Min/+} *Dnmt1*-hypomorphic mice
polyp inhibition, 1296
- Min mice**
CEA-based vaccine antitumor activity, 6944
cyclin D1, 4562
- Multiple myeloma**
CCI-779 efficacy, 5027
chromosome 13 abnormalities, 715
PTK787/ZK222584 activity, 5019
telomerase activity modulation by cytokines, 3876
- Mutagenesis**
ionizing radiation, solid tissue, 1518
- Mutagenicity**
crocidolite asbestos, 99
- Mutations: See also Deletions**
androgen receptor
prostate cancer, 1496
- APC**
growth advantages, colorectal tumors, 363
polymerase β and, colon tumors, 3271
- AR gene**
relapsed CWR22 prostate cancer cell growth, 6606
- BCR/ABL**, leukemia, 5995
- Bcrp1 hot spot**
and doxorubicin resistance, 2294
- BRAF**
colorectal tumors, 6451
lung adenocarcinoma, 7001
- BRCA1**
carriers
tumor gene profiling, 7110
- Brc2**
cancer susceptibility, mice, 990
genomic instability, 6194
- BRCA1-BRCA2 mutation carrier**
breast cancer, 2741
- β -catenin**
gastric cancer, 3503
colonic mutated crypts, ulcerative colitis, 2236
- compound *Apc* and *Smad2*
tumors, mice, 4558
- DNA repair genes, MSI+ endometrial cancer, 4095
- EGFR**
asbestos-induced proliferation inhibition, lung epithelium, 4169
- FH**, hereditary leiomyomatosis and renal cell cancer, 4554
- frameshift TCF-4, MSI-high colorectal cancer, 3009
- germ-line
and breast cancer survival, 3052
- hMSH2* and *hMLH1* promoter region, colorectal cancer, 38
- hMSH2* hematological malignancy and caf -au-lait spots, 359
- MSH2* and *MLH1* mutations
prediction, hereditary nonpolyposis colorectal cancer, 3485
- p53
and chemical carcinogenesis, mice, 3024
- hCDC4*, endometrial cancer, 4535
- hExo1*
alterations, hereditary nonpolyposis colorectal cancer, 6026
- N*-hydroxy-4-acetylaminobiphenyl, 4325
- KRAS** gene
colorectal tumors, 6451
- lacI*
electromagnetic near field, mice, 1956
- MMR*-deficient colorectal cancer, 1284
- MMR*-deficient tumors, review, 2447
- mtDNA, prostate cancer, 6470
- neo-poly(A) polymerase
HHC class II-restricted recognition, 5495
- Nkx3.1*
prostate cancer initiation, mice, 2999
- oncogenic
and tumor growth angiogenesis dependence, review, 1931
- p53
gene amplification induction, 3264
genomic instability, 6194
- hsMADI and, 2618
and smoking, breast cancer, 1987
- point
DNA ligase I, mice, 4065
Znf11a1/Karos gene, murine lymphoma, 2650
- short mononucleotide tract length polymorphisms, gastrointestinal cancer, 1961
- somatic
MET oncogene, carcinoma metastases, 7025
- mtDNA, breast cancer, 972
- RNF6*, esophageal squamous cell carcinoma, 4191
- stable
 β -catenin, mouse liver, 1971
- sucrose-rich diet, rat colon, 4339
- target gene, MSI-H cancer, 1609
- topoisomerase I, novel, 3716
- MutL homologue**
human *hMLH1*
hypermethylation
HPP1 hypermethylation and, gastric adenocarcinoma, 5637
- promoter region germ-line mutations, colorectal cancer, 38
- MLHI**
germ-line mutations
prediction, hereditary nonpolyposis colorectal cancer, 3485
- hypermethylation, hereditary nonpolyposis colorectal cancer, 3925
- MutS homologue**
human *hMSH2*
germ-line mutations
hematological malignancy and caf -au-lait spots, 359
- promoter region germ-line mutations, colorectal cancer, 38
- MSH2**
germ-line mutations
prediction, hereditary nonpolyposis colorectal cancer, 3485
- inactivation, hereditary nonpolyposis colorectal cancer, 848
- Msh2*-deficient mice
colitis-associated tumors, 2092
- Msh2*^{+/+} mice
cell lineage effects, 5134
- MV6401**
combined with photodynamic therapy
microvasculature effects, mammary tumors, 2151
- Myc**
-induced apoptosis
Omomyc and, 3507
- tumorigenesis
inhibition by *E2f1*, 3276
- MYCN**
circulating DNA, neuroblastoma, 3646
- MCM7* transactivation, neuroblastoma, 1123
- Myelogenous hyperplasia**
NQO1 disruption, mice, 3030
- Myeloma**
growth inhibition by PS-341, 4996
multiple
CCI-779 efficacy, 5027
chromosome 13 abnormalities, 715
PTK787/ZK222584 activity, 5019
telomerase activity modulation by cytokines, 3876
- N**
- NAD(P)H**
epithelial precancer fluorescent biomarker, 682
- NAD(P)H:quinone oxidoreductase (NQO1/DIA4)**
NQO1 gene disruption, myelogenous hyperplasia, 3030
nuclear localization, cancer, 1420
polymorphisms
and sputum promoter methylation, 2248
- Nasopharyngeal carcinoma**
EBV peptide-pulsed dendritic cell immunotherapy, 6952
late-stage
Met expression, 589
tumor-targeted gene therapy, 171
- National Cancer Institute (NCI)**
workshop on childhood atypical teratoid/rhabdoid tumors, meeting report, 323
- Natural killer T cells**
CD8+
tumor targeting, 5785
- Neoglycans**
anticancer agents, 3722
- Neoplasia**
B-cell
growth inhibition by S-3APG, mice, 2300
benzo(a)pyrene-induced transformation, lung fibroblasts, 4605
- epithelial
stromal regulation, 79

SUBJECT INDEX TO VOLUME 62

- lymphoid**
immunodeficient nonobese diabetic mice, 5828
- multiple endocrine function-impaired RET-MEN2A repair**, 2414
- Neo-poly(A) polymerase mutations**
MHC class II-restricted recognition, 5495
- NESH**
cell migration and metastasis inhibition, 2215
- Neural stem cells**
IL-12, glioma therapy, 5657
-mediated TRAIL delivery, glioma therapy, 7170
- Neuroblastic cells**
neuroblastoma, 2986
- Neuroblastoma**
allelotype, 1761
angiogenesis inhibition by SPARC, 7357
angiogenesis inhibition by TrkA, 1802
chemotherapy
 BDNF-TrkB-PI3K pathway protection, 6756
chemotherapy resistance
 mediation by TrkB, 6462
chromosome 1p36.3 imprinting absence, 6481
circulating *MYCN* DNA, 3646
familial
 chromosome 16p12–13 mapping, 6651
fenretinide-induced apoptosis, 5158
MCM7 transactivation by *MYCN*, 1123
neuroblastic cells, 2986
prognosis
 Id2 and, 301
purging
 virus-directed enzyme prodrug therapy, 5001
retSDR1 and retinol metabolism, 1196
Schwannian stromal cells, 2986
transformation to neuronal cells by VHL protein, 7004
- Neuroendocrine differentiation**
activation by ERK, 1549
- Neurofibromatosis**
type 1
 -associated pilocytic astrocytoma
 gene expression analysis, 2085
 malignant peripheral nerve sheath tumors
 international consensus statement, 1573
NF1 gene
 aberrant splicing, tumors, 1503
Nfl:p53 mouse tumor cells
 EGFR signaling, 4507
type 2
 NF2 gene
 aberrant splicing, tumors, 1503
- Neuronal cells**
neuroblastoma transformation by VHL protein, 7004
- Neurotensin**
protein kinase D activation, pancreatic cancer, 1632
- Neutron capture therapy**
molecular EGFR targeting, glioma, 3159
- NIH 3T3 cells**
telomerase inhibition, 2104
- 90K (Mac-2 binding protein)**
non-small cell lung cancer, 2535
- NIP3**
induction by desferri-exochelin, 6924
- Nitric oxide**
alkyltransferase inactivation and degradation, 3037
apoptosis inhibition, 1648
- irradiation-induced, endothelial
apoptosis induction, 1450
- Nitric oxide synthase**
inducible
 deficiency
 lung tumorigenesis reduction, mouse, 6850
 induction by glioma-associated hyaluronan, dendritic cells, 2583
 inhibitor
 combined with COX-2 inhibitor, chemopreventive effects, colon cancer, 165
- 3-Nitroflavones**
electron-donating ability
and colon cancer prevention, 6506
- Nitroreductase**
suicide gene therapy
bystander effects, 3D cell cultures, 1425
- NKG2D**
MHC class I-related chain A and UL16-binding protein recognition, tumors, 6178
- Nkx-3.1 gene**
C154T polymorphism, 2654
mutations, prostate cancer initiation, 2999
prostate-derived Ets factor interactions, 338
- NM-3**
combined with chemotherapy, antineoplastic effects, 789
- Nobiletin**
tumor invasion inhibition, fibrosarcoma, 1025
- Nonsteroidal anti-inflammatory drugs**
effects
modulation by PGE₂, *APC*^{Min/+} mice, 403
and GATA-6, colorectal cancer, 1178
15-lipoxygenase-1 upregulation, colorectal cancer, 1178
- Noscapine**
melanoma treatment, murine, 4109
- N-ras gene**
tumor suppressor activity, 4514
- Nuclear factor E2 p45-related factor 2 (Nrf2)**
-regulated genes
cancer chemoprevention, 5196
- Nuclear factor κB**
activation
 Mig-6-induced, 5668
 PAF, 1809
 promotion by protein kinase CK2, breast cancer, 6770
 TP53-inactive keratinocytes, 1213
BPDE-induced transactivation
 inhibition by berry extracts, 6857
and faslodex resistance, 3428
inhibitors
 adhesion-dependent colon cancer apoptosis, 6870
 platelet-activating factor-induced angiogenesis, 1809
radiation-induced
 inhibition by anti-Ras scFv, 2318
upregulation by Akt/protein kinase B activation, melanoma, 7335
- Nuclear magnetic resonance**
lipid accumulation, 1394
mobile lipid compartment dimensions, C6 cells, 5672
- Nuclear matrix protein**
alterations, colon cancer, 2437
- Nucleophosmin**
and faslodex resistance, 3428
- Nucleophosmin-anaplastic lymphoma kinase**
expression downregulation by 17-AAG, anaplastic large cell lymphoma, 1559
- Nucleoporin gene NUP98**
NUP98-HOXC11 fusion gene, t(11;12)-acute myeloid leukemia, 4571
- NUP98-HOXD11** fusion gene, t(2;11)-acute myeloid leukemia, 33
- Nucleotide excision repair**
global
regulation by p53, fibroblasts, 5288
transcription-coupled
and cisplatin sensitivity, 4899
- NY-ESO-1 119–143**
T-helper epitope, 213
- O**
- Okadaic acid**
tumor promotion
blockade by TAM-67, 3044
- Oligodeoxynucleotides**
antisense
DNA-PKcs inactivation, 6621
CpG-ODN
combined with HPV-16 E7, immune therapy, 7234
- Oligonucleotides**
c-myc antisense
growth inhibition, MCF-7 breast cancer cells, 3126
C-raf antisense
colorectal cancer liver metastasis inhibition, 5393
Ku86 antisense
effects, malignant glioma, 5888
microarrays
gene expression analysis, gastric cancer, 233
- Omomyc**
and Myc-induced apoptosis, 3507
- Oncogenesis**
bcl-2, rat, 6297
- ONYX-015**
malignant glioma xenografts, 764
- Oral carcinoma**
14–3–3 σ methylation, 2072
second malignancy
loss of heterozygosity and, 6447
squamous cell
inhibition by curcumin, 5451
Stat3 downregulation by sulindac, 1004
- Oral dysplasia**
epithelial, severe
p16INK4a and *p14ARF* alterations, 5295
molecular analysis, 4757
- Oral mucosa**
carcinogen bioactivation inhibition by curcumin, 5451
- Oral premalignant lesions**
lymphocyte chromosome instability and, 2813
- Osteoblastic lesions**
zoledronate treatment, SCID mouse model, 5564
- Osteoblasts**
inhibition by Trk receptor, 986
- Osteolytic lesions**
zoledronate treatment, SCID mouse model, 5564
- Osteonectin**
induction by β_3 integrin, melanoma, 226
- Osteopontin**
brain
 astrocytoma cell migration promotion, 5336
and breast cancer, 3417
melanocyte survival, 4820
- Osteoprotegerin**
survival factor, prostate cancer, 1619
- Osteosarcoma**
VP-16-induced fragmentation
DNASIL3, 4439

SUBJECT INDEX TO VOLUME 62

- Outdoors time**
and melanoma risk, 3992
- Ovarian cancer**
Ad5-Δ24RGD treatment, 1266
apoptosome activation, dysfunctional, 924
calpain-dependent apoptosis
induction by *ARHI*, 7264
candidate oncogene *SEI-1*, identification, 7157
CXCL12 role, 5930
epigenetic factors and *BRCA* genes, 4151
epithelial
cDNA array and, 2923
cell migration promotion by periostin, 5358
malignant
hyaluronan levels, 6410
risk
CYP17 and *COMT* polymorphisms and, 3058
gene transfer
retroviral vs lentiviral vectors, 6099
growth inhibition by phospholipid scramblase 1, 397
hK11 biomarker, 295
lysophosphatidic acid-induced migration inhibition by alendronate, 6015
MAD2 expression, 1662
measles virus therapy, 4656
mitotic checkpoint control, 1662
MKK4 metastasis suppressor activity, 6717
molecular profiling, 4722
paclitaxel resistance and RAR- γ , 2192
Pi3k inhibition and paclitaxel, 1087
reovirus therapy, 1696
sporadic
parallel analysis by SKY, CGH, and microarray analysis, 3466
suppression subtraction hybridization libraries, 262
survival
diptidyl peptidase IV overexpression and, 2753
- Ovarian surface epithelial cells**
telomerase regulation by JNK, 4575
- Ovarian tumors**
epithelial
malignant
hyaluronidase activity, 6410
- Oxidative metabolism**
and α -particle irradiation bystander effects, fibroblasts, 5436
- Oxidative stress**
expression profiles, breast cancer, 6246
- Oxygen**
carbonic anhydrase IX expression activation by PI3K, 4469
intra-tumoral distribution, photodynamic therapy, 7273
- Oxygen-dependent degradation**
TAT-ODD fusion protein
antitumor effects, 2013
- Oxytocin**
functional signaling, small cell lung cancer, 4623
Kaposi's sarcoma growth factor, 2406
- P**
- p14^{ARF}**
alterations, severe oral epithelial dysplasia, 5295
expression
and p53 resistance, 1305
hypermethylation, ulcerative colitis-associated colorectal cancer, 1148
- p16^{INK4a}**
alterations, severe oral epithelial dysplasia, 5295
and p53 deficiency, murine tumorigenesis, 2761
promoter methylation
sputum
germ-line polymorphisms and, 2248
- p21^{Cip1/Waf1}**
deficiency, mouse mammary tumors, 2077
and horizontal gene transfer, 575
- p27**
 Δ EGFR/PI3-K/Akt/p27 signaling, glioblastoma, 6764
- p38^{HOG}**
senescence role, 5076
- p53**
activation
Gadd45a-dependent, 7305
AdΔ2-p53, oncolytic potency, 6165
adenoviral gene transfer
phosphorylation, glioma, 1069
alterations, flat urothelial neoplasia, 809
and chemoradiation response, cervical cancer, 7364
damage response
mediation by TGF- β 1, 5627
deficiency
p16^{INK4a} and, murine tumorigenesis, 2761
functional loss, tumor progression, 2897
GART inhibitor cytotoxicity independence, 5236
and genetic stability, 1129
global excision repair regulation, fibroblasts, 5288
hypermutable bases
secondary structure positions, 5641
IL-6 production, renal cell carcinoma, 932
and lung cancer risk, 2819
mutations
gene amplification induction, 3264
genomic instability, 6194
germ-line
and chemical carcinogenesis, mice, 3024
hsMAD1 and, 2618
and smoking, breast cancer, 1987
- p53*-targeted disruption
Helicobacter-induced gastric cancer inhibition, 696
radiation response targets
tissue-specific induction, 7316
- regulated genes
modulation by thymidylate synthase, 2644
- regulation
ING1b, 4890
mdmx, 3221
resistance
p14ARF expression and, 1305
STAT3 activity modulation, breast cancer, 376
wild-type
-specific CD4 $^{+}$ T-helper cells, antitumor efficacy, 6187
WT1 gene interactions, 6615
- p53₂₆₄₋₂₇₂**
-specific T cells, head and neck squamous cell carcinoma, 3521
- p53AIP1**
apoptosis regulation, 2884
- p70^{S6K}**
UV-induced phosphorylation, signal pathways, 5689
- p73**
 Δ Np73, oncogenic potential, 636
- p185^{HER2}:** See **HER-2/neu**
- p300**
AR transactivation by IL-6, 5632
BRCA1 inhibition modulation, 141
downregulation
and melanocyte senescence, 6231
- Paclitaxel**
combined with ET-743, breast cancer, 6909
PI3k inhibition and, ovarian cancer, 1087
resistance
and RAR- γ , ovarian carcinoma, 2192
- Pain**
bone cancer
blockade by COX-2 inhibitors, 7343
- Pancreatic adenocarcinoma**
peptidomimetic marker peptide discovery, 4894
risk
XRCC1 Arg399Gln polymorphism and, 4630
- Pancreatic cancer**
apoptosis
T-cell activation, 2347
CCK-B receptor missplicing, 947
chemoresistance
IL-1 β and, 910
differential gene expression, cDNA microarray, 2890
familial
BRCA2 mutations, 3789
growth, fluorescence imaging, 1534
growth inhibition by COX-2 inhibitors
IGF-I and, BxPC-3 cells, 7372
IL-R-targeted therapy, 3575
interglanular heterogeneity, 835
magnetic resonance imaging, transgenic mouse model, 1555
metastasis
fluorescence imaging, 1534
VEGF-R and EGF-R, 1996
mitogenic blockade by trEGFR, 5611
protein kinase D activation
neurotensin-induced, 1632
secretin receptor, 5223
serial analysis of gene expression, 819
ssi2 gene transfer, antitumor effects, 6124
- Pancreatic ductal adenocarcinoma**
HIP/PAP-I, 1868
- Pancreatic islet cell tumors**
VHL-associated
loss of heterozygosity, 1952
- Par-4**
function, neoplastic T lymphocytes, 1768
- PC-cell-derived growth factor/acroganin:**
See **Progranulin**
- PC-3 cells**
5-HETE stimulation, 6817
- PC12 cells**
catecholamine regulation pVHL, 1682
- PCPH oncogene**
and cellular stress response, 2690
- PC-SPEs**
growth inhibition, colon cancer, 5204
molecular effects, 3920
- PD173955**
c-Abl complex
kinase domain crystal structures, 4236
- PD180970**
activity against imatinib-resistant Abl mutants, 7149
- Pediatric tumors**
atypical teratoid/rhabdoid tumors, meeting report, 323
caspase 8 and *caspase 10* expression, 5897
solid tumors
MS-27-275 antitumor activity, 6108
- Pegylated arginine deiminase (ADI-SS)**
PEG_{20,000 mw})
melanoma and hepatocellular carcinoma in-

SUBJECT INDEX TO VOLUME 62

- hibition, 5443
- Pegylated interferon α -2b**
combined with docetaxel
prostate cancer inhibition, nude mice, 5720
- Peloruside A**
microtubule-stabilizing activity, 3356
- Pemetrexed**
transporter, mesothelioma, 6434
- Peptides**
arginine-glycine-aspartic acid (Arg-Gly-Asp) (RGD)
radiolabeled, tumor targeting, 6146
tumor cell binding, 5139
- EBNA1 peptide helpers, CD4⁺ T cells, 7195
- EBV peptide-pulsed dendritic cell immunotherapy, nasopharyngeal carcinoma, 6952
- laminin, metastasis, 3549
- MHC class I and class II dual-specific, 3630
- modified PF-4
angiogenesis inhibition, 6884
- multiple antigen
cellular processing, 1471
- RGD binding, tumor cells, 5139
- synthetic combinatorial libraries
positional scanning format
recognition by tyrosinase-specific CTLs, 2058
- Peptidomics**
marker peptide discovery, pancreatic adenocarcinoma, 4894
- Perifosine**
cell cycle arrest, SCC, 1401
- Periostin**
cell migration promotion, epithelial ovarian carcinoma, 5358
- Peripheral blood**
lymphocytes
micronuclei
and pleural malignant mesothelioma susceptibility, 5418
- progenitor cells
mobilization by combination defibrotide and rhG-CSF, mice, 6152
- stem cells
transplantation, autologous adenoviral purging, 5013
- Peripheral nerve sheath tumors**
malignant
neurofibromatosis 1
international consensus statement, 1573
- Peroxosome proliferator-activated receptors**
K-Ras transformation modulation, intestinal epithelial cells, 3282
- P-glycoprotein**
expression
and Tc-MIBI scintimammography, 617
- Phagomid gene transfer**
carcinoma, 977
- Phagocytic cells**
IFN- γ -dependent
tumor growth regulation, metastatic mammary carcinoma, 4406
- Phenethyl isothiocyanate**
apoptosis
ERKs, prostate cancer, 3615
- Phenotype**
dendritic cell
interferon stimulated gene 15 and, melanoma, 3453
- Gli2 NH₂-terminal fragment and, skin tumor, 5308
- metastatic
and IGF-IRs, breast cancer, 6529
- microphthalmia transcription factor and,
- melanoma, 2098
- 1-Phenylazo-2-hydroxynaphthalol:** *See* Sudan I
- PHLDA1/TDAG51 gene**
function, metastatic melanoma, 5920
- Phosphatidylinositol 3-kinase**
BDNF-TrkB-PI3K pathway
protection against chemotherapy, neuroblastoma, 6756
- carbonic anhydrase IX expression activation oxygen levels, 4469
- Δ EGFR/PI3-K/Akt/p27 signaling, glioblastoma, 6764
- inhibition
herceptin-induced, 4132
and paclitaxel, ovarian cancer, 1087
- PI3K/Akt pathway
anchorage-independent growth and hematogenous metastasis, liver cancer, 2971
irradiated endothelium, 4671
- PI3K/PTEN/Akt pathway
and fatty acid synthase, LNCaP prostate cancer cells, 642
- TRAIL-induced apoptosis, non-small cell lung cancer, 4929
- Phosphatidylserine**
tumor vessel marker, 6132
- 6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase**
inducible
expression, cancer, 5881
- 3-Phosphoinositide-dependent protein kinase 1**
mammary epithelial cell transformation, 3538
- Phospholipids**
anionic
exposure, tumor blood vessels, 6132
- metabolism
adaptive changes to chloroethylnitrosourea, melanoma, 1890
- Phospholipid scramblase 1**
growth inhibition, ovarian cancer, 397
- Phosphoproteins**
ribosomal
breast
downregulation by GnRH, 1036
- Photodynamic therapy**
antitumor vaccines, 1604
- antivascular effects, mammary tumors, 2151
- combined with COX-2 inhibition, 3956
- combined with inducible suicide gene therapy, 1458
- fractionated
vascular and tumor cell targeting, breast tumors, 4289
- intra-tumoral oxygen distribution, 7273
- sensitivity
extracellular signal-regulated kinase and, 5528
- Piocyteic astrocytoma**
gene expression analysis, 2085
- Pinomondeazole**
binding
and treatment outcome, head and neck cancer, 7066
- oral, 6827
- Piroxicam**
effects, canine invasive bladder cancer, 356
esophageal tumorigenesis effects, rat, 4376
- Pituitary adenomas**
HMG2A overexpression, 2398
- PKI-166**
growth inhibition, prostate cancer, 5254
- Placental growth factor**
survival factor, tumor endothelial cells and macrophages, 2749
- Plant-derived HPV16 E7**
tumor protection, 3654
- Plasmid-based deletion assay**
Werner syndrome fibroblasts, 547
- Plasminogen activator inhibitor type 1**
predictive impact, breast cancer, 4617
- Plasticity**
collective melanoma cell migration, 2125
- Platelet-activating factor**
angiogenesis
nuclear factor κ B, 1809
- Platelet-derived growth factor**
autocrine signaling, glioblastoma, 3729
- receptor
antagonists
chemotherapy enhancement, 5476
- Platelet-derived growth factor BB**
and osteosclerotic bone metastasis, breast cancer, 917
- Platelet-derived growth factor D**
expression, cancer, 2468
- Platelet factor 4**
modified peptides
angiogenesis inhibition, 6884
- Pleomorphic adenoma gene (PLAG) proteins**
tumorigenic characteristics, 1510
- Pleural mesothelioma**
malignant
EGFR inhibition, 5242
susceptibility
peripheral blood lymphocyte micronuclei and, 5418
- PML gene**
induction by β -catenin, 5947
- Podosomes**
formation
N-WASP, 669
- Polo-like kinase 1**
and cancer cell proliferation inhibition, 4186
- Poly(ADP-ribose) polymerase**
CHS 828 sensitivity, mouse fibroblasts, 4206
- gene therapy, prostate cancer, 6879
- $\text{PARP-1}^{-/-}$ mice
Ku80 heterozygosity and hepatocellular carcinoma, 6990
- Polyamines**
histone acetyltransferase and histone deacetylase regulation, murine skin and tumors, 67
- Polyzystic kidney disease**
c-myc-induced apoptosis, 2210
- Polyethylene glycol**
conjugated d-amino acid oxidase
tumor-targeted H₂O₂ generation, 3138
- pegylated arginine deiminase (ADI-SS)
PEG_{20,000 mw})
melanoma and hepatocellular carcinoma inhibition, 5443
- pegylated IFN- α -2b
combined with docetaxel
prostate cancer inhibition, nude mice, 5720
- Poly-L-arginine**
vaccination, 1477
- Polymerase chain reaction**
real-time
metastatic cascade rate-limiting steps, 7083
- reverse transcriptase
preoperative RT-PCR-hK2 status and prostate cancer progression, 5974
- Polys**
inhibition, *Apc*^{Min/+} *Dnmt1*-hypomorphic mice, 1296
- intestinal
angiogenesis, mouse models, 506
- COX-2 expression, 6846

SUBJECT INDEX TO VOLUME 62

- multiplicity, CASTB6F1 *Mom1^{SV}*, *Apc^{Mm/+}* mice, 5413
- Polyunsaturated fatty acids**
and skin cancer, HPV-16 transgenic mice, 433
- Positron emission tomography**
FLT-PET, lung nodules, 3331
in vivo VEGF imaging, 5912
proliferation assessment, advanced intra-abdominal malignancy, 5698
- Potassium channels**
HERG
tumor cell apoptosis and growth regulation, 4843
- PP1**
RET-transforming activity inhibition, 1077
- Precancer**
epithelial
NAD(P)H/collagen fluorescent biomarkers, 682
- oral premalignant lesions
lymphocyte chromosome instability and, 2813
- pRL1a**
cellular processing, 1471
- Prodrugs**
carboxypeptidase G2 suicide gene therapy, 1724
enzyme-activated prodrug therapy
combined adenoviral and cytostatic therapy, 6089
P450 gene-directed
apoptotic factors and, 6928
virus-directed enzyme prodrug therapy
neuroblastoma purging, 5001
- Progesterone**
growth inhibition, endometrial cancer, 881
- Progranulin**
tumor progression, 5590
- Prolactinoma**
HMG A2 overexpression, 2398
- Prostacyclin:** *See Prostaglandin I₂*
- Prostaglandin E**
receptor EP₄
colon carcinogenesis, 28
- Prostaglandin E₂**
COX-2-derived
tumor growth promotion, head and neck cancer, 6706
NSAID effects modulation, *APC^{Mm/+}* mice, 403
- Prostaglandin I₂ synthase**
gene transfer, colon cancer, 63
overexpression
chemoprevention, murine lung cancer, 734
- Prostate**
angiogenesis inhibition by bisphosphonates, rats, 6538
cellular interactions, type I collagen gels, 58
epithelial cell senescence
characterization by SAGE, 6255
epithelium
FGF8b overexpression, mouse, 5096
RXR α allele inactivation, prostatic intra-epithelial neoplasia, 4812
- Prostate cancer**
AlbZIP expression and regulation, 721
androgen receptor mutations, 1496
androgen-refractory
cell proliferation
androgen receptor, 1008
apoptosis
induction by quinazolines, 597
induction by raloxifene, 5365
induction by raloxifene, LNCaP cells, 3649
RhoA-dependent, 2630
Simac, LNCaP cells, 18
- autocrine regulation by VEGF, 854
candidate gene targets
clinical validation, tissue microarrays, 1256
chemoresistance modulation by rapamycin, 6141
cholesterol and Akt signaling, 2227
coxsackie adenovirus receptor expression, 3812
Cten downregulation, 4217
cytokine gene polymorphisms and, 3369
detection by proteomic profiling, 3609
E2F-1 and cyclin B modulation by CD437, 3842
gene expression analysis
comprehensive, 4499
electronic expression profiling, 3308
meta-analysis, 4427
growth inhibition
combination pegylated IFN- α -2b and docetaxel, nude mice, 5720
HEPSIN, 6812
PKI-166, xenografts, 5254
silibinin, 3063
growth modulation by selenium, 2540
HEPSIN functions, 6812
HER2, 5485
HIF-1 α inhibition by geldanamycin, 2478
hK11 biomarker, 295
HMGI(Y) and chromosomal rearrangements, 647
HOOGY variants and, 2253
IGFIR expression, 2942
initiation, *Nkx3.1* mutant mice, 2999
invasion
inhibition by alendronate, 2708
inhibition by *HEPSIN*, 6812
lecithin:retinol acyltransferase levels, 1654
12-lipoxygenase inhibition, 2721
MAP kinase activation by hydroxyflutamide, 6039
metastasis
inhibition by combination pegylated IFN- α -2b and docetaxel, nude mice, 5720
8p suppressor gene, rat, 367
metastasis to bone
stromal cell-derived factor-1/CXCR4, 1832
 α -methylacyl-CoA racemase, 2220
MMP-9 regulation by translational efficiency, murine, 1910
mtDNA mutations, 6470
osteoprotegerin survival factor, 1619
PARP-based gene therapy, 6879
PEITC-induced apoptosis
ERKs, 3615
PI3k/PTEN/Akt kinase and fatty acid synthase, LNCaP cells, 642
PRC1/7 amplification, 5420
prevention by toremifene, 1370
progression
gene expression profiles, 5325
preoperative RT-PCR-hK2 status and, 5974
selenoprotein-P downregulation, mice, 5325
RASSF1A methylation, 3498
-reactive CTLs, 5807
-reactive stroma
TGF- β and angiogenesis, 6021
recurrent
adenoviral double suicide gene therapy, phase I study, 4968
PKC ϵ , 2423
relapsed growth
AR mutations, CWR22 cells, 6606
retinol metabolism reduction, 1654
- RhoA-dependent cell proliferation, 2630
risk
AMACR sequence variants and, 6485
Stat3 activation, 6659
susceptibility
HSD3B genes and, 1784
- Prostate cancer gene 17 (PRC17)**
amplification, prostate cancer, 5420
- Prostate carcinogenesis**
chemoprevention by 9-cis-retinoic acid, rats, 5178
- Prostate-derived Ets factor**
NKX-3.1 interactions, 338
- Prostate-specific membrane antigen**
selective tumor infarction, 5470
- Prostate-specific RNA aptamers**, 4029
- Prostate stem cell antigen**
therapy target, 2546
- Prostate tumorigenesis**
chromosome 20q13 genes and, 6803
early telomere shortening, 6405
reactive stroma and, 3298
- Prostate tumors**
DDC^{PCASL} gene marker, 2695
progression to malignancy
FGFR1 phosphotyrosine 766, 1898
- Prostatic intraepithelial neoplasia**
FGF8b mouse model, 5096
inhibition by 9-cis-retinoic acid, rats, 5178
RXR α allele inactivation, prostate epithelium, 4812
- Proteasome**
nuclear
and drug resistance, 5008
- Proteasome activator PA28**
tumor epitope presentation rescue, melanoma, 2875
- Proteasome inhibitor PS-341**
adult T-cell leukemia therapy, murine model, 1083
tumor growth inhibition, myeloma, 4996
- Protein kinase**
RNA-regulated
translation regulation, 2272
- Protein kinase B**
Akt/PKB
and TRAIL resistance, non-small cell lung cancer, 4929
tumor progression, melanoma, 7335
- Protein kinase C α**
PDK1 mammary epithelial cell transformation, 3538
- Protein kinase C ϵ**
recurrent prostate cancer, 2423
- Protein kinase CK2**
NF- κ B activation promotion, breast cancer, 6770
- Protein kinase C ζ**
inducible chemoresistance factor, 1815
RhoA-dependent cell proliferation and apoptosis, prostate cancer, 2630
- Protein kinase D**
activation
neurotensin-induced, pancreatic cancer, 1632
- Protein phosphatase 1 α**
BRCA1 interactions, 6357
- Protein tyrosine phosphatase**
low-molecular-weight
 β -catenin interactions, cell-cell adhesion, 6489
- Proteomic profiling**
breast ductal carcinoma *in situ*, 6740
prostate cancer detection, 3609
- Proto-oncogenes**
cadmium-responsive, novel, 703
- PS-341**
adult T-cell leukemia therapy, murine

SUBJECT INDEX TO VOLUME 62

- model, 1083
tumor growth inhibition, myeloma, 4996
- Psoriasis**
expression, mammary epithelial cells, 43
- PTEN**
hyaluronic acid-induced invasion inhibition, glioblastoma, 6318
PI3K/PTEN/Akt pathway
and fatty acid synthase, LNCaP prostate cancer cells, 642
TRAIL-induced apoptosis, non-small cell lung cancer, 4929
- PTK787/ZK 222584**
activity, multiple myeloma, 5019
tumor vascular bed effects, 4015
- Pulmonary fibrosis**
radiation-induced
genetic loci, murine, 3782
- Pulmonary metastasis**
CXCR4 expression and, murine B16 melanoma cells, 7328
prevention by angiogenesis II type I antagonist, renal cell carcinoma, 4176
ZD6126 effects, lung adenocarcinoma, 3711
- Purging**
adenoviral, autologous PBSC transplantation, 5013
virus-directed enzyme prodrug therapy, neuroblastoma, 5001
- Pyrimidine**
regulation
uridine phosphorylase knockout and, 2313
- Pyrimidine nucleoside monophosphate kinase**
characterization and l-form deoxycytidine analogue monophosphate phosphorylation, 1624
- Q**
- Quinazolines**
apoptosis induction, prostate cancer, 597
- R**
- ²²³Ra**
antitumor effects, skeletal metastases, 3120
- Rac**
survival regulation, glioma, 2131
- Rad6**
overexpression
chromosomal instability induction, 2115
- Rad51**
elevated levels, tumor cells, 219
- Radiation**
 α -particle
bystander effects
oxidative metabolism and, fibroblasts, 5436
radionuclide ²²³Ra antitumor effects, skeletal metastases, 3120
bystander effects
membrane signaling, 2531
chemoradiation resistance
mediation by EGFR, glioblastoma, 4307
chemoradiation response
p53 and, cervical cancer, 7364
- G₂ delay**
cdc2 regulation, 241
- ionizing
endothelium response
PI3K/Akt signaling, 4671
-induced NO, endothelial
apoptosis induction, 1450
- Ku G₂ checkpoint effects, 6031
- mutagenesis, solid tissue, 1518
- sensitivity
modulation by insulin, 3555
- S-phase checkpoint
Bcr/ABL requirements, 4588
- NF- κ B activation
inhibition by anti-Ras scFv, 2318
- pulmonary fibrosis
genetic loci, murine, 3782
- thyroid tumors
mtDNA deletions, 7031
- tumor response
arsenic trioxide and, 4202
tissue-specific induction, 7316
ZD1839 effects, 4300
- ultraviolet
carcinogenesis
inhibition by DFMO, *Xpa*^{-/-} mice, 1338
- melanomagenesis
Ink4a/Arf deficiency and, 6724
- p70^{SGK} phosphorylation, signal pathways, 5689
- smoothened* mutations, xeroderma pigmentosum basal cell carcinoma, 7186
- ultraviolet B
flux
and melanoma risk, 3992
- Radiation-induced fibrosarcoma RIF-1**
tumor tissue
redox mapping, 307
- Radioimmunotherapy**
combined with cilengitide, breast cancer, 4263
pretargeted ⁹⁰Y-labeled DOTA-biotin, mice, 5755
- Radioresistance**
cyclin B1 and, head and neck squamous cell carcinoma, 6414
Ras-mediated, 4142
- Radiosensitivity**
tissue-specific induction, 7316
- Radiosensitization**
dodecafluoropentane, hypoxic tumor cells, 3626
rapamycin, U87 xenografts, 7291
- Radiotherapy**
combined with Ad5- Δ 24RGD, glioma, 5736
SU6668 adjuvant, 1702
- Ral A**
EGF receptor-regulated cell motility, 982
- Raloxifene**
apoptosis induction
androgen-independent prostate cancer, 5365
prostate cancer LNCaP cells, 3649
- Raman spectroscopy**
breast microcalcifications, 5375
- RANTES**
promalignant activity, breast cancer, 1093
- Rapamycin**
chemoresistance modulation, prostate cancer, 6141
radiosensitization, U87 xenografts, 7291
TSC renal tumor inhibition, 5645
- Ras**
anti-Ras scFv
radiation-induced NF- κ B activation inhibition, 2318
- CD95 expression inhibition
reversal by farnesyltransferase inhibitors, 450
- cell transformation
reversal by IND 12, 1718
- mediated radiosensitivity, 4142
- micrometastasis growth regulation, 887
- mutations, lung cancer and melanoma, 6997
- organ specificity, mammary cancer, 1241
- Raspberry extracts**
effects on BPDE-induced AP-1 and NF- κ B, 6857
- RASSFIA gene**
epigenetic inactivation, medulloblastoma, 5906
- methylation, prostate cancer, 3498
silencing, thyroid carcinoma, 3698
- RBK1 gene**
amplification, retinoblastoma, 967
- Receptors**
advanced glycation end product-binding motif, amphotericin
metastasis blockade, 4805
- androgen
cell proliferation, androgen-refractory prostate cancer, 1008
mutations, prostate cancer, 1496
transactivation by IL-6
mediation by p300, 5632
- benzodiazepine
peripheral
ligands, apoptosis resistance reversal, 1388
- chemokine CCR7
CD45RA⁺CCR7⁺ cytotoxic T lymphocytes, melanoma, 1743
expression, lymph node metastasis, 2937
- chemokine CXCR4
and B16 lung metastases, murine, 7328
cell migration and adhesion regulation, small cell lung cancer, 6304
neutralization, non-Hodgkin's lymphoma, 3106
prostate cancer metastasis to bone, 1832
regulation by VEGF
invasion promotion, breast cancer, 7203
- cholecytokinin B
missplicing, pancreatic cancer, 947
- coxsackie adenovirus
expression, prostate cancer, 3812
- endothelin A
blockade
growth inhibition, cervical cancer, 6381
- epidermal growth factor
anti-EGFR therapy resistance
mediation by IGFR-1, glioblastoma, 200
and bladder tumorigenesis, 4157
- Δ EGFR/PI3-K/Akt/p27 signaling, glioblastoma, 6764
-dependent angiogenesis, skin carcinogenesis, 3402
expression
head and neck squamous cell carcinoma, 7350
induction by *Egr-1*, hypoxia, 827
- inhibition
angiogenic effects, 2554
effects, breast epithelial proliferation, 122
metastatic pancreatic cancer, 1996
molecular targeting, neutron capture therapy, 3159
mutations
asbestos-induced proliferation inhibition, lung epithelium, 4169
radiation and BCNU resistance mediation, glioblastoma, 4307
-regulated cell motility
Ral A, 982
signaling
inhibition by ZD1839, 5749
- Nfl/p53* mouse tumor cells, 4507
- signal transactivation, head and neck squamous cell carcinoma, 6329
- truncated trEGFR
mitogenic blockade, pancreatic cancer, 5611
- epidermal growth factor 2
human: See **HER-2/neu**

SUBJECT INDEX TO VOLUME 62

- epidermal growth factor VIII
invasion gene activation, 3335
- estrogen
 β cx protein, ER α -positive breast cancer, 4849
 inhibition by BRCA1
 modulation by p300, 141
 SERM-ER complexes
 gene expression profiles, breast cancer, 4419
- estrogen α
 absent, mammary tumor onset delay, 2798
 β cx protein, breast cancer, 4849
 lung cancer, 2141
- estrogen β , lung cancer, 2141
- estrogen-related, breast cancer, 6510
- fibroblast growth factor
 FGFR4 Arg³⁸⁸ allele
 and tumor progression, 840
- fibroblast growth factor 1
 phosphotyrosine 766, prostate tumor progression, 1898
- G protein-coupled
 Kaposi's sarcoma-associated herpesvirus
 viral
 gene expression modulation, 4525
 KISS1, 5399
- hBUBR1*
 inactivation, 13
- IL-13 receptor α 2
 IL-4 signaling inhibition, glioblastoma, 1103
- insulin-like growth factor I
 anti-EGFR therapy resistance mediation, glioblastoma, 200
 expression prostate cancer, 2942
 metastatic phenotype and, breast cancer, 6529
 signaling blockade by proinflammatory cytokines, breast cancer, 4746
- interleukin 4, pancreatic cancer therapy, 3575
- laminin 67-kDa
 and cell motility, 1321
- lymphotoxin- β
 angiogenesis induction, 4034
- platelet-derived growth factor
 antagonists, chemotherapy enhancement, 5476
- prostaglandin E EP₄, colon carcinogenesis, 28
- retinoic acid β
 loss, lung cancer, 3945
- retinoic acid β 2
 reactivation, breast cancer, 2455
- retinoic acid γ
 paclitaxel resistance and, ovarian carcinoma, 2192
- retinoid-related orphan ROR γ -deficient mice
 T-cell lymphoma, 901
- secretin, pancreatic cancer, 5223
- sigma-2
 agonists, apoptotic pathway, 313
- somatostatin subtype 2
 sst2 gene transfer, pancreatic cancer, 6124
- T-cell
 human TCR-like MUC1-specific recombinant antibodies, 5835
 -like telomerase-specific recombinant antibodies, 3184
- transcripts, multiple melanoma metastases, 5664
- ζ chain
 granzyme B-mediated degradation, 4884
- TRAIL decoy DcR1 and DcR2
- hypermethylation, tumors, 2157
- Trk
 osteoblast inhibition, 986
- tumor necrosis factor-Rp55 knockout mice
 liver metastasis, 6682
- vascular endothelial growth factor
 metastatic pancreatic cancer, 1996
 phosphorylation inhibition by green tea catechins, 381
- vascular endothelial growth factor 2
 DNAzyme, 5463
- vascular endothelial growth factor 3
 progression marker, cutaneous melanoma, 7059
- Redox**
mapping, RIF-1 tumor tissue, 307
tumor status
 glutathione levels and, 307
- Rejection**
tumor
 IL-12-induced
 effector mechanism, 5069
 IFN- γ , 4696
- Renal cell carcinoma**
adenoviral gene therapy, 4273
diagnosis
 array-based comparative genomic hybridization, 957
- families
 FH mutations, 4554
- hypoxia-inducible factor expression, 2957
- hypoxia regulation of cyclin D1
 VHL-mediated, 3014
- IL-6 production, 932
- metastasis
 postoperative azotemia and, 5218
- metastasis to lung
 prevention by angiotensin II type I antagonist, 4176
- TRAIL/Apo2L-induced apoptosis, 3093
- VEGF_{165b} downregulation, 4123
- Renal tumors**
growth inhibition
 rAAV-mediated tsFlk-1 expression, mice, 3077
- tuberous sclerosis complex
 inhibition by rapamycin, 5645
- Reovirus**
colon and ovarian cancer therapy, 1696
- Resveratrol**
mammary carcinogenesis inhibition, rats, 4945
- and prostate cancer cells, S phase, 2488
- RET**
kinase inhibition by ZD6474, 7284
- RET-MEN type 2A
 function-impaired
 repair, 2414
- transformational inhibition by PP1, 1077
- Retinoblastoma**
Msh2^{-/-}/*Rb*^{-/-} mice
 cell lineage effects, 5134
- Rb* gene
 and genetic stability, mouse, 2498
- RBK1N* amplification, 967
- Rb protein
 protection by adeno-associated virus, 2982
- tumor formation, preclinical mouse model, 1862
- tumor suppressor RB
 transcriptional repression, profiling, 6587
- Retinoblastoma 94**
head and neck squamous cell carcinoma treatment, 4637
- Retinoic acid**
receptor β
 loss, lung cancer, 3945
- receptor β
 reactivation, breast cancer, 2455
- receptor γ
 paclitaxel resistance and, ovarian carcinoma, 2192
- 9-cis-Retinoic acid**
prostatic intraepithelial neoplasia inhibition, rats, 5178
- Retinoid**
acyclic
 growth inhibition, hepatoma, 3997
- COX-2 induction inhibition, 2522
- Retinoid-related orphan receptor ROR γ -deficient mice**
T-cell lymphoma, 901
- Retinoid X receptor α gene (RXR α)**
allele inactivation, prostate epithelium, 4812
- Retinol**
metabolism
 reduction, prostate cancer, 1654
- retSDR1 and, neuroblastoma, 1196
- Retrovirus**
gene therapy
 bone marrow TGF- β signaling blockade, 7135
- gene transfer, ovarian cancer, 6099
- retSDR1**
and retinol metabolism, neuroblastoma, 1196
- Rhabdoid tumors**
childhood atypical
workshop meeting report, 323
- INI1* and SWI/SNF complex, meeting report, 323
- Rhabdomyosarcoma**
alveolar
 fusion-negative, 4704
- RhoA**
-dependent cell proliferation and apoptosis, prostate cancer, 2630
- RhoGDI2**
invasion and metastasis suppressor gene, cancer, 6418
- Rho-like GTPase**
autocrine motility factor-induced changes, 4484
- Ribonucleoprotein D**
heterogeneous nuclear hnRNPD
overexpression, mice tumorigenesis, 1489
- Ribosomal phosphoproteins**
breast
downregulation by GnRH, 1036
- Ritonavir**
antitumor effects, 6901
-boosted docetaxel exposure, mice, 6158
- RK3E epithelial cells**
GLI-regulated transcripts, 5867
- RNA**
antisense
 bcl-xL expression downregulation, 2175
- prostate-specific aptamers, 4029
- small interfering siRNAs
 DNA-PKcs silencing by, 6400
- RNA polymerase II holoenzyme**
BRCA1 and BARD1 and, 4222
- RNA-regulated protein kinase**
translation regulation, 2272
- RNF6 gene**
mutations
 somatic, esophageal squamous cell carcinoma, 4191
- Runx1/AML-1 gene**
T-cell lymphoma role, 7181
- S
- S100A calcium binding proteins**
overexpression, gastric cancer, 6823

SAGE: *See Serial analysis of gene expression*

S-3APG: *See S-3-Amino-phthalimido-glutamide*

Saquinavir apoptosis induction, 5230

Sarcoma β -actin/AUF1 transgenic mice, 1489
Ewing's
 EWS and *EWS-FLII* fusion gene
 BARD1 interactions, 4583
 EWSR1-CIZ fusion gene, acute leukemia, 5408

Kaposi's
 -associated herpesvirus viral G protein-coupled receptor
 gene expression modulation, 4525
oxytocin growth factor, 2406

metastasis
 CD44 gene effects, 2281

soft tissue
 chromosomal aberrations and, 3980
 inhibition, 2034

synovial
 gene expression
 genome-wide analysis, 5859
 SYT-SSX and cyclin D1 expression, 3861
 SYT-SSX fusion and, 135

uterine
 1,2-dimethylhydrazine-induced, p53 transgenic mice, 3024

SBEM gene breast tumor biomarker, 2736

Schwannian cells neuroblastoma, 2986

Scintimammography Tc-MIBI
 Pgp/MRP expression and, 617

Secondary lymphoid tissue chemokine combined SLC/CD40L-mediated immunotherapy, antitumor activity, 6545

Secreted protein acidic and rich in cysteine (SPARC) glioma invasion promotion, 6270
induction by β_1 integrin, melanoma, 226
neuroblastoma tumor angiogenesis inhibition, 7357

Secretin receptor, pancreatic cancer, 5223

SEI-1 oncogene candidate identification, ovarian cancer, 7157

Selectin tumor angiogenesis, nude rats, 6289

Selective estrogen receptor modulators SERM-ER complexes
 gene expression profiles, breast cancer, 4419
SP500263
 effects against breast cancer, 1439

Selenium cell proliferation modulation, prostate cancer, 2540
chemopreventive mechanisms, breast cancer, 708

Selenoprotein-P downregulation, prostate cancer progression, 5325

"Self"- antigen tumor expression
 and CD4 $^+$ T-cell function, 5144

SEL1L expression
 and tumor cell aggressiveness, breast tumors, 567

Semaphorin 3B tumor inhibition, adenocarcinoma, 542

Semaphorin 3F tumor inhibition, 2637

Senescence induction by DNA damage, tumor cells, 1876
p300 downregulation and, melanocytes, 6231
p38^{HOG} role, 5076
prostate epithelial cells
 characterization by SAGE, 6255

Sensitivity anticancer drug
 expression profiles, 518
CC1-779, multiple myeloma, 5027
CHS 828, PARP-1 fibroblasts, 4206
cisplatin
 transcription-coupled nucleotide excision repair and, 4899

photodynamic therapy
 extracellular signal-regulated kinase and, 5528

SEPTIN6 *MLL-SEPTIN6* fusion, infant t(X;11)(q24;q23) acute myeloid leukemia, 333

SEREX: *See Serological identification of tumor antigens by cDNA expression cloning*

Serial analysis of gene expression epithelial senescence characterization, prostate, 6255
gastric cancer, 6823
pancreatic cancer, 819

Serological identification of tumor antigens by cDNA expression cloning melanoma antigen isolation, 4836
new design, lung cancer, 1751

SGN-30 antitumor activity, Hodgkin's disease, 3736

SHPI gene aberrant methylation, leukemias/lymphomas, 6390

SHPS-1 and cancer dissemination inhibition, 3929

Sialyl Lewis antigens COX-2 and, colon cancer, 1567

Sialyl Lewis X antigen dependent lung colonization, melanoma, 4194

Sigma-2 receptor agonists, apoptotic pathway, 313

Signal transducer and activator of transcription 3 activation, prostate cancer, 6659
downregulation by sulindac, oral squamous cell carcinoma, 1004
head and neck squamous cell carcinoma, 3351
modulation by p53, breast cancer, 376

Silibinin growth inhibition, prostate cancer, 3063

Silica dendrite-like cells, 1050

Simian virus 40 large T antigen
 Kin17 interactions, 5425

Single nucleotide polymorphisms (SNPs) *hOGGI*
 and prostate cancer, 2253
MDRI, acute myeloid leukemia, 4955
MMP2
 and lung cancer risk, 6430

2G
 MMP-1 promoter
 and gene expression, 7200

Skeletal metastases ^{225}Ra antitumor effects, 3120

Skeletal muscle ubiquitin-proteasome-dependent proteolysis, 2771

Skin histone acetyltransferase and histone deacetylase regulation by polyamines, murine, 67
p16 expression
 α -MSH and, 875

Skin cancer non-melanoma
 XRCC1 and, 152
PUFAs and, HPV-16 transgenic mice, 433

Skin carcinogenesis EGFR-dependent angiogenesis, 3402
enhancement by cyclin D1, 1641
inhibition by cyclooxygenase 2, mice, 2516

Skin tumorigenesis *e12S-LOX*, mouse, 4610
JNK1, mice, 1343
reduction by COX-1 or COX-2 deficiency, 3395

Skin tumors okadaic acid-induced promotion
blockade by TAM-67, 3044
phenotype
 Gli2 NH₂-terminal fragment and, 5308

SLC2 gene tumor suppressor activity, 5874

SLUG zinc-finger protein E-cadherin inhibition, breast cancer, 1613

Smac apoptosis, prostate cancer LNCaP cells, 18

Smad signaling alterations, breast cancer, 497

Smad4 anoxia induction, 6045

Smad2 (*Madh2*) *Apc/Smad2* compound mutant mice
 invasive tumors, 5955
null mutation
 and malignant intestinal polyp progression, *Apc^{Δ716}* knockout mice, 4558

Smad ubiquitin ligase Smurf2 expression, esophageal squamous cell carcinoma, 7162

Small cell lung cancer cell migration and adhesion
 regulation by CXCR4 and c-Kit, 6304
oxytocin functional signaling, 4623

Smokeless tobacco cessation NNK metabolites, 129

Smokers, former bronchial epithelium and sputum hypermethylation, 2370
p16, DAPK, and GSTP1 methylation, 351

Smoking bronchial epithelium and sputum hypermethylation, 2370
ERCC2 polymorphisms and, lung cancer, 1377
p53 mutations and, breast cancer, 1987

Smoothened gene mutations, xeroderma pigmentosum basal cell carcinoma, 7186

Soft tissue sarcoma chromosomal aberrations and, 3980
inhibition, 2034

Solid tissue ionizing radiation mutagenesis, 1518

Solid tumors cell killing by viral fusogenic membrane glycoproteins, 6566
drug resistance
 nuclear proteasome and, 5008
growth inhibition by CSF-1 antisense, 5317
pediatric
 MS-27-275 antitumor activity, 6108

Somatostatin cytotoxic analogue AN-238
 and colon cancer, 781

SUBJECT INDEX TO VOLUME 62

- receptor subtype 2
sst2 gene transfer, pancreatic cancer, 6124
- Sonic hedgehog Shh**
 medulloblastoma induction, mice, 6385
- SOX10**
 tumor-associated antigen, 3020
- SP500263**
 effects on breast cancer, 1439
- SPARC:** *See Secreted protein acidic and rich in cysteine*
- Spectral karyotyping**
 sporadic ovarian cancer analysis, 3466
- S-phase kinase-associated protein 2 (Skp2)**
 deficiency, recovery from partial hepatectomy, 995
 expression, gastric cancer, 3819
- Splicing alterations**
 allele separation and, 4579
NF1, *NF2*, and *TSC2*, tumors, 1503
- Sputum**
 hypermethylation, smokers, 2370
- Squamous cell carcinoma**
 esophageal
p16 silencing modes, 4938
RNF6 mutations, 4191
Smur2 expression and, 7162
WWOX alterations, 2258
- head and neck
 combination IL-2 gene therapy and cisplatin, 4023
 EGFR expression, 7350
 gene expression profiling, 1184
 growth promotion by COX-2-derived PGE₂, 6706
 growth promotion by K-ras, 7154
 hypoxia-inducible factors, 2493
 lymphangiogenesis, 1315
p53-specific T cells, 3521
 radiotherapy resistance
 cyclin B1 and, 6414
 retinoblastoma 94 treatment, 4637
Stat3, 3351
 treatment outcome
 pimonidazole binding and tumor vascularity and, 7066
- oral
 inhibition by curcumin, 5451
Stat3 downregulation by sulindac, 1004
 progression
 gene expression and activity alterations, 3759
- Src kinase**
 activation by endostatin, endothelial cells, 5580
 activity
 homotypic adhesion disruption, colon cancer, 2669
 function-impaired RET-MEN2A repair, 2414
- SRPK1 gene**
 inhibition
 bleomycin resistance and, 4453
- SSX gene**
SYT-SSX fusion genes
 and cyclin D1 expression, synovial sarcoma, 3861
 and synovial sarcoma, 135
- Stanniocalcin 2**
 expression, breast cancer, 1289
- Stathmin**
 and antimicrotubule drugs, breast cancer, 6864
- Stem cells**
 acute myeloid leukemia
DT₃₈₈IL3 cytotoxicity, 1730
 mesenchymal
 IFN- β tumor delivery, 3603
 mobilization by combination defibrotide and rhG-CSF, mice, 6152
- neural
 IL-12, glioma therapy, 5657
- peripheral blood
 autologous transplantation
 adenoviral purging, 5013
- STI-571:** *See Imatinib*
- Stress**
 cellular response
PCPH oncogene and, 2690
 oxidative
 expression profiles, breast cancer, 6246
- Stroma**
 epithelial neoplasia regulation, 79
 gene expression
 MMP-1 2G single nucleotide polymorphism and, 7200
 neuroblastic and Schwannian cells, neuroblastoma, 2986
 prostate cancer-reactive
 TGF- β and angiogenesis, 6021
 reactive
 and prostate tumorigenesis, 3298
- Stromal cell-derived factor-1/CXCR4**
 prostate cancer metastasis to bone, 1832
- Stromelysin-1 (MMP-3) promoter**
 mutations, MSI-H colorectal cancer, 3855
- SU6668**
 combined with B7.2-IgG fusion protein, breast tumor therapy, 5727
 tumor radiotherapy adjuvant, 1702
- Sucrose-rich diet**
 mutations, rat colon, 4339
- Sudan I**
 metabolism by CYP1A1, 5678
- Suicide gene therapy**
 carboxypeptidase G2
 prodrugs, 1724
- double
 adenoviral, locally recurrent prostate cancer, 4968
 inducible
 combined with photodynamic therapy, 1458
 nitroreductase
 bystander effects, 3D cell cultures, 1425
- Sulfonamide anilides**
 anticancer agents, 4325
- Sulfonate-derived methylating agents**
 DNMT1 protein depletion, 1592
- Sulforaphane**
 -induced Nrf2-regulated genes, identification, 5196
- Sulindac**
Stat3 downregulation, oral squamous cell carcinoma, 1004
- Sulindac derivative IND 12**
 Ras-induced cell transformation reversal, 1718
- Superchemosensitization**
 Herceptin pretreatment, breast cancer, 5703
- Suppression subtraction hybridization**
 ovarian cancer libraries, 262
- Surgery**
 postoperative azotemia
 and metastatic renal cell carcinoma, 5218
- Survivin**
 microtubule stability regulation, 2462
- SW 480 cells**
 migration inhibition by GABA, 6467
- SWI/SNF complex**
 rhabdoid tumors, meeting report, 323
- Syndecan-1**
 prognostic value, lung cancer, 5210
- Synovial sarcoma**
 gene expression
 genome-wide analysis, 5859
- SYT-SSX** and cyclin D1 expression, 3861
SYT-SSX fusion and, 135
- Synthetic combinatorial peptide libraries**
 positional scanning format
 recognition by tyrosinase-specific CTLs, 2058
- SYT-SSX fusion genes**
 and cyclin D1 expression, synovial sarcoma, 3861
 and synovial sarcoma, 135
- SZF1**
 DNA binding, 3773
- T**
- TAF15**
TAF15-CIZ fusion, acute leukemia, 5408
- Tag microarrays**
 expressed CpG island sequence, 3214
- TAM-67**
 okadaic acid-induced tumor promotion blockade, 3044
- Tamoxifen**
 combined with urokinase-derived $\ddot{\text{A}}$ 6
 angiogenesis inhibition, breast cancer, 4678
 genistein interactions, breast cancer, 2474
 VEGF regulation, breast cancer, 4977
- T antigen**
Kin17 interactions, 5425
- TAP:** *See Transporter for antigen presentation*
- TAT-ODD fusion protein**
 antitumor effects, 2013
- TBX2**
 amplification, *BRCA1*- and *BRCA2*-related breast tumors, 3587
- T cell factor**
 transcription
 regulation by Wnt-1, esophageal cancer, 277
- T cell factor-4**
 mutations
 frameshift, MSI-high colorectal cancer, 3009
- T cell receptor**
 human TCR-like MUC1-specific recombinant antibodies, 5835
 -like telomerase-specific recombinant antibodies, 3184
 transcripts, multiple melanoma metastases, 5664
- T-cell receptor**
 ζ chain
 degradation
 granzyme B-mediated, 4884
- TDAG51/PHLD1 gene**
 function, metastatic melanoma, 5920
- Technetium-99m methoxyisobutylisonitrile scintimammography**
 PgP/MRP expression and, 617
- TEL-AML1**
 acute leukemia induction, mice, 3904
- Telomerase**
 activity
MKT-077 and, 4434
 modulation by cytokines, multiple myeloma, 3876
 inhibition, NIH 3T3 cells, 2104
 inhibitors
 G-quadruplex-related, TRAP assay, 3365
 regulation by JNK, ovarian surface epithelial cells, 4575
 -specific TCR-like recombinant antibodies, 3184
- Telomerase reverse transcriptase**
 human hTERT
 COOH-terminal fragment polypeptide

SUBJECT INDEX TO VOLUME 62

- telomere dysfunction, HeLa cells, 3226
 HLA DR7-restricted epitopes, 2600
- Telomerase RNA**
 -transfected dendritic cells, 5041
- Telomeres**
 dysfunction
 fTERT COOH-terminal fragment polypeptide, HeLa cells, 3226
 early shortening, prostate tumorigenesis, 6405
 short
 angiogenesis, mice, 552
- Telomeric repeat amplification protocol (TRAP)**
 G-quadruplex-related telomerase inhibitor assay, 3365
- Temozolomide**
 cell invasion reduction, glioma, 1915
- Tenascin-C**
 isoform expression, breast cancer, 3289
 microvascular cell migration promotion, 2660
- Teratocarcinoma**
 flt-1 promoter transcriptional targeting, 1271
- Teratoid/rhabdoid tumors**
 childhood atypical
 workshop meeting report, 323
- Testicular germ cell tumorigenesis**
 FHIT , 512
 gene expression profiling, 2359
- Testicular germ cell tumors**
 DAD-R and, 1822
- Testis antigen**
 gene expression, lung cancer, 3971
- 1,4,7,10-Tetraazacyclododecane-*N,N',N'',N'''*-tetraacetic acid (DOTA)-biotin**
 ^{90}Y -labeled
 pretargeted
 radioimmunotherapy, mice, 5755
- Tetrancleotide repeats**
 mutations, DNA damage, 6052
- Tetrathiomolybdate**
 tumor growth and metastasis inhibition, 4854
- Thiol antioxidants**
 apoptosis induction, tumor cells, 1443
- Thioredoxin-1**
 $\text{HIF-1}\alpha$ increase, 5089
- 3D cell cultures**
 bystander effects, 1425
- Thrombospondin 1**
 and tumor vascularity, glioblastoma, 1191
- Thrombospondin 2**
 cell-based antiangiogenic gene therapy, 2004
- Thrombotic infarction**
 selective, 5470
- Thromboxane A₂ synthase**
 gene transfer, colon cancer, 63
- Thymic lymphoma**
 prevention by dexamethasone, $\text{Atm}^{-/-}$ mice, 5153
- Thymidine phosphorylase**
 2-deoxy-L-ribose functional effects, 2834
- Thymidylate synthase**
 p53 -regulated gene modulation, 2644
 promoter polymorphisms
 and colorectal adenomas, 3361
- Thyroid carcinoma**
 RASSF1A silencing, 3698
- Thyroid hormone**
 receptor $\beta 1$
 gene inactivation, early stage breast cancer, 1939
- Thyroid tumors**
 mtDNA deletions, 7031
- Tirapazamine**
 topo II poison, 5248
- Tissue**
 CPI-0004Na distribution, 2327
 glutathione levels
 and tumor redox status, 307
 microarrays
 candidate gene target validation, prostate cancer, 1256
- T lymphocytes**
 activation
 apoptotic pancreatic tumor cells, 2347
 inhibition by CD40-expressing carcinoma, 2052
 adoptive
 combined with lymphocyte transgene therapy, 2043
 CD4+
 indirect tumor killing mediation, 2611
 “self-” antigen tumor expression and, 5144
 CD8+
 antigen-presenting cell interactions, 5065
 -mediated tumor killing
 IFN- γ and, mice, 5058
 memory
 activation, 6438
 epitope hierarchy, lymphoma
 subversion, 1116
 helper
 CD4+
 EBNA1 peptides, 7195
 wtp53-specific, antitumor efficacy, 6187
 HPV16 E2-specific responses, 472
 NY-ESO-1 119–143 epitope, 213
 leukemia
 adult
 PS-341 therapy, murine model, 1083
 lymphokine-activated killer-derived inhibition by HLA class I molecules, 480
 lymphoma
 cutaneous
 Fax splice variant, 5389
 DNA vaccines against, 1757
 ROR γ -deficient mice, 901
 migration to tumor masses
 CCR5, 3751
 neoplastic
 Par-4 function, 1768
 p53_{264–272}-specific, head and neck cancer, 3521
 receptor
 human TCR-like MUC1-specific recombinant antibodies, 5835
 -like telomerase-specific recombinant antibodies, 3184
 transcripts, multiple melanoma metastases, 5664
 ζ chain
 granzyme B-mediated degradation, 4884
 | regulatory
 CTL inhibition, colorectal cancer, 5267
 synergy with anti-HER2 mAb trastuzumab, 2244
 tumor antigen response, poly-L-arginine vaccination, 1477
Topoisomerase I
 mutations, novel, 3716
- Topoisomerase II**
 hypoxia-activated poison tirapazamine, 5248
- Topoisomerase II-directed drugs**
 resistance
 nuclear proteasome and, 5008
- Toremifene**
 chemopreventive activity, prostate cancer, 1370
- Toxicity**
 aflatoxin B₁, bronchial cells, 105
- antibody-dependent cellular cytotoxicity
 anti-adhesive antibody and, 6891
 antifolate
 uracil misincorporation, 4909
 CPI-0004Na , 2327
 discodermolide and epothilone B, non-small cell lung cancer, 4081
 DT_{388} IL3, acute myeloid leukemia stem cells, 1730
ET-743, female rat, 4256
GART inhibitor
 $p53$ independence, 5236
glycinamide ribonucleotide formyltransferase inhibitors, 5236
- Transcription**
 -coupled nucleotide excision repair and cisplatin sensitivity, 4899
 repression
 RB-mediated, profiling, 6587
 -targeted chemotherapy agent ET-743, 3377
- Transcriptome mapping**
 non-small cell lung cancer, 3340
- Transforming growth factor β**
 and angiogenesis, prostate cancer-reactive stroma, 6021
 bone marrow signaling
 blockade, cancer gene therapy, 7135
 signaling
 early loss, endometrial carcinoma, 2778
- Transforming growth factor $\beta 1$**
 germ-free TGF- $\beta 1$ -deficient mice
 colon cancer elimination, 6362
 $p53$ damage response mediation, 5627
- Transgenes**
 cancer-inducible
 expression by Grp94 promoter, 7207
- Translation**
 regulation by caspases and RNA-regulated protein kinase, 2272
- Transplantation**
 autologous peripheral blood stem cells
 adenoviral purging, 5013
- Transporter for antigen presentation (TAP)-1**
 -deficient tumors, 2856
- Trastuzumab (herceptin)**
 gastric cancer, 5813
 phosphatidylinositol 3-kinase and Akt inhibition induction, 4132
 pretreatment
 superchemosensitization, breast cancer, 5703
 rapid accumulation and internalization, inflammatory breast cancer, 860
 synergy with T cells, 2244
- Trk**
 receptor
 osteoblast inhibition, 986
- TrkB**
 angiogenesis inhibition, neuroblastoma, 1802
 dose and function, 4867
- TrkA**
 BDNF-TrkB-PI3K pathway
 protection against chemotherapy, neuroblastoma, 6756
 chemotherapy resistance mediation, neuroblastoma, 6462
- TSCL1 gene**
 DAL-1 association, lung cancer, 5129
- TSP50 gene**
 activation, breast cancer, 290
- Tuberin**
 14-3-3 interactions, 6475
- Tuberous sclerosis complex**
 renal tumors
 inhibition by rapamycin, 5645
- TSC2 gene**

SUBJECT INDEX TO VOLUME 62

- aberrant splicing, tumors, 1503
loss
 HMGA2 expression and, uterine leiomyoma, 3766
- Tubulin**
new cancercidal ligand 3-iodoacetamido benzoyl ethyl ester, 6080
small molecule
2-aryliindole inhibitors, 3113
- Tubulogenesis**
hepatocyte growth factor-induced
 N-WASP, 2503
- Tumor angiogenesis:** *See Angiogenesis*
- Tumor-associated antigen**
melanoma with vitiligo
 isolation by SEREX, 4836
-primed dendritic cells, cancer vaccines, 1884
SOX10, 3020
T-cell response, poly-L-arginine vaccination, 1477
- Tumor cells**
apoptosis
 regulation
 $HERG K^+$ channel, 4843
CML28 overexpression, 5517
dissemination
 inhibition
 SHPS-1 and, 3929
 MAGE-A expression, 251
E6/E7-immortalized
 combination HPV-16 E7 and CpG-ODN immune therapy, 7234
endothelial
 placental growth factor survival factor, 2749
extracellular membrane vesicles
 angiogenic activity, 6312
furamidine analogue distribution, 7219
genomic instability-null, 6345
hypoxic
 radiosensitization by dodecafluoropentane, 3626
RGD-peptide binding, 5139
senescence
 induction by DNA damage, 1876
- Tumor cell vaccines**
fusion, melanoma, 5495
- Tumor growth**
angiogenesis dependence, review, 1931
APC mutations and, colorectal tumors, 363
assessment with PET, 5698
chromogranin A and, mouse models, 941
enhancement by complement inhibitor, breast cancer, 1110
fluorescence imaging, pancreatic cancer, 1534
GPIIb/IIIa and $\alpha v \beta 3$ integrins and, 2824
inhibition
 AAV-encoded angiostatin, glioma, 756
 adenoviral endostatin delivery, mammary tumors, 3934
 allele-specific, 2024
 combination pegylated IFN- α -2b and docetaxel, prostate cancer, 5720
 combination urokinase-derived $\tilde{\text{A}}_6$ and tamoxifen, breast cancer, 4678
CSF-1 antisense, solid tumors, 5317
 ^{64}Cu -PTSM, 445
human anti-MUC18, melanoma, 5106
IL-12, mammary carcinoma, 747
mediation by CD4+ T-cells, 2611
metallothionein, 5370
PC-SPES, colon cancer, 5204
PS-341, myeloma, 4996
- rAAV-mediated *tsFlk-1* expression, renal tumors, 3077
S-3APG, mice, 2300
SPARC, glioma, 6270
sulfonamide anilides, novel, 4325
tetrathiomolybdate, 4854
thrombospondin 2, cell-based antiangiogenic gene therapy, 2004
vascular endothelial-cadherin antibody
 E4G10, 2567
ZD1839, 5749
- prevention
 FTY720, mouse breast cancer, 1410
- promotion
 COX-2-derived PGE₂, head and neck cancer, 6706
fibroblast activation protein, 4767
morphine, 4491
- regulation
 $HERG K^+$ channel, 4843
IFN- γ -dependent phagocytic cells, metastatic mammary carcinoma, 4406
IGF-I, colon cancer, 1030
- Tumorigenesis**
AUFI/hnRNPD overexpression, mice, 1489
DNA polymerase β and, 3511
EGFR signaling, *Nfl/p53* mouse tumor cells, 4507
HIF-1 α , 2962
inhibition by *semaphorin 3F*, 2637
Myc-induced
 inhibition by *E2f1*, 3276
p16^{Ink4a} and p53 deficiency, murine, 2761
Rb-dependent
 preclinical mouse model, 1862
- Tumorigenicity**
VEGF and, glioma, 1854
- Tumor immunity**
central nervous system
 induction by *L. monocytogenes* vaccine, 2287
- Tumor infarction**
selective, 5470
- Tumor-infiltrating macrophages**
and tumor angiogenesis, 7042
- Tumor load**
reduction by vitamin D₃ compounds, *Apc^{min}* mice, 741
- Tumor masses**
T cell migration
 CCR5, 3751
- Tumor necrosis factor**
receptor p55
 TNF-Rp55 knockout mice
 liver metastasis, 6682
- Tumor necrosis factor-related apoptosis-inducing ligand**
apoptosis
 PI3K/PTEN/Akt kinase pathway, 4929
cytochrome c release
 blockade by epidermal growth factor, 488
decoy receptors DcR1 and DcR2
 hypermethylation, tumors, 2157
GFP/TRAIL fusion protein
 targeted expression, hepatocytes, 3620
neural stem cell-mediated delivery, glioma therapy, 7170
TRAIL/Apo2L-induced apoptosis, colorectal cancer, 1583
- Tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand**
apoptosis
 COX-2 and, colon cancer, 4903
 sensitization by casein kinase II inhibition, 4180
apoptosis, renal cell carcinoma, 3093
combined with chemotherapy, colon tumors,
- 5800
- Tumor-primed dendritic cells**
cancer vaccines, 1884
- Tumors**
Apc and *Smad2* compound mutant mice, 4558
ARF^{-/-}/*Bax*^{-/-} mice, 2184
blood flow
 antivascular therapy and monitoring, high-frequency Doppler ultrasound, 6371
colitis-associated
 Msh2-deficient mice, 2092
- dormant
 solitary cells and, 2162
- eradication
 CD4 $^+$ T-cell-mediated
 IFN- γ and, mice, 5058
 Hsp70 depletion, xenografts, 7139
focal adhesion kinase signaling *in vivo*, 2699
histone acetyltransferase and histone deacetylase regulation by polyamines, murine, 67
intra-tumoral oxygen distribution, photodynamic therapy, 7273
IRS-1 activation, 6035
large
 immunotherapy
 anti-4-1BB mAb and, 3459
liposome distribution, 6831
microenvironment
 and tumor therapy, 1462
microvascular endothelium
 heparin-binding VEGF substructure binding, 7118
NFI, *NF2*, and *TSC2* aberrant splicing, 1503
progression
 Akt role, melanoma, 7335
 FGFR4 Arg³⁸⁸ allele and, 840
 programulin, 5590
radiation response
 arsenic trioxide and, 4202
radiotherapy
 SU6668 adjuvant, 1702
redox status
 glutathione levels and, 307
rejection
 IL-12-induced
 effector mechanism, 5069
 IFN- γ , 4696
- RIF-1**
redox mapping, 307
- TRAIL decoy receptors DcR1 and DcR2
 hypermethylation, 2157
- vascularity
 destruction by ZD6126, 7247
 PTK787/ZK 222584 effects, 4015
 reduction by TSP-1 overexpression, glioblastoma, 1191
 and treatment outcome, head and neck cancer, 7066
- Tumor suppressor genes**
chromosome 3p21.3 homozygous deletion region, 2715
chromosome 15q15 candidates, B-cell lymphoma, 7175
X chromosome
 MEF, 6579
- Tumor vaccines**
enhancement by immunized donor leukocyte infusion, 796
fusion, melanoma, 5495
photodynamic therapy, 1604
tumor-primed dendritic cells, 1884
- Tumor vessels**
anionic phospholipid exposure, 6132
phosphatidylserine marker, 6132

SUBJECT INDEX TO VOLUME 62

- Tyrosinase**
-specific CTLs
PS-SCL recognition, 2058
- U**
- Ubiquitin ligase**
Chfr activity, 1797
- Ubiquitin-proteasome**
-dependent proteolysis
skeletal muscle, 2771
- UCN-01:** *See* 7-Hydroxystaurosporine
- UL16-binding proteins**
recognition by NKG2D, tumors, 6178
- Ulcerative colitis**
-associated colorectal cancer
HPP1 aberrant methylation, 6820
p14^{ARF} hypermethylation, 1148
colonic mutated crypts, 2236
- Ultrasound**
chemotherapy drug delivery, rat model, 7280
high-frequency Doppler
antivascular therapy monitoring, 6371
- Ultraviolet B radiation**
flux
and melanoma risk, 3992
- Ultraviolet radiation**
carcinogenesis
inhibition by DFMO, *Xpa*^{-/-} mice, 1338
melanomagenesis
Ink4a/Arf deficiency and, 6724
p70^{S6K} phosphorylation, signal pathways, 5689
smoothened mutations, xeroderma pigmentosum basal cell carcinoma, 7186
- Upper urinary tract cancer**
microsatellite instability, 6796
- Uracil**
misincorporation, antifolate toxicity, 4909
- Uridine phosphorylase**
knockout
and pyrimidine regulation, 2313
- Urinary tract cancer**
upper
microsatellite instability, 6796
- Urokinase**
and tumor metastasis *in vivo*, 2390
- Urokinase-derived Å**
combined with tamoxifen
angiogenesis inhibition, breast cancer, 4678
- Urokinase-type plasminogen activator**
predictive impact, breast cancer, 4617
- Uroplakin II promoter**
human, identification and use, 3743
- Urothelial neoplasia**
flat
genetic alterations, 809
- Uterine leiomyoma**
HMGA2 expression and TSC2 loss, 3766
- Uterine sarcoma**
1,2-dimethylhydrazine-induced, p53 transgenic mice, 3024
- Uterine tumors**
LMP2^{-/-} mice, 24
- V**
- Vaccination**
CD40L-transduced lymphoma cell, 3195
DNA
B-cell lymphoma, 5845
DNA electrovaccination, melanoma, 5489
HLA-A'0201 HPV16 tumor model, 5792
poly-l-arginine, 1477
- Vaccines**
candidate chronic myelogenous leukemia
rAAV dendritic cell-targeted, 3175
- dendritic cell-based
IL-18 gene-transduced, immunotherapy, 5853
- DNA**
against T-cell lymphoma, 1757
MHC class I and class II dual-specific peptides, 3630
recombinant HSP110-HER-2/*neu* protein, 1737
- telomerase RNA-transfected dendritic cells, 5041
- tumor
enhancement by immunized donor leukocyte infusion, 796
fusion, melanoma, 5495
photodynamic therapy, 1604
tumor-primed dendritic cells, 1884
tumor-primed dendritic cells, 1884
vector-based
combined with cytokines, 5770
- Vascular endothelial growth factor**
autocrine regulation, prostate cancer, 854
CXCR4 regulation
invasion promotion, breast cancer, 7203
DNA-binding protein B expression, 4985
heparin-binding substructure
glycosaminoglycans binding and tumor endothelium localization, 7118
in vivo imaging, 5912
isoforms
and tumor vessel patterning, melanoma, 1838
receptor
metastatic pancreatic cancer, 1996
phosphorylation inhibition by green tea catechins, 381
receptor 2
DNAzyme, 5463
receptor 3
progression marker, cutaneous melanoma, 7059
regulation
estrogen, breast cancer, 4977
hormonal, breast cancer, 1948
MT1-MMP, glioma, 580
secretion by tumor-infiltrating macrophages
and tumor angiogenesis, 7042
signaling inhibition by ZD6474, 4645
and tumorigenicity, glioma, 1854
and tumor progression, β -cell carcinogenesis, 603
- Vascular endothelial growth factor 165**
peritumor lymphatic drain, MR mapping, 6731
- Vascular endothelial growth factor-A₁₆₅**
vascularity effects, melanoma brain metastases, 341
- Vascular endothelial growth factor_{165b}**
downregulation, renal cell carcinoma, 4123
- Vascular endothelial growth factor-D**
prognostic value, colorectal cancer, 1669
- Vascularity**
antivascular liposomal doxorubicin effects, rat brain tumor model, 2561
ionizing radiation response
PI3K/Akt signaling, 4671
- tumor
PTK787/ZK 222584 effects, 4015
and treatment outcome, head and neck cancer, 7066
VEGF-A₁₆₅ effects, melanoma brain metastases, 341
- Vasculogenic mimicry**
hemodynamics, inflammatory breast cancer, 560
- Vaults**
and drug resistance, murine, 7298
- VG76e**
[¹²⁵I]iodinated-, 5912
- Vinyl chloride**
-induced *N²,3-ethenoguanine*
molecular dosimetry and repair, rats, 5189
rat brain and liver, 5183
- Virosomes**
antirat neu, cancer therapy, 437
- Virus-directed enzyme prodrug therapy**
neuroblastoma purging, 5001
- Vitamin D₃**
adenoviral replication enhancement, 3084
compounds
tumor load reduction, *Apc*^{min} mice, 741
differentiation
blockade by leukemia-associated fusion proteins, 7050
- Vitamin K₃**
and gap junctional intercellular communication, 4922
- Vitiligo**
melanoma
tumor-associated antigen, isolation, 4836
- von Hippel-Lindau disease**
cyclin D1 modifier, 3803
- von Hippel-Lindau gene VHL**
β1-integrin fibrillar adhesion formation, 2929
hypoxia regulation of cyclin D1, renal cell carcinoma, 3014
- von Hippel-Lindau protein pVHL**
catecholamine regulation, PC12 cells, 1682
neuroblastoma transformation to neuronal cells, 7004
- von Hippel-Lindau tumorigenesis**
malignant conversion, 1952
- W**
- Waardenburg syndrome type 4 gene SOX10**
tumor-associated antigen, 3020
- Wall, Monroe E.**
in memoriam, 7377
- Werner syndrome**
plasmid-based deletion assay, fibroblasts, 547
- Wilms' tumor**
gene expression profiling, 6598
WT1 gene
p53 gene interactions, 6615
- Wiskott-Aldrich syndrome protein**
neuronal N-WASP
hepatocyte growth factor-induced tubulogenesis, 2503
podosome formation, 669
- WK175**
apoptosis induction, leukemia, 1057
- Wnt**
Met expression regulation, colorectal cancer, 5126
- Wnt-1**
T cell factor transcription regulation, esophageal cancer, 277
- Wnt-5a**
loss of expression, invasive breast cancer, 409
- WRN gene**
loss, effects, 547
- WWOX (WW domain containing oxidoreductase) gene**
alterations, esophageal squamous cell carcinoma, 2258
- X**
- X chromosome**
MEF tumor suppressor gene, 6579
- Xeroderma pigmentosum**
basal cell carcinoma

SUBJECT INDEX TO VOLUME 62

smoothened mutations, 7186

Xpa^{-/-} mice

UV carcinogenesis inhibition by DFMO,
1338

XPD

cisplatin resistance regulation, 5457

**X-ray cross-complementing group 1 gene
(XRCC1)**

Arg399Gln polymorphism

and pancreatic adenocarcinoma risk, 4630
camptothecin resistance, 459
and non-melanoma skin cancer, 152

Y

Yeast cytosine deaminase

expression under CEA promoter, 2337

YKL-40

serum levels, malignant glioma, 4364

Yttrium-90

-labeled DOTA-biotin
pretargeted
radioimmunotherapy, mice, 5755

Z

ZBRK1

DNA-binding site, 3773

ZD1839 (Iressa)

antiangiogenic effects, 2554
EGFR signaling and tumor growth inhibition, 5749
radiation response and tumor-induced angi-

genesis effects, 4300

ZD6126

pulmonary metastases effects, lung adenocarcinoma, 3711
tumor vasculature destruction, 7247

ZD6474

RET kinase inhibition, 7284
VEGF signaling inhibition, 4645

ZK 222584: See PTK787

Znfn1a1/Ikaros gene

alterations, murine lymphoma, 2650

Zoledronate

osteoblastic *versus* osteolytic lesion treatment, SCID mouse model, 5564

